ID ATD3A_HUMAN Reviewed; 586 AA. AC Q9NVI7; B3KPB3; D2K8Q1; G3V1I6; Q5SV23; Q8N275; Q96A50; DT 13-SEP-2005, integrated into UniProtKB/Swiss-Prot. DT 09-APR-2025, sequence version 3. DT 28-JAN-2026, entry version 205. DE RecName: Full=ATPase family AAA domain-containing protein 3A {ECO:0000305}; DE EC=3.6.1.- {ECO:0000269|PubMed:20154147, ECO:0000305|PubMed:39116259}; GN Name=ATAD3A {ECO:0000303|PubMed:37832546, ECO:0000312|HGNC:HGNC:25567}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Lung adenocarcinoma; RX PubMed=20332122; DOI=10.1242/jcs.062034; RA Fang H.Y., Chang C.L., Hsu S.H., Huang C.Y., Chiang S.F., Chiou S.H., RA Huang C.H., Hsiao Y.T., Lin T.Y., Chiang I.P., Hsu W.H., Sugano S., RA Chen C.Y., Lin C.Y., Ko W.J., Chow K.C.; RT "ATPase family AAA domain-containing 3A is a novel anti-apoptotic factor in RT lung adenocarcinoma cells."; RL J. Cell Sci. 123:1171-1180(2010). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3). RC TISSUE=Teratocarcinoma, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ASP-15. RC TISSUE=Brain, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 2-9; 202-208; 228-238; 291-298; 395-403; 431-439 AND RP 558-568 (ISOFORMS 1/2), PROTEIN SEQUENCE OF 93-104 (ISOFORM 2), CLEAVAGE OF RP INITIATOR METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Colon carcinoma; RA Bienvenut W.V., Heiserich L., Boulahbel H., Gottlieb E.; RL Submitted (JUL-2007) to UniProtKB. RN [7] RP FUNCTION, SUBCELLULAR LOCATION, AND ASSOCIATION WITH NUCLEOIDS. RX PubMed=17210950; DOI=10.1083/jcb.200609158; RA He J., Mao C.C., Reyes A., Sembongi H., Di Re M., Granycome C., RA Clippingdale A.B., Fearnley I.M., Harbour M., Robinson A.J., Reichelt S., RA Spelbrink J.N., Walker J.E., Holt I.J.; RT "The AAA+ protein ATAD3 has displacement loop binding properties and is RT involved in mitochondrial nucleoid organization."; RL J. Cell Biol. 176:141-146(2007). RN [8] RP SUBCELLULAR LOCATION, TOPOLOGY, AND ASSOCIATION WITH NUCLEOIDS. RX PubMed=18063578; DOI=10.1074/jbc.m708444200; RA Bogenhagen D.F., Rousseau D., Burke S.; RT "The layered structure of human mitochondrial DNA nucleoids."; RL J. Biol. Chem. 283:3665-3675(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [10] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-491, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [11] RP SUBCELLULAR LOCATION, AND TOPOLOGY. RX PubMed=20349121; DOI=10.1007/s10863-010-9269-8; RA Hubstenberger A., Merle N., Charton R., Brandolin G., Rousseau D.; RT "Topological analysis of ATAD3A insertion in purified human mitochondria."; RL J. Bioenerg. Biomembr. 42:143-150(2010). RN [12] RP FUNCTION, CATALYTIC ACTIVITY, HOMOOLIGOMERIZATION, INDUCTION, SUBCELLULAR RP LOCATION, TOPOLOGY, AND MUTAGENESIS OF LYS-358 AND ASP-411. RX PubMed=20154147; DOI=10.1128/mcb.00007-10; RA Gilquin B., Taillebourg E., Cherradi N., Hubstenberger A., Gay O., RA Merle N., Assard N., Fauvarque M.O., Tomohiro S., Kuge O., Baudier J.; RT "The AAA+ ATPase ATAD3A controls mitochondrial dynamics at the interface of RT the inner and outer membranes."; RL Mol. Cell. Biol. 30:1984-1996(2010). RN [13] RP INTERACTION WITH S100B, AND MUTAGENESIS OF VAL-293; LEU-297 AND RP 301-ILE-GLN-302. RX PubMed=20351179; DOI=10.1128/mcb.01468-09; RA Gilquin B., Cannon B.R., Hubstenberger A., Moulouel B., Falk E., Merle N., RA Assard N., Kieffer S., Rousseau D., Wilder P.T., Weber D.J., Baudier J.; RT "The calcium-dependent interaction between S100B and the mitochondrial AAA RT ATPase ATAD3A and the role of this complex in the cytoplasmic processing of RT ATAD3A."; RL Mol. Cell. Biol. 30:2724-2736(2010). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP INTERACTION WITH ATAD3B AND HSPD1. RX PubMed=22664726; DOI=10.1016/j.mito.2012.05.005; RA Merle N., Feraud O., Gilquin B., Hubstenberger A., Kieffer-Jacquinot S., RA Assard N., Bennaceur-Griscelli A., Honnorat J., Baudier J.; RT "ATAD3B is a human embryonic stem cell specific mitochondrial protein, re- RT expressed in cancer cells, that functions as dominant negative for the RT ubiquitous ATAD3A."; RL Mitochondrion 12:441-448(2012). RN [16] RP FUNCTION, INTERACTION WITH PROTEINS INVOLVED IN MITOCHONDRIAL TRANSLATION; RP RNA METABOLISM; LIPID METABOLISM; GADD45GIP1 AND FAM210A, AND INDUCTION. RX PubMed=22453275; DOI=10.1093/nar/gks266; RA He J., Cooper H.M., Reyes A., Di Re M., Sembongi H., Litwin T.R., Gao J., RA Neuman K.C., Fearnley I.M., Spinazzola A., Walker J.E., Holt I.J.; RT "Mitochondrial nucleoid interacting proteins support mitochondrial protein RT synthesis."; RL Nucleic Acids Res. 40:6109-6121(2012). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-321, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [19] RP INTERACTION WITH CLPB, AND FUNCTION. RX PubMed=31522117; DOI=10.1016/j.isci.2019.08.056; RA Yoshinaka T., Kosako H., Yoshizumi T., Furukawa R., Hirano Y., Kuge O., RA Tamada T., Koshiba T.; RT "Structural Basis of Mitochondrial Scaffolds by Prohibitin Complexes: RT Insight into a Role of the Coiled-Coil Region."; RL IScience 19:1065-1078(2019). RN [20] RP FUNCTION. RX PubMed=37832546; DOI=10.1016/j.molcel.2023.09.026; RA Fu Y., Sacco O., DeBitetto E., Kanshin E., Ueberheide B., Sfeir A.; RT "Mitochondrial DNA breaks activate an integrated stress response to RT reestablish homeostasis."; RL Mol. Cell 83:3740-3753(2023). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH EIF2AK3, AND MUTAGENESIS RP OF GLU-412. RX PubMed=39116259; DOI=10.1126/science.adp7114; RA Brar K.K., Hughes D.T., Morris J.L., Subramanian K., Krishna S., Gao F., RA Rieder L.S., Uhrig S., Freeman J., Smith H.L., Jukes-Jones R., Avezov E., RA Nunnari J., Prudent J., Butcher A.J., Mallucci G.R.; RT "PERK-ATAD3A interaction provides a subcellular safe haven for protein RT synthesis during ER stress."; RL Science 0:0-0(2024). RN [22] RP VARIANTS HAYOS ILE-53 AND TRP-528, AND INVOLVEMENT IN HAYOS. RX PubMed=27640307; DOI=10.1016/j.ajhg.2016.08.007; RG Baylor-Hopkins Center for Mendelian Genomics; RG University of Washington Center for Mendelian Genomics; RA Harel T., Yoon W.H., Garone C., Gu S., Coban-Akdemir Z., Eldomery M.K., RA Posey J.E., Jhangiani S.N., Rosenfeld J.A., Cho M.T., Fox S., Withers M., RA Brooks S.M., Chiang T., Duraine L., Erdin S., Yuan B., Shao Y., RA Moussallem E., Lamperti C., Donati M.A., Smith J.D., McLaughlin H.M., RA Eng C.M., Walkiewicz M., Xia F., Pippucci T., Magini P., Seri M., RA Zeviani M., Hirano M., Hunter J.V., Srour M., Zanigni S., Lewis R.A., RA Muzny D.M., Lotze T.E., Boerwinkle E., Gibbs R.A., Hickey S.E., RA Graham B.H., Yang Y., Buhas D., Martin D.M., Potocki L., Graziano C., RA Bellen H.J., Lupski J.R.; RT "Recurrent de novo and biallelic variation of ATAD3A, encoding a RT mitochondrial membrane protein, Results in distinct neurological RT syndromes."; RL Am. J. Hum. Genet. 99:831-845(2016). RN [23] RP VARIANTS PHRINL ARG-77 AND 164-GLN--SER-586 DEL, AND INVOLVEMENT IN PHRINL. RX PubMed=29053797; DOI=10.1093/brain/awx239; RA Peeters-Scholte C.M.P.C.D., Adama van Scheltema P.N., Klumper F.J.C.M., RA Everwijn S.M.P., Koopmans M., Hoffer M.J.V., Koopmann T.T., RA Ruivenkamp C.A.L., Steggerda S.J., van der Knaap M.S., Santen G.W.E.; RT "Genotype-phenotype correlation in ATAD3A deletions: not just of scientific RT relevance."; RL Brain 140:e66-e66(2017). RN [24] RP VARIANT PHRINL ARG-406, INVOLVEMENT IN PHRINL, AND CHARACTERIZATION OF RP VARIANT PHRINL ARG-406. RX PubMed=31727539; DOI=10.1016/j.ymgme.2019.10.012; RA Peralta S., Gonzalez-Quintana A., Ybarra M., Delmiro A., Perez-Perez R., RA Docampo J., Arenas J., Blazquez A., Ugalde C., Martin M.A.; RT "Novel ATAD3A recessive mutation associated to fatal cerebellar hypoplasia RT with multiorgan involvement and mitochondrial structural abnormalities."; RL Mol. Genet. Metab. 128:452-462(2019). CC -!- FUNCTION: Essential for mitochondrial network organization, CC mitochondrial metabolism and cell growth at organism and cellular level CC (PubMed:17210950, PubMed:20154147, PubMed:22453275, PubMed:31522117, CC PubMed:37832546, PubMed:39116259). May play an important role in CC mitochondrial protein synthesis (PubMed:22453275). May also participate CC in mitochondrial DNA replication (PubMed:17210950). May bind to CC mitochondrial DNA D-loops and contribute to nucleoid stability CC (PubMed:17210950). Required for enhanced channeling of cholesterol for CC hormone-dependent steroidogenesis (PubMed:22453275). Involved in CC mitochondrial-mediated antiviral innate immunity (PubMed:31522117). CC Required to protect mitochondria from the PERK-mediated unfolded CC protein response: specifically inhibits the activity of EIF2AK3/PERK at CC mitochondria-endoplasmic reticulum contact sites, thereby providing a CC safe haven for mitochondrial protein translation during endoplasmic CC reticulum stress (PubMed:39116259). Ability to inhibit EIF2AK3/PERK is CC independent of its ATPase activity (PubMed:39116259). Also involved in CC the mitochondrial DNA damage response by promoting signaling between CC damaged genomes and the mitochondrial membrane, leading to activation CC of the integrated stress response (ISR) (PubMed:37832546). CC {ECO:0000269|PubMed:17210950, ECO:0000269|PubMed:20154147, CC ECO:0000269|PubMed:22453275, ECO:0000269|PubMed:31522117, CC ECO:0000269|PubMed:37832546, ECO:0000269|PubMed:39116259}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; CC Evidence={ECO:0000269|PubMed:20154147, ECO:0000305|PubMed:39116259}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13066; CC Evidence={ECO:0000269|PubMed:20154147, ECO:0000305|PubMed:39116259}; CC -!- SUBUNIT: Can form homooligomers (PubMed:20154147). Homodimer formation CC at the N-terminus may be regulated by ATP and is required for the CC interaction with the inner surface of the mitochondrial outer membrane CC and correct mitochondrial homeostasis (PubMed:20154147). Interacts with CC components of the mitochondrial ribosome and with other proteins CC involved in mitochondrial RNA metabolism (PubMed:22453275). May also CC interact with protein involved in lipid metabolism, including STARD9 CC (PubMed:22453275). May interact with FAM210A (PubMed:22453275). CC Interacts with GADD45GIP1 (PubMed:22453275). Interacts with S100B in a CC Ca(+2)- and Zn(+2)-dependent manner; this interaction probably occurs CC in the cytosol prior to mitochondrial targeting (PubMed:20351179). CC S100B could assist ATAD3A cytoplasmic processing, preventing CC aggregation and favoring mitochondrial localization (PubMed:20351179). CC Interacts with HSP60/HSPD1 (PubMed:22664726). Forms heterooligomers CC with ATAD3B; this interaction may affect ATAD3A activity CC (PubMed:22664726). Interacts with CLPB (PubMed:31522117). Interacts CC with EIF2AK3/PERK; ATAD3A and EIF2S1/eIF-2-alpha occupy a common CC binding site within the cytoplasmic loop of EIF2AK3/PERK, leading to CC prevent EIF2AK3/PERK association with its substrate EIF2S1/eIF-2-alpha CC (PubMed:39116259). {ECO:0000269|PubMed:20154147, CC ECO:0000269|PubMed:20351179, ECO:0000269|PubMed:22453275, CC ECO:0000269|PubMed:22664726, ECO:0000269|PubMed:31522117, CC ECO:0000269|PubMed:39116259}. CC -!- INTERACTION: CC Q9NVI7; O00429: DNM1L; NbExp=4; IntAct=EBI-352007, EBI-724571; CC Q9NVI7; P10809: HSPD1; NbExp=4; IntAct=EBI-352007, EBI-352528; CC Q9NVI7-2; Q9NVI7-2: ATAD3A; NbExp=2; IntAct=EBI-5456381, EBI-5456381; CC Q9NVI7-2; O00429: DNM1L; NbExp=5; IntAct=EBI-5456381, EBI-724571; CC -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane CC {ECO:0000269|PubMed:18063578, ECO:0000269|PubMed:20154147, CC ECO:0000269|PubMed:20332122, ECO:0000269|PubMed:20349121}; Single-pass CC membrane protein {ECO:0000269|PubMed:20154147, CC ECO:0000269|PubMed:20349121}. Mitochondrion matrix, mitochondrion CC nucleoid {ECO:0000269|PubMed:17210950, ECO:0000269|PubMed:18063578}. CC Note=In the mitochondrial inner membrane, enriched in sites with the CC potential to form contacts with the outer membrane (PubMed:20154147, CC PubMed:20349121). The N-terminal domain interacts with the inner CC surface of the mitochondrial outer membrane and the C-terminal domain CC localizes in a specific matrix compartment, where it is associated with CC nucleoids (PubMed:18063578). Also present at mitochondria-endoplasmic CC reticulum contact sites; where it interacts with EIF2AK3/PERK CC (PubMed:39116259). {ECO:0000269|PubMed:18063578, CC ECO:0000269|PubMed:20154147, ECO:0000269|PubMed:20349121, CC ECO:0000269|PubMed:39116259}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=2; CC IsoId=Q9NVI7-2; Sequence=Displayed; CC Name=1; CC IsoId=Q9NVI7-1; Sequence=VSP_062536; CC Name=3; CC IsoId=Q9NVI7-3; Sequence=VSP_062535; CC -!- TISSUE SPECIFICITY: Overexpressed in lung adenocarcinomas (at protein CC level). {ECO:0000269|PubMed:20332122}. CC -!- INDUCTION: Up-regulated by Angiotensin/AGT. CC {ECO:0000269|PubMed:20154147, ECO:0000269|PubMed:22453275}. CC -!- DOMAIN: The transmembrane domain and a C-terminal adjacent region CC contain all information necessary for mitochondrial targeting. CC {ECO:0000269|PubMed:20154147}. CC -!- DISEASE: Harel-Yoon syndrome (HAYOS) [MIM:617183]: A syndrome CC characterized by global developmental delay, hypotonia, intellectual CC disability, and axonal neuropathy. Some patients have optic atrophy and CC hypertrophic cardiomyopathy. HAYOS inheritance can be autosomal CC dominant or autosomal recessive. {ECO:0000269|PubMed:27640307}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Pontocerebellar hypoplasia, hypotonia, and respiratory CC insufficiency syndrome, neonatal lethal (PHRINL) [MIM:618810]: An CC autosomal recessive multisystem disorder with onset in utero and death CC in the neonatal period. Affected infants show respiratory insufficiency CC and almost no spontaneous movement at birth. Additional features CC include corneal clouding, seizures, dysmorphic facies, contractures, CC and progressive pontocerebellar hypoplasia with simplified gyral CC pattern and white matter abnormalities. Some patients may have cardiac CC anomalies or cardiac hypertrophy. {ECO:0000269|PubMed:29053797, CC ECO:0000269|PubMed:31727539}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the AAA ATPase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; GU189416; ACZ80514.1; -; mRNA. DR EMBL; AK001571; BAA91764.1; -; mRNA. DR EMBL; AK056099; BAG51625.1; -; mRNA. DR EMBL; AK091144; BAC03595.1; -; mRNA. DR EMBL; AL645728; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471183; EAW56187.1; -; Genomic_DNA. DR EMBL; CH471183; EAW56190.1; -; Genomic_DNA. DR EMBL; BC007803; AAH07803.1; -; mRNA. DR EMBL; BC011814; AAH11814.1; -; mRNA. DR EMBL; BC014101; AAH14101.1; -; mRNA. DR EMBL; BC033109; AAH33109.1; -; mRNA. DR EMBL; BC063607; AAH63607.1; -; mRNA. DR CCDS; CCDS31.1; -. [Q9NVI7-1] DR CCDS; CCDS53259.1; -. [Q9NVI7-2] DR CCDS; CCDS53260.1; -. [Q9NVI7-3] DR RefSeq; NP_001164006.1; NM_001170535.3. [Q9NVI7-2] DR RefSeq; NP_001164007.1; NM_001170536.3. [Q9NVI7-3] DR RefSeq; NP_060658.3; NM_018188.4. [Q9NVI7-1] DR AlphaFoldDB; Q9NVI7; -. DR SMR; Q9NVI7; -. DR BioGRID; 120506; 374. DR DIP; DIP-33194N; -. DR FunCoup; Q9NVI7; 2296. DR IntAct; Q9NVI7; 295. DR MINT; Q9NVI7; -. DR STRING; 9606.ENSP00000368030; -. DR iPTMnet; Q9NVI7; -. DR MetOSite; Q9NVI7; -. DR PhosphoSitePlus; Q9NVI7; -. DR SwissPalm; Q9NVI7; -. DR BioMuta; ATAD3A; -. DR DMDM; 84028405; -. DR jPOST; Q9NVI7; -. DR MassIVE; Q9NVI7; -. DR PaxDb; 9606-ENSP00000368030; -. DR PeptideAtlas; Q9NVI7; -. DR PRIDE; Q9NVI7; -. DR ProteomicsDB; 32346; -. DR ProteomicsDB; 82815; -. [Q9NVI7-1] DR ProteomicsDB; 82816; -. [Q9NVI7-2] DR Pumba; Q9NVI7; -. DR Antibodypedia; 26400; 166 antibodies from 25 providers. DR DNASU; 55210; -. DR Ensembl; ENST00000378755.9; ENSP00000368030.5; ENSG00000197785.15. [Q9NVI7-1] DR Ensembl; ENST00000378756.8; ENSP00000368031.3; ENSG00000197785.15. [Q9NVI7-2] DR Ensembl; ENST00000536055.6; ENSP00000439290.1; ENSG00000197785.15. [Q9NVI7-3] DR GeneID; 55210; -. DR KEGG; hsa:55210; -. DR MANE-Select; ENST00000378756.8; ENSP00000368031.3; NM_001170535.3; NP_001164006.1. DR UCSC; uc001afz.3; human. [Q9NVI7-2] DR AGR; HGNC:25567; -. DR ClinPGx; PA134872099; -. DR CTD; 55210; -. DR DisGeNET; 55210; -. DR GeneCards; ATAD3A; -. DR HGNC; HGNC:25567; ATAD3A. DR HPA; ENSG00000197785; Low tissue specificity. DR MalaCards; ATAD3A; -. DR MIM; 612316; gene. DR MIM; 617183; phenotype. DR MIM; 618810; phenotype. DR OpenTargets; ENSG00000197785; -. DR Orphanet; 656279; 1p36.33 duplication syndrome. DR Orphanet; 615983; Lethal pontocerebellar hypoplasia-hypotonia-respiratory insufficiency syndrome due to a point mutation. DR Orphanet; 615986; Lethal pontocerebellar hypoplasia-hypotonia-respiratory insufficiency syndrome due to biallelic deletions in the ATAD3 gene cluster. DR Orphanet; 496790; Ocular anomalies-axonal neuropathy-developmental delay syndrome. DR VEuPathDB; HostDB:ENSG00000197785; -. DR eggNOG; KOG0742; Eukaryota. DR GeneTree; ENSGT00730000111059; -. DR HOGENOM; CLU_011488_2_0_1; -. DR InParanoid; Q9NVI7; -. DR OMA; HKSITGG; -. DR OrthoDB; 199596at2759; -. DR PAN-GO; Q9NVI7; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9NVI7; -. DR PathwayCommons; Q9NVI7; -. DR SignaLink; Q9NVI7; -. DR Agora; ENSG00000197785; -. DR BioGRID-ORCS; 55210; 46 hits in 1120 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; ATAD3A; human. DR GenomeRNAi; 55210; -. DR Pharos; Q9NVI7; Tbio. DR PRO; PR:Q9NVI7; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9NVI7; protein. DR Bgee; ENSG00000197785; Expressed in sural nerve and 179 other cell types or tissues. DR ExpressionAtlas; Q9NVI7; baseline and differential. DR GO; GO:0044233; C:mitochondria-associated endoplasmic reticulum membrane contact site; IDA:UniProtKB. DR GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProtKB. DR GO; GO:0042645; C:mitochondrial nucleoid; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IMP:FlyBase. DR GO; GO:0016887; F:ATP hydrolysis activity; IMP:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; IDA:UniProtKB. DR GO; GO:0140374; P:antiviral innate immune response; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0140468; P:HRI-mediated signaling; IDA:UniProtKB. DR GO; GO:0007005; P:mitochondrion organization; IMP:FlyBase. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:1903898; P:negative regulation of PERK-mediated unfolded protein response; IDA:UniProtKB. DR GO; GO:0001558; P:regulation of cell growth; IMP:UniProtKB. DR CDD; cd19512; RecA-like_ATAD3-like; 1. DR FunFam; 3.40.50.300:FF:000470; ATPase family, AAA domain containing 3A; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR003593; AAA+_ATPase. DR InterPro; IPR021911; ATAD3_N. DR InterPro; IPR003959; ATPase_AAA_core. DR InterPro; IPR027417; P-loop_NTPase. DR PANTHER; PTHR23075:SF5; ATPASE FAMILY AAA DOMAIN-CONTAINING PROTEIN 3A; 1. DR PANTHER; PTHR23075; PUTATIVE ATP-ASE; 1. DR Pfam; PF00004; AAA; 1. DR Pfam; PF12037; ATAD3_N; 1. DR SMART; SM00382; AAA; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. PE 1: Evidence at protein level; KW Acetylation; Alternative splicing; ATP-binding; Coiled coil; KW Direct protein sequencing; Disease variant; Hydrolase; Membrane; KW Mitochondrion; Mitochondrion inner membrane; Mitochondrion nucleoid; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Transmembrane; Transmembrane helix. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.6" FT CHAIN 2..586 FT /note="ATPase family AAA domain-containing protein 3A" FT /id="PRO_0000084799" FT TOPO_DOM 2..246 FT /note="Mitochondrial intermembrane" FT /evidence="ECO:0000255" FT TRANSMEM 247..264 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 265..586 FT /note="Mitochondrial matrix" FT /evidence="ECO:0000255" FT REGION 1..55 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2..50 FT /note="Required for interaction with the inner surface of FT the mitochondrial outer membrane" FT /evidence="ECO:0000269|PubMed:18063578" FT REGION 111..134 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 290..305 FT /note="S100B-binding" FT /evidence="ECO:0000269|PubMed:20351179" FT COILED 86..219 FT /evidence="ECO:0000255" FT COMPBIAS 17..26 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 32..48 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 111..125 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 352..359 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0000269|Ref.6" FT MOD_RES 321 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 491 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT VAR_SEQ 1..79 FT /note="Missing (in isoform 3)" FT /id="VSP_062535" FT VAR_SEQ 94 FT /note="K -> KMRLEALSLLHTLVWAWSLCRAGAVQTQERLSGSASPEQVPAGECCA FT LQ (in isoform 1)" FT /id="VSP_062536" FT VARIANT 15 FT /note="G -> D (in dbSNP:rs2274435)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_023526" FT VARIANT 53 FT /note="T -> I (in HAYOS; dbSNP:rs1057517687)" FT /evidence="ECO:0000269|PubMed:27640307" FT /id="VAR_082788" FT VARIANT 77 FT /note="L -> R (in PHRINL; dbSNP:rs1570319915)" FT /evidence="ECO:0000269|PubMed:29053797" FT /id="VAR_083867" FT VARIANT 164..586 FT /note="Missing (in PHRINL; dbSNP:rs760826883)" FT /evidence="ECO:0000269|PubMed:29053797" FT /id="VAR_083868" FT VARIANT 406 FT /note="L -> R (in PHRINL; decreased protein levels in FT patient cells; dbSNP:rs1570345942)" FT /evidence="ECO:0000269|PubMed:31727539" FT /id="VAR_083869" FT VARIANT 528 FT /note="R -> W (in HAYOS; dbSNP:rs1057517686)" FT /evidence="ECO:0000269|PubMed:27640307" FT /id="VAR_082789" FT MUTAGEN 293 FT /note="V->S: Loss of S100B-binding; when associated with S- FT 297." FT /evidence="ECO:0000269|PubMed:20351179" FT MUTAGEN 297 FT /note="L->S: Loss of S100B-binding; when associated with S- FT 293." FT /evidence="ECO:0000269|PubMed:20351179" FT MUTAGEN 301..302 FT /note="Missing: Decrease in S100B-binding." FT /evidence="ECO:0000269|PubMed:20351179" FT MUTAGEN 358 FT /note="K->E: No effect on homooligomerization. Immediate FT fragmentation of the mitochondrial network." FT /evidence="ECO:0000269|PubMed:20154147" FT MUTAGEN 411 FT /note="D->Q: No effect on homooligomerization. Immediate FT fragmentation of the mitochondrial network." FT /evidence="ECO:0000269|PubMed:20154147" FT MUTAGEN 412 FT /note="E->Q: Abolished ATPase activity without affecting FT its ability to interact with and inhibit EIF2AK3/PERK." FT /evidence="ECO:0000269|PubMed:39116259" FT CONFLICT 176 FT /note="R -> Q (in Ref. 2; BAG51625)" FT /evidence="ECO:0000305" FT CONFLICT 207 FT /note="I -> T (in Ref. 2; BAC03595)" FT /evidence="ECO:0000305" SQ SEQUENCE 586 AA; 66218 MW; 1E83D08AE33D550F CRC64; MSWLFGINKG PKGEGAGPPP PLPPAQPGAE GGGDRGLGDR PAPKDKWSNF DPTGLERAAK AARELEHSRY AKDALNLAQM QEQTLQLEQQ SKLKEYEAAV EQLKSEQIRA QAEERRKTLS EETRQHQARA QYQDKLARQR YEDQLKQQQL LNEENLRKQE ESVQKQEAMR RATVEREMEL RHKNEMLRVE AEARARAKAE RENADIIREQ IRLKAAEHRQ TVLESIRTAG TLFGEGFRAF VTDWDKVTAT VAGLTLLAVG VYSAKNATLV AGRFIEARLG KPSLVRETSR ITVLEALRHP IQVSRRLLSR PQDALEGVVL SPSLEARVRD IAIATRNTKK NRSLYRNILM YGPPGTGKTL FAKKLALHSG MDYAIMTGGD VAPMGREGVT AMHKLFDWAN TSRRGLLLFV DEADAFLRKR ATEKISEDLR ATLNAFLYRT GQHSNKFMLV LASNQPEQFD WAINDRINEM VHFDLPGQEE RERLVRMYFD KYVLKPATEG KQRLKLAQFD YGRKCSEVAR LTEGMSGREI AQLAVSWQAT AYASEDGVLT EAMMDTRVQD AVQQHQQKMC WLKAEGPGRG DEPSPS // ID BRAF_HUMAN Reviewed; 766 AA. AC P15056; A4D1T4; B6HY61; B6HY62; B6HY63; B6HY64; B6HY65; B6HY66; Q13878; AC Q3MIN6; Q9UDP8; Q9Y6T3; DT 01-NOV-1990, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 4. DT 28-JAN-2026, entry version 267. DE RecName: Full=Serine/threonine-protein kinase B-raf {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; DE AltName: Full=Proto-oncogene B-Raf; DE AltName: Full=p94; DE AltName: Full=v-Raf murine sarcoma viral oncogene homolog B1; GN Name=BRAF {ECO:0000312|HGNC:HGNC:1097}; Synonyms=BRAF1, RAFB1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, FUNCTION, AND RP PHOSPHORYLATION AT THR-373. RC TISSUE=Testis; RX PubMed=1508179; DOI=10.1128/mcb.12.9.3733-3742.1992; RA Stephens R.M., Sithanandam G., Copeland T.D., Kaplan D.R., Rapp U.R., RA Morrison D.K.; RT "95-kilodalton B-Raf serine/threonine kinase: identification of the protein RT and its major autophosphorylation site."; RL Mol. Cell. Biol. 12:3733-3742(1992). RN [2] RP SEQUENCE REVISION TO 31-33. RA Albert S., Wixler L., Rapp U.R.; RL Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-200. RC TISSUE=Placenta; RX PubMed=1630826; RA Eychene A., Barnier J.V., Apiou F., Dutrillaux B., Calothy G.; RT "Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B- RT raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene."; RL Oncogene 7:1657-1660(1992). RN [8] RP PROTEIN SEQUENCE OF 2-51; 56-95; 151-158; 189-199; 253-260; 294-354; RP 361-424; 444-507; 510-522; 559-570; 579-626; 663-680; 692-698; 702-719; RP 727-735 AND 753-766, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT RP ALA-2, PHOSPHORYLATION AT SER-365; THR-396; SER-399; THR-401 AND SER-729, RP AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Colon carcinoma, and Hepatoma; RA Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 117-766. RC TISSUE=Testis; RX PubMed=2284096; RA Sithanandam G., Kolch W., Duh F.-M., Rapp U.R.; RT "Complete coding sequence of a human B-raf cDNA and detection of B-raf RT protein kinase with isozyme specific antibodies."; RL Oncogene 5:1775-1780(1990). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 381-766, DISEASE, AND CHROMOSOMAL RP REARRANGEMENT. RC TISSUE=Brain; RX PubMed=18974108; DOI=10.1158/0008-5472.can-08-2097; RA Jones D.T.W., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., RA Ichimura K., Collins V.P.; RT "Tandem duplication producing a novel oncogenic BRAF fusion gene defines RT the majority of pilocytic astrocytomas."; RL Cancer Res. 68:8673-8677(2008). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 439-766. RX PubMed=3043188; DOI=10.1128/mcb.8.6.2651-2654.1988; RA Ikawa S., Fukui M., Ueyama Y., Tamaoki N., Yamamoto T., Toyoshima K.; RT "B-raf, a new member of the raf family, is activated by DNA RT rearrangement."; RL Mol. Cell. Biol. 8:2651-2654(1988). RN [12] RP PHOSPHORYLATION AT SER-365 BY SGK1. RX PubMed=11410590; DOI=10.1074/jbc.m102808200; RA Zhang B.H., Tang E.D., Zhu T., Greenberg M.E., Vojtek A.B., Guan K.L.; RT "Serum- and glucocorticoid-inducible kinase SGK phosphorylates and RT negatively regulates B-Raf."; RL J. Biol. Chem. 276:31620-31626(2001). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401; SER-446; SER-447 AND RP SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP SUBUNIT, INTERACTION WITH DGKH, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-753 BY MAPK1. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [18] RP INTERACTION WITH AKAP13; MAP2K1 AND KSR1. RX PubMed=21102438; DOI=10.1038/ncb2130; RA Smith F.D., Langeberg L.K., Cellurale C., Pawson T., Morrison D.K., RA Davis R.J., Scott J.D.; RT "AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade."; RL Nat. Cell Biol. 12:1242-1249(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [20] RP INTERACTION WITH KSR2, SUBUNIT, CATALYTIC ACTIVITY, FUNCTION, AND RP MUTAGENESIS OF LYS-483. RX PubMed=21441910; DOI=10.1038/nature09860; RA Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L., RA Shokat K.M., Barford D.; RT "A Raf-induced allosteric transition of KSR stimulates phosphorylation of RT MEK."; RL Nature 472:366-369(2011). RN [21] RP INTERACTION WITH PRMT5, METHYLATION AT ARG-671, CHARACTERIZATION OF VARIANT RP CRC GLU-600, AND MUTAGENESIS OF ARG-671. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [23] RP UBIQUITINATION BY RNF149. RX PubMed=22628551; DOI=10.1074/jbc.m111.319822; RA Hong S.W., Jin D.H., Shin J.S., Moon J.H., Na Y.S., Jung K.A., Kim S.M., RA Kim J.C., Kim K.P., Hong Y.S., Lee J.L., Choi E.K., Lee J.S., Kim T.W.; RT "Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v- RT Raf murine sarcoma viral oncogene homolog B1 (BRAF)."; RL J. Biol. Chem. 287:24017-24025(2012). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; SER-365; THR-401; RP SER-446 AND SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP UBIQUITINATION AT LYS-578, AND MUTAGENESIS OF LYS-578. RX PubMed=23907581; DOI=10.1038/srep02344; RA An L., Jia W., Yu Y., Zou N., Liang L., Zhao Y., Fan Y., Cheng J., Shi Z., RA Xu G., Li G., Yang J., Zhang H.; RT "Lys63-linked polyubiquitination of BRAF at lysine 578 is required for RT BRAF-mediated signaling."; RL Sci. Rep. 3:2344-2344(2013). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP INTERACTION WITH FNIP1 AND FNIP2. RX PubMed=27353360; DOI=10.1038/ncomms12037; RA Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D., RA Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W., RA Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W., RA Bratslavsky G., Mollapour M.; RT "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance RT drug binding."; RL Nat. Commun. 7:12037-12037(2016). RN [28] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [29] RP FUNCTION, AND SUBUNIT. RX PubMed=36402789; DOI=10.1038/s41467-022-34907-0; RA McGrail K., Granado-Martinez P., Esteve-Puig R., Garcia-Ortega S., Ding Y., RA Sanchez-Redondo S., Ferrer B., Hernandez-Losa J., Canals F., Manzano A., RA Navarro-Sabate A., Bartrons R., Yanes O., Perez-Alea M., Munoz-Couselo E., RA Garcia-Patos V., Recio J.A.; RT "BRAF activation by metabolic stress promotes glycolysis sensitizing RT NRASQ61-mutated melanomas to targeted therapy."; RL Nat. Commun. 13:7113-7113(2022). RN [30] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [31] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [32] RP X-RAY CRYSTALLOGRAPHY (2.57 ANGSTROMS) OF 444-719 IN COMPLEX WITH RP INHIBITOR. RX PubMed=18287029; DOI=10.1073/pnas.0711741105; RA Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., RA Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., RA Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., RA Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., RA Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., RA Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G.; RT "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent RT antimelanoma activity."; RL Proc. Natl. Acad. Sci. U.S.A. 105:3041-3046(2008). RN [33] {ECO:0007744|PDB:5VR3, ECO:0007744|PDB:5VYK} RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 36-110, FUNCTION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH KSR1; KSR2; MAP2K1 AND RP MAP2K2, AND MUTAGENESIS OF MET-53; LYS-88; ARG-509 AND ILE-666. RX PubMed=29433126; DOI=10.1038/nature25478; RA Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T., RA Kurinov I., Sicheri F., Therrien M.; RT "MEK drives BRAF activation through allosteric control of KSR proteins."; RL Nature 554:549-553(2018). RN [34] RP VARIANTS LNCR VAL-466 AND ARG-597. RX PubMed=12460919; RA Naoki K., Chen T.-H., Richards W.G., Sugarbaker D.J., Meyerson M.; RT "Missense mutations of the BRAF gene in human lung adenocarcinoma."; RL Cancer Res. 62:7001-7003(2002). RN [35] RP VARIANTS CANCER GLU-464; VAL-464; ALA-466; GLU-466; VAL-466; ALA-469; RP GLU-469; LYS-586; LEU-595; ARG-596; ARG-597; VAL-597; GLU-600 AND ASP-600, RP AND CHARACTERIZATION OF VARIANTS CANCER VAL-464; ALA-469; VAL-597 AND RP GLU-600. RX PubMed=12068308; DOI=10.1038/nature00766; RA Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., RA Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., RA Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., RA Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., RA Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., RA Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., RA Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W.C., RA Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., RA Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.; RT "Mutations of the BRAF gene in human cancer."; RL Nature 417:949-954(2002). RN [36] RP VARIANTS CRC ILE-462; SER-463; GLU-464; GLU-600 AND GLU-601. RX PubMed=12198537; DOI=10.1038/418934a; RA Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., RA Velculescu V.E.; RT "Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status."; RL Nature 418:934-934(2002). RN [37] RP VARIANTS NHL ALA-469; ARG-469 AND GLY-594. RX PubMed=14612909; DOI=10.1038/sj.bjc.6601371; RA Lee J.W., Yoo N.J., Soung Ark W.S., Kim S.Y., Lee J.H., Park J.Y., RA Cho Y.G., Kim C.J., Ko Y.H., Kim S.H., Nam S.W., Lee J.Y., Lee S.H.; RT "BRAF mutations in non-Hodgkin's lymphoma."; RL Br. J. Cancer 89:1958-1960(2003). RN [38] RP CHARACTERIZATION OF VARIANT MELANOMA GLU-600. RX PubMed=14500344; RA Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A.; RT "Suppression of BRAF(V599E) in human melanoma abrogates transformation."; RL Cancer Res. 63:5198-5202(2003). RN [39] RP VARIANTS CFC1 PRO-246; ARG-257; GLU-469; PHE-485; GLU-499; LYS-501; GLY-501 RP AND ASP-581. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [40] RP VARIANT [LARGE SCALE ANALYSIS] GLU-600. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS CFC1 ARG-257; ALA-467; SER-468; GLU-469; PHE-485; GLU-499; RP LYS-501; GLY-501; ASP-581; LEU-595 AND VAL-596. RX PubMed=16439621; DOI=10.1126/science.1124642; RA Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., RA Cruz M.S., McCormick F., Rauen K.A.; RT "Germline mutations in genes within the MAPK pathway cause cardio-facio- RT cutaneous syndrome."; RL Science 311:1287-1290(2006). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] SER-301; ALA-469; VAL-469; SER-581; RP ARG-596; ARG-597; VAL-597 AND GLU-600. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [43] RP VARIANTS CFC1 PRO-241; PRO-244; PRO-246; ARG-257; LYS-262; SER-468; RP GLU-469; GLU-499; ASN-499; ASP-580; ASP-581 AND LEU-595. RX PubMed=18042262; DOI=10.1111/j.1399-0004.2007.00931.x; RA Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A., RA Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C., RA Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B., RA Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H., Spranger S., RA Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.; RT "Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous RT and Costello syndrome."; RL Clin. Genet. 73:62-70(2008). RN [44] RP VARIANT LPRD3 PRO-241, VARIANTS NS7 ARG-241; MET-241; CYS-531 AND VAL-597, RP AND VARIANTS CFC1 PHE-245; PRO-246; ARG-257; LYS-275; GLU-469; PHE-485; RP ASN-499; LYS-501; PRO-525; LEU-595; ARG-599; GLN-601; GLU-638 AND ARG-709. RX PubMed=19206169; DOI=10.1002/humu.20955; RA Sarkozy A., Carta C., Moretti S., Zampino G., Digilio M.C., Pantaleoni F., RA Scioletti A.P., Esposito G., Cordeddu V., Lepri F., Petrangeli V., RA Dentici M.L., Mancini G.M., Selicorni A., Rossi C., Mazzanti L., Marino B., RA Ferrero G.B., Silengo M.C., Memo L., Stanzial F., Faravelli F., Stuppia L., RA Puxeddu E., Gelb B.D., Dallapiccola B., Tartaglia M.; RT "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous RT syndromes: molecular diversity and associated phenotypic spectrum."; RL Hum. Mutat. 30:695-702(2009). RN [45] RP VARIANT CRC GLU-600. RX PubMed=23263490; DOI=10.1038/ng.2503; RG CORGI Consortium; RG WGS500 Consortium; RA Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., RA Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., RA Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., RA Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., RA Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., RA Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., RA Houlston R.S., Tomlinson I.; RT "Germline mutations affecting the proofreading domains of POLE and POLD1 RT predispose to colorectal adenomas and carcinomas."; RL Nat. Genet. 45:136-144(2013). RN [46] RP VARIANT CRC GLU-600. RX PubMed=24455489; DOI=10.3389/fonc.2013.00333; RA D'mello S.A., Flanagan J.U., Green T.N., Leung E.Y., Askarian-Amiri M.E., RA Joseph W.R., McCrystal M.R., Isaacs R.J., Shaw J.H., Furneaux C.E., RA During M.J., Finlay G.J., Baguley B.C., Kalev-Zylinska M.L.; RT "Evidence that GRIN2A mutations in melanoma correlate with decreased RT survival."; RL Front. Oncol. 3:333-333(2014). CC -!- FUNCTION: Protein kinase involved in the transduction of mitogenic CC signals from the cell membrane to the nucleus (Probable). CC Phosphorylates MAP2K1, and thereby activates the MAP kinase signal CC transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates CC PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses CC of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, CC ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, CC ECO:0000269|PubMed:36402789, ECO:0000305}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250}; CC -!- ACTIVITY REGULATION: In quiescent cells, maintained in an inactive CC state via an intramolecular interaction between the protein kinase and CC N-terminal domains. Following mitogen-mediated cell activation, binds CC via its RGB domain to active HRAS (GTP-bound) which releases the CC inhibitory intramolecular interaction between the two domains. This CC allows the MAP2K1-mediated dimerization of KSR1 or KSR2, and BRAF which CC activates BRAF. {ECO:0000269|PubMed:29433126}. CC -!- SUBUNIT: Monomer (PubMed:19710016). Homodimer (PubMed:19710016, CC PubMed:36402789). Heterodimerizes with RAF1, and the heterodimer CC possesses a highly increased kinase activity compared to the respective CC homodimers or monomers (PubMed:19710016). Heterodimerization is CC mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 CC activation can induce a negative feedback that promotes the CC dissociation of the heterodimer by phosphorylating BRAF at Thr-753. CC Heterodimerizes (via N-terminus) with KSR1 (via N-terminus) or KSR2 CC (via N-terminus) in a MAP2K1-dependent manner (PubMed:29433126). CC Interacts with MAP2K1 and MAP2K2 (PubMed:29433126). Found in a complex CC with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14. Interacts with RIT1. CC Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with RAF1, a CC ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH CC (PubMed:19710016). Interacts with PRMT5 (PubMed:21917714). Interacts CC with KSR2 (PubMed:21441910). Interacts with AKAP13, MAP2K1 and KSR1. CC Identified in a complex with AKAP13, MAP2K1 and KSR1 (PubMed:21102438). CC Interacts with FNIP1 and FNIP2 (PubMed:27353360). {ECO:0000250, CC ECO:0000269|PubMed:18287029, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:21102438, ECO:0000269|PubMed:21441910, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:27353360, CC ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:36402789}. CC -!- INTERACTION: CC P15056; P21399: ACO1; NbExp=4; IntAct=EBI-365980, EBI-2847111; CC P15056; P31749: AKT1; NbExp=4; IntAct=EBI-365980, EBI-296087; CC P15056; P10398: ARAF; NbExp=9; IntAct=EBI-365980, EBI-365961; CC P15056; P49407: ARRB1; NbExp=4; IntAct=EBI-365980, EBI-743313; CC P15056; O14965: AURKA; NbExp=5; IntAct=EBI-365980, EBI-448680; CC P15056; P25311: AZGP1; NbExp=3; IntAct=EBI-365980, EBI-2513837; CC P15056; Q92560: BAP1; NbExp=4; IntAct=EBI-365980, EBI-1791447; CC P15056; Q07817: BCL2L1; NbExp=7; IntAct=EBI-365980, EBI-78035; CC P15056; Q92843: BCL2L2; NbExp=4; IntAct=EBI-365980, EBI-707714; CC P15056; P15056: BRAF; NbExp=14; IntAct=EBI-365980, EBI-365980; CC P15056; P40259: CD79B; NbExp=3; IntAct=EBI-365980, EBI-2873732; CC P15056; Q6P1J9: CDC73; NbExp=4; IntAct=EBI-365980, EBI-930143; CC P15056; P42772: CDKN2B; NbExp=4; IntAct=EBI-365980, EBI-711280; CC P15056; P61024: CKS1B; NbExp=4; IntAct=EBI-365980, EBI-456371; CC P15056; P35221: CTNNA1; NbExp=4; IntAct=EBI-365980, EBI-701918; CC P15056; Q13618: CUL3; NbExp=2; IntAct=EBI-365980, EBI-456129; CC P15056; Q16254: E2F4; NbExp=4; IntAct=EBI-365980, EBI-448943; CC P15056; Q9GZV4: EIF5A2; NbExp=4; IntAct=EBI-365980, EBI-748028; CC P15056; Q7Z589: EMSY; NbExp=4; IntAct=EBI-365980, EBI-6598631; CC P15056; P18074: ERCC2; NbExp=3; IntAct=EBI-365980, EBI-6380590; CC P15056; P28715: ERCC5; NbExp=3; IntAct=EBI-365980, EBI-765885; CC P15056; O43524: FOXO3; NbExp=5; IntAct=EBI-365980, EBI-1644164; CC P15056; Q8WXI9: GATAD2B; NbExp=3; IntAct=EBI-365980, EBI-923440; CC P15056; P17174: GOT1; NbExp=5; IntAct=EBI-365980, EBI-727329; CC P15056; P49840: GSK3A; NbExp=6; IntAct=EBI-365980, EBI-1044067; CC P15056; O95714: HERC2; NbExp=2; IntAct=EBI-365980, EBI-1058922; CC P15056; P01112: HRAS; NbExp=9; IntAct=EBI-365980, EBI-350145; CC P15056; P08238: HSP90AB1; NbExp=5; IntAct=EBI-365980, EBI-352572; CC P15056; O75874: IDH1; NbExp=4; IntAct=EBI-365980, EBI-715695; CC P15056; O14920: IKBKB; NbExp=5; IntAct=EBI-365980, EBI-81266; CC P15056; P46940: IQGAP1; NbExp=4; IntAct=EBI-365980, EBI-297509; CC P15056; P27987: ITPKB; NbExp=4; IntAct=EBI-365980, EBI-751388; CC P15056; Q14145: KEAP1; NbExp=16; IntAct=EBI-365980, EBI-751001; CC P15056; Q02750: MAP2K1; NbExp=65; IntAct=EBI-365980, EBI-492564; CC P15056; P36507: MAP2K2; NbExp=13; IntAct=EBI-365980, EBI-1056930; CC P15056; Q13233: MAP3K1; NbExp=2; IntAct=EBI-365980, EBI-49776; CC P15056; Q15759: MAPK11; NbExp=4; IntAct=EBI-365980, EBI-298304; CC P15056; Q16659: MAPK6; NbExp=3; IntAct=EBI-365980, EBI-1384105; CC P15056; Q13164: MAPK7; NbExp=5; IntAct=EBI-365980, EBI-1213983; CC P15056; Q9NX70: MED29; NbExp=4; IntAct=EBI-365980, EBI-394656; CC P15056; O00255: MEN1; NbExp=4; IntAct=EBI-365980, EBI-592789; CC P15056; P07196: NEFL; NbExp=4; IntAct=EBI-365980, EBI-475646; CC P15056; P01111: NRAS; NbExp=8; IntAct=EBI-365980, EBI-721993; CC P15056; Q9BRP1: PDCD2L; NbExp=6; IntAct=EBI-365980, EBI-2372173; CC P15056; P48736: PIK3CG; NbExp=4; IntAct=EBI-365980, EBI-1030384; CC P15056; P27986: PIK3R1; NbExp=3; IntAct=EBI-365980, EBI-79464; CC P15056; P16885: PLCG2; NbExp=4; IntAct=EBI-365980, EBI-617403; CC P15056; Q07864: POLE; NbExp=6; IntAct=EBI-365980, EBI-348526; CC P15056; O15297: PPM1D; NbExp=4; IntAct=EBI-365980, EBI-1551512; CC P15056; Q02156: PRKCE; NbExp=3; IntAct=EBI-365980, EBI-706254; CC P15056; P57735: RAB25; NbExp=4; IntAct=EBI-365980, EBI-1050500; CC P15056; P04049: RAF1; NbExp=73; IntAct=EBI-365980, EBI-365996; CC P15056; Q12967: RALGDS; NbExp=4; IntAct=EBI-365980, EBI-365861; CC P15056; P61224: RAP1B; NbExp=4; IntAct=EBI-365980, EBI-358143; CC P15056; Q15349: RPS6KA2; NbExp=2; IntAct=EBI-365980, EBI-1384149; CC P15056; Q8N122: RPTOR; NbExp=4; IntAct=EBI-365980, EBI-1567928; CC P15056; Q8IYM1: SEPTIN12; NbExp=4; IntAct=EBI-365980, EBI-2585067; CC P15056; P31947: SFN; NbExp=6; IntAct=EBI-365980, EBI-476295; CC P15056; Q9UMX1: SUFU; NbExp=4; IntAct=EBI-365980, EBI-740595; CC P15056; P04637: TP53; NbExp=4; IntAct=EBI-365980, EBI-366083; CC P15056; Q13114: TRAF3; NbExp=2; IntAct=EBI-365980, EBI-357631; CC P15056; P40337: VHL; NbExp=7; IntAct=EBI-365980, EBI-301246; CC P15056; P31946: YWHAB; NbExp=14; IntAct=EBI-365980, EBI-359815; CC P15056; P62258: YWHAE; NbExp=11; IntAct=EBI-365980, EBI-356498; CC P15056; P61981: YWHAG; NbExp=12; IntAct=EBI-365980, EBI-359832; CC P15056; P27348: YWHAQ; NbExp=12; IntAct=EBI-365980, EBI-359854; CC P15056; P63104: YWHAZ; NbExp=15; IntAct=EBI-365980, EBI-347088; CC P15056; Q61097: Ksr1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-1536336; CC P15056; P29678: MAP2K1; Xeno; NbExp=2; IntAct=EBI-365980, EBI-1631983; CC P15056; Q99N57: Raf1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-397757; CC P15056; Q8CGE9: Rgs12; Xeno; NbExp=2; IntAct=EBI-365980, EBI-7340552; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm CC {ECO:0000269|PubMed:19710016}. Cell membrane CC {ECO:0000269|PubMed:19710016}. Note=Colocalizes with RGS14 and RAF1 in CC both the cytoplasm and membranes. {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Brain and testis. CC -!- PTM: Phosphorylation at Ser-365 by SGK1 inhibits its activity (Ref.8, CC PubMed:11410590). Phosphorylation at Thr-753 by MAPK1 CC (PubMed:19710016). Dephosphorylation of Ser-365 by the SHOC2-MRAS-PP1c CC (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and the CC catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or PPP1CC); CC this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35830882). {ECO:0000269|PubMed:11410590, CC ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|Ref.8}. CC -!- PTM: Methylation at Arg-671 decreases stability and kinase activity. CC {ECO:0000269|PubMed:21917714}. CC -!- PTM: Ubiquitinated by RNF149; which leads to proteasomal degradation. CC Polyubiquitinated at Lys-578 in response to EGF. CC {ECO:0000269|PubMed:22628551, ECO:0000269|PubMed:23907581}. CC -!- DISEASE: Note=Defects in BRAF are found in a wide range of cancers. CC {ECO:0000269|PubMed:18974108}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12198537, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, CC ECO:0000269|PubMed:24455489}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that CC starts in cells of the lymph system, which is part of the body's immune CC system. NHLs can occur at any age and are often marked by enlarged CC lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A CC multiple congenital anomaly disorder characterized by a distinctive CC facial appearance, heart defects and intellectual disability. Heart CC defects include pulmonic stenosis, atrial septal defects and CC hypertrophic cardiomyopathy. Some affected individuals present with CC ectodermal abnormalities such as sparse, friable hair, hyperkeratotic CC skin lesions and a generalized ichthyosis-like condition. Typical CC facial features are similar to Noonan syndrome. They include high CC forehead with bitemporal constriction, hypoplastic supraorbital ridges, CC downslanting palpebral fissures, a depressed nasal bridge, and CC posteriorly angulated ears with prominent helices. CC {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, CC ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:19206169}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=A chromosomal aberration involving BRAF is found in CC pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to CC the expression of a KIAA1549-BRAF fusion protein with a constitutive CC kinase activity and inducing cell transformation. CC {ECO:0000269|PubMed:18974108}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD43193.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAQ43111.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43112.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43113.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43114.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43115.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43116.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/828/BRAF"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M95712; AAA35609.2; -; mRNA. DR EMBL; AC006344; AAD43193.1; ALT_SEQ; Genomic_DNA. DR EMBL; EU600171; ACD11489.1; -; Genomic_DNA. DR EMBL; AC006347; AAD15551.1; -; Genomic_DNA. DR EMBL; CH236950; EAL24023.1; -; Genomic_DNA. DR EMBL; BC101757; AAI01758.1; -; mRNA. DR EMBL; BC112079; AAI12080.1; -; mRNA. DR EMBL; X65187; CAA46301.1; -; Genomic_DNA. DR EMBL; M21001; AAA96495.1; -; mRNA. DR EMBL; AM989472; CAQ43111.1; ALT_INIT; mRNA. DR EMBL; AM989473; CAQ43112.1; ALT_INIT; mRNA. DR EMBL; AM989474; CAQ43113.1; ALT_INIT; mRNA. DR EMBL; AM989475; CAQ43114.1; ALT_INIT; mRNA. DR EMBL; AM989476; CAQ43115.1; ALT_INIT; mRNA. DR EMBL; AM989477; CAQ43116.1; ALT_INIT; mRNA. DR CCDS; CCDS5863.1; -. DR PIR; A57977; TVHUBF. DR RefSeq; NP_004324.2; NM_004333.4. DR PDB; 1UWH; X-ray; 2.95 A; A/B=448-723. DR PDB; 1UWJ; X-ray; 3.50 A; A/B=448-723. DR PDB; 2FB8; X-ray; 2.90 A; A/B=445-723. DR PDB; 2L05; NMR; -; A=149-232. DR PDB; 3C4C; X-ray; 2.57 A; A/B=444-721. DR PDB; 3D4Q; X-ray; 2.80 A; A/B=433-726. DR PDB; 3IDP; X-ray; 2.70 A; A/B=434-727. DR PDB; 3II5; X-ray; 2.79 A; A/B=432-726. DR PDB; 3NY5; X-ray; 1.99 A; A/B/C/D=153-237. DR PDB; 3OG7; X-ray; 2.45 A; A/B=448-720. DR PDB; 3PPJ; X-ray; 3.70 A; A/B=432-726. DR PDB; 3PPK; X-ray; 3.00 A; A/B=432-726. DR PDB; 3PRF; X-ray; 2.90 A; A/B=432-726. DR PDB; 3PRI; X-ray; 3.50 A; A/B=432-726. DR PDB; 3PSB; X-ray; 3.40 A; A/B=433-726. DR PDB; 3PSD; X-ray; 3.60 A; A/B=433-726. DR PDB; 3Q4C; X-ray; 3.20 A; A/B=432-726. DR PDB; 3Q96; X-ray; 3.10 A; A/B=446-727. DR PDB; 3SKC; X-ray; 3.20 A; A/B=432-726. DR PDB; 3TV4; X-ray; 3.40 A; A/B=432-726. DR PDB; 3TV6; X-ray; 3.30 A; A/B=432-726. DR PDB; 4CQE; X-ray; 2.30 A; A/B=448-723. DR PDB; 4DBN; X-ray; 3.15 A; A/B=445-726. DR PDB; 4E26; X-ray; 2.55 A; A/B=432-726. DR PDB; 4E4X; X-ray; 3.60 A; A/B=432-726. DR PDB; 4EHE; X-ray; 3.30 A; A/B=432-726. DR PDB; 4EHG; X-ray; 3.50 A; A/B=432-726. DR PDB; 4FC0; X-ray; 2.95 A; A/B=445-726. DR PDB; 4FK3; X-ray; 2.65 A; A/B=444-723. DR PDB; 4G9C; X-ray; 3.50 A; A/B=432-726. DR PDB; 4G9R; X-ray; 3.20 A; A/B=432-726. DR PDB; 4H58; X-ray; 3.10 A; A/B/C=448-722. DR PDB; 4JVG; X-ray; 3.09 A; A/B/C/D=444-723. DR PDB; 4KSP; X-ray; 2.93 A; A/B=445-726. DR PDB; 4KSQ; X-ray; 3.30 A; A/B=445-726. DR PDB; 4MBJ; X-ray; 3.60 A; A/B=432-723. DR PDB; 4MNE; X-ray; 2.85 A; B/C/F/G=432-726. DR PDB; 4MNF; X-ray; 2.80 A; A/B=432-736. DR PDB; 4PP7; X-ray; 3.40 A; A/B=432-726. DR PDB; 4R5Y; X-ray; 3.50 A; A/B=444-723. DR PDB; 4RZV; X-ray; 2.99 A; A/B=443-723. DR PDB; 4RZW; X-ray; 3.49 A; A/B=443-723. DR PDB; 4WO5; X-ray; 2.83 A; A/B=444-723. DR PDB; 4XV1; X-ray; 2.47 A; A/B=444-705. DR PDB; 4XV2; X-ray; 2.50 A; A/B=444-705. DR PDB; 4XV3; X-ray; 2.80 A; A/B=444-705. DR PDB; 4XV9; X-ray; 2.00 A; A=442-705. DR PDB; 4YHT; X-ray; 3.05 A; A/B=449-720. DR PDB; 5C9C; X-ray; 2.70 A; A/B=432-726. DR PDB; 5CSW; X-ray; 2.66 A; A/B=442-721. DR PDB; 5CSX; X-ray; 2.51 A; A=442-721. DR PDB; 5CT7; X-ray; 3.17 A; A/B=445-723. DR PDB; 5FD2; X-ray; 2.89 A; A/B=433-726. DR PDB; 5HI2; X-ray; 2.51 A; A=444-737. DR PDB; 5HID; X-ray; 2.50 A; A/B=444-737. DR PDB; 5HIE; X-ray; 3.00 A; A/B/C/D=432-726. DR PDB; 5ITA; X-ray; 1.95 A; A/B=448-723. DR PDB; 5J17; NMR; -; A=151-232. DR PDB; 5J18; NMR; -; A=151-232. DR PDB; 5J2R; NMR; -; A=151-232. DR PDB; 5JRQ; X-ray; 2.29 A; A/B=448-723. DR PDB; 5JSM; X-ray; 2.19 A; A/B/C/D=448-723. DR PDB; 5JT2; X-ray; 2.70 A; A/B/C/D=448-723. DR PDB; 5VAL; X-ray; 2.26 A; A/B=445-723. DR PDB; 5VAM; X-ray; 2.10 A; A/B=445-723. DR PDB; 5VR3; X-ray; 2.10 A; A=36-114. DR PDB; 5VYK; X-ray; 1.75 A; A/C=36-110. DR PDB; 6B8U; X-ray; 2.68 A; A/B=445-723. DR PDB; 6CAD; X-ray; 2.55 A; A/B=444-723. DR PDB; 6N0P; X-ray; 2.37 A; A/B=449-721. DR PDB; 6N0Q; X-ray; 2.04 A; A/B=445-723. DR PDB; 6NSQ; X-ray; 3.05 A; A/B=444-723. DR PDB; 6NYB; EM; 4.10 A; A=1-766. DR PDB; 6P3D; X-ray; 2.11 A; A=448-721. DR PDB; 6P7G; X-ray; 2.65 A; A/B/C/D=448-723. DR PDB; 6PP9; X-ray; 2.59 A; A=445-723. DR PDB; 6Q0J; EM; 4.90 A; A/B=1-766. DR PDB; 6Q0K; EM; 6.80 A; A/B=1-766. DR PDB; 6Q0T; EM; 5.70 A; A/B=1-766. DR PDB; 6U2G; X-ray; 2.89 A; B=432-726. DR PDB; 6U2H; X-ray; 2.50 A; C/D=447-735. DR PDB; 6UAN; EM; 3.90 A; B/C=1-766. DR PDB; 6UUO; X-ray; 3.29 A; A/B=444-723. DR PDB; 6V2U; X-ray; 3.78 A; A/B=445-723. DR PDB; 6V2W; X-ray; 3.12 A; A=445-723. DR PDB; 6V34; X-ray; 3.15 A; A/B=448-721. DR PDB; 6XAG; X-ray; 3.30 A; C/D=447-735. DR PDB; 6XFP; X-ray; 2.00 A; A=442-721. DR PDB; 6XLO; X-ray; 2.49 A; A/B=442-721. DR PDB; 7K0V; X-ray; 1.93 A; A/B/C/D=444-723. DR PDB; 7M0T; X-ray; 3.19 A; A=445-723. DR PDB; 7M0U; X-ray; 3.09 A; A=445-723. DR PDB; 7M0V; X-ray; 3.16 A; A=445-723. DR PDB; 7M0W; X-ray; 3.09 A; A=445-723. DR PDB; 7M0X; X-ray; 2.47 A; A=445-723. DR PDB; 7M0Y; X-ray; 3.45 A; A=445-723. DR PDB; 7M0Z; X-ray; 3.12 A; A=445-723. DR PDB; 7MFD; EM; 3.66 A; A=1-766. DR PDB; 7MFE; EM; 4.07 A; A=1-766. DR PDB; 7MFF; EM; 3.89 A; A/B=1-766. DR PDB; 7P3V; X-ray; 2.37 A; A/B=448-719. DR PDB; 7SHV; X-ray; 2.88 A; A/B=432-726. DR PDB; 7ZR0; EM; 3.40 A; K=1-766. DR PDB; 7ZR5; EM; 3.90 A; K=1-766. DR PDB; 7ZR6; EM; 4.20 A; K=1-766. DR PDB; 8C7X; X-ray; 1.65 A; A/B=444-721. DR PDB; 8C7Y; X-ray; 1.65 A; A/B=444-721. DR PDB; 8DGS; EM; 4.30 A; A=1-766. DR PDB; 8DGT; EM; 3.90 A; A=1-766. DR PDB; 8F7O; X-ray; 3.54 A; A/B=441-723. DR PDB; 8F7P; X-ray; 2.74 A; A/B=441-723. DR PDB; 8QQG; X-ray; 2.98 A; A/B/C=448-722. DR PDB; 8VSO; X-ray; 1.50 A; P=361-369. DR PDB; 8VYO; EM; 3.74 A; A=1-766. DR PDB; 8VYP; EM; 3.29 A; C=1-766. DR PDB; 8VYQ; EM; 4.43 A; C=360-734. DR PDB; 8VYR; EM; 4.32 A; A=1-766. DR PDB; 8VYS; EM; 3.06 A; A=1-766. DR PDB; 8VYU; EM; 4.07 A; A=1-766. DR PDB; 8VYV; EM; 5.86 A; C=1-766. DR PDB; 8VYW; EM; 4.76 A; C=360-734. DR PDB; 9AXX; X-ray; 2.07 A; B/D=445-723. DR PDB; 9AXY; X-ray; 3.60 A; A=445-723. DR PDB; 9BFB; X-ray; 1.92 A; A=445-723. DR PDB; 9BP8; X-ray; 1.73 A; A=445-723. DR PDB; 9EW6; X-ray; 1.65 A; P=361-369. DR PDB; 9F35; X-ray; 2.30 A; B=360-370. DR PDBsum; 1UWH; -. DR PDBsum; 1UWJ; -. DR PDBsum; 2FB8; -. DR PDBsum; 2L05; -. DR PDBsum; 3C4C; -. DR PDBsum; 3D4Q; -. DR PDBsum; 3IDP; -. DR PDBsum; 3II5; -. DR PDBsum; 3NY5; -. DR PDBsum; 3OG7; -. DR PDBsum; 3PPJ; -. DR PDBsum; 3PPK; -. DR PDBsum; 3PRF; -. DR PDBsum; 3PRI; -. DR PDBsum; 3PSB; -. DR PDBsum; 3PSD; -. DR PDBsum; 3Q4C; -. DR PDBsum; 3Q96; -. DR PDBsum; 3SKC; -. DR PDBsum; 3TV4; -. DR PDBsum; 3TV6; -. DR PDBsum; 4CQE; -. DR PDBsum; 4DBN; -. DR PDBsum; 4E26; -. DR PDBsum; 4E4X; -. DR PDBsum; 4EHE; -. DR PDBsum; 4EHG; -. DR PDBsum; 4FC0; -. DR PDBsum; 4FK3; -. DR PDBsum; 4G9C; -. DR PDBsum; 4G9R; -. DR PDBsum; 4H58; -. DR PDBsum; 4JVG; -. DR PDBsum; 4KSP; -. DR PDBsum; 4KSQ; -. DR PDBsum; 4MBJ; -. DR PDBsum; 4MNE; -. DR PDBsum; 4MNF; -. DR PDBsum; 4PP7; -. DR PDBsum; 4R5Y; -. DR PDBsum; 4RZV; -. DR PDBsum; 4RZW; -. DR PDBsum; 4WO5; -. DR PDBsum; 4XV1; -. DR PDBsum; 4XV2; -. DR PDBsum; 4XV3; -. DR PDBsum; 4XV9; -. DR PDBsum; 4YHT; -. DR PDBsum; 5C9C; -. DR PDBsum; 5CSW; -. DR PDBsum; 5CSX; -. DR PDBsum; 5CT7; -. DR PDBsum; 5FD2; -. DR PDBsum; 5HI2; -. DR PDBsum; 5HID; -. DR PDBsum; 5HIE; -. DR PDBsum; 5ITA; -. DR PDBsum; 5J17; -. DR PDBsum; 5J18; -. DR PDBsum; 5J2R; -. DR PDBsum; 5JRQ; -. DR PDBsum; 5JSM; -. DR PDBsum; 5JT2; -. DR PDBsum; 5VAL; -. DR PDBsum; 5VAM; -. DR PDBsum; 5VR3; -. DR PDBsum; 5VYK; -. DR PDBsum; 6B8U; -. DR PDBsum; 6CAD; -. DR PDBsum; 6N0P; -. DR PDBsum; 6N0Q; -. DR PDBsum; 6NSQ; -. DR PDBsum; 6NYB; -. DR PDBsum; 6P3D; -. DR PDBsum; 6P7G; -. DR PDBsum; 6PP9; -. DR PDBsum; 6Q0J; -. DR PDBsum; 6Q0K; -. DR PDBsum; 6Q0T; -. DR PDBsum; 6U2G; -. DR PDBsum; 6U2H; -. DR PDBsum; 6UAN; -. DR PDBsum; 6UUO; -. DR PDBsum; 6V2U; -. DR PDBsum; 6V2W; -. DR PDBsum; 6V34; -. DR PDBsum; 6XAG; -. DR PDBsum; 6XFP; -. DR PDBsum; 6XLO; -. DR PDBsum; 7K0V; -. DR PDBsum; 7M0T; -. DR PDBsum; 7M0U; -. DR PDBsum; 7M0V; -. DR PDBsum; 7M0W; -. DR PDBsum; 7M0X; -. DR PDBsum; 7M0Y; -. DR PDBsum; 7M0Z; -. DR PDBsum; 7MFD; -. DR PDBsum; 7MFE; -. DR PDBsum; 7MFF; -. DR PDBsum; 7P3V; -. DR PDBsum; 7SHV; -. DR PDBsum; 7ZR0; -. DR PDBsum; 7ZR5; -. DR PDBsum; 7ZR6; -. DR PDBsum; 8C7X; -. DR PDBsum; 8C7Y; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8F7O; -. DR PDBsum; 8F7P; -. DR PDBsum; 8QQG; -. DR PDBsum; 8VSO; -. DR PDBsum; 8VYO; -. DR PDBsum; 8VYP; -. DR PDBsum; 8VYQ; -. DR PDBsum; 8VYR; -. DR PDBsum; 8VYS; -. DR PDBsum; 8VYU; -. DR PDBsum; 8VYV; -. DR PDBsum; 8VYW; -. DR PDBsum; 9AXX; -. DR PDBsum; 9AXY; -. DR PDBsum; 9BFB; -. DR PDBsum; 9BP8; -. DR PDBsum; 9EW6; -. DR PDBsum; 9F35; -. DR AlphaFoldDB; P15056; -. DR BMRB; P15056; -. DR EMDB; EMD-0541; -. DR EMDB; EMD-14875; -. DR EMDB; EMD-14883; -. DR EMDB; EMD-14884; -. DR EMDB; EMD-20550; -. DR EMDB; EMD-20551; -. DR EMDB; EMD-20552; -. DR EMDB; EMD-20708; -. DR EMDB; EMD-23813; -. DR EMDB; EMD-23814; -. DR EMDB; EMD-23815; -. DR EMDB; EMD-27428; -. DR EMDB; EMD-27429; -. DR EMDB; EMD-43673; -. DR EMDB; EMD-43674; -. DR EMDB; EMD-43675; -. DR EMDB; EMD-43676; -. DR EMDB; EMD-43677; -. DR EMDB; EMD-43678; -. DR EMDB; EMD-43679; -. DR EMDB; EMD-43680; -. DR SMR; P15056; -. DR BioGRID; 107141; 185. DR CORUM; P15056; -. DR DIP; DIP-1045N; -. DR FunCoup; P15056; 5390. DR IntAct; P15056; 446. DR MINT; P15056; -. DR STRING; 9606.ENSP00000419060; -. DR BindingDB; P15056; -. DR ChEMBL; CHEMBL5145; -. DR DrugBank; DB08553; (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime. DR DrugBank; DB15068; Agerafenib. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB12854; BMS-908662. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB14773; Lifirafenib. DR DrugBank; DB07000; N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide. DR DrugBank; DB06999; PLX-4720. DR DrugBank; DB16038; PLX8394. DR DrugBank; DB05984; RAF-265. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB08881; Vemurafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P15056; -. DR GuidetoPHARMACOLOGY; 1943; -. DR TCDB; 8.A.23.1.48; the basigin (basigin) family. DR GlyGen; P15056; 1 site. DR iPTMnet; P15056; -. DR PhosphoSitePlus; P15056; -. DR SwissPalm; P15056; -. DR BioMuta; BRAF; -. DR DMDM; 50403720; -. DR CPTAC; CPTAC-3112; -. DR CPTAC; CPTAC-3113; -. DR CPTAC; CPTAC-5771; -. DR CPTAC; CPTAC-5817; -. DR CPTAC; CPTAC-5818; -. DR CPTAC; CPTAC-5819; -. DR CPTAC; CPTAC-5820; -. DR CPTAC; CPTAC-5821; -. DR CPTAC; CPTAC-5822; -. DR CPTAC; non-CPTAC-5352; -. DR CPTAC; non-CPTAC-5353; -. DR CPTAC; non-CPTAC-5354; -. DR CPTAC; non-CPTAC-5355; -. DR CPTAC; non-CPTAC-5356; -. DR CPTAC; non-CPTAC-5357; -. DR CPTAC; non-CPTAC-5727; -. DR CPTAC; non-CPTAC-5728; -. DR CPTAC; non-CPTAC-5729; -. DR jPOST; P15056; -. DR MassIVE; P15056; -. DR PaxDb; 9606-ENSP00000288602; -. DR PeptideAtlas; P15056; -. DR ProteomicsDB; 53102; -. DR Pumba; P15056; -. DR Antibodypedia; 751; 2321 antibodies from 54 providers. DR CPTC; P15056; 7 antibodies. DR DNASU; 673; -. DR Ensembl; ENST00000646891.2; ENSP00000493543.1; ENSG00000157764.15. DR GeneID; 673; -. DR KEGG; hsa:673; -. DR MANE-Select; ENST00000646891.2; ENSP00000493543.1; NM_004333.6; NP_004324.2. DR UCSC; uc003vwc.5; human. DR AGR; HGNC:1097; -. DR CIViC; 673; 6 clinical assertions and 454 evidence items across 166 molecular profiles. DR ClinPGx; PA25408; -. DR CTD; 673; -. DR DisGeNET; 673; -. DR GeneCards; BRAF; -. DR GeneReviews; BRAF; -. DR HGNC; HGNC:1097; BRAF. DR HPA; ENSG00000157764; Low tissue specificity. DR MalaCards; BRAF; -. DR MIM; 114500; phenotype. DR MIM; 115150; phenotype. DR MIM; 164757; gene. DR MIM; 211980; phenotype. DR MIM; 605027; phenotype. DR MIM; 613706; phenotype. DR MIM; 613707; phenotype. DR OpenTargets; ENSG00000157764; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 58017; Classic hairy cell leukemia. DR Orphanet; 54595; Craniopharyngioma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 389; Langerhans cell histiocytosis. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 840; Syringocystadenoma papilliferum. DR VEuPathDB; HostDB:ENSG00000157764; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156154; -. DR HOGENOM; CLU_023684_1_0_1; -. DR InParanoid; P15056; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P15056; 3 GO annotations based on evolutionary models. DR PhylomeDB; P15056; -. DR BRENDA; 2.7.10.2; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P15056; -. DR Reactome; R-HSA-1295596; Spry regulation of FGF signaling. DR Reactome; R-HSA-170968; Frs2-mediated activation. DR Reactome; R-HSA-170984; ARMS-mediated activation. DR Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR SignaLink; P15056; -. DR SIGNOR; P15056; -. DR Agora; ENSG00000157764; -. DR BioGRID-ORCS; 673; 88 hits in 1213 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; BRAF; human. DR EvolutionaryTrace; P15056; -. DR GeneWiki; BRAF_(gene); -. DR GenomeRNAi; 673; -. DR Pharos; P15056; Tclin. DR PRO; PR:P15056; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P15056; protein. DR Bgee; ENSG00000157764; Expressed in buccal mucosa cell and 183 other cell types or tissues. DR ExpressionAtlas; P15056; baseline and differential. DR GO; GO:0044297; C:cell body; IEA:Ensembl. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0043005; C:neuron projection; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0098793; C:presynapse; IEA:GOC. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004708; F:MAP kinase kinase activity; IMP:UniProtKB. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc. DR GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; IEA:Ensembl. DR GO; GO:0043367; P:CD4-positive, alpha-beta T cell differentiation; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:BHF-UCL. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0072577; P:endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IBA:GO_Central. DR GO; GO:0090150; P:establishment of protein localization to membrane; IDA:CACAO. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0060323; P:head morphogenesis; IEA:Ensembl. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IDA:UniProtKB. DR GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0010764; P:negative regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000301; P:negative regulation of synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0048680; P:positive regulation of axon regeneration; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0010828; P:positive regulation of D-glucose transmembrane transport; IDA:CACAO. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0099170; P:postsynaptic modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0045580; P:regulation of T cell differentiation; IEA:Ensembl. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0016079; P:synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd20871; C1_B-Raf; 1. DR CDD; cd17134; RBD_BRAF; 1. DR CDD; cd14062; STKc_Raf; 1. DR DisProt; DP03825; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR PANTHER; PTHR44329:SF240; SERINE_THREONINE-PROTEIN KINASE B-RAF; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Allosteric enzyme; ATP-binding; Cardiomyopathy; KW Cell membrane; Chromosomal rearrangement; Cytoplasm; Deafness; KW Direct protein sequencing; Disease variant; Ectodermal dysplasia; KW Intellectual disability; Isopeptide bond; Kinase; Membrane; Metal-binding; KW Methylation; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation; Zinc; KW Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.8" FT CHAIN 2..766 FT /note="Serine/threonine-protein kinase B-raf" FT /id="PRO_0000085665" FT DOMAIN 155..227 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 457..717 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 234..280 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 1..38 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 308..454 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..13 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 314..341 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 348..363 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..447 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 576 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 235 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 248 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 251 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 261 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 264 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 269 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 272 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 280 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 463..471 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 483 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 380..381 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT SITE 438..439 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 365 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000269|PubMed:11410590, ECO:0000269|Ref.8, FT ECO:0007744|PubMed:23186163" FT MOD_RES 373 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1508179" FT MOD_RES 396 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 446 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 447 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 671 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 729 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 750 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 753 FT /note="Phosphothreonine; by MAPK1" FT /evidence="ECO:0000269|PubMed:19710016" FT CROSSLNK 578 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23907581" FT VARIANT 241 FT /note="T -> M (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058620" FT VARIANT 241 FT /note="T -> P (in CFC1 and LPRD3; dbSNP:rs387906661)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058621" FT VARIANT 241 FT /note="T -> R (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058622" FT VARIANT 244 FT /note="T -> P (in CFC1; dbSNP:rs397507465)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065171" FT VARIANT 245 FT /note="L -> F (in CFC1; dbSNP:rs397507466)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058623" FT VARIANT 246 FT /note="A -> P (in CFC1; dbSNP:rs180177034)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_026113" FT VARIANT 257 FT /note="Q -> R (in CFC1; dbSNP:rs180177035)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_026114" FT VARIANT 262 FT /note="Q -> K (in CFC1; dbSNP:rs397507470)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065172" FT VARIANT 275 FT /note="E -> K (in CFC1; dbSNP:rs2129044284)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058624" FT VARIANT 301 FT /note="P -> S (in dbSNP:rs34776339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040391" FT VARIANT 462 FT /note="R -> I (in CRC; dbSNP:rs180177032)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018613" FT VARIANT 463 FT /note="I -> S (in CRC; dbSNP:rs180177033)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018614" FT VARIANT 464 FT /note="G -> E (in CRC; dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537" FT /id="VAR_018615" FT VARIANT 464 FT /note="G -> V (in a colorectal cancer cell line; elevated FT kinase activity; efficiently induces cell transformation; FT dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018616" FT VARIANT 466 FT /note="G -> A (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018617" FT VARIANT 466 FT /note="G -> E (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018618" FT VARIANT 466 FT /note="G -> V (in LNCR; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919" FT /id="VAR_018512" FT VARIANT 467 FT /note="S -> A (in CFC1; dbSNP:rs869025606)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035096" FT VARIANT 468 FT /note="F -> S (in CFC1; dbSNP:rs397507473)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:18042262" FT /id="VAR_035097" FT VARIANT 469 FT /note="G -> A (in NHL; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:14612909, ECO:0000269|PubMed:17344846" FT /id="VAR_018620" FT VARIANT 469 FT /note="G -> E (in CFC1 and colon cancer; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_018621" FT VARIANT 469 FT /note="G -> R (in NHL; dbSNP:rs121913357)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018622" FT VARIANT 469 FT /note="G -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040392" FT VARIANT 485 FT /note="L -> F (in CFC1; dbSNP:rs180177036)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026115" FT VARIANT 499 FT /note="K -> E (in CFC1; dbSNP:rs180177037)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026116" FT VARIANT 499 FT /note="K -> N (in CFC1; dbSNP:rs397507476)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058625" FT VARIANT 501 FT /note="E -> G (in CFC1; dbSNP:rs180177039)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404" FT /id="VAR_026117" FT VARIANT 501 FT /note="E -> K (in CFC1; dbSNP:rs180177038)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026118" FT VARIANT 525 FT /note="L -> P (in CFC1; dbSNP:rs869025340)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058626" FT VARIANT 531 FT /note="W -> C (in NS7; dbSNP:rs606231228)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058627" FT VARIANT 580 FT /note="N -> D (in CFC1; dbSNP:rs2128999571)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065173" FT VARIANT 581 FT /note="N -> D (in CFC1; dbSNP:rs180177040)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026119" FT VARIANT 581 FT /note="N -> S (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913370)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040393" FT VARIANT 586 FT /note="E -> K (in ovarian cancer; dbSNP:rs121913340)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018623" FT VARIANT 594 FT /note="D -> G (in NHL; dbSNP:rs121913338)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018624" FT VARIANT 595 FT /note="F -> L (in CFC1; also found in colon cancer; FT dbSNP:rs121913341)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_018625" FT VARIANT 596 FT /note="G -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913361)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846" FT /id="VAR_018626" FT VARIANT 596 FT /note="G -> V (in CFC1; dbSNP:rs397507483)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035098" FT VARIANT 597 FT /note="L -> R (in LNCR; also found in an ovarian serous FT carcinoma sample; somatic mutation; dbSNP:rs121913366)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919, ECO:0000269|PubMed:17344846" FT /id="VAR_018513" FT VARIANT 597 FT /note="L -> V (in NS7; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913369)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19206169" FT /id="VAR_018627" FT VARIANT 599 FT /note="T -> R (in CFC1; dbSNP:rs121913375)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058628" FT VARIANT 600 FT /note="V -> D (in a melanoma cell line; requires 2 FT nucleotide substitutions; dbSNP:rs121913377)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018628" FT VARIANT 600 FT /note="V -> E (in CRC; also found in sarcoma, metastatic FT melanoma, ovarian serous carcinoma, pilocytic astrocytoma; FT somatic mutation; most common mutation; constitutive and FT elevated kinase activity; efficiently induces cell FT transformation; suppression of mutation in melanoma causes FT growth arrest and promotes apoptosis; loss of regulation by FT PMRT5; dbSNP:rs113488022)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:14500344, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, FT ECO:0000269|PubMed:24455489" FT /id="VAR_018629" FT VARIANT 601 FT /note="K -> E (in CRC; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018630" FT VARIANT 601 FT /note="K -> Q (in CFC1; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058629" FT VARIANT 638 FT /note="D -> E (in CFC1; dbSNP:rs180177042)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058630" FT VARIANT 709 FT /note="Q -> R (in CFC1; dbSNP:rs397507486)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058631" FT MUTAGEN 53 FT /note="M->D: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 88 FT /note="K->E: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 483 FT /note="K->S: Reduces kinase activity with MAP2K1." FT /evidence="ECO:0000269|PubMed:21441910" FT MUTAGEN 509 FT /note="R->H: Loss of MAP2K1-mediated-BRAF-KSR1 FT dimerization." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 578 FT /note="K->R: Blocks EGF-induced ubiquitination and ERK FT activation." FT /evidence="ECO:0000269|PubMed:23907581" FT MUTAGEN 666 FT /note="I->R: No effect on MAP2K1-mediated-BRAF-KSR1 FT dimerization, however loss of BRAF-mediated phosphorylation FT of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 671 FT /note="R->K: Increased kinase activity and stability in FT response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 766 FT /note="H -> D (in Ref. 11; AAA96495)" FT /evidence="ECO:0000305" FT HELIX 43..68 FT /evidence="ECO:0007829|PDB:5VYK" FT HELIX 76..103 FT /evidence="ECO:0007829|PDB:5VYK" FT STRAND 156..161 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 162..164 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 165..170 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 177..186 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 192..194 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 195..199 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 214..217 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 221..226 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 448..450 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 454..456 FT /evidence="ECO:0007829|PDB:5JRQ" FT STRAND 458..466 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 469..484 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 487..489 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 492..505 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 516..520 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 522..524 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 526..530 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 534..536 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 537..542 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 543..545 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 550..569 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 579..581 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 582..585 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 586..588 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 589..592 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 598..600 FT /evidence="ECO:0007829|PDB:6XFP" FT TURN 602..605 FT /evidence="ECO:0007829|PDB:4RZV" FT HELIX 609..612 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 614..619 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 622..626 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 629..631 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 635..651 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 655..658 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 662..671 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 678..680 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 683..685 FT /evidence="ECO:0007829|PDB:5JRQ" FT HELIX 687..696 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 701..703 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 707..721 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 723..726 FT /evidence="ECO:0007829|PDB:6U2H" SQ SEQUENCE 766 AA; 84437 MW; 0798C2AAB487E813 CRC64; MAALSGGGGG GAEPGQALFN GDMEPEAGAG AGAAASSAAD PAIPEEVWNI KQMIKLTQEH IEALLDKFGG EHNPPSIYLE AYEEYTSKLD ALQQREQQLL ESLGNGTDFS VSSSASMDTV TSSSSSSLSV LPSSLSVFQN PTDVARSNPK SPQKPIVRVF LPNKQRTVVP ARCGVTVRDS LKKALMMRGL IPECCAVYRI QDGEKKPIGW DTDISWLTGE ELHVEVLENV PLTTHNFVRK TFFTLAFCDF CRKLLFQGFR CQTCGYKFHQ RCSTEVPLMC VNYDQLDLLF VSKFFEHHPI PQEEASLAET ALTSGSSPSA PASDSIGPQI LTSPSPSKSI PIPQPFRPAD EDHRNQFGQR DRSSSAPNVH INTIEPVNID DLIRDQGFRG DGGSTTGLSA TPPASLPGSL TNVKALQKSP GPQRERKSSS SSEDRNRMKT LGRRDSSDDW EIPDGQITVG QRIGSGSFGT VYKGKWHGDV AVKMLNVTAP TPQQLQAFKN EVGVLRKTRH VNILLFMGYS TKPQLAIVTQ WCEGSSLYHH LHIIETKFEM IKLIDIARQT AQGMDYLHAK SIIHRDLKSN NIFLHEDLTV KIGDFGLATV KSRWSGSHQF EQLSGSILWM APEVIRMQDK NPYSFQSDVY AFGIVLYELM TGQLPYSNIN NRDQIIFMVG RGYLSPDLSK VRSNCPKAMK RLMAECLKKK RDERPLFPQI LASIELLARS LPKIHRSASE PSLNRAGFQT EDFSLYACAS PKTPIQAGGY GAFPVH // ID COX1_HUMAN Reviewed; 513 AA. AC P00395; Q34770; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 28-JAN-2026, entry version 230. DE RecName: Full=Cytochrome c oxidase subunit 1; DE EC=7.1.1.9; DE AltName: Full=Cytochrome c oxidase polypeptide I; GN Name=MT-CO1; Synonyms=COI, COXI, MTCO1; OS Homo sapiens (Human). OG Mitochondrion. OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=7219534; DOI=10.1038/290457a0; RA Anderson S., Bankier A.T., Barrell B.G., de Bruijn M.H.L., Coulson A.R., RA Drouin J., Eperon I.C., Nierlich D.P., Roe B.A., Sanger F., Schreier P.H., RA Smith A.J.H., Staden R., Young I.G.; RT "Sequence and organization of the human mitochondrial genome."; RL Nature 290:457-465(1981). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-235 AND ALA-415. RC TISSUE=Placenta; RX PubMed=7530363; DOI=10.1073/pnas.92.2.532; RA Horai S., Hayasaka K., Kondo R., Tsugane K., Takahata N.; RT "Recent African origin of modern humans revealed by complete sequences of RT hominoid mitochondrial DNAs."; RL Proc. Natl. Acad. Sci. U.S.A. 92:532-536(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=12949126; DOI=10.1093/molbev/msg230; RA Moilanen J.S., Finnila S., Majamaa K.; RT "Lineage-specific selection in human mtDNA: lack of polymorphisms in a RT segment of MTND5 gene in haplogroup J."; RL Mol. Biol. Evol. 20:2132-2142(2003). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=11130070; DOI=10.1038/35047064; RA Ingman M., Kaessmann H., Paeaebo S., Gyllensten U.; RT "Mitochondrial genome variation and the origin of modern humans."; RL Nature 408:708-713(2000). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=12840039; DOI=10.1101/gr.686603; RA Ingman M., Gyllensten U.; RT "Mitochondrial genome variation and evolutionary history of Australian and RT New Guinean aborigines."; RL Genome Res. 13:1600-1606(2003). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=14760490; DOI=10.1007/s00414-004-0427-6; RA Coble M.D., Just R.S., O'Callaghan J.E., Letmanyi I.H., Peterson C.T., RA Irwin J.A., Parsons T.J.; RT "Single nucleotide polymorphisms over the entire mtDNA genome that increase RT the power of forensic testing in Caucasians."; RL Int. J. Legal Med. 118:137-146(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-187. RX PubMed=6260957; DOI=10.1016/0022-2836(80)90196-5; RA Sanger F., Coulson A.R., Barrell B.G., Smith A.J.H., Roe B.A.; RT "Cloning in single-stranded bacteriophage as an aid to rapid DNA RT sequencing."; RL J. Mol. Biol. 143:161-178(1980). RN [8] RP INVOLVEMENT IN DFNM. RX PubMed=10577941; DOI=10.1086/302658; RA Pandya A., Xia X.J., Erdenetungalag R., Amendola M., Landa B., RA Radnaabazar J., Dangaasuren B., Van Tuyle G., Nance W.E.; RT "Heterogenous point mutations in the mitochondrial tRNA Ser(UCN) precursor RT coexisting with the A1555G mutation in deaf students from Mongolia."; RL Am. J. Hum. Genet. 65:1803-1806(1999). RN [9] RP INTERACTION WITH COA3 AND SMIM20. RX PubMed=26321642; DOI=10.1016/j.celrep.2015.08.009; RA Dennerlein S., Oeljeklaus S., Jans D., Hellwig C., Bareth B., Jakobs S., RA Deckers M., Warscheid B., Rehling P.; RT "MITRAC7 acts as a COX1-specific chaperone and reveals a checkpoint during RT cytochrome c oxidase assembly."; RL Cell Rep. 12:1644-1655(2015). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [11] RP INTERACTION WITH TMEM177. RX PubMed=29154948; DOI=10.1016/j.bbamcr.2017.11.010; RA Lorenzi I., Oeljeklaus S., Aich A., Ronsoer C., Callegari S., Dudek J., RA Warscheid B., Dennerlein S., Rehling P.; RT "The mitochondrial TMEM177 associates with COX20 during COX2 biogenesis."; RL Biochim. Biophys. Acta 1865:323-333(2017). RN [12] RP STRUCTURE BY ELECTRON MICROSCOPY (3.90 ANGSTROMS), AND SUBUNIT. RX PubMed=28844695; DOI=10.1016/j.cell.2017.07.050; RA Guo R., Zong S., Wu M., Gu J., Yang M.; RT "Architecture of human mitochondrial respiratory megacomplex I2III2IV2."; RL Cell 170:1247-1257(2017). RN [13] RP STRUCTURE BY ELECTRON MICROSCOPY (3.60 ANGSTROMS). RX PubMed=30030519; DOI=10.1038/s41422-018-0071-1; RA Zong S., Wu M., Gu J., Liu T., Guo R., Yang M.; RT "Structure of the intact 14-subunit human cytochrome c oxidase."; RL Cell Res. 28:1026-1034(2018). RN [14] RP VARIANTS ALA-10; CYS-94; LEU-155; ALA-224 AND LEU-305. RX PubMed=1757091; DOI=10.1007/bf00206061; RA Marzuki S., Noer A.S., Lertrit P., Thyagarajan D., Kapsa R., RA Utthanaphol P., Byrne E.; RT "Normal variants of human mitochondrial DNA and translation products: the RT building of a reference data base."; RL Hum. Genet. 88:139-145(1991). RN [15] RP VARIANT LHON LYS-GLN-LYS-513 INS. RX PubMed=1322638; RA Brown M.D., Yang C.-C., Trounce I., Torroni A., Lott M.T., Wallace D.C.; RT "A mitochondrial DNA variant, identified in Leber hereditary optic RT neuropathy patients, which extends the amino acid sequence of cytochrome c RT oxidase subunit I."; RL Am. J. Hum. Genet. 51:378-385(1992). RN [16] RP VARIANTS THR-273 AND THR-280, AND POSSIBLE INVOLVEMENT IN ACQUIRED RP IDIOPATHIC SIDEROBLASTIC ANEMIA. RX PubMed=9389715; RA Gattermann N., Retzlaff S., Wang Y.L., Hofhaus G., Heinisch J., Aul C., RA Schneider W.; RT "Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of RT cytochrome c oxidase in two patients with acquired idiopathic sideroblastic RT anemia."; RL Blood 90:4961-4972(1997). RN [17] RP VARIANTS THR-273 AND THR-280, AND POSSIBLE INVOLVEMENT IN ACQUIRED RP IDIOPATHIC SIDEROBLASTIC ANEMIA. RX PubMed=9851701; DOI=10.1046/j.1432-1327.1998.2580132.x; RA Broker S., Meunier B., Rich P., Gattermann N., Hofhaus G.; RT "MtDNA mutations associated with sideroblastic anaemia cause a defect of RT mitochondrial cytochrome c oxidase."; RL Eur. J. Biochem. 258:132-138(1998). RN [18] RP INVOLVEMENT IN RM-MT. RX PubMed=10980727; DOI=10.1212/wnl.55.5.644; RA Karadimas C.L., Greenstein P., Sue C.M., Joseph J.T., Tanji K., RA Haller R.G., Taivassalo T., Davidson M.M., Shanske S., Bonilla E., RA DiMauro S.; RT "Recurrent myoglobinuria due to a nonsense mutation in the COX I gene of RT mitochondrial DNA."; RL Neurology 55:644-649(2000). RN [19] RP VARIANT MT-C4D ILE-196. RX PubMed=12140182; DOI=10.1093/hmg/11.16.1797; RA Varlamov D.A., Kudin A.P., Vielhaber S., Schroeder R., Sassen R., RA Becker A., Kunz D., Haug K., Rebstock J., Heils A., Elger C.E., Kunz W.S.; RT "Metabolic consequences of a novel missense mutation of the mtDNA CO I RT gene."; RL Hum. Mol. Genet. 11:1797-1805(2002). RN [20] RP VARIANT MT-C4D PHE-142, AND CHARACTERIZATION OF VARIANT MT-C4D PHE-142. RX PubMed=16284789; DOI=10.1007/s10048-005-0015-z; RA Lucioli S., Hoffmeier K., Carrozzo R., Tessa A., Ludwig B., RA Santorelli F.M.; RT "Introducing a novel human mtDNA mutation into the Paracoccus denitrificans RT COX I gene explains functional deficits in a patient."; RL Neurogenetics 7:51-57(2006). RN [21] RP VARIANTS CRC ASP-125 AND PRO-458. RX PubMed=16407113; DOI=10.1073/pnas.0505903103; RA Greaves L.C., Preston S.L., Tadrous P.J., Taylor R.W., Barron M.J., RA Oukrif D., Leedham S.J., Deheragoda M., Sasieni P., Novelli M.R., RA Jankowski J.A.Z., Turnbull D.M., Wright N.A., McDonald S.A.C.; RT "Mitochondrial DNA mutations are established in human colonic stem cells, RT and mutated clones expand by crypt fission."; RL Proc. Natl. Acad. Sci. U.S.A. 103:714-719(2006). RN [22] RP CHARACTERIZATION OF VARIANTS CRC ASP-125 AND PRO-458. RX PubMed=19218458; DOI=10.1073/pnas.0811450106; RA Namslauer I., Brzezinski P.; RT "A mitochondrial DNA mutation linked to colon cancer results in proton RT leaks in cytochrome c oxidase."; RL Proc. Natl. Acad. Sci. U.S.A. 106:3402-3407(2009). CC -!- FUNCTION: Component of the cytochrome c oxidase, the last enzyme in the CC mitochondrial electron transport chain which drives oxidative CC phosphorylation. The respiratory chain contains 3 multisubunit CC complexes succinate dehydrogenase (complex II, CII), ubiquinol- CC cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CC CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to CC transfer electrons derived from NADH and succinate to molecular oxygen, CC creating an electrochemical gradient over the inner membrane that CC drives transmembrane transport and the ATP synthase. Cytochrome c CC oxidase is the component of the respiratory chain that catalyzes the CC reduction of oxygen to water. Electrons originating from reduced CC cytochrome c in the intermembrane space (IMS) are transferred via the CC dinuclear copper A center (CU(A)) of subunit 2 and heme A of subunit 1 CC to the active site in subunit 1, a binuclear center (BNC) formed by CC heme A3 and copper B (CU(B)). The BNC reduces molecular oxygen to 2 CC water molecules using 4 electrons from cytochrome c in the IMS and 4 CC protons from the mitochondrial matrix. {ECO:0000250|UniProtKB:P00401}. CC -!- CATALYTIC ACTIVITY: CC Reaction=4 Fe(II)-[cytochrome c] + O2 + 8 H(+)(in) = 4 Fe(III)- CC [cytochrome c] + 2 H2O + 4 H(+)(out); Xref=Rhea:RHEA:11436, CC Rhea:RHEA-COMP:10350, Rhea:RHEA-COMP:14399, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:29033, CC ChEBI:CHEBI:29034; EC=7.1.1.9; CC Evidence={ECO:0000250|UniProtKB:P00401}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:11437; CC Evidence={ECO:0000250|UniProtKB:P00401}; CC -!- COFACTOR: CC Name=heme; Xref=ChEBI:CHEBI:30413; CC Evidence={ECO:0000269|PubMed:30030519}; CC Note=Binds 2 heme A groups non-covalently per subunit. CC {ECO:0000269|PubMed:30030519}; CC -!- COFACTOR: CC Name=Cu cation; Xref=ChEBI:CHEBI:23378; CC Evidence={ECO:0000269|PubMed:30030519}; CC Note=Binds a copper B center. {ECO:0000269|PubMed:30030519}; CC -!- PATHWAY: Energy metabolism; oxidative phosphorylation. CC {ECO:0000250|UniProtKB:P00401}. CC -!- SUBUNIT: Component of the cytochrome c oxidase (complex IV, CIV), a CC multisubunit enzyme composed of 14 subunits. The complex is composed of CC a catalytic core of 3 subunits MT-CO1, MT-CO2 and MT-CO3, encoded in CC the mitochondrial DNA, and 11 supernumerary subunits COX4I1 (or CC COX4I2), COX5A, COX5B, COX6A1 (or COX6A2), COX6B1 (or COX6B2), COX6C, CC COX7A2 (or COX7A1), COX7B, COX7C, COX8A and COXFA4, which are encoded CC in the nuclear genome (PubMed:30030519). The complex exists as a CC monomer or a dimer and forms supercomplexes (SCs) in the inner CC mitochondrial membrane with NADH-ubiquinone oxidoreductase (complex I, CC CI) and ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, CC complex III, CIII), resulting in different assemblies (supercomplex CC SCI(1)III(2)IV(1) and megacomplex MCI(2)III(2)IV(2)) (PubMed:28844695). CC As a newly synthesized protein, rapidly incorporates into a multi- CC subunit assembly intermediate in the inner membrane, called MITRAC CC (mitochondrial translation regulation assembly intermediate of CC cytochrome c oxidase) complex, whose core components are COA3/MITRAC12 CC and COX14. Within the MITRAC complex, interacts with COA3 and with CC SMIM20/MITRAC7; the interaction with SMIM20 stabilizes the newly CC synthesized MT-CO1 and prevents its premature turnover CC (PubMed:26321642). Interacts with TMEM177 in a COX20-dependent manner CC (PubMed:29154948). {ECO:0000269|PubMed:26321642, CC ECO:0000269|PubMed:28844695, ECO:0000269|PubMed:29154948, CC ECO:0000269|PubMed:30030519}. CC -!- INTERACTION: CC P00395; Q9Y2R0: COA3; NbExp=11; IntAct=EBI-2117234, EBI-6570446; CC P00395; P13073: COX4I1; NbExp=3; IntAct=EBI-2117234, EBI-1056574; CC P00395; Q9BVV7: TIMM21; NbExp=3; IntAct=EBI-2117234, EBI-6570759; CC -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane CC {ECO:0000269|PubMed:30030519}; Multi-pass membrane protein CC {ECO:0000269|PubMed:30030519}. CC -!- DISEASE: Leber hereditary optic neuropathy (LHON) [MIM:535000]: A CC maternally inherited form of Leber hereditary optic neuropathy, a CC mitochondrial disease resulting in bilateral painless loss of central CC vision due to selective degeneration of the retinal ganglion cells and CC their axons. The disorder shows incomplete penetrance and male CC predominance. Cardiac conduction defects and neurological defects have CC also been described in some LHON patients. LHON results from primary CC mitochondrial DNA mutations affecting the respiratory chain complexes. CC {ECO:0000269|PubMed:1322638}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=MT-CO1 may play a role in the pathogenesis of acquired CC idiopathic sideroblastic anemia, a disease characterized by inadequate CC formation of heme and excessive accumulation of iron in mitochondria. CC Mitochondrial iron overload may be attributable to mutations of CC mitochondrial DNA because these can cause respiratory chain CC dysfunction, thereby impairing reduction of ferric iron to ferrous CC iron. The reduced form of iron is essential to the last step of CC mitochondrial heme biosynthesis. {ECO:0000269|PubMed:9389715, CC ECO:0000269|PubMed:9851701}. CC -!- DISEASE: Mitochondrial complex IV deficiency (MT-C4D) [MIM:220110]: A CC disorder of the mitochondrial respiratory chain with heterogeneous CC clinical manifestations, ranging from isolated myopathy to severe CC multisystem disease affecting several tissues and organs. Features CC include hypertrophic cardiomyopathy, hepatomegaly and liver CC dysfunction, hypotonia, muscle weakness, exercise intolerance, CC developmental delay, delayed motor development and intellectual CC disability. Some affected individuals manifest a fatal hypertrophic CC cardiomyopathy resulting in neonatal death. A subset of patients CC manifest Leigh syndrome. {ECO:0000269|PubMed:12140182, CC ECO:0000269|PubMed:16284789}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Recurrent myoglobinuria mitochondrial (RM-MT) [MIM:550500]: CC Recurrent myoglobinuria is characterized by recurrent attacks of CC rhabdomyolysis (necrosis or disintegration of skeletal muscle) CC associated with muscle pain and weakness, and followed by excretion of CC myoglobin in the urine. {ECO:0000269|PubMed:10980727}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Deafness, sensorineural, mitochondrial (DFNM) [MIM:500008]: A CC form of non-syndromic deafness with maternal inheritance. Affected CC individuals manifest progressive, postlingual, sensorineural hearing CC loss involving high frequencies. {ECO:0000269|PubMed:10577941}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:16407113, CC ECO:0000269|PubMed:19218458}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- SIMILARITY: Belongs to the heme-copper respiratory oxidase family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; V00662; CAA24028.1; -; Genomic_DNA. DR EMBL; J01415; AAB58945.1; -; Genomic_DNA. DR EMBL; D38112; BAA07292.1; -; Genomic_DNA. DR EMBL; AY339402; AAP89038.1; -; Genomic_DNA. DR EMBL; AY339403; AAP89051.1; -; Genomic_DNA. DR EMBL; AY339404; AAP89064.1; -; Genomic_DNA. DR EMBL; AY339405; AAP89077.1; -; Genomic_DNA. DR EMBL; AY339406; AAP89090.1; -; Genomic_DNA. DR EMBL; AY339407; AAP89103.1; -; Genomic_DNA. DR EMBL; AY339408; AAP89116.1; -; Genomic_DNA. DR EMBL; AY339409; AAP89129.1; -; Genomic_DNA. DR EMBL; AY339410; AAP89142.1; -; Genomic_DNA. DR EMBL; AY339411; AAP89155.1; -; Genomic_DNA. DR EMBL; AY339412; AAP89168.1; -; Genomic_DNA. DR EMBL; AY339421; AAP89285.1; -; Genomic_DNA. DR EMBL; AY339422; AAP89298.1; -; Genomic_DNA. DR EMBL; AY339423; AAP89311.1; -; Genomic_DNA. DR EMBL; AY339424; AAP89324.1; -; Genomic_DNA. DR EMBL; AY339425; AAP89337.1; -; Genomic_DNA. DR EMBL; AY339426; AAP89350.1; -; Genomic_DNA. DR EMBL; AY339427; AAP89363.1; -; Genomic_DNA. DR EMBL; AY339428; AAP89376.1; -; Genomic_DNA. DR EMBL; AY339429; AAP89389.1; -; Genomic_DNA. DR EMBL; AY339430; AAP89402.1; -; Genomic_DNA. DR EMBL; AY339431; AAP89415.1; -; Genomic_DNA. DR EMBL; AY339432; AAP89428.1; -; Genomic_DNA. DR EMBL; AY339433; AAP89441.1; -; Genomic_DNA. DR EMBL; AY339434; AAP89454.1; -; Genomic_DNA. DR EMBL; AY339435; AAP89467.1; -; Genomic_DNA. DR EMBL; AY339436; AAP89480.1; -; Genomic_DNA. DR EMBL; AY339437; AAP89493.1; -; Genomic_DNA. DR EMBL; AY339438; AAP89506.1; -; Genomic_DNA. DR EMBL; AY339439; AAP89519.1; -; Genomic_DNA. DR EMBL; AY339440; AAP89532.1; -; Genomic_DNA. DR EMBL; AY339441; AAP89545.1; -; Genomic_DNA. DR EMBL; AY339442; AAP89558.1; -; Genomic_DNA. DR EMBL; AY339443; AAP89571.1; -; Genomic_DNA. DR EMBL; AY339444; AAP89584.1; -; Genomic_DNA. DR EMBL; AY339445; AAP89597.1; -; Genomic_DNA. DR EMBL; AY339451; AAP89675.1; -; Genomic_DNA. DR EMBL; AY339452; AAP89688.1; -; Genomic_DNA. DR EMBL; AY339453; AAP89701.1; -; Genomic_DNA. DR EMBL; AY339454; AAP89714.1; -; Genomic_DNA. DR EMBL; AY339455; AAP89727.1; -; Genomic_DNA. DR EMBL; AY339456; AAP89740.1; -; Genomic_DNA. DR EMBL; AY339457; AAP89753.1; -; Genomic_DNA. DR EMBL; AY339458; AAP89766.1; -; Genomic_DNA. DR EMBL; AY339459; AAP89779.1; -; Genomic_DNA. DR EMBL; AY339460; AAP89792.1; -; Genomic_DNA. DR EMBL; AY339461; AAP89805.1; -; Genomic_DNA. DR EMBL; AY339462; AAP89818.1; -; Genomic_DNA. DR EMBL; AY339463; AAP89831.1; -; Genomic_DNA. DR EMBL; AY339464; AAP89844.1; -; Genomic_DNA. DR EMBL; AY339465; AAP89857.1; -; Genomic_DNA. DR EMBL; AY339466; AAP89870.1; -; Genomic_DNA. DR EMBL; AY339467; AAP89883.1; -; Genomic_DNA. DR EMBL; AY339468; AAP89896.1; -; Genomic_DNA. DR EMBL; AY339469; AAP89909.1; -; Genomic_DNA. DR EMBL; AY339470; AAP89922.1; -; Genomic_DNA. DR EMBL; AY339471; AAP89935.1; -; Genomic_DNA. DR EMBL; AY339472; AAP89948.1; -; Genomic_DNA. DR EMBL; AY339473; AAP89961.1; -; Genomic_DNA. DR EMBL; AY339474; AAP89974.1; -; Genomic_DNA. DR EMBL; AY339475; AAP89987.1; -; Genomic_DNA. DR EMBL; AY339476; AAP90000.1; -; Genomic_DNA. DR EMBL; AY339477; AAP90013.1; -; Genomic_DNA. DR EMBL; AY339478; AAP90026.1; -; Genomic_DNA. DR EMBL; AY339479; AAP90039.1; -; Genomic_DNA. DR EMBL; AY339480; AAP90052.1; -; Genomic_DNA. DR EMBL; AY339481; AAP90065.1; -; Genomic_DNA. DR EMBL; AY339482; AAP90078.1; -; Genomic_DNA. DR EMBL; AY339483; AAP90091.1; -; Genomic_DNA. DR EMBL; AY339484; AAP90104.1; -; Genomic_DNA. DR EMBL; AY339485; AAP90117.1; -; Genomic_DNA. DR EMBL; AY339486; AAP90130.1; -; Genomic_DNA. DR EMBL; AY339487; AAP90143.1; -; Genomic_DNA. DR EMBL; AY339488; AAP90156.1; -; Genomic_DNA. DR EMBL; AY339489; AAP90169.1; -; Genomic_DNA. DR EMBL; AY339490; AAP90182.1; -; Genomic_DNA. DR EMBL; AY339491; AAP90195.1; -; Genomic_DNA. DR EMBL; AY339492; AAP90208.1; -; Genomic_DNA. DR EMBL; AY339493; AAP90221.1; -; Genomic_DNA. DR EMBL; AY339494; AAP90234.1; -; Genomic_DNA. DR EMBL; AY339495; AAP90247.1; -; Genomic_DNA. DR EMBL; AY339496; AAP90260.1; -; Genomic_DNA. DR EMBL; AY339497; AAP90273.1; -; Genomic_DNA. DR EMBL; AY339498; AAP90286.1; -; Genomic_DNA. DR EMBL; AY339499; AAP90299.1; -; Genomic_DNA. DR EMBL; AY339500; AAP90312.1; -; Genomic_DNA. DR EMBL; AY339501; AAP90325.1; -; Genomic_DNA. DR EMBL; AY339502; AAP90338.1; -; Genomic_DNA. DR EMBL; AY339503; AAP90351.1; -; Genomic_DNA. DR EMBL; AY339504; AAP90364.1; -; Genomic_DNA. DR EMBL; AY339505; AAP90377.1; -; Genomic_DNA. DR EMBL; AY339506; AAP90390.1; -; Genomic_DNA. DR EMBL; AY339507; AAP90403.1; -; Genomic_DNA. DR EMBL; AY339508; AAP90416.1; -; Genomic_DNA. DR EMBL; AY339509; AAP90429.1; -; Genomic_DNA. DR EMBL; AY339510; AAP90442.1; -; Genomic_DNA. DR EMBL; AY339511; AAP90455.1; -; Genomic_DNA. DR EMBL; AY339512; AAP90468.1; -; Genomic_DNA. DR EMBL; AY339513; AAP90481.1; -; Genomic_DNA. DR EMBL; AY339514; AAP90494.1; -; Genomic_DNA. DR EMBL; AY339515; AAP90507.1; -; Genomic_DNA. DR EMBL; AY339516; AAP90520.1; -; Genomic_DNA. DR EMBL; AY339517; AAP90533.1; -; Genomic_DNA. DR EMBL; AY339518; AAP90546.1; -; Genomic_DNA. DR EMBL; AY339519; AAP90559.1; -; Genomic_DNA. DR EMBL; AY339520; AAP90572.1; -; Genomic_DNA. DR EMBL; AY339521; AAP90585.1; -; Genomic_DNA. DR EMBL; AY339522; AAP90598.1; -; Genomic_DNA. DR EMBL; AY339523; AAP90611.1; -; Genomic_DNA. DR EMBL; AY339524; AAP90624.1; -; Genomic_DNA. DR EMBL; AY339525; AAP90637.1; -; Genomic_DNA. DR EMBL; AY339526; AAP90650.1; -; Genomic_DNA. DR EMBL; AY339527; AAP90663.1; -; Genomic_DNA. DR EMBL; AY339528; AAP90676.1; -; Genomic_DNA. DR EMBL; AY339529; AAP90689.1; -; Genomic_DNA. DR EMBL; AY339530; AAP90702.1; -; Genomic_DNA. DR EMBL; AY339531; AAP90715.1; -; Genomic_DNA. DR EMBL; AY339532; AAP90728.1; -; Genomic_DNA. DR EMBL; AY339533; AAP90741.1; -; Genomic_DNA. DR EMBL; AY339534; AAP90754.1; -; Genomic_DNA. DR EMBL; AY339535; AAP90767.1; -; Genomic_DNA. DR EMBL; AY339536; AAP90780.1; -; Genomic_DNA. DR EMBL; AY339537; AAP90793.1; -; Genomic_DNA. DR EMBL; AY339538; AAP90806.1; -; Genomic_DNA. DR EMBL; AY339539; AAP90819.1; -; Genomic_DNA. DR EMBL; AY339540; AAP90832.1; -; Genomic_DNA. DR EMBL; AY339541; AAP90845.1; -; Genomic_DNA. DR EMBL; AY339542; AAP90858.1; -; Genomic_DNA. DR EMBL; AY339543; AAP90871.1; -; Genomic_DNA. DR EMBL; AY339544; AAP90884.1; -; Genomic_DNA. DR EMBL; AY339545; AAP90897.1; -; Genomic_DNA. DR EMBL; AY339546; AAP90910.1; -; Genomic_DNA. DR EMBL; AY339547; AAP90923.1; -; Genomic_DNA. DR EMBL; AY339548; AAP90936.1; -; Genomic_DNA. DR EMBL; AY339549; AAP90949.1; -; Genomic_DNA. DR EMBL; AY339550; AAP90962.1; -; Genomic_DNA. DR EMBL; AY339551; AAP90975.1; -; Genomic_DNA. DR EMBL; AY339552; AAP90988.1; -; Genomic_DNA. DR EMBL; AY339553; AAP91001.1; -; Genomic_DNA. DR EMBL; AY339554; AAP91014.1; -; Genomic_DNA. DR EMBL; AY339555; AAP91027.1; -; Genomic_DNA. DR EMBL; AY339556; AAP91040.1; -; Genomic_DNA. DR EMBL; AY339557; AAP91053.1; -; Genomic_DNA. DR EMBL; AY339558; AAP91066.1; -; Genomic_DNA. DR EMBL; AY339559; AAP91079.1; -; Genomic_DNA. DR EMBL; AY339560; AAP91092.1; -; Genomic_DNA. DR EMBL; AY339563; AAP91131.1; -; Genomic_DNA. DR EMBL; AY339564; AAP91144.1; -; Genomic_DNA. DR EMBL; AY339566; AAP91170.1; -; Genomic_DNA. DR EMBL; AY339567; AAP91183.1; -; Genomic_DNA. DR EMBL; AY339568; AAP91196.1; -; Genomic_DNA. DR EMBL; AY339569; AAP91209.1; -; Genomic_DNA. DR EMBL; AY339570; AAP91222.1; -; Genomic_DNA. DR EMBL; AY339571; AAP91235.1; -; Genomic_DNA. DR EMBL; AY339572; AAP91248.1; -; Genomic_DNA. DR EMBL; AY339573; AAP91261.1; -; Genomic_DNA. DR EMBL; AY339574; AAP91274.1; -; Genomic_DNA. DR EMBL; AY339575; AAP91287.1; -; Genomic_DNA. DR EMBL; AY339576; AAP91300.1; -; Genomic_DNA. DR EMBL; AY339577; AAP91313.1; -; Genomic_DNA. DR EMBL; AY339578; AAP91326.1; -; Genomic_DNA. DR EMBL; AY339579; AAP91339.1; -; Genomic_DNA. DR EMBL; AY339580; AAP91352.1; -; Genomic_DNA. DR EMBL; AY339581; AAP91365.1; -; Genomic_DNA. DR EMBL; AY339582; AAP91378.1; -; Genomic_DNA. DR EMBL; AY339583; AAP91391.1; -; Genomic_DNA. DR EMBL; AY339584; AAP91404.1; -; Genomic_DNA. DR EMBL; AY339585; AAP91417.1; -; Genomic_DNA. DR EMBL; AY339586; AAP91430.1; -; Genomic_DNA. DR EMBL; AY339587; AAP91443.1; -; Genomic_DNA. DR EMBL; AY339588; AAP91456.1; -; Genomic_DNA. DR EMBL; AY339589; AAP91469.1; -; Genomic_DNA. DR EMBL; AY339590; AAP91482.1; -; Genomic_DNA. DR EMBL; AY339591; AAP91495.1; -; Genomic_DNA. DR EMBL; AY339592; AAP91508.1; -; Genomic_DNA. DR EMBL; AY339593; AAP91521.1; -; Genomic_DNA. DR EMBL; AF346963; AAK17209.1; -; Genomic_DNA. DR EMBL; AF346964; AAK17222.1; -; Genomic_DNA. DR EMBL; AF346965; AAK17235.1; -; Genomic_DNA. DR EMBL; AF346966; AAK17248.1; -; Genomic_DNA. DR EMBL; AF346967; AAK17261.1; -; Genomic_DNA. DR EMBL; AF346970; AAK17300.1; -; Genomic_DNA. DR EMBL; AF346971; AAK17313.1; -; Genomic_DNA. DR EMBL; AF346972; AAK17326.1; -; Genomic_DNA. DR EMBL; AF346973; AAK17339.1; -; Genomic_DNA. DR EMBL; AF346974; AAK17352.1; -; Genomic_DNA. DR EMBL; AF346975; AAK17365.1; -; Genomic_DNA. DR EMBL; AF346976; AAK17378.1; -; Genomic_DNA. DR EMBL; AF346977; AAK17391.1; -; Genomic_DNA. DR EMBL; AF346978; AAK17404.1; -; Genomic_DNA. DR EMBL; AF346979; AAK17417.1; -; Genomic_DNA. DR EMBL; AF346980; AAK17430.1; -; Genomic_DNA. DR EMBL; AF346981; AAK17443.1; -; Genomic_DNA. DR EMBL; AF346982; AAK17456.1; -; Genomic_DNA. DR EMBL; AF346983; AAK17469.1; -; Genomic_DNA. DR EMBL; AF346984; AAK17482.1; -; Genomic_DNA. DR EMBL; AF346988; AAK17534.1; -; Genomic_DNA. DR EMBL; AF346989; AAK17547.1; -; Genomic_DNA. DR EMBL; AF346990; AAK17560.1; -; Genomic_DNA. DR EMBL; AF346991; AAK17573.1; -; Genomic_DNA. DR EMBL; AF346993; AAK17599.1; -; Genomic_DNA. DR EMBL; AF346994; AAK17612.1; -; Genomic_DNA. DR EMBL; AF346995; AAK17625.1; -; Genomic_DNA. DR EMBL; AF346998; AAK17664.1; -; Genomic_DNA. DR EMBL; AF347000; AAK17690.1; -; Genomic_DNA. DR EMBL; AF347001; AAK17703.1; -; Genomic_DNA. DR EMBL; AF347003; AAK17729.1; -; Genomic_DNA. DR EMBL; AF347004; AAK17742.1; -; Genomic_DNA. DR EMBL; AF347007; AAK17781.1; -; Genomic_DNA. DR EMBL; AF347010; AAK17820.1; -; Genomic_DNA. DR EMBL; AF347011; AAK17833.1; -; Genomic_DNA. DR EMBL; AF347012; AAK17846.1; -; Genomic_DNA. DR EMBL; AF347013; AAK17859.1; -; Genomic_DNA. DR EMBL; AF347014; AAK17872.1; -; Genomic_DNA. DR EMBL; AF347015; AAK17885.1; -; Genomic_DNA. DR EMBL; AY289051; AAP47882.1; -; Genomic_DNA. DR EMBL; AY289052; AAP47895.1; -; Genomic_DNA. DR EMBL; AY289053; AAP47908.1; -; Genomic_DNA. DR EMBL; AY289055; AAP47934.1; -; Genomic_DNA. DR EMBL; AY289056; AAP47947.1; -; Genomic_DNA. DR EMBL; AY289057; AAP47960.1; -; Genomic_DNA. DR EMBL; AY289058; AAP47973.1; -; Genomic_DNA. DR EMBL; AY289059; AAP47986.1; -; Genomic_DNA. DR EMBL; AY289060; AAP47999.1; -; Genomic_DNA. DR EMBL; AY289061; AAP48012.1; -; Genomic_DNA. DR EMBL; AY289062; AAP48025.1; -; Genomic_DNA. DR EMBL; AY289064; AAP48051.1; -; Genomic_DNA. DR EMBL; AY289065; AAP48064.1; -; Genomic_DNA. DR EMBL; AY289066; AAP48077.1; -; Genomic_DNA. DR EMBL; AY289067; AAP48090.1; -; Genomic_DNA. DR EMBL; AY289068; AAP48103.1; -; Genomic_DNA. DR EMBL; AY289069; AAP48116.1; -; Genomic_DNA. DR EMBL; AY289070; AAP48129.1; -; Genomic_DNA. DR EMBL; AY289071; AAP48142.1; -; Genomic_DNA. DR EMBL; AY289073; AAP48168.1; -; Genomic_DNA. DR EMBL; AY289074; AAP48181.1; -; Genomic_DNA. DR EMBL; AY289075; AAP48194.1; -; Genomic_DNA. DR EMBL; AY289076; AAP48207.1; -; Genomic_DNA. DR EMBL; AY289077; AAP48220.1; -; Genomic_DNA. DR EMBL; AY289078; AAP48233.1; -; Genomic_DNA. DR EMBL; AY289079; AAP48246.1; -; Genomic_DNA. DR EMBL; AY289080; AAP48259.1; -; Genomic_DNA. DR EMBL; AY289081; AAP48272.1; -; Genomic_DNA. DR EMBL; AY289082; AAP48285.1; -; Genomic_DNA. DR EMBL; AY289083; AAP48298.1; -; Genomic_DNA. DR EMBL; AY289084; AAP48311.1; -; Genomic_DNA. DR EMBL; AY289085; AAP48324.1; -; Genomic_DNA. DR EMBL; AY289086; AAP48337.1; -; Genomic_DNA. DR EMBL; AY289088; AAP48363.1; -; Genomic_DNA. DR EMBL; AY289089; AAP48376.1; -; Genomic_DNA. DR EMBL; AY289090; AAP48389.1; -; Genomic_DNA. DR EMBL; AY289092; AAP48415.1; -; Genomic_DNA. DR EMBL; AY289093; AAP48427.1; -; Genomic_DNA. DR EMBL; AY289094; AAP48440.1; -; Genomic_DNA. DR EMBL; AY289095; AAP48453.1; -; Genomic_DNA. DR EMBL; AY289096; AAP48466.1; -; Genomic_DNA. DR EMBL; AY289097; AAP48479.1; -; Genomic_DNA. DR EMBL; AY289098; AAP48492.1; -; Genomic_DNA. DR EMBL; AY289099; AAP48505.1; -; Genomic_DNA. DR EMBL; AY289100; AAP48518.1; -; Genomic_DNA. DR EMBL; AY289101; AAP48531.1; -; Genomic_DNA. DR EMBL; AY289102; AAP48544.1; -; Genomic_DNA. DR EMBL; AY495090; AAR92498.1; -; Genomic_DNA. DR EMBL; AY495091; AAR92511.1; -; Genomic_DNA. DR EMBL; AY495092; AAR92524.1; -; Genomic_DNA. DR EMBL; AY495093; AAR92537.1; -; Genomic_DNA. DR EMBL; AY495094; AAR92550.1; -; Genomic_DNA. DR EMBL; AY495095; AAR92563.1; -; Genomic_DNA. DR EMBL; AY495096; AAR92576.1; -; Genomic_DNA. DR EMBL; AY495097; AAR92589.1; -; Genomic_DNA. DR EMBL; AY495098; AAR92602.1; -; Genomic_DNA. DR EMBL; AY495099; AAR92615.1; -; Genomic_DNA. DR EMBL; AY495100; AAR92628.1; -; Genomic_DNA. DR EMBL; AY495101; AAR92641.1; -; Genomic_DNA. DR EMBL; AY495102; AAR92654.1; -; Genomic_DNA. DR EMBL; AY495103; AAR92667.1; -; Genomic_DNA. DR EMBL; AY495104; AAR92680.1; -; Genomic_DNA. DR EMBL; AY495105; AAR92693.1; -; Genomic_DNA. DR EMBL; AY495106; AAR92706.1; -; Genomic_DNA. DR EMBL; AY495107; AAR92719.1; -; Genomic_DNA. DR EMBL; AY495108; AAR92732.1; -; Genomic_DNA. DR EMBL; AY495109; AAR92745.1; -; Genomic_DNA. DR EMBL; AY495110; AAR92758.1; -; Genomic_DNA. DR EMBL; AY495111; AAR92771.1; -; Genomic_DNA. DR EMBL; AY495112; AAR92784.1; -; Genomic_DNA. DR EMBL; AY495113; AAR92797.1; -; Genomic_DNA. DR EMBL; AY495114; AAR92810.1; -; Genomic_DNA. DR EMBL; AY495116; AAR92836.1; -; Genomic_DNA. DR EMBL; AY495117; AAR92849.1; -; Genomic_DNA. DR EMBL; AY495118; AAR92862.1; -; Genomic_DNA. DR EMBL; AY495119; AAR92875.1; -; Genomic_DNA. DR EMBL; AY495120; AAR92888.1; -; Genomic_DNA. DR EMBL; AY495121; AAR92901.1; -; Genomic_DNA. DR EMBL; AY495122; AAR92914.1; -; Genomic_DNA. DR EMBL; AY495123; AAR92927.1; -; Genomic_DNA. DR EMBL; AY495124; AAR92940.1; -; Genomic_DNA. DR EMBL; AY495125; AAR92953.1; -; Genomic_DNA. DR EMBL; AY495126; AAR92966.1; -; Genomic_DNA. DR EMBL; AY495127; AAR92979.1; -; Genomic_DNA. DR EMBL; AY495128; AAR92992.1; -; Genomic_DNA. DR EMBL; AY495129; AAR93005.1; -; Genomic_DNA. DR EMBL; AY495130; AAR93018.1; -; Genomic_DNA. DR EMBL; AY495131; AAR93031.1; -; Genomic_DNA. DR EMBL; AY495132; AAR93044.1; -; Genomic_DNA. DR EMBL; AY495133; AAR93057.1; -; Genomic_DNA. DR EMBL; AY495134; AAR93070.1; -; Genomic_DNA. DR EMBL; AY495135; AAR93083.1; -; Genomic_DNA. DR EMBL; AY495136; AAR93096.1; -; Genomic_DNA. DR EMBL; AY495137; AAR93109.1; -; Genomic_DNA. DR EMBL; AY495138; AAR93122.1; -; Genomic_DNA. DR EMBL; AY495139; AAR93135.1; -; Genomic_DNA. DR EMBL; AY495140; AAR93148.1; -; Genomic_DNA. DR EMBL; AY495141; AAR93161.1; -; Genomic_DNA. DR EMBL; AY495142; AAR93174.1; -; Genomic_DNA. DR EMBL; AY495143; AAR93187.1; -; Genomic_DNA. DR EMBL; AY495144; AAR93200.1; -; Genomic_DNA. DR EMBL; AY495145; AAR93213.1; -; Genomic_DNA. DR EMBL; AY495147; AAR93239.1; -; Genomic_DNA. DR EMBL; AY495148; AAR93252.1; -; Genomic_DNA. DR EMBL; AY495149; AAR93265.1; -; Genomic_DNA. DR EMBL; AY495150; AAR93278.1; -; Genomic_DNA. DR EMBL; AY495151; AAR93291.1; -; Genomic_DNA. DR EMBL; AY495152; AAR93304.1; -; Genomic_DNA. DR EMBL; AY495153; AAR93317.1; -; Genomic_DNA. DR EMBL; AY495154; AAR93330.1; -; Genomic_DNA. DR EMBL; AY495155; AAR93343.1; -; Genomic_DNA. DR EMBL; AY495156; AAR93356.1; -; Genomic_DNA. DR EMBL; AY495157; AAR93369.1; -; Genomic_DNA. DR EMBL; AY495158; AAR93382.1; -; Genomic_DNA. DR EMBL; AY495159; AAR93395.1; -; Genomic_DNA. DR EMBL; AY495160; AAR93408.1; -; Genomic_DNA. DR EMBL; AY495161; AAR93421.1; -; Genomic_DNA. DR EMBL; AY495162; AAR93434.1; -; Genomic_DNA. DR EMBL; AY495163; AAR93447.1; -; Genomic_DNA. DR EMBL; AY495164; AAR93460.1; -; Genomic_DNA. DR EMBL; AY495165; AAR93473.1; -; Genomic_DNA. DR EMBL; AY495166; AAR93486.1; -; Genomic_DNA. DR EMBL; AY495167; AAR93499.1; -; Genomic_DNA. DR EMBL; AY495168; AAR93512.1; -; Genomic_DNA. DR EMBL; AY495169; AAR93525.1; -; Genomic_DNA. DR EMBL; AY495170; AAR93538.1; -; Genomic_DNA. DR EMBL; AY495171; AAR93551.1; -; Genomic_DNA. DR EMBL; AY495172; AAR93564.1; -; Genomic_DNA. DR EMBL; AY495173; AAR93577.1; -; Genomic_DNA. DR EMBL; AY495174; AAR93590.1; -; Genomic_DNA. DR EMBL; AY495175; AAR93603.1; -; Genomic_DNA. DR EMBL; AY495176; AAR93616.1; -; Genomic_DNA. DR EMBL; AY495177; AAR93629.1; -; Genomic_DNA. DR EMBL; AY495178; AAR93642.1; -; Genomic_DNA. DR EMBL; AY495179; AAR93655.1; -; Genomic_DNA. DR EMBL; AY495180; AAR93668.1; -; Genomic_DNA. DR EMBL; AY495181; AAR93681.1; -; Genomic_DNA. DR EMBL; AY495182; AAR93694.1; -; Genomic_DNA. DR EMBL; AY495183; AAR93707.1; -; Genomic_DNA. DR EMBL; AY495184; AAR93720.1; -; Genomic_DNA. DR EMBL; AY495185; AAR93733.1; -; Genomic_DNA. DR EMBL; AY495186; AAR93746.1; -; Genomic_DNA. DR EMBL; AY495187; AAR93759.1; -; Genomic_DNA. DR EMBL; AY495188; AAR93772.1; -; Genomic_DNA. DR EMBL; AY495189; AAR93785.1; -; Genomic_DNA. DR EMBL; AY495190; AAR93798.1; -; Genomic_DNA. DR EMBL; AY495191; AAR93811.1; -; Genomic_DNA. DR EMBL; AY495192; AAR93824.1; -; Genomic_DNA. DR EMBL; AY495193; AAR93837.1; -; Genomic_DNA. DR EMBL; AY495194; AAR93850.1; -; Genomic_DNA. DR EMBL; AY495195; AAR93863.1; -; Genomic_DNA. DR EMBL; AY495196; AAR93876.1; -; Genomic_DNA. DR EMBL; AY495197; AAR93889.1; -; Genomic_DNA. DR EMBL; AY495198; AAR93902.1; -; Genomic_DNA. DR EMBL; AY495199; AAR93915.1; -; Genomic_DNA. DR EMBL; AY495200; AAR93928.1; -; Genomic_DNA. DR EMBL; AY495201; AAR93941.1; -; Genomic_DNA. DR EMBL; AY495202; AAR93954.1; -; Genomic_DNA. DR EMBL; AY495203; AAR93967.1; -; Genomic_DNA. DR EMBL; AY495204; AAR93980.1; -; Genomic_DNA. DR EMBL; AY495205; AAR93993.1; -; Genomic_DNA. DR EMBL; AY495206; AAR94006.1; -; Genomic_DNA. DR EMBL; AY495207; AAR94019.1; -; Genomic_DNA. DR EMBL; AY495208; AAR94032.1; -; Genomic_DNA. DR EMBL; AY495209; AAR94045.1; -; Genomic_DNA. DR EMBL; AY495210; AAR94058.1; -; Genomic_DNA. DR EMBL; AY495211; AAR94071.1; -; Genomic_DNA. DR EMBL; AY495212; AAR94084.1; -; Genomic_DNA. DR EMBL; AY495213; AAR94097.1; -; Genomic_DNA. DR EMBL; AY495214; AAR94110.1; -; Genomic_DNA. DR EMBL; AY495215; AAR94123.1; -; Genomic_DNA. DR EMBL; AY495216; AAR94136.1; -; Genomic_DNA. DR EMBL; AY495217; AAR94149.1; -; Genomic_DNA. DR EMBL; AY495218; AAR94162.1; -; Genomic_DNA. DR EMBL; AY495219; AAR94175.1; -; Genomic_DNA. DR EMBL; AY495220; AAR94188.1; -; Genomic_DNA. DR EMBL; AY495221; AAR94201.1; -; Genomic_DNA. DR EMBL; AY495222; AAR94214.1; -; Genomic_DNA. DR EMBL; AY495223; AAR94227.1; -; Genomic_DNA. DR EMBL; AY495224; AAR94240.1; -; Genomic_DNA. DR EMBL; AY495225; AAR94253.1; -; Genomic_DNA. DR EMBL; AY495226; AAR94266.1; -; Genomic_DNA. DR EMBL; AY495228; AAR94292.1; -; Genomic_DNA. DR EMBL; AY495230; AAR94318.1; -; Genomic_DNA. DR EMBL; AY495231; AAR94331.1; -; Genomic_DNA. DR EMBL; AY495232; AAR94344.1; -; Genomic_DNA. DR EMBL; AY495233; AAR94357.1; -; Genomic_DNA. DR EMBL; AY495234; AAR94370.1; -; Genomic_DNA. DR EMBL; AY495235; AAR94383.1; -; Genomic_DNA. DR EMBL; AY495236; AAR94396.1; -; Genomic_DNA. DR EMBL; AY495237; AAR94409.1; -; Genomic_DNA. DR EMBL; AY495239; AAR94435.1; -; Genomic_DNA. DR EMBL; AY495240; AAR94448.1; -; Genomic_DNA. DR EMBL; AY495241; AAR94461.1; -; Genomic_DNA. DR EMBL; AY495242; AAR94474.1; -; Genomic_DNA. DR EMBL; AY495243; AAR94487.1; -; Genomic_DNA. DR EMBL; AY495244; AAR94500.1; -; Genomic_DNA. DR EMBL; AY495245; AAR94513.1; -; Genomic_DNA. DR EMBL; AY495246; AAR94526.1; -; Genomic_DNA. DR EMBL; AY495247; AAR94539.1; -; Genomic_DNA. DR EMBL; AY495248; AAR94552.1; -; Genomic_DNA. DR EMBL; AY495249; AAR94565.1; -; Genomic_DNA. DR EMBL; AY495250; AAR94578.1; -; Genomic_DNA. DR EMBL; AY495251; AAR94591.1; -; Genomic_DNA. DR EMBL; AY495252; AAR94604.1; -; Genomic_DNA. DR EMBL; AY495253; AAR94617.1; -; Genomic_DNA. DR EMBL; AY495254; AAR94630.1; -; Genomic_DNA. DR EMBL; AY495255; AAR94643.1; -; Genomic_DNA. DR EMBL; AY495256; AAR94656.1; -; Genomic_DNA. DR EMBL; AY495258; AAR94682.1; -; Genomic_DNA. DR EMBL; AY495259; AAR94695.1; -; Genomic_DNA. DR EMBL; AY495261; AAR94721.1; -; Genomic_DNA. DR EMBL; AY495262; AAR94734.1; -; Genomic_DNA. DR EMBL; AY495263; AAR94747.1; -; Genomic_DNA. DR EMBL; AY495264; AAR94760.1; -; Genomic_DNA. DR EMBL; AY495265; AAR94773.1; -; Genomic_DNA. DR EMBL; AY495266; AAR94786.1; -; Genomic_DNA. DR EMBL; AY495267; AAR94799.1; -; Genomic_DNA. DR EMBL; AY495268; AAR94812.1; -; Genomic_DNA. DR EMBL; AY495269; AAR94825.1; -; Genomic_DNA. DR EMBL; AY495270; AAR94838.1; -; Genomic_DNA. DR EMBL; AY495271; AAR94851.1; -; Genomic_DNA. DR EMBL; AY495272; AAR94864.1; -; Genomic_DNA. DR EMBL; AY495273; AAR94877.1; -; Genomic_DNA. DR EMBL; AY495274; AAR94890.1; -; Genomic_DNA. DR EMBL; AY495275; AAR94903.1; -; Genomic_DNA. DR EMBL; AY495276; AAR94916.1; -; Genomic_DNA. DR EMBL; AY495277; AAR94929.1; -; Genomic_DNA. DR EMBL; AY495278; AAR94942.1; -; Genomic_DNA. DR EMBL; AY495279; AAR94955.1; -; Genomic_DNA. DR EMBL; AY495280; AAR94968.1; -; Genomic_DNA. DR EMBL; AY495281; AAR94981.1; -; Genomic_DNA. DR EMBL; AY495282; AAR94994.1; -; Genomic_DNA. DR EMBL; AY495283; AAR95007.1; -; Genomic_DNA. DR EMBL; AY495284; AAR95020.1; -; Genomic_DNA. DR EMBL; AY495285; AAR95033.1; -; Genomic_DNA. DR EMBL; AY495286; AAR95046.1; -; Genomic_DNA. DR EMBL; AY495287; AAR95059.1; -; Genomic_DNA. DR EMBL; AY495288; AAR95072.1; -; Genomic_DNA. DR EMBL; AY495289; AAR95085.1; -; Genomic_DNA. DR EMBL; AY495290; AAR95098.1; -; Genomic_DNA. DR EMBL; AY495291; AAR95111.1; -; Genomic_DNA. DR EMBL; AY495292; AAR95124.1; -; Genomic_DNA. DR EMBL; AY495293; AAR95137.1; -; Genomic_DNA. DR EMBL; AY495294; AAR95150.1; -; Genomic_DNA. DR EMBL; AY495295; AAR95163.1; -; Genomic_DNA. DR EMBL; AY495297; AAR95189.1; -; Genomic_DNA. DR EMBL; AY495298; AAR95202.1; -; Genomic_DNA. DR EMBL; AY495299; AAR95215.1; -; Genomic_DNA. DR EMBL; AY495300; AAR95228.1; -; Genomic_DNA. DR EMBL; AY495301; AAR95241.1; -; Genomic_DNA. DR EMBL; AY495302; AAR95254.1; -; Genomic_DNA. DR EMBL; AY495303; AAR95267.1; -; Genomic_DNA. DR EMBL; AY495304; AAR95280.1; -; Genomic_DNA. DR EMBL; AY495305; AAR95293.1; -; Genomic_DNA. DR EMBL; AY495306; AAR95306.1; -; Genomic_DNA. DR EMBL; AY495307; AAR95319.1; -; Genomic_DNA. DR EMBL; AY495308; AAR95332.1; -; Genomic_DNA. DR EMBL; AY495309; AAR95345.1; -; Genomic_DNA. DR EMBL; AY495310; AAR95358.1; -; Genomic_DNA. DR EMBL; AY495311; AAR95371.1; -; Genomic_DNA. DR EMBL; AY495312; AAR95384.1; -; Genomic_DNA. DR EMBL; AY495313; AAR95397.1; -; Genomic_DNA. DR EMBL; AY495314; AAR95410.1; -; Genomic_DNA. DR EMBL; AY495315; AAR95423.1; -; Genomic_DNA. DR EMBL; AY495316; AAR95436.1; -; Genomic_DNA. DR EMBL; AY495317; AAR95449.1; -; Genomic_DNA. DR EMBL; AY495318; AAR95462.1; -; Genomic_DNA. DR EMBL; AY495319; AAR95475.1; -; Genomic_DNA. DR EMBL; AY495320; AAR95488.1; -; Genomic_DNA. DR EMBL; AY495322; AAR95514.1; -; Genomic_DNA. DR EMBL; AY495323; AAR95527.1; -; Genomic_DNA. DR EMBL; AY495324; AAR95540.1; -; Genomic_DNA. DR EMBL; AY495325; AAR95553.1; -; Genomic_DNA. DR EMBL; AY495326; AAR95566.1; -; Genomic_DNA. DR EMBL; AY495327; AAR95579.1; -; Genomic_DNA. DR EMBL; AY495328; AAR95592.1; -; Genomic_DNA. DR EMBL; AY495329; AAR95605.1; -; Genomic_DNA. DR EMBL; AY495330; AAR95618.1; -; Genomic_DNA. DR EMBL; M10546; AAA65503.1; -; Genomic_DNA. DR PIR; A00463; ODHU1. DR RefSeq; YP_003024028.1; NC_012920.1. DR PDB; 5Z62; EM; 3.60 A; A=1-513. DR PDBsum; 5Z62; -. DR AlphaFoldDB; P00395; -. DR SMR; P00395; -. DR BioGRID; 110615; 70. DR ComplexPortal; CPX-6123; Mitochondrial respiratory chain complex IV. DR CORUM; P00395; -. DR FunCoup; P00395; 219. DR IntAct; P00395; 65. DR MINT; P00395; -. DR STRING; 9606.ENSP00000354499; -. DR BindingDB; P00395; -. DR ChEMBL; CHEMBL6173; -. DR DrugBank; DB02659; Cholic Acid. DR DrugBank; DB09130; Copper. DR DrugBank; DB06778; Cupric sulfate. DR DrugBank; DB04464; N-Formylmethionine. DR DrugBank; DB09140; Oxygen. DR TCDB; 3.D.4.11.1; the proton-translocating cytochrome oxidase (cox) superfamily. DR GlyCosmos; P00395; 1 site, 1 glycan. DR GlyGen; P00395; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P00395; -. DR PhosphoSitePlus; P00395; -. DR SwissPalm; P00395; -. DR BioMuta; MT-CO1; -. DR DMDM; 116977; -. DR jPOST; P00395; -. DR MassIVE; P00395; -. DR PaxDb; 9606-ENSP00000354499; -. DR PeptideAtlas; P00395; -. DR ProteomicsDB; 51246; -. DR Pumba; P00395; -. DR TopDownProteomics; P00395; -. DR Antibodypedia; 4261; 210 antibodies from 32 providers. DR DNASU; 4512; -. DR Ensembl; ENST00000361624.2; ENSP00000354499.2; ENSG00000198804.2. DR GeneID; 4512; -. DR KEGG; hsa:4512; -. DR AGR; HGNC:7419; -. DR ClinPGx; PA31225; -. DR CTD; 4512; -. DR DisGeNET; 4512; -. DR GeneCards; MT-CO1; -. DR GeneReviews; MT-CO1; -. DR HGNC; HGNC:7419; MT-CO1. DR HPA; ENSG00000198804; Tissue enhanced (heart muscle, tongue). DR MalaCards; MT-CO1; -. DR MIM; 114500; phenotype. DR MIM; 220110; phenotype. DR MIM; 500008; phenotype. DR MIM; 516030; gene. DR MIM; 535000; phenotype. DR MIM; 550500; phenotype. DR OpenTargets; ENSG00000198804; -. DR Orphanet; 99845; Genetic recurrent myoglobinuria. DR Orphanet; 254905; Isolated cytochrome C oxidase deficiency. DR Orphanet; 104; Leber hereditary optic neuropathy. DR Orphanet; 550; MELAS. DR Orphanet; 90641; Rare mitochondrial non-syndromic sensorineural deafness. DR VEuPathDB; HostDB:ENSG00000198804; -. DR eggNOG; KOG4769; Eukaryota. DR GeneTree; ENSGT00390000001518; -. DR HOGENOM; CLU_011899_7_3_1; -. DR InParanoid; P00395; -. DR OMA; WAMMSIG; -. DR PAN-GO; P00395; 4 GO annotations based on evolutionary models. DR PhylomeDB; P00395; -. DR BioCyc; MetaCyc:HS00026-MONOMER; -. DR BRENDA; 7.1.1.9; 2681. DR PathwayCommons; P00395; -. DR Reactome; R-HSA-5419276; Mitochondrial translation termination. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-611105; Respiratory electron transport. DR Reactome; R-HSA-9707564; Cytoprotection by HMOX1. DR Reactome; R-HSA-9837999; Mitochondrial protein degradation. DR Reactome; R-HSA-9864848; Complex IV assembly. DR SignaLink; P00395; -. DR SIGNOR; P00395; -. DR UniPathway; UPA00705; -. DR Agora; ENSG00000198804; -. DR BioGRID-ORCS; 4512; 0 hits in 3 CRISPR screens. DR ChiTaRS; MT-CO1; human. DR GeneWiki; MT-CO1; -. DR GenomeRNAi; 4512; -. DR Pharos; P00395; Tchem. DR PRO; PR:P00395; -. DR Proteomes; UP000005640; Mitochondrion MT. DR RNAct; P00395; protein. DR Bgee; ENSG00000198804; Expressed in right uterine tube and 95 other cell types or tissues. DR ExpressionAtlas; P00395; baseline and differential. DR GO; GO:0005743; C:mitochondrial inner membrane; TAS:Reactome. DR GO; GO:0031966; C:mitochondrial membrane; IDA:ComplexPortal. DR GO; GO:0005739; C:mitochondrion; HTP:FlyBase. DR GO; GO:0045277; C:respiratory chain complex IV; IDA:UniProtKB. DR GO; GO:0004129; F:cytochrome-c oxidase activity; IEA:UniProtKB-EC. DR GO; GO:0020037; F:heme binding; IEA:InterPro. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0009060; P:aerobic respiration; IBA:GO_Central. DR GO; GO:0045333; P:cellular respiration; NAS:ComplexPortal. DR GO; GO:0021549; P:cerebellum development; IEA:Ensembl. DR GO; GO:0006123; P:mitochondrial electron transport, cytochrome c to oxygen; NAS:ComplexPortal. DR GO; GO:0022904; P:respiratory electron transport chain; IBA:GO_Central. DR GO; GO:0046688; P:response to copper ion; IEA:Ensembl. DR GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl. DR GO; GO:0001666; P:response to hypoxia; IEA:Ensembl. DR GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl. DR CDD; cd01663; Cyt_c_Oxidase_I; 1. DR FunFam; 1.20.210.10:FF:000001; Cytochrome c oxidase subunit 1; 1. DR Gene3D; 1.20.210.10; Cytochrome c oxidase-like, subunit I domain; 1. DR InterPro; IPR023616; Cyt_c_oxase-like_su1_dom. DR InterPro; IPR036927; Cyt_c_oxase-like_su1_sf. DR InterPro; IPR000883; Cyt_C_Oxase_1. DR InterPro; IPR023615; Cyt_c_Oxase_su1_BS. DR InterPro; IPR033944; Cyt_c_oxase_su1_dom. DR PANTHER; PTHR10422; CYTOCHROME C OXIDASE SUBUNIT 1; 1. DR PANTHER; PTHR10422:SF18; CYTOCHROME C OXIDASE SUBUNIT 1; 1. DR Pfam; PF00115; COX1; 1. DR PRINTS; PR01165; CYCOXIDASEI. DR SUPFAM; SSF81442; Cytochrome c oxidase subunit I-like; 1. DR PROSITE; PS50855; COX1; 1. DR PROSITE; PS00077; COX1_CUB; 1. PE 1: Evidence at protein level; KW 3D-structure; Calcium; Copper; Deafness; Disease variant; KW Electron transport; Heme; Iron; Leber hereditary optic neuropathy; KW Magnesium; Membrane; Metal-binding; Mitochondrion; KW Mitochondrion inner membrane; Non-syndromic deafness; KW Primary mitochondrial disease; Proteomics identification; KW Reference proteome; Respiratory chain; Sodium; Translocase; Transmembrane; KW Transmembrane helix; Transport. FT CHAIN 1..513 FT /note="Cytochrome c oxidase subunit 1" FT /id="PRO_0000183345" FT TOPO_DOM 1..11 FT /note="Mitochondrial matrix" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 12..40 FT /note="Helical; Name=I" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 41..50 FT /note="Mitochondrial intermembrane" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 51..86 FT /note="Helical; Name=II" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 87..94 FT /note="Mitochondrial matrix" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 95..117 FT /note="Helical; Name=III" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 118..140 FT /note="Mitochondrial intermembrane" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 141..170 FT /note="Helical; Name=IV" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 171..182 FT /note="Mitochondrial matrix" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 183..212 FT /note="Helical; Name=V" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 213..227 FT /note="Mitochondrial intermembrane" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 228..261 FT /note="Helical; Name=VI" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 262..269 FT /note="Mitochondrial matrix" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 270..286 FT /note="Helical; Name=VII" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 287..298 FT /note="Mitochondrial intermembrane" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 299..327 FT /note="Helical; Name=VIII" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 328..335 FT /note="Mitochondrial matrix" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 336..357 FT /note="Helical; Name=IX" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 358..370 FT /note="Mitochondrial intermembrane" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 371..400 FT /note="Helical; Name=X" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 401..406 FT /note="Mitochondrial matrix" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 407..433 FT /note="Helical; Name=XI" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 434..446 FT /note="Mitochondrial intermembrane" FT /evidence="ECO:0000269|PubMed:30030519" FT TRANSMEM 447..478 FT /note="Helical; Name=XII" FT /evidence="ECO:0000250|UniProtKB:P00396" FT TOPO_DOM 479..513 FT /note="Mitochondrial matrix" FT /evidence="ECO:0000269|PubMed:30030519" FT BINDING 40 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /evidence="ECO:0000250|UniProtKB:P00401" FT BINDING 45 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /evidence="ECO:0000250|UniProtKB:P00401" FT BINDING 61 FT /ligand="Fe(II)-heme a" FT /ligand_id="ChEBI:CHEBI:61715" FT /ligand_note="low-spin" FT /ligand_part="Fe" FT /ligand_part_id="ChEBI:CHEBI:18248" FT /note="axial binding residue" FT /evidence="ECO:0000269|PubMed:30030519" FT BINDING 240 FT /ligand="Cu cation" FT /ligand_id="ChEBI:CHEBI:23378" FT /ligand_label="B" FT /evidence="ECO:0000269|PubMed:30030519" FT BINDING 244 FT /ligand="O2" FT /ligand_id="ChEBI:CHEBI:15379" FT /evidence="ECO:0000250|UniProtKB:P00396" FT BINDING 290 FT /ligand="Cu cation" FT /ligand_id="ChEBI:CHEBI:23378" FT /ligand_label="B" FT /evidence="ECO:0000269|PubMed:30030519" FT BINDING 291 FT /ligand="Cu cation" FT /ligand_id="ChEBI:CHEBI:23378" FT /ligand_label="B" FT /evidence="ECO:0000269|PubMed:30030519" FT BINDING 368 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_note="ligand shared with MT-CO2" FT /evidence="ECO:0000269|PubMed:30030519" FT BINDING 369 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_note="ligand shared with MT-CO2" FT /evidence="ECO:0000269|PubMed:30030519" FT BINDING 376 FT /ligand="heme a3" FT /ligand_id="ChEBI:CHEBI:83282" FT /ligand_note="high-spin" FT /ligand_part="Fe" FT /ligand_part_id="ChEBI:CHEBI:18248" FT /note="axial binding residue" FT /evidence="ECO:0000269|PubMed:30030519" FT BINDING 378 FT /ligand="Fe(II)-heme a" FT /ligand_id="ChEBI:CHEBI:61715" FT /ligand_note="low-spin" FT /ligand_part="Fe" FT /ligand_part_id="ChEBI:CHEBI:18248" FT /note="axial binding residue" FT /evidence="ECO:0000269|PubMed:30030519" FT CROSSLNK 240..244 FT /note="1'-histidyl-3'-tyrosine (His-Tyr)" FT /evidence="ECO:0000250|UniProtKB:P00396" FT VARIANT 10 FT /note="T -> A" FT /evidence="ECO:0000269|PubMed:1757091" FT /id="VAR_008566" FT VARIANT 94 FT /note="F -> C" FT /evidence="ECO:0000269|PubMed:1757091" FT /id="VAR_008567" FT VARIANT 125 FT /note="G -> D (in CRC; displays steady-state catalytic FT activity linked to proton pumping that is approximately 34% FT of wild-type; an intrinsic proton leak is find in the FT enzyme, which will lead to decreased overall energy- FT conversion efficiency of the respiratory chain, perturbing FT transport processes such as protein, ion and metabolite FT trafficking; dbSNP:rs281865417)" FT /evidence="ECO:0000269|PubMed:16407113, FT ECO:0000269|PubMed:19218458" FT /id="VAR_064154" FT VARIANT 142 FT /note="S -> F (in MT-C4D; significant decrease in enzyme FT activity; dbSNP:rs267606883)" FT /evidence="ECO:0000269|PubMed:16284789" FT /id="VAR_033055" FT VARIANT 155 FT /note="V -> L (in dbSNP:rs370673798)" FT /evidence="ECO:0000269|PubMed:1757091" FT /id="VAR_008568" FT VARIANT 196 FT /note="L -> I (in MT-C4D; dbSNP:rs28461189)" FT /evidence="ECO:0000269|PubMed:12140182" FT /id="VAR_033056" FT VARIANT 224 FT /note="G -> A" FT /evidence="ECO:0000269|PubMed:1757091" FT /id="VAR_008569" FT VARIANT 235 FT /note="F -> S (in dbSNP:rs2853818)" FT /evidence="ECO:0000269|PubMed:7530363" FT /id="VAR_011342" FT VARIANT 273 FT /note="M -> T (found in two patients with acquired FT idiopathic sideroblastic anemia; dbSNP:rs199476127)" FT /evidence="ECO:0000269|PubMed:9389715, FT ECO:0000269|PubMed:9851701" FT /id="VAR_008385" FT VARIANT 280 FT /note="I -> T (found in two patients with acquired FT idiopathic sideroblastic anemia; dbSNP:rs199476126)" FT /evidence="ECO:0000269|PubMed:9389715, FT ECO:0000269|PubMed:9851701" FT /id="VAR_008386" FT VARIANT 305 FT /note="F -> L (in dbSNP:rs368552121)" FT /evidence="ECO:0000269|PubMed:1757091" FT /id="VAR_008570" FT VARIANT 415 FT /note="T -> A (in dbSNP:rs372136420)" FT /evidence="ECO:0000269|PubMed:7530363" FT /id="VAR_011343" FT VARIANT 458 FT /note="S -> P (in CRC; the mutant is probably not FT expressed, indicating that the amino acid substitution FT results in a severely altered overall structure of the FT enzyme; dbSNP:rs267606884)" FT /evidence="ECO:0000269|PubMed:16407113, FT ECO:0000269|PubMed:19218458" FT /id="VAR_064155" FT VARIANT 513 FT /note="S -> SKQK (in LHON; secondary mutation; does not FT seem to directly cause the disease)" FT /evidence="ECO:0000269|PubMed:1322638" FT /id="VAR_008387" SQ SEQUENCE 513 AA; 57041 MW; DBCBFE808650AE0D CRC64; MFADRWLFST NHKDIGTLYL LFGAWAGVLG TALSLLIRAE LGQPGNLLGN DHIYNVIVTA HAFVMIFFMV MPIMIGGFGN WLVPLMIGAP DMAFPRMNNM SFWLLPPSLL LLLASAMVEA GAGTGWTVYP PLAGNYSHPG ASVDLTIFSL HLAGVSSILG AINFITTIIN MKPPAMTQYQ TPLFVWSVLI TAVLLLLSLP VLAAGITMLL TDRNLNTTFF DPAGGGDPIL YQHLFWFFGH PEVYILILPG FGMISHIVTY YSGKKEPFGY MGMVWAMMSI GFLGFIVWAH HMFTVGMDVD TRAYFTSATM IIAIPTGVKV FSWLATLHGS NMKWSAAVLW ALGFIFLFTV GGLTGIVLAN SSLDIVLHDT YYVVAHFHYV LSMGAVFAIM GGFIHWFPLF SGYTLDQTYA KIHFTIMFIG VNLTFFPQHF LGLSGMPRRY SDYPDAYTTW NILSSVGSFI SLTAVMLMIF MIWEAFASKR KVLMVEEPSM NLEWLYGCPP PYHTFEEPVY MKS // ID RAF1_HUMAN Reviewed; 648 AA. AC P04049; B0LPH8; B2R5N3; Q15278; Q9UC20; DT 01-NOV-1986, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1986, sequence version 1. DT 28-JAN-2026, entry version 269. DE RecName: Full=RAF proto-oncogene serine/threonine-protein kinase {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:17603483}; DE AltName: Full=Proto-oncogene c-RAF; DE Short=cRaf; DE AltName: Full=Raf-1; GN Name=RAF1 {ECO:0000312|HGNC:HGNC:9829}; Synonyms=RAF; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3003687; DOI=10.1093/nar/14.2.1009; RA Bonner T.I., Oppermann H., Seeburg P., Kerby S.B., Gunnell M.A., RA Young A.C., Rapp U.R.; RT "The complete coding sequence of the human raf oncogene and the RT corresponding structure of the c-raf-1 gene."; RL Nucleic Acids Res. 14:1009-1015(1986). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LEU-308. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-308. RG NIEHS SNPs program; RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 228-648. RX PubMed=2993863; DOI=10.1128/mcb.5.6.1400-1407.1985; RA Bonner T.I., Kerby S.B., Sutrave P., Gunnell M.A., Mark G., Rapp U.R.; RT "Structure and biological activity of human homologs of the raf/mil RT oncogene."; RL Mol. Cell. Biol. 5:1400-1407(1985). RN [7] RP PROTEIN SEQUENCE OF 42-53; 60-65; 310-316 AND 564-572, INTERACTION WITH RP PRMT5, METHYLATION AT ARG-563, PHOSPHORYLATION AT SER-289; SER-296; RP SER-301; SER-338 AND SER-621, AND MUTAGENESIS OF ARG-563. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [8] RP PROTEIN SEQUENCE OF 254-278, AND PHOSPHORYLATION AT THR-269. RX PubMed=7477354; DOI=10.1038/378307a0; RA Yao B., Zhang Y., Delikat S., Mathias S., Basu S., Kolesnick R.; RT "Phosphorylation of Raf by ceramide-activated protein kinase."; RL Nature 378:307-310(1995). RN [9] RP PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND TISSUE RP SPECIFICITY. RC TISSUE=Placenta; RX PubMed=1886707; RA Dozier C., Ansieau S., Ferreira E., Coll J., Stehelin D.; RT "An alternatively spliced c-mil/raf mRNA is predominantly expressed in RT chicken muscular tissues and conserved among vertebrate species."; RL Oncogene 6:1307-1311(1991). RN [10] RP PHOSPHORYLATION AT SER-43; SER-259; THR-268; SER-499 AND SER-621. RX PubMed=8349614; DOI=10.1016/s0021-9258(19)85336-x; RA Morrison D.K., Heidecker G., Rapp U.R., Copeland T.D.; RT "Identification of the major phosphorylation sites of the Raf-1 kinase."; RL J. Biol. Chem. 268:17309-17316(1993). RN [11] RP INTERACTION WITH YWHAZ, AND FUNCTION. RX PubMed=9360956; DOI=10.1074/jbc.272.46.28882; RA Dubois T., Rommel C., Howell S., Steinhussen U., Soneji Y., Morrice N., RA Moelling K., Aitken A.; RT "14-3-3 is phosphorylated by casein kinase I on residue 233. RT Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction."; RL J. Biol. Chem. 272:28882-28888(1997). RN [12] RP PHOSPHORYLATION. RX PubMed=9823899; DOI=10.1038/24184; RA King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., RA Marshall M.S.; RT "The protein kinase Pak3 positively regulates Raf-1 activity through RT phosphorylation of serine 338."; RL Nature 396:180-183(1998). RN [13] RP ERRATUM OF PUBMED:9823899. RA King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., RA Marshall M.S.; RL Nature 406:439-439(2000). RN [14] RP PHOSPHORYLATION AT SER-259 BY PKB/AKT1, ACTIVITY REGULATION, AND RP INTERACTION WITH PKB/AKT1. RX PubMed=10576742; DOI=10.1126/science.286.5445.1741; RA Zimmermann S., Moelling K.; RT "Phosphorylation and regulation of Raf by Akt (protein kinase B)."; RL Science 286:1741-1744(1999). RN [15] RP PHOSPHORYLATION AT SER-259 AND SER-621, DEPHOSPHORYLATION AT SER-43; RP SER-259 AND SER-621, ACTIVITY REGULATION, AND INTERACTION WITH PPP2CA AND RP PPP2R1B. RX PubMed=10801873; DOI=10.1074/jbc.m003259200; RA Abraham D., Podar K., Pacher M., Kubicek M., Welzel N., Hemmings B.A., RA Dilworth S.M., Mischak H., Kolch W., Baccarini M.; RT "Raf-1-associated protein phosphatase 2A as a positive regulator of kinase RT activation."; RL J. Biol. Chem. 275:22300-22304(2000). RN [16] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-491 AND SER-494. RX PubMed=11447113; DOI=10.1093/emboj/20.14.3716; RA Chong H., Lee J., Guan K.L.; RT "Positive and negative regulation of Raf kinase activity and function by RT phosphorylation."; RL EMBO J. 20:3716-3727(2001). RN [17] RP FUNCTION, AND INTERACTION WITH MAP3K5/ASK1. RX PubMed=11427728; DOI=10.1073/pnas.141224398; RA Chen J., Fujii K., Zhang L., Roberts T., Fu H.; RT "Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating RT kinase 1 through a MEK-ERK independent mechanism."; RL Proc. Natl. Acad. Sci. U.S.A. 98:7783-7788(2001). RN [18] RP FUNCTION IN PHOSPHORYLATION OF PPP1R12A, AND INTERACTION WITH PPP1R12A. RX PubMed=11719507; DOI=10.1074/jbc.m106343200; RA Broustas C.G., Grammatikakis N., Eto M., Dent P., Brautigan D.L., Kasid U.; RT "Phosphorylation of the myosin-binding subunit of myosin phosphatase by RT Raf-1 and inhibition of phosphatase activity."; RL J. Biol. Chem. 277:3053-3059(2002). RN [19] RP PHOSPHORYLATION AT SER-338 BY PAK1, ACTIVITY REGULATION, AND INTERACTION RP WITH PAK1. RX PubMed=11733498; DOI=10.1074/jbc.m110000200; RA Zang M., Hayne C., Luo Z.; RT "Interaction between active Pak1 and Raf-1 is necessary for phosphorylation RT and activation of Raf-1."; RL J. Biol. Chem. 277:4395-4405(2002). RN [20] RP PHOSPHORYLATION AT SER-259, DEPHOSPHORYLATION AT SER-259, AND SUBCELLULAR RP LOCATION. RX PubMed=11756411; DOI=10.1074/jbc.m108733200; RA Kubicek M., Pacher M., Abraham D., Podar K., Eulitz M., Baccarini M.; RT "Dephosphorylation of Ser-259 regulates Raf-1 membrane association."; RL J. Biol. Chem. 277:7913-7919(2002). RN [21] RP COMPETITION WITH RIN1. RX PubMed=11784866; DOI=10.1128/mcb.22.3.916-926.2001; RA Wang Y., Waldron R.T., Dhaka A., Patel A., Riley M.M., Rozengurt E., RA Colicelli J.; RT "The RAS effector RIN1 directly competes with RAF and is regulated by 14-3- RT 3 proteins."; RL Mol. Cell. Biol. 22:916-926(2002). RN [22] RP ACTIVITY REGULATION, AND INTERACTION WITH SPRY2 AND SPRY4. RX PubMed=12717443; DOI=10.1038/ncb978; RA Sasaki A., Taketomi T., Kato R., Saeki K., Nonami A., Sasaki M., RA Kuriyama M., Saito N., Shibuya M., Yoshimura A.; RT "Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to RT Raf1."; RL Nat. Cell Biol. 5:427-432(2003). RN [23] RP PHOSPHORYLATION AT SER-259. RX PubMed=15047712; DOI=10.1074/jbc.m314192200; RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RT "LGI1, a putative tumor metastasis suppressor gene, controls in vitro RT invasiveness and expression of matrix metalloproteinases in glioma cells RT through the ERK1/2 pathway."; RL J. Biol. Chem. 279:23151-23157(2004). RN [24] RP ERRATUM OF PUBMED:15047712. RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RL J. Biol. Chem. 282:2752-2752(2007). RN [25] RP FUNCTION IN PHOSPHORYLATION OF ADCY2; ADCY5 AND ADCY6, AND INTERACTION WITH RP ADCY2; ADCY5 AND ADCY6. RX PubMed=15385642; DOI=10.1124/mol.66.4.921; RA Ding Q., Gros R., Gray I.D., Taussig R., Ferguson S.S., Feldman R.D.; RT "Raf kinase activation of adenylyl cyclases: isoform-selective RT regulation."; RL Mol. Pharmacol. 66:921-928(2004). RN [26] RP INTERACTION WITH STK3/MST2, AND FUNCTION. RX PubMed=15618521; DOI=10.1126/science.1103233; RA O'Neill E., Rushworth L., Baccarini M., Kolch W.; RT "Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene RT product Raf-1."; RL Science 306:2267-2270(2004). RN [27] RP INTERACTION WITH RCAN1/DSCR1. RX PubMed=15935327; DOI=10.1016/j.abb.2005.05.002; RA Cho Y.J., Abe M., Kim S.Y., Sato Y.; RT "Raf-1 is a binding partner of DSCR1."; RL Arch. Biochem. Biophys. 439:121-128(2005). RN [28] RP REVIEW ON FUNCTION. RX PubMed=15943972; DOI=10.1016/j.febslet.2005.03.024; RA Baccarini M.; RT "Second nature: biological functions of the Raf-1 'kinase'."; RL FEBS Lett. 579:3271-3277(2005). RN [29] RP FUNCTION IN PHOSPHORYLATION OF BAD, PHOSPHORYLATION AT SER-338 AND SER-339 RP BY PAK1, SUBCELLULAR LOCATION, AND INTERACTION WITH BCL2. RX PubMed=15849194; DOI=10.1074/jbc.m413374200; RA Jin S., Zhuo Y., Guo W., Field J.; RT "p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates RT its mitochondrial localization, phosphorylation of BAD, and Bcl-2 RT association."; RL J. Biol. Chem. 280:24698-24705(2005). RN [30] RP PHOSPHORYLATION AT SER-471. RX PubMed=16093354; DOI=10.1091/mbc.e05-02-0090; RA Zhu J., Balan V., Bronisz A., Balan K., Sun H., Leicht D.T., Luo Z., RA Qin J., Avruch J., Tzivion G.; RT "Identification of Raf-1 S471 as a novel phosphorylation site critical for RT Raf-1 and B-Raf kinase activities and for MEK binding."; RL Mol. Biol. Cell 16:4733-4744(2005). RN [31] RP IDENTIFICATION IN A COMPLEX WITH PP1CA; PPP1CB; PPP1CC; SHOC2 AND MRAS, RP PHOSPHORYLATION AT SER-259, AND CHARACTERIZATION OF VARIANT ALA-259. RX PubMed=16630891; DOI=10.1016/j.molcel.2006.03.027; RA Rodriguez-Viciana P., Oses-Prieto J., Burlingame A., Fried M., RA McCormick F.; RT "A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit RT of PP1 functions as an M-Ras effector to modulate Raf activity."; RL Mol. Cell 22:217-230(2006). RN [32] RP SUBUNIT. RX PubMed=16508002; DOI=10.1128/mcb.26.6.2262-2272.2006; RA Rushworth L.K., Hindley A.D., O'Neill E., Kolch W.; RT "Regulation and role of Raf-1/B-Raf heterodimerization."; RL Mol. Cell. Biol. 26:2262-2272(2006). RN [33] RP FUNCTION AS KINASE, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-259; RP SER-338; TYR-340; TYR-341 AND SER-621, DEPHOSPHORYLATION AT SER-338 BY RP PPP5C, AND MUTAGENESIS OF 338-SER-SER-339; 340-TYR-TYR-341; THR-491 AND RP SER-494. RX PubMed=16892053; DOI=10.1038/ncb1465; RA von Kriegsheim A., Pitt A., Grindlay G.J., Kolch W., Dhillon A.S.; RT "Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5."; RL Nat. Cell Biol. 8:1011-1016(2006). RN [34] RP REVIEW ON REGULATION. RX PubMed=17218791; DOI=10.4161/cc.6.1.3593; RA Dhillon A.S., von Kriegsheim A., Grindlay J., Kolch W.; RT "Phosphatase and feedback regulation of Raf-1 signaling."; RL Cell Cycle 6:3-7(2007). RN [35] RP FUNCTION. RX PubMed=16924233; DOI=10.1038/sj.onc.1209902; RA Wang Z., Wade P., Mandell K.J., Akyildiz A., Parkos C.A., Mrsny R.J., RA Nusrat A.; RT "Raf 1 represses expression of the tight junction protein occludin via RT activation of the zinc-finger transcription factor slug."; RL Oncogene 26:1222-1230(2007). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-252, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [37] RP ACTIVITY REGULATION, AND INTERACTION WITH PEBP1/RKIP. RX PubMed=18294816; DOI=10.1016/j.cellsig.2008.01.012; RA Rath O., Park S., Tang H.H., Banfield M.J., Brady R.L., Lee Y.C., RA Dignam J.D., Sedivy J.M., Kolch W., Yeung K.C.; RT "The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the RT phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated RT phosphorylation of MEK."; RL Cell. Signal. 20:935-941(2008). RN [38] RP PHOSPHORYLATION AT SER-338 BY PAK5. RX PubMed=18465753; DOI=10.1002/jcb.21809; RA Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.; RT "p21 activated kinase 5 activates Raf-1 and targets it to mitochondria."; RL J. Cell. Biochem. 105:167-175(2008). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [40] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP SUBCELLULAR LOCATION. RX PubMed=19298812; DOI=10.1016/j.yexcr.2009.03.004; RA Smith J., Bunaciu R.P., Reiterer G., Coder D., George T., Asaly M., Yen A.; RT "Retinoic acid induces nuclear accumulation of Raf1 during differentiation RT of HL-60 cells."; RL Exp. Cell Res. 315:2241-2248(2009). RN [43] RP ACTIVITY REGULATION, SUBUNIT, SUBCELLULAR LOCATION, AND INTERACTION WITH RP DGKH. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289 AND SER-301, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [45] RP REVIEW. RX PubMed=20674547; DOI=10.1016/j.bbrc.2010.07.092; RA Roskoski R. Jr.; RT "RAF protein-serine/threonine kinases: structure and regulation."; RL Biochem. Biophys. Res. Commun. 399:313-317(2010). RN [46] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [47] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [48] RP REVIEW. RX PubMed=21779496; DOI=10.1177/1947601911407323; RA Matallanas D., Birtwistle M., Romano D., Zebisch A., Rauch J., RA von Kriegsheim A., Kolch W.; RT "Raf family kinases: old dogs have learned new tricks."; RL Genes Cancer 2:232-260(2011). RN [49] RP MUTAGENESIS OF LYS-375, AND INTERACTION WITH NEK10 AND MAP2K1. RX PubMed=20956560; DOI=10.1128/mcb.00648-10; RA Moniz L.S., Stambolic V.; RT "Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response RT to UV irradiation."; RL Mol. Cell. Biol. 31:30-42(2011). RN [50] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [51] RP INTERACTION WITH FAM83B. RX PubMed=22886302; DOI=10.1172/jci60517; RA Cipriano R., Graham J., Miskimen K.L., Bryson B.L., Bruntz R.C., RA Scott S.A., Brown H.A., Stark G.R., Jackson M.W.; RT "FAM83B mediates EGFR- and RAS-driven oncogenic transformation."; RL J. Clin. Invest. 122:3197-3210(2012). RN [52] RP INTERACTION WITH GLS. RX PubMed=22538822; DOI=10.1073/pnas.1116573109; RA Thangavelu K., Pan C.Q., Karlberg T., Balaji G., Uttamchandani M., RA Suresh V., Schuler H., Low B.C., Sivaraman J.; RT "Structural basis for the allosteric inhibitory mechanism of human kidney- RT type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in RT cancer cell metabolism."; RL Proc. Natl. Acad. Sci. U.S.A. 109:7705-7710(2012). RN [53] RP INTERACTION WITH MFHAS1. RX PubMed=23327923; DOI=10.1182/blood-2011-10-385252; RA Kumkhaek C., Aerbajinai W., Liu W., Zhu J., Uchida N., Kurlander R., RA Hsieh M.M., Tisdale J.F., Rodgers G.P.; RT "MASL1 induces erythroid differentiation in human erythropoietin-dependent RT CD34+ cells through the Raf/MEK/ERK pathway."; RL Blood 121:3216-3227(2013). RN [54] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296; SER-301 AND SER-642, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [55] RP INTERACTION WITH PDE8A. RX PubMed=23509299; DOI=10.1073/pnas.1303004110; RA Brown K.M., Day J.P., Huston E., Zimmermann B., Hampel K., Christian F., RA Romano D., Terhzaz S., Lee L.C., Willis M.J., Morton D.B., Beavo J.A., RA Shimizu-Albergine M., Davies S.A., Kolch W., Houslay M.D., Baillie G.S.; RT "Phosphodiesterase-8A binds to and regulates Raf-1 kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 110:E1533-E1542(2013). RN [56] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [57] RP IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; CDC37; PPP5C; TSC1; TSC2; RP AKT; CDK4 AND NR3C1. RX PubMed=29127155; DOI=10.15252/embj.201796700; RA Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L., RA Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H., RA Bourboulia D., Bratslavsky G., Wong M., Mollapour M.; RT "Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding RT of kinase and non-kinase clients."; RL EMBO J. 36:3650-3665(2017). RN [58] RP INTERACTION WITH LZTR1. RX PubMed=30368668; DOI=10.1007/s00439-018-1951-7; RA Umeki I., Niihori T., Abe T., Kanno S.I., Okamoto N., Mizuno S., RA Kurosawa K., Nagasaki K., Yoshida M., Ohashi H., Inoue S.I., Matsubara Y., RA Fujiwara I., Kure S., Aoki Y.; RT "Delineation of LZTR1 mutation-positive patients with Noonan syndrome and RT identification of LZTR1 binding to RAF1-PPP1CB complexes."; RL Hum. Genet. 138:21-35(2019). RN [59] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [60] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [61] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [62] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [63] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 51-131. RX PubMed=7791872; DOI=10.1038/375554a0; RA Nassar N., Horn G., Herrmann C., Scherer A., McCormick F., Wittinghofer A.; RT "The 2.2 A crystal structure of the Ras-binding domain of the RT serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue."; RL Nature 375:554-560(1995). RN [64] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 56-131. RX PubMed=8756332; DOI=10.1038/nsb0896-723; RA Nassar N., Horn G., Herrmann C., Block C., Janknecht R., Wittinghofer A.; RT "Ras/Rap effector specificity determined by charge reversal."; RL Nat. Struct. Biol. 3:723-729(1996). RN [65] RP STRUCTURE BY NMR OF 55-132. RX PubMed=7766599; DOI=10.1021/bi00021a001; RA Emerson S.D., Madison V.S., Palermo R.E., Waugh D.S., Scheffler J.E., RA Tsao K.L., Kiefer S.E., Liu S.P., Fry D.C.; RT "Solution structure of the Ras-binding domain of c-Raf-1 and identification RT of its Ras interaction surface."; RL Biochemistry 34:6911-6918(1995). RN [66] RP STRUCTURE BY NMR OF 136-187. RX PubMed=8710867; DOI=10.1073/pnas.93.16.8312; RA Mott H.R., Carpenter J.W., Zhong S., Ghosh S., Bell R.M., Campbell S.L.; RT "The solution structure of the Raf-1 cysteine-rich domain: a novel ras and RT phospholipid binding site."; RL Proc. Natl. Acad. Sci. U.S.A. 93:8312-8317(1996). RN [67] RP VARIANTS NS5 SER-256; LEU-257; PHE-259; ARG-260; LEU-261; SER-261; ASN-486; RP GLY-486; ILE-491; ARG-491 AND THR-612, VARIANT HYPERTROPHIC CARDIOMYOPATHY RP ILE-260, VARIANTS LPRD2 LEU-257 AND VAL-613, CHARACTERIZATION OF VARIANTS RP NS5 SER-261; ASN-486 AND ILE-491, CHARACTERIZATION OF VARIANT LPRD2 RP VAL-613, AND CATALYTIC ACTIVITY. RX PubMed=17603483; DOI=10.1038/ng2073; RA Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K., Martinelli S., RA Pogna E.A., Schackwitz W., Ustaszewska A., Landstrom A., Bos J.M., RA Ommen S.R., Esposito G., Lepri F., Faul C., Mundel P., Lopez Siguero J.P., RA Tenconi R., Selicorni A., Rossi C., Mazzanti L., Torrente I., Marino B., RA Digilio M.C., Zampino G., Ackerman M.J., Dallapiccola B., Tartaglia M., RA Gelb B.D.; RT "Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with RT hypertrophic cardiomyopathy."; RL Nat. Genet. 39:1007-1012(2007). RN [68] RP VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND VAL-613, AND RP CHARACTERIZATION OF VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND RP VAL-613. RX PubMed=17603482; DOI=10.1038/ng2078; RA Razzaque M.A., Nishizawa T., Komoike Y., Yagi H., Furutani M., Amo R., RA Kamisago M., Momma K., Katayama H., Nakagawa M., Fujiwara Y., RA Matsushima M., Mizuno K., Tokuyama M., Hirota H., Muneuchi J., RA Higashinakagawa T., Matsuoka R.; RT "Germline gain-of-function mutations in RAF1 cause Noonan syndrome."; RL Nat. Genet. 39:1013-1017(2007). RN [69] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-259 AND HIS-335. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [70] RP VARIANT NS5 SER-261. RX PubMed=20683980; DOI=10.1002/ajmg.a.33564; RA Longoni M., Moncini S., Cisternino M., Morella I.M., Ferraiuolo S., RA Russo S., Mannarino S., Brazzelli V., Coi P., Zippel R., Venturin M., RA Riva P.; RT "Noonan syndrome associated with both a new Jnk-activating familial SOS1 RT and a de novo RAF1 mutations."; RL Am. J. Med. Genet. A 152:2176-2184(2010). RN [71] RP INVOLVEMENT IN CMD1NN, VARIANTS CMD1NN THR-237; ALA-310; ALA-332; PRO-603; RP ARG-626 AND MET-641, AND CHARACTERIZATION OF VARIANTS CMD1NN THR-237; RP ALA-310; ALA-332; PRO-603; ARG-626 AND MET-641. RX PubMed=24777450; DOI=10.1038/ng.2963; RA Dhandapany P.S., Razzaque M.A., Muthusami U., Kunnoth S., Edwards J.J., RA Mulero-Navarro S., Riess I., Pardo S., Sheng J., Rani D.S., Rani B., RA Govindaraj P., Flex E., Yokota T., Furutani M., Nishizawa T., Nakanishi T., RA Robbins J., Limongelli G., Hajjar R.J., Lebeche D., Bahl A., Khullar M., RA Rathinavel A., Sadler K.C., Tartaglia M., Matsuoka R., Thangaraj K., RA Gelb B.D.; RT "RAF1 mutations in childhood-onset dilated cardiomyopathy."; RL Nat. Genet. 46:635-639(2014). CC -!- FUNCTION: Serine/threonine-protein kinase that acts as a regulatory CC link between the membrane-associated Ras GTPases and the MAPK/ERK CC cascade, and this critical regulatory link functions as a switch CC determining cell fate decisions including proliferation, CC differentiation, apoptosis, survival and oncogenic transformation. RAF1 CC activation initiates a mitogen-activated protein kinase (MAPK) cascade CC that comprises a sequential phosphorylation of the dual-specific MAPK CC kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal- CC regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form CC of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates CC BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl CC cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. CC Phosphorylates PPP1R12A resulting in inhibition of the phosphatase CC activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote CC NF-kB activation and inhibit signal transducers involved in motility CC (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and CC angiogenesis (RB1). Can protect cells from apoptosis also by CC translocating to the mitochondria where it binds BCL2 and displaces CC BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and CC migration, and is required for normal wound healing. Plays a role in CC the oncogenic transformation of epithelial cells via repression of the CC TJ protein, occludin (OCLN) by inducing the up-regulation of a CC transcriptional repressor SNAI2/SLUG, which induces down-regulation of CC OCLN. Restricts caspase activation in response to selected stimuli, CC notably Fas stimulation, pathogen-mediated macrophage apoptosis, and CC erythroid differentiation. {ECO:0000269|PubMed:11427728, CC ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642, CC ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194, CC ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233, CC ECO:0000269|PubMed:9360956}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17603483}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:17603483}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17603483}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:17603483}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Note=Binds 2 Zn(2+) ions per subunit.; CC -!- ACTIVITY REGULATION: Regulation is a highly complex process involving CC membrane recruitment, protein-protein interactions, dimerization, and CC phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the CC membrane, thereby promoting its activation. The inactive conformation CC of RAF1 is maintained by autoinhibitory interactions occurring between CC the N-terminal regulatory and the C-terminal catalytic domains and by CC the binding of a 14-3-3 protein that contacts two phosphorylation CC sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1A CC cooperate to release autoinhibition and the subsequent phosphorylation CC of activating sites: Ser-338, Tyr-341, Thr-491, and Ser-494, yields a CC fully active kinase. Through a negative feedback mechanism involving CC MAPK1/ERK2, RAF1 is phosphorylated on Ser-29, Ser-43, Ser-289, Ser-296, CC Ser-301 and Ser-642 by MAPK1/ERK2, which yields an inactive, CC desensitized kinase. The signaling-competent conformation of RAF1 is CC finally re-established by the coordinated action of PIN1, a prolyl CC isomerase that converts pSer and pThr residues from the cis to the CC trans conformation, which is preferentially recognized and CC dephosphorylated by PPP2R1A. Activated by homodimerization and CC heterodimerization (with BRAF). Also regulated through association with CC other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP, PHB/prohibitin CC and SPRY4. PEBP1/RKIP acts by dissociating RAF1 from its substrates CC MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitin facilitates the CC displacement of 14-3-3 from RAF1 by activated Ras, thereby promoting CC cell membrane localization and phosphorylation of RAF1 at the CC activating Ser-338. SPRY4 inhibits Ras-independent, but not Ras- CC dependent, activation of RAF1. CNKSR1/CNK1 regulates Src-mediated RAF1 CC activation. {ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873, CC ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498, CC ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:16892053, CC ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016}. CC -!- SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and this CC heterodimer possesses a highly increased kinase activity compared to CC the respective homodimers or monomers (PubMed:16508002). CC Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins CC (PubMed:16508002). MAPK1/ERK2 activation can induce a negative feedback CC that promotes the dissociation of the heterodimer (PubMed:16508002). CC Forms a multiprotein complex with Ras (M-Ras/MRAS), SHOC2 and protein CC phosphatase 1 (PPP1CA, PPP1CB and PPP1CC) (PubMed:16630891). Interacts CC with LZTR1 (PubMed:30368668). Interacts with Ras proteins; the CC interaction is antagonized by RIN1 (PubMed:11784866). Weakly interacts CC with RIT1. Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with BRAF, a CC ternary complex inhibited by GNAI1 (By similarity). Probably forms a CC complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37, CC PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this CC complex does not contain co-chaperones STIP1/HOP and PTGES3/p23 CC (PubMed:29127155). Interacts with STK3/MST2; the interaction inhibits CC its pro-apoptotic activity (PubMed:15618521). Interacts (when CC phosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') CC (PubMed:31024343, PubMed:9360956). Interacts with MAP2K1/MEK1 and CC MAP2K2/MEK2 (By similarity). Interacts with MAP3K5/ASF1 (via N- CC terminus) and this interaction inhibits the proapoptotic function of CC MAP3K5/ASK1 (PubMed:11427728). Interacts with PAK1 (via kinase domain) CC (PubMed:11733498). The phosphorylated form interacts with PIN1 (By CC similarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1) CC interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIP and CC this interaction is enhanced if RAF1 is phosphorylated on residues Ser- CC 338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816). Interacts with CC ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A, PKB/AKT1, PPP2CA, CC PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 and PHB/prohibitin CC (PubMed:10576742, PubMed:10801873, PubMed:11719507, PubMed:12717443, CC PubMed:15385642, PubMed:15935327, PubMed:19710016). Interacts with CC ROCK2 (By similarity). In its active form, interacts with PRMT5 CC (PubMed:21917714). Interacts with FAM83B; displaces 14-3-3 proteins CC from RAF1 and activates RAF1 (PubMed:22886302). Interacts with PDE8A; CC the interaction promotes RAF1 activity (PubMed:23509299). Interacts CC with MFHAS1 (PubMed:23327923). Interacts with GLS (PubMed:22538822). CC Interacts with NEK10 and MAP2K1; the interaction is direct with NEK10 CC and required for ERK1/2-signaling pathway activation in response to UV CC irradiation (PubMed:20956560). {ECO:0000250|UniProtKB:P11345, CC ECO:0000250|UniProtKB:Q99N57, ECO:0000269|PubMed:10576742, CC ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11427728, CC ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:11733498, CC ECO:0000269|PubMed:11784866, ECO:0000269|PubMed:12717443, CC ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:15618521, CC ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:15935327, CC ECO:0000269|PubMed:16508002, ECO:0000269|PubMed:16630891, CC ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:20956560, ECO:0000269|PubMed:21917714, CC ECO:0000269|PubMed:22538822, ECO:0000269|PubMed:22886302, CC ECO:0000269|PubMed:23327923, ECO:0000269|PubMed:23509299, CC ECO:0000269|PubMed:29127155, ECO:0000269|PubMed:30368668, CC ECO:0000269|PubMed:9360956}. CC -!- INTERACTION: CC P04049; P31749: AKT1; NbExp=3; IntAct=EBI-365996, EBI-296087; CC P04049; P05067: APP; NbExp=3; IntAct=EBI-365996, EBI-77613; CC P04049; Q99933: BAG1; NbExp=2; IntAct=EBI-365996, EBI-1030678; CC P04049; O95816: BAG2; NbExp=12; IntAct=EBI-365996, EBI-355275; CC P04049; P15056: BRAF; NbExp=73; IntAct=EBI-365996, EBI-365980; CC P04049; Q14790: CASP8; NbExp=3; IntAct=EBI-365996, EBI-78060; CC P04049; P49368: CCT3; NbExp=8; IntAct=EBI-365996, EBI-356673; CC P04049; P30304: CDC25A; NbExp=4; IntAct=EBI-365996, EBI-747671; CC P04049; Q16543: CDC37; NbExp=20; IntAct=EBI-365996, EBI-295634; CC P04049; P31327: CPS1; NbExp=4; IntAct=EBI-365996, EBI-536811; CC P04049; P00533: EGFR; NbExp=3; IntAct=EBI-365996, EBI-297353; CC P04049; O15371: EIF3D; NbExp=4; IntAct=EBI-365996, EBI-353818; CC P04049; O95714: HERC2; NbExp=6; IntAct=EBI-365996, EBI-1058922; CC P04049; P01112: HRAS; NbExp=30; IntAct=EBI-365996, EBI-350145; CC P04049; P07900: HSP90AA1; NbExp=15; IntAct=EBI-365996, EBI-296047; CC P04049; P08238: HSP90AB1; NbExp=17; IntAct=EBI-365996, EBI-352572; CC P04049; P11021: HSPA5; NbExp=5; IntAct=EBI-365996, EBI-354921; CC P04049; P01116: KRAS; NbExp=6; IntAct=EBI-365996, EBI-367415; CC P04049; P01116-2: KRAS; NbExp=3; IntAct=EBI-365996, EBI-367427; CC P04049; P05783: KRT18; NbExp=5; IntAct=EBI-365996, EBI-297888; CC P04049; P08727: KRT19; NbExp=2; IntAct=EBI-365996, EBI-742756; CC P04049; Q8IVT5: KSR1; NbExp=5; IntAct=EBI-365996, EBI-486984; CC P04049; Q02750: MAP2K1; NbExp=39; IntAct=EBI-365996, EBI-492564; CC P04049; P36507: MAP2K2; NbExp=7; IntAct=EBI-365996, EBI-1056930; CC P04049; Q15773: MLF2; NbExp=4; IntAct=EBI-365996, EBI-1051875; CC P04049; Q12968: NFATC3; NbExp=2; IntAct=EBI-365996, EBI-5278441; CC P04049; P01111: NRAS; NbExp=12; IntAct=EBI-365996, EBI-721993; CC P04049; O43482: OIP5; NbExp=4; IntAct=EBI-365996, EBI-536879; CC P04049; Q13153: PAK1; NbExp=2; IntAct=EBI-365996, EBI-1307; CC P04049; Q13177: PAK2; NbExp=2; IntAct=EBI-365996, EBI-1045887; CC P04049; Q6TCH7: PAQR3; NbExp=3; IntAct=EBI-365996, EBI-15654365; CC P04049; P30086: PEBP1; NbExp=10; IntAct=EBI-365996, EBI-716384; CC P04049; Q96S96: PEBP4; NbExp=4; IntAct=EBI-365996, EBI-8563667; CC P04049; Q13526: PIN1; NbExp=2; IntAct=EBI-365996, EBI-714158; CC P04049; P14618: PKM; NbExp=3; IntAct=EBI-365996, EBI-353408; CC P04049; P62136: PPP1CA; NbExp=2; IntAct=EBI-365996, EBI-357253; CC P04049; P67775: PPP2CA; NbExp=2; IntAct=EBI-365996, EBI-712311; CC P04049; Q13362: PPP2R5C; NbExp=2; IntAct=EBI-365996, EBI-1266156; CC P04049; P04049: RAF1; NbExp=6; IntAct=EBI-365996, EBI-365996; CC P04049; P62834: RAP1A; NbExp=2; IntAct=EBI-365996, EBI-491414; CC P04049; P06400: RB1; NbExp=3; IntAct=EBI-365996, EBI-491274; CC P04049; P53805-2: RCAN1; NbExp=4; IntAct=EBI-365996, EBI-1541912; CC P04049; P31947: SFN; NbExp=9; IntAct=EBI-365996, EBI-476295; CC P04049; Q13485: SMAD4; NbExp=6; IntAct=EBI-365996, EBI-347263; CC P04049; Q13188: STK3; NbExp=6; IntAct=EBI-365996, EBI-992580; CC P04049; Q9UNE7: STUB1; NbExp=8; IntAct=EBI-365996, EBI-357085; CC P04049; Q3ZCQ8: TIMM50; NbExp=7; IntAct=EBI-365996, EBI-355175; CC P04049; P31946: YWHAB; NbExp=39; IntAct=EBI-365996, EBI-359815; CC P04049; P62258: YWHAE; NbExp=24; IntAct=EBI-365996, EBI-356498; CC P04049; P61981: YWHAG; NbExp=25; IntAct=EBI-365996, EBI-359832; CC P04049; Q04917: YWHAH; NbExp=27; IntAct=EBI-365996, EBI-306940; CC P04049; P27348: YWHAQ; NbExp=25; IntAct=EBI-365996, EBI-359854; CC P04049; P63104: YWHAZ; NbExp=35; IntAct=EBI-365996, EBI-347088; CC P04049; P32883: Kras; Xeno; NbExp=2; IntAct=EBI-365996, EBI-644267; CC P04049; P28301: Lox; Xeno; NbExp=2; IntAct=EBI-365996, EBI-642911; CC P04049; Q9ESN9-2: Mapk8ip3; Xeno; NbExp=2; IntAct=EBI-365996, EBI-9549291; CC P04049; P03495: NS; Xeno; NbExp=2; IntAct=EBI-365996, EBI-2548993; CC P04049; O39474: NS5A; Xeno; NbExp=4; IntAct=EBI-365996, EBI-7016711; CC P04049; P01120: RAS2; Xeno; NbExp=2; IntAct=EBI-365996, EBI-14838; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion. Nucleus. CC Note=Colocalizes with RGS14 and BRAF in both the cytoplasm and CC membranes. Phosphorylation at Ser-259 impairs its membrane CC accumulation. Recruited to the cell membrane by the active Ras protein. CC Phosphorylation at Ser-338 and Ser-339 by PAK1 is required for its CC mitochondrial localization. Retinoic acid-induced Ser-621 CC phosphorylated form of RAF1 is predominantly localized at the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=6C; CC IsoId=P04049-1; Sequence=Displayed; CC Name=2; Synonyms=1A; CC IsoId=P04049-2; Sequence=VSP_034649; CC -!- TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundant than CC isoform 2. {ECO:0000269|PubMed:1886707}. CC -!- PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 and Ser-494 CC results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, CC Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results in its inactivation. CC Phosphorylation at Ser-259 induces the interaction with YWHAZ and CC inactivates kinase activity. Dephosphorylation of Ser-259 by the SHOC2- CC MRAS-PP1c (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and CC the catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or CC PPP1CC); this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35831509, PubMed:35830882). Phosphorylation at CC Ser-338 by PAK1 and PAK5 and Ser-339 by PAK1 is required for its CC mitochondrial localization. Phosphorylation at Ser-621 in response to CC growth factor treatment stabilizes the protein, possibly by preventing CC proteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, CC Ser-338 and Ser-621 are somehow linked to the methylation potential of CC cells. Treatment of cells with HGF in the presence of the methylation CC inhibitor 5'-methylthioadenosine (MTA) results in increased CC phosphorylation at Ser-338 and Ser-621 and decreased phosphorylation at CC Ser-296, Ser-301 and Ser-338. Dephosphorylation at Ser-338 by PPP5C CC results in an activity decrease. {ECO:0000269|PubMed:10576742, CC ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113, CC ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11756411, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15849194, CC ECO:0000269|PubMed:16093354, ECO:0000269|PubMed:16630891, CC ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18465753, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509, CC ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614, CC ECO:0000269|PubMed:9823899}. CC -!- PTM: Methylated at Arg-563 in response to EGF treatment. This CC modification leads to destabilization of the protein, possibly through CC proteasomal degradation. {ECO:0000269|PubMed:21917714}. CC -!- DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:17603482, CC ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:17603483}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1NN (CMD1NN) [MIM:615916]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42032/RAF1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X03484; CAA27204.1; -; mRNA. DR EMBL; AY271661; AAP03432.1; -; Genomic_DNA. DR EMBL; AK312248; BAG35180.1; -; mRNA. DR EMBL; EU332868; ABY87557.1; -; Genomic_DNA. DR EMBL; CH471055; EAW64134.1; -; Genomic_DNA. DR EMBL; BC018119; AAH18119.1; -; mRNA. DR EMBL; L00212; AAA60247.1; -; Genomic_DNA. DR EMBL; L00206; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00207; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00208; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00209; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00210; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00211; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00213; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; M11376; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; X54851; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS2612.1; -. [P04049-1] DR CCDS; CCDS87047.1; -. [P04049-2] DR PIR; A00637; TVHUF6. DR PIR; S60341; S60341. DR RefSeq; NP_001341618.1; NM_001354689.3. [P04049-2] DR RefSeq; NP_001341619.1; NM_001354690.3. [P04049-1] DR RefSeq; NP_002871.1; NM_002880.4. [P04049-1] DR RefSeq; XP_011532276.1; XM_011533974.3. [P04049-1] DR RefSeq; XP_047304605.1; XM_047448649.1. [P04049-1] DR RefSeq; XP_047304606.1; XM_047448650.1. [P04049-1] DR RefSeq; XP_054203389.1; XM_054347414.1. [P04049-1] DR RefSeq; XP_054203390.1; XM_054347415.1. [P04049-1] DR RefSeq; XP_054203391.1; XM_054347416.1. [P04049-1] DR PDB; 1C1Y; X-ray; 1.90 A; B=55-131. DR PDB; 1FAQ; NMR; -; A=136-187. DR PDB; 1FAR; NMR; -; A=136-187. DR PDB; 1GUA; X-ray; 2.00 A; B=51-131. DR PDB; 1RFA; NMR; -; A=55-132. DR PDB; 3CU8; X-ray; 2.40 A; P/Q=256-264. DR PDB; 3IQJ; X-ray; 1.15 A; P=255-264. DR PDB; 3IQU; X-ray; 1.05 A; P=255-260. DR PDB; 3IQV; X-ray; 1.20 A; P=255-260. DR PDB; 3KUC; X-ray; 1.92 A; B=51-131. DR PDB; 3KUD; X-ray; 2.15 A; B=51-131. DR PDB; 3NKX; X-ray; 2.40 A; P/Q=255-264. DR PDB; 3O8I; X-ray; 2.00 A; B=255-264. DR PDB; 3OMV; X-ray; 4.00 A; A/B=323-618. DR PDB; 4FJ3; X-ray; 1.95 A; P=229-264. DR PDB; 4G0N; X-ray; 2.45 A; B=54-131. DR PDB; 4G3X; X-ray; 3.25 A; B=55-131. DR PDB; 4IEA; X-ray; 1.70 A; P=618-625. DR PDB; 4IHL; X-ray; 2.20 A; P=229-264. DR PDB; 6NTC; X-ray; 2.90 A; B=55-131. DR PDB; 6NTD; X-ray; 3.15 A; B=55-131. DR PDB; 6PTS; NMR; -; D=56-187. DR PDB; 6PTW; NMR; -; D=56-187. DR PDB; 6VJJ; X-ray; 1.40 A; B=52-131. DR PDB; 6XGU; X-ray; 2.70 A; B=52-188. DR PDB; 6XGV; X-ray; 2.11 A; B=52-188. DR PDB; 6XHA; X-ray; 2.87 A; B=52-188. DR PDB; 6XHB; X-ray; 2.50 A; B=52-188. DR PDB; 6XI7; X-ray; 1.95 A; B=52-188. DR PDB; 7JHP; X-ray; 2.77 A; C=55-187. DR PDB; 7Z37; EM; 3.67 A; CP1=1-648. DR PDB; 7Z38; EM; 3.16 A; C=1-648. DR PDB; 8A68; X-ray; 1.60 A; B=255-263. DR PDB; 8A6F; X-ray; 1.60 A; P=255-264. DR PDB; 8A6H; X-ray; 1.60 A; P=255-264. DR PDB; 8ATR; X-ray; 1.70 A; P=255-263. DR PDB; 8ATS; X-ray; 1.40 A; P=255-263. DR PDB; 8AV0; X-ray; 1.50 A; P=256-264. DR PDB; 8CHF; EM; 4.25 A; A/B=1-648. DR PDB; 8CPD; EM; 3.46 A; A/B=1-648. DR PDB; 8EPW; X-ray; 2.00 A; B=52-131. DR PDB; 8GAE; EM; 3.30 A; D=404-610. DR PDB; 8GFT; EM; 3.80 A; D=336-618. DR PDB; 8JOF; NMR; -; A=51-131. DR PDB; 8JOG; NMR; -; A=51-131. DR PDB; 8Q5C; X-ray; 2.00 A; P=255-264. DR PDB; 8S42; X-ray; 1.70 A; P=255-263. DR PDB; 8T74; X-ray; 1.65 A; B=52-131. DR PDB; 8T75; X-ray; 2.65 A; B/D/F/H=52-188. DR PDB; 8U1L; EM; 3.70 A; C=2-648. DR PDB; 9AXA; EM; 4.36 A; A/C=306-648. DR PDB; 9AXC; EM; 4.16 A; A/C=306-648. DR PDB; 9AY7; X-ray; 2.41 A; A=337-615. DR PDB; 9AYA; X-ray; 2.59 A; A/C=337-615. DR PDB; 9EW1; X-ray; 1.40 A; P=255-263. DR PDB; 9EW3; X-ray; 1.40 A; P=255-263. DR PDB; 9EW4; X-ray; 1.60 A; P=255-263. DR PDB; 9EW5; X-ray; 1.50 A; C/F=255-265. DR PDB; 9EW7; X-ray; 1.80 A; P=255-264. DR PDBsum; 1C1Y; -. DR PDBsum; 1FAQ; -. DR PDBsum; 1FAR; -. DR PDBsum; 1GUA; -. DR PDBsum; 1RFA; -. DR PDBsum; 3CU8; -. DR PDBsum; 3IQJ; -. DR PDBsum; 3IQU; -. DR PDBsum; 3IQV; -. DR PDBsum; 3KUC; -. DR PDBsum; 3KUD; -. DR PDBsum; 3NKX; -. DR PDBsum; 3O8I; -. DR PDBsum; 3OMV; -. DR PDBsum; 4FJ3; -. DR PDBsum; 4G0N; -. DR PDBsum; 4G3X; -. DR PDBsum; 4IEA; -. DR PDBsum; 4IHL; -. DR PDBsum; 6NTC; -. DR PDBsum; 6NTD; -. DR PDBsum; 6PTS; -. DR PDBsum; 6PTW; -. DR PDBsum; 6VJJ; -. DR PDBsum; 6XGU; -. DR PDBsum; 6XGV; -. DR PDBsum; 6XHA; -. DR PDBsum; 6XHB; -. DR PDBsum; 6XI7; -. DR PDBsum; 7JHP; -. DR PDBsum; 7Z37; -. DR PDBsum; 7Z38; -. DR PDBsum; 8A68; -. DR PDBsum; 8A6F; -. DR PDBsum; 8A6H; -. DR PDBsum; 8ATR; -. DR PDBsum; 8ATS; -. DR PDBsum; 8AV0; -. DR PDBsum; 8CHF; -. DR PDBsum; 8CPD; -. DR PDBsum; 8EPW; -. DR PDBsum; 8GAE; -. DR PDBsum; 8GFT; -. DR PDBsum; 8JOF; -. DR PDBsum; 8JOG; -. DR PDBsum; 8Q5C; -. DR PDBsum; 8S42; -. DR PDBsum; 8T74; -. DR PDBsum; 8T75; -. DR PDBsum; 8U1L; -. DR PDBsum; 9AXA; -. DR PDBsum; 9AXC; -. DR PDBsum; 9AY7; -. DR PDBsum; 9AYA; -. DR PDBsum; 9EW1; -. DR PDBsum; 9EW3; -. DR PDBsum; 9EW4; -. DR PDBsum; 9EW5; -. DR PDBsum; 9EW7; -. DR AlphaFoldDB; P04049; -. DR BMRB; P04049; -. DR EMDB; EMD-14472; -. DR EMDB; EMD-14473; -. DR EMDB; EMD-16660; -. DR EMDB; EMD-16779; -. DR EMDB; EMD-29895; -. DR EMDB; EMD-29949; -. DR EMDB; EMD-29957; -. DR EMDB; EMD-29973; -. DR EMDB; EMD-29976; -. DR EMDB; EMD-29984; -. DR EMDB; EMD-41816; -. DR EMDB; EMD-43931; -. DR EMDB; EMD-43932; -. DR SMR; P04049; -. DR BioGRID; 111831; 1867. DR CORUM; P04049; -. DR DIP; DIP-1048N; -. DR FunCoup; P04049; 4763. DR IntAct; P04049; 435. DR MINT; P04049; -. DR STRING; 9606.ENSP00000401888; -. DR BindingDB; P04049; -. DR ChEMBL; CHEMBL1906; -. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB17568; Belvarafenib. DR DrugBank; DB08862; Cholecystokinin. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB04367; Debromohymenialdisine. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB05268; iCo-007. DR DrugBank; DB04973; LErafAON. DR DrugBank; DB18865; Naporafenib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB12094; Semapimod. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P04049; -. DR GuidetoPHARMACOLOGY; 2184; -. DR MoonDB; P04049; Predicted. DR GlyCosmos; P04049; 1 site, 1 glycan. DR GlyGen; P04049; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P04049; -. DR PhosphoSitePlus; P04049; -. DR SwissPalm; P04049; -. DR BioMuta; RAF1; -. DR DMDM; 125651; -. DR CPTAC; CPTAC-1335; -. DR CPTAC; CPTAC-1336; -. DR CPTAC; CPTAC-1546; -. DR CPTAC; CPTAC-1762; -. DR CPTAC; CPTAC-5778; -. DR CPTAC; CPTAC-5779; -. DR CPTAC; CPTAC-5780; -. DR CPTAC; CPTAC-5828; -. DR CPTAC; CPTAC-5829; -. DR CPTAC; non-CPTAC-5431; -. DR CPTAC; non-CPTAC-5432; -. DR CPTAC; non-CPTAC-5433; -. DR CPTAC; non-CPTAC-5569; -. DR CPTAC; non-CPTAC-5570; -. DR CPTAC; non-CPTAC-5734; -. DR jPOST; P04049; -. DR MassIVE; P04049; -. DR PaxDb; 9606-ENSP00000251849; -. DR PeptideAtlas; P04049; -. DR ProteomicsDB; 51637; -. [P04049-1] DR ProteomicsDB; 51638; -. [P04049-2] DR Pumba; P04049; -. DR ABCD; P04049; 5 sequenced antibodies. DR Antibodypedia; 1131; 3127 antibodies from 52 providers. DR CPTC; P04049; 8 antibodies. DR DNASU; 5894; -. DR Ensembl; ENST00000251849.9; ENSP00000251849.4; ENSG00000132155.15. [P04049-1] DR Ensembl; ENST00000442415.7; ENSP00000401888.2; ENSG00000132155.15. [P04049-2] DR Ensembl; ENST00000685653.1; ENSP00000509968.1; ENSG00000132155.15. [P04049-1] DR Ensembl; ENST00000691899.1; ENSP00000508763.1; ENSG00000132155.15. [P04049-1] DR GeneID; 5894; -. DR KEGG; hsa:5894; -. DR MANE-Select; ENST00000251849.9; ENSP00000251849.4; NM_002880.4; NP_002871.1. DR UCSC; uc003bxf.5; human. [P04049-1] DR AGR; HGNC:9829; -. DR CIViC; 5894; 7 evidence items across 4 molecular profiles. DR ClinPGx; PA34183; -. DR CTD; 5894; -. DR DisGeNET; 5894; -. DR GeneCards; RAF1; -. DR GeneReviews; RAF1; -. DR HGNC; HGNC:9829; RAF1. DR HPA; ENSG00000132155; Low tissue specificity. DR MalaCards; RAF1; -. DR MIM; 164760; gene. DR MIM; 611553; phenotype. DR MIM; 611554; phenotype. DR MIM; 615916; phenotype. DR OpenTargets; ENSG00000132155; -. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR VEuPathDB; HostDB:ENSG00000132155; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156084; -. DR InParanoid; P04049; -. DR OMA; SAYKRHA; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P04049; 5 GO annotations based on evolutionary models. DR PhylomeDB; P04049; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P04049; -. DR Reactome; R-HSA-2672351; Stimuli-sensing channels. DR Reactome; R-HSA-392517; Rap1 signalling. DR Reactome; R-HSA-430116; GP1b-IX-V activation signalling. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR Reactome; R-HSA-9732724; IFNG signaling activates MAPKs. DR SignaLink; P04049; -. DR SIGNOR; P04049; -. DR Agora; ENSG00000132155; -. DR BioGRID-ORCS; 5894; 99 hits in 1206 CRISPR screens. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; RAF1; human. DR EvolutionaryTrace; P04049; -. DR GeneWiki; C-Raf; -. DR GenomeRNAi; 5894; -. DR Pharos; P04049; Tclin. DR PRO; PR:P04049; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P04049; protein. DR Bgee; ENSG00000132155; Expressed in gastrocnemius and 214 other cell types or tissues. DR ExpressionAtlas; P04049; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IPI:MGI. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:ProtInc. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0031143; C:pseudopodium; IEA:Ensembl. DR GO; GO:0010856; F:adenylate cyclase activator activity; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; EXP:Reactome. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006915; P:apoptotic process; TAS:GO_Central. DR GO; GO:0071550; P:death-inducing signaling complex assembly; IEA:Ensembl. DR GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl. DR GO; GO:0035773; P:insulin secretion involved in cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0045104; P:intermediate filament cytoskeleton organization; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IBA:GO_Central. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:GO_Central. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB. DR GO; GO:0045595; P:regulation of cell differentiation; TAS:UniProtKB. DR GO; GO:0035023; P:regulation of Rho protein signal transduction; TAS:UniProtKB. DR GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0044342; P:type B pancreatic cell proliferation; IEA:Ensembl. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; TAS:Reactome. DR GO; GO:0042060; P:wound healing; TAS:UniProtKB. DR CDD; cd20870; C1_A_C-Raf; 1. DR CDD; cd17135; RBD_CRAF; 1. DR CDD; cd14149; STKc_C-Raf; 1. DR DisProt; DP00171; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00292; -. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329:SF22; RAF PROTO-ONCOGENE SERINE_THREONINE-PROTEIN KINASE; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cardiomyopathy; KW Cell membrane; Cytoplasm; Deafness; Direct protein sequencing; KW Disease variant; Kinase; Membrane; Metal-binding; Methylation; KW Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..648 FT /note="RAF proto-oncogene serine/threonine-protein kinase" FT /id="PRO_0000086596" FT DOMAIN 56..131 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 349..609 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 138..184 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 220..334 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 331..349 FT /note="Interaction with PEBP1/RKIP" FT COMPBIAS 239..271 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 275..285 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 286..301 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 468 FT /note="Proton acceptor" FT BINDING 139 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 152 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 155 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 165 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 168 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 173 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 184 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 355..363 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 375 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 29 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000250|UniProtKB:Q99N57" FT MOD_RES 43 FT /note="Phosphoserine; by PKA and MAPK1" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 252 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 259 FT /note="Phosphoserine; by PKA, PKC and PKB/AKT1" FT /evidence="ECO:0000269|PubMed:10576742, FT ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11756411, FT ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:16630891, FT ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:8349614" FT MOD_RES 268 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 269 FT /note="Phosphothreonine; by PKA" FT /evidence="ECO:0000269|PubMed:7477354" FT MOD_RES 289 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000269|PubMed:21917714, FT ECO:0007744|PubMed:19690332" FT MOD_RES 296 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 301 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000269|PubMed:21917714, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 338 FT /note="Phosphoserine; by PAK1, PAK2, PAK3 and PAK5" FT /evidence="ECO:0000269|PubMed:11733498, FT ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16892053, FT ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714" FT MOD_RES 339 FT /note="Phosphoserine; by PAK1, PAK2 and PAK3" FT /evidence="ECO:0000269|PubMed:15849194" FT MOD_RES 340 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:16892053" FT MOD_RES 341 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:16892053" FT MOD_RES 471 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:16093354" FT MOD_RES 491 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:11447113" FT MOD_RES 494 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11447113" FT MOD_RES 499 FT /note="Phosphoserine; by PKC" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 563 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 621 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:10801873, FT ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:21917714, FT ECO:0000269|PubMed:8349614" FT MOD_RES 642 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 278 FT /note="E -> ENNNLSASPRAWSRRFCLRGR (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_034649" FT VARIANT 237 FT /note="A -> T (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs587777588)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071844" FT VARIANT 256 FT /note="R -> S (in NS5; dbSNP:rs397516826)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037807" FT VARIANT 257 FT /note="S -> L (in NS5 and LPRD2; shows in vitro greater FT kinase activity and enhanced ERK activation than wild-type; FT dbSNP:rs80338796)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483" FT /id="VAR_037808" FT VARIANT 259 FT /note="S -> A (in an ovarian serous carcinoma sample; FT somatic mutation; increased ERK activation; FT dbSNP:rs3730271)" FT /evidence="ECO:0000269|PubMed:16630891, FT ECO:0000269|PubMed:17344846" FT /id="VAR_041037" FT VARIANT 259 FT /note="S -> F (in NS5; dbSNP:rs397516827)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037809" FT VARIANT 260 FT /note="T -> I (in hypertrophic cardiomyopathy; uncertain FT significance; dbSNP:rs869025501)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037810" FT VARIANT 260 FT /note="T -> R (in NS5)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037811" FT VARIANT 261 FT /note="P -> A (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs121434594)" FT /evidence="ECO:0000269|PubMed:17603482" FT /id="VAR_037812" FT VARIANT 261 FT /note="P -> L (in NS5; shows greater kinase activity and FT enhanced MAPK1 activation than wild-type; FT dbSNP:rs397516828)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037813" FT VARIANT 261 FT /note="P -> S (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs121434594)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980" FT /id="VAR_037814" FT VARIANT 263 FT /note="V -> A (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs397516830)" FT /evidence="ECO:0000269|PubMed:17603482" FT /id="VAR_037815" FT VARIANT 308 FT /note="P -> L (in dbSNP:rs5746220)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.3" FT /id="VAR_018840" FT VARIANT 310 FT /note="T -> A (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs778155315)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071845" FT VARIANT 332 FT /note="P -> A (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs1057403865)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071846" FT VARIANT 335 FT /note="Q -> H (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041038" FT VARIANT 486 FT /note="D -> G (in NS5; dbSNP:rs397516815)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037816" FT VARIANT 486 FT /note="D -> N (in NS5; has reduced or absent kinase FT activity; dbSNP:rs80338798)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037817" FT VARIANT 491 FT /note="T -> I (in NS5; has reduced or absent kinase FT activity; dbSNP:rs80338799)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037818" FT VARIANT 491 FT /note="T -> R (in NS5; dbSNP:rs80338799)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037819" FT VARIANT 603 FT /note="L -> P (in CMD1NN; shows impaired kinase activity FT and reduced MAPK3 activation with this mutation; FT dbSNP:rs587777586)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071847" FT VARIANT 612 FT /note="S -> T (in NS5; dbSNP:rs1448392469)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037820" FT VARIANT 613 FT /note="L -> V (in NS5 and LPRD2; shows in vitro greater FT kinase activity and enhanced MAPK1 activation than wild- FT type; dbSNP:rs80338797)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483" FT /id="VAR_037821" FT VARIANT 626 FT /note="H -> R (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs1553609795)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071848" FT VARIANT 641 FT /note="T -> M (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs587777587)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071849" FT MUTAGEN 338..339 FT /note="SS->AA: Reduced kinase activity; when associated FT with 340-D-D-341." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 338..339 FT /note="SS->DE: Non-inhibited by PPP5C. Constitutively FT active and non-inhibited by PPP5C; when associated with FT 340-D-D-341." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 340..341 FT /note="YY->DD: Constitutively active and highly FT phosphorylated on S-338, inhibited by PPP5C. Reduced kinase FT activity; when associated with 338-A-A-339. Constitutively FT active and non-inhibited by PPP5C; when associated with FT 338-D-E-339." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 375 FT /note="K->W: Catalytically inactive." FT /evidence="ECO:0000269|PubMed:20956560" FT MUTAGEN 491 FT /note="T->D: Increased kinase activity but can still be FT inhibited by PPP5C; when associated with D-494." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 494 FT /note="S->D: Increased kinase activity but can still be FT inhibited by PPP5C; when associated with D-491." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 563 FT /note="R->K: Loss of methylation. Increased stability and FT catalytic activity in response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 240 FT /note="F -> L (in Ref. 6; AAA60247)" FT /evidence="ECO:0000305" FT CONFLICT 542 FT /note="M -> I (in Ref. 6; AAA60247)" FT /evidence="ECO:0000305" FT STRAND 57..61 FT /evidence="ECO:0007829|PDB:6VJJ" FT TURN 63..65 FT /evidence="ECO:0007829|PDB:8T74" FT STRAND 67..71 FT /evidence="ECO:0007829|PDB:6VJJ" FT HELIX 78..88 FT /evidence="ECO:0007829|PDB:6VJJ" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 96..100 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 103..107 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:8T74" FT HELIX 118..121 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 125..130 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 132..134 FT /evidence="ECO:0007829|PDB:6PTW" FT STRAND 135..137 FT /evidence="ECO:0007829|PDB:6XGV" FT STRAND 141..145 FT /evidence="ECO:0007829|PDB:6XI7" FT TURN 153..155 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 160..165 FT /evidence="ECO:0007829|PDB:6XI7" FT TURN 166..168 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 170..172 FT /evidence="ECO:0007829|PDB:7JHP" FT HELIX 174..179 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 182..185 FT /evidence="ECO:0007829|PDB:6XGV" FT STRAND 350..353 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 363..376 FT /evidence="ECO:0007829|PDB:8CPD" FT HELIX 384..397 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 408..412 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 414..416 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 418..422 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 434..437 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 442..461 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 471..473 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 478..480 FT /evidence="ECO:0007829|PDB:8GAE" FT STRAND 481..484 FT /evidence="ECO:0007829|PDB:8GAE" FT STRAND 510..512 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 514..518 FT /evidence="ECO:0007829|PDB:7Z38" FT STRAND 520..522 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 527..542 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 547..550 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 554..563 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 593..595 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 599..611 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 612..614 FT /evidence="ECO:0007829|PDB:7Z38" SQ SEQUENCE 648 AA; 73052 MW; EF821B5349711BC3 CRC64; MEHIQGAWKT ISNGFGFKDA VFDGSSCISP TIVQQFGYQR RASDDGKLTD PSKTSNTIRV FLPNKQRTVV NVRNGMSLHD CLMKALKVRG LQPECCAVFR LLHEHKGKKA RLDWNTDAAS LIGEELQVDF LDHVPLTTHN FARKTFLKLA FCDICQKFLL NGFRCQTCGY KFHEHCSTKV PTMCVDWSNI RQLLLFPNST IGDSGVPALP SLTMRRMRES VSRMPVSSQH RYSTPHAFTF NTSSPSSEGS LSQRQRSTST PNVHMVSTTL PVDSRMIEDA IRSHSESASP SALSSSPNNL SPTGWSQPKT PVPAQRERAP VSGTQEKNKI RPRGQRDSSY YWEIEASEVM LSTRIGSGSF GTVYKGKWHG DVAVKILKVV DPTPEQFQAF RNEVAVLRKT RHVNILLFMG YMTKDNLAIV TQWCEGSSLY KHLHVQETKF QMFQLIDIAR QTAQGMDYLH AKNIIHRDMK SNNIFLHEGL TVKIGDFGLA TVKSRWSGSQ QVEQPTGSVL WMAPEVIRMQ DNNPFSFQSD VYSYGIVLYE LMTGELPYSH INNRDQIIFM VGRGYASPDL SKLYKNCPKA MKRLVADCVK KVKEERPLFP QILSSIELLQ HSLPKINRSA SEPSLHRAAH TEDINACTLT TSPRLPVF // ID RASH_HUMAN Reviewed; 189 AA. AC P01112; B5BUA0; Q14080; Q6FHV9; Q9BR65; Q9UCE2; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 28-JAN-2026, entry version 279. DE RecName: Full=GTPase HRas; DE EC=3.6.5.2 {ECO:0000269|PubMed:9020151}; DE AltName: Full=H-Ras-1; DE AltName: Full=Ha-Ras; DE AltName: Full=Transforming protein p21; DE AltName: Full=c-H-ras; DE AltName: Full=p21ras; DE Contains: DE RecName: Full=GTPase HRas, N-terminally processed; DE Flags: Precursor; GN Name=HRAS; Synonyms=HRAS1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INVOLVEMENT IN BLADDER CANCER. RX PubMed=6298635; DOI=10.1038/302033a0; RA Capon D.J., Chen E.Y., Levinson A.D., Seeburg P.H., Goeddel D.V.; RT "Complete nucleotide sequences of the T24 human bladder carcinoma oncogene RT and its normal homologue."; RL Nature 302:33-37(1983). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INVOLVEMENT IN BLADDER CANCER. RX PubMed=6844927; DOI=10.1126/science.6844927; RA Reddy E.P.; RT "Nucleotide sequence analysis of the T24 human bladder carcinoma RT oncogene."; RL Science 220:1061-1063(1983). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=6087347; DOI=10.1073/pnas.81.15.4771; RA Sekiya T., Fushimi M., Hori H., Hirohashi S., Nishimura S., Sugimura T.; RT "Molecular cloning and the total nucleotide sequence of the human c-Ha-ras- RT 1 gene activated in a melanoma from a Japanese patient."; RL Proc. Natl. Acad. Sci. U.S.A. 81:4771-4775(1984). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, INTERACTION WITH RACK1, RP SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND RP MUTAGENESIS OF SER-17. RX PubMed=14500341; RA Guil S., de La Iglesia N., Fernandez-Larrea J., Cifuentes D., Ferrer J.C., RA Guinovart J.J., Bach-Elias M.; RT "Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras RT family protein that trafficks to cytoplasm and nucleus."; RL Cancer Res. 63:5178-5187(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RA Puhl H.L. III, Ikeda S.R., Aronstam R.S.; RT "cDNA clones of human proteins involved in signal transduction sequenced by RT the Guthrie cDNA resource center (www.cdna.org)."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Lung carcinoma; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP PROTEIN SEQUENCE OF 1-41; 43-117; 129-161 AND 170-185, CLEAVAGE OF RP INITIATOR METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND IDENTIFICATION BY RP MASS SPECTROMETRY. RC TISSUE=Cervix carcinoma; RA Bienvenut W.V., Calvo F., Kolch W.; RL Submitted (FEB-2008) to UniProtKB. RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37. RX PubMed=6290897; DOI=10.1038/300143a0; RA Tabin C.J., Bradley S.M., Bargmann C.I., Weinberg R.A., Papageorge A.G., RA Scolnick E.M., Dhar R., Lowy D.R., Chang E.H.; RT "Mechanism of activation of a human oncogene."; RL Nature 300:143-149(1982). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RX PubMed=3670300; DOI=10.1128/mcb.7.8.2933-2940.1987; RA Honkawa H., Masahashi W., Hashimoto S., Hashimoto-Gotoh T.; RT "Identification of the principal promoter sequence of the c-H-ras RT transforming oncogene: deletion analysis of the 5'-flanking region by focus RT formation assay."; RL Mol. Cell. Biol. 7:2933-2940(1987). RN [15] RP PROTEIN SEQUENCE OF 108-117 AND 132-153. RX PubMed=8393791; DOI=10.1111/j.1432-1033.1993.tb18056.x; RA Loew A., Sprinzl M., Faulhammer H.G.; RT "Affinity labeling of c-H-ras p21 consensus elements with periodate- RT oxidized GDP and GTP."; RL Eur. J. Biochem. 215:473-479(1993). RN [16] RP MUTAGENESIS OF ALA-83; ASP-119 AND THR-144. RX PubMed=3088563; DOI=10.1073/pnas.83.13.4607; RA Feig L.A., Pan B.-T., Roberts T.M., Cooper G.M.; RT "Isolation of ras GTP-binding mutants using an in situ colony-binding RT assay."; RL Proc. Natl. Acad. Sci. U.S.A. 83:4607-4611(1986). RN [17] RP MUTAGENESIS OF 164-ARG-GLN-165. RX PubMed=3011420; DOI=10.1002/j.1460-2075.1986.tb04267.x; RA Lacal J.C., Anderson P.S., Aaronson S.A.; RT "Deletion mutants of Harvey ras p21 protein reveal the absolute requirement RT of at least two distant regions for GTP-binding and transforming RT activities."; RL EMBO J. 5:679-687(1986). RN [18] RP PALMITOYLATION AT CYS-181 AND CYS-184. RX PubMed=2661017; DOI=10.1016/0092-8674(89)90054-8; RA Hancock J.F., Magee A.I., Childs J.E., Marshall C.J.; RT "All ras proteins are polyisoprenylated but only some are palmitoylated."; RL Cell 57:1167-1177(1989). RN [19] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=8626586; DOI=10.1074/jbc.271.17.10217; RA Popoff M.R., Chaves-Olarte E., Lemichez E., von Eichel-Streiber C., RA Thelestam M., Chardin P., Cussac D., Antonny B., Chavrier P., Flatau G., RA Giry M., de Gunzburg J., Boquet P.; RT "Ras, Rap, and Rac small GTP-binding proteins are targets for Clostridium RT sordellii lethal toxin glucosylation."; RL J. Biol. Chem. 271:10217-10224(1996). RN [20] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=8626575; DOI=10.1074/jbc.271.17.10149; RA Just I., Selzer J., Hofmann F., Green G.A., Aktories K.; RT "Inactivation of Ras by Clostridium sordellii lethal toxin-catalyzed RT glucosylation."; RL J. Biol. Chem. 271:10149-10153(1996). RN [21] RP PALMITOYLATION AT CYS-181 AND CYS-184, ISOPRENYLATION AT CYS-186, RP METHYLATION AT CYS-186, AND MUTAGENESIS OF CYS-181 AND CYS-184. RX PubMed=8626715; DOI=10.1074/jbc.271.19.11541; RA Dudler T., Gelb M.H.; RT "Palmitoylation of Ha-Ras facilitates membrane binding, activation of RT downstream effectors, and meiotic maturation in Xenopus oocytes."; RL J. Biol. Chem. 271:11541-11547(1996). RN [22] RP S-NITROSYLATION AT CYS-118, FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS RP OF CYS-118. RX PubMed=9020151; DOI=10.1074/jbc.272.7.4323; RA Lander H.M., Hajjar D.P., Hempstead B.L., Mirza U.A., Chait B.T., RA Campbell S., Quilliam L.A.; RT "A molecular redox switch on p21(ras). Structural basis for the nitric RT oxide-p21(ras) interaction."; RL J. Biol. Chem. 272:4323-4326(1997). RN [23] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=9632667; DOI=10.1074/jbc.273.26.16134; RA Herrmann C., Ahmadian M.R., Hofmann F., Just I.; RT "Functional consequences of monoglucosylation of Ha-Ras at effector domain RT amino acid threonine 35."; RL J. Biol. Chem. 273:16134-16139(1998). RN [24] RP INTERACTION WITH IKZF3. RX PubMed=10369681; DOI=10.1093/emboj/18.12.3419; RA Romero F., Martinez-A C., Camonis J., Rebollo A.; RT "Aiolos transcription factor controls cell death in T cells by regulating RT Bcl-2 expression and its cellular localization."; RL EMBO J. 18:3419-3430(1999). RN [25] RP INTERACTION WITH RAPGEF2. RX PubMed=10608844; DOI=10.1074/jbc.274.53.37815; RA Liao Y., Kariya K., Hu C.-D., Shibatohge M., Goshima M., Okada T., RA Watari Y., Gao X., Jin T.-G., Yamawaki-Kataoka Y., Kataoka T.; RT "RA-GEF, a novel Rap1A guanine nucleotide exchange factor containing a RT Ras/Rap1A-associating domain, is conserved between nematode and humans."; RL J. Biol. Chem. 274:37815-37820(1999). RN [26] RP INTERACTION WITH PLCE1, CHARACTERIZATION OF VARIANT VAL-12, AND MUTAGENESIS RP OF SER-17; ASN-26; VAL-29; TYR-32; PRO-34; THR-35; GLU-37; ASP-38 AND RP SER-39. RX PubMed=11022048; DOI=10.1074/jbc.m008324200; RA Song C., Hu C.-D., Masago M., Kariya K., Yamawaki-Kataoka Y., RA Shibatohge M., Wu D., Satoh T., Kataoka T.; RT "Regulation of a novel human phospholipase C, PLCepsilon, through membrane RT targeting by Ras."; RL J. Biol. Chem. 276:2752-2757(2001). RN [27] RP INTERACTION WITH RAPGEF2. RX PubMed=11598133; DOI=10.1074/jbc.m108373200; RA Pham N., Rotin D.; RT "Nedd4 regulates ubiquitination and stability of the guanine-nucleotide RT exchange factor CNrasGEF."; RL J. Biol. Chem. 276:46995-47003(2001). RN [28] RP IDENTIFICATION IN A COMPLEX WITH RASGRP1 AND DGKZ. RX PubMed=11257115; DOI=10.1083/jcb.152.6.1135; RA Topham M.K., Prescott S.M.; RT "Diacylglycerol kinase zeta regulates Ras activation by a novel RT mechanism."; RL J. Cell Biol. 152:1135-1143(2001). RN [29] RP INTERACTION WITH PDE6D. RX PubMed=11980706; DOI=10.1093/emboj/21.9.2095; RA Hanzal-Bayer M., Renault L., Roversi P., Wittinghofer A., Hillig R.C.; RT "The complex of Arl2-GTP and PDE delta: from structure to function."; RL EMBO J. 21:2095-2106(2002). RN [30] RP LIPIDATION AT CYS-184, AND MUTAGENESIS OF CYS-184. RX PubMed=12684535; DOI=10.1073/pnas.0735842100; RA Oliva J.L., Perez-Sala D., Castrillo A., Martinez N., Canada F.J., RA Bosca L., Rojas J.M.; RT "The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and RT activates H-Ras."; RL Proc. Natl. Acad. Sci. U.S.A. 100:4772-4777(2003). RN [31] RP FUNCTION, VARIANT CYS-89, AND CHARACTERIZATION OF VARIANT CYS-89. RX PubMed=22821884; DOI=10.1002/ajmg.a.35449; RA Gripp K.W., Bifeld E., Stabley D.L., Hopkins E., Meien S., Vinette K., RA Sol-Church K., Rosenberger G.; RT "A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased RT downstream signaling suggests a new dimension of RAS pathway dysregulation RT in human development."; RL Am. J. Med. Genet. A 158A:2106-2118(2012). RN [32] RP CHARACTERIZATION OF CSTLO VARIANT VAL-12. RX PubMed=15546861; DOI=10.1074/jbc.m410775200; RA Liu F., Iqbal K., Grundke-Iqbal I., Rossie S., Gong C.X.; RT "Dephosphorylation of tau by protein phosphatase 5: impairment in RT Alzheimer's disease."; RL J. Biol. Chem. 280:1790-1796(2005). RN [33] RP PALMITOYLATION AT CYS-181 AND CYS-184. RX PubMed=16000296; DOI=10.1074/jbc.m504113200; RA Swarthout J.T., Lobo S., Farh L., Croke M.R., Greentree W.K., RA Deschenes R.J., Linder M.E.; RT "DHHC9 and GCP16 constitute a human protein fatty acyltransferase with RT specificity for H- and N-Ras."; RL J. Biol. Chem. 280:31141-31148(2005). RN [34] RP PALMITOYLATION AT CYS-181 AND CYS-184, MUTAGENESIS OF CYS-181 AND CYS-184, RP AND SUBCELLULAR LOCATION. RX PubMed=15705808; DOI=10.1126/science.1105654; RA Rocks O., Peyker A., Kahms M., Verveer P.J., Koerner C., Lumbierres M., RA Kuhlmann J., Waldmann H., Wittinghofer A., Bastiaens P.I.H.; RT "An acylation cycle regulates localization and activity of palmitoylated RT Ras isoforms."; RL Science 307:1746-1752(2005). RN [35] RP INTERACTION WITH TBC1D10C. RX PubMed=17230191; DOI=10.1038/nature05476; RA Pan F., Sun L., Kardian D.B., Whartenby K.A., Pardoll D.M., Liu J.O.; RT "Feedback inhibition of calcineurin and Ras by a dual inhibitory protein RT Carabin."; RL Nature 445:433-436(2007). RN [36] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=19744486; DOI=10.1016/j.febslet.2009.09.006; RA Huelsenbeck S.C., Klose I., Reichenbach M., Huelsenbeck J., Genth H.; RT "Distinct kinetics of (H/K/N)Ras glucosylation and Rac1 glucosylation RT catalysed by Clostridium sordellii lethal toxin."; RL FEBS Lett. 583:3133-3139(2009). RN [37] RP ACYLATION, AND MUTAGENESIS OF 167-LYS--LYS-185. RX PubMed=29239724; DOI=10.7554/elife.32436; RA Jing H., Zhang X., Wisner S.A., Chen X., Spiegelman N.A., Linder M.E., RA Lin H.; RT "SIRT2 and lysine fatty acylation regulate the transforming activity of K- RT Ras4a."; RL Elife 6:0-0(2017). RN [38] RP UBIQUITINATION AT LYS-170, AND MUTAGENESIS OF LYS-170. RX PubMed=30442762; DOI=10.1126/science.aap7607; RA Steklov M., Pandolfi S., Baietti M.F., Batiuk A., Carai P., Najm P., RA Zhang M., Jang H., Renzi F., Cai Y., Abbasi Asbagh L., Pastor T., RA De Troyer M., Simicek M., Radaelli E., Brems H., Legius E., Tavernier J., RA Gevaert K., Impens F., Messiaen L., Nussinov R., Heymans S., Eyckerman S., RA Sablina A.A.; RT "Mutations in LZTR1 drive human disease by dysregulating RAS RT ubiquitination."; RL Science 362:1177-1182(2018). RN [39] RP INTERACTION WITH PPP1CA; PPP1CB AND SHOC2. RX PubMed=36175670; DOI=10.1038/s41594-022-00841-4; RA Bonsor D.A., Alexander P., Snead K., Hartig N., Drew M., Messing S., RA Finci L.I., Nissley D.V., McCormick F., Esposito D., Rodriguez-Viciana P., RA Stephen A.G., Simanshu D.K.; RT "Structure of the SHOC2-MRAS-PP1c complex provides insights into RAF RT activation and Noonan syndrome."; RL Nat. Struct. Mol. Biol. 29:966-977(2022). RN [40] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [41] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2, AND MUTAGENESIS OF RP GLN-61. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS). RX PubMed=2448879; DOI=10.1126/science.2448879; RA de Vos A.M., Tong L., Milburn M.V., Matias P.M., Jancarik J., Noguchi S., RA Nishimura S., Miura K., Ohtsuka E., Kim S.-H.; RT "Three-dimensional structure of an oncogene protein: catalytic domain of RT human c-H-ras p21."; RL Science 239:888-893(1988). RN [43] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS). RX PubMed=2476675; DOI=10.1038/341209a0; RA Pai E.F., Kabsch W., Krengel U., Holmes K.C., John J., Wittinghofer A.; RT "Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene RT product p21 in the triphosphate conformation."; RL Nature 341:209-214(1989). RN [44] {ECO:0007744|PDB:5P21} RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS). RX PubMed=2196171; DOI=10.1002/j.1460-2075.1990.tb07409.x; RA Pai E.F., Krengel U., Petsko G.A., Goody R.S., Kabsch W., Wittinghofer A.; RT "Refined crystal structure of the triphosphate conformation of H-ras p21 at RT 1.35-A resolution: implications for the mechanism of GTP hydrolysis."; RL EMBO J. 9:2351-2359(1990). RN [45] {ECO:0007744|PDB:1Q21, ECO:0007744|PDB:2Q21} RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS). RX PubMed=1899707; DOI=10.1016/0022-2836(91)90753-s; RA Tong L.A., de Vos A.M., Milburn M.V., Kim S.H.; RT "Crystal structures at 2.2-A resolution of the catalytic domains of normal RT ras protein and an oncogenic mutant complexed with GDP."; RL J. Mol. Biol. 217:503-516(1991). RN [46] {ECO:0007744|PDB:121P} RP STRUCTURE BY NMR OF 1-166. RX PubMed=8142349; DOI=10.1021/bi00178a008; RA Kraulis P.J., Domaille P.J., Campbell-Burk S.L., van Aken T., Laue E.D.; RT "Solution structure and dynamics of ras p21.GDP determined by heteronuclear RT three- and four-dimensional NMR spectroscopy."; RL Biochemistry 33:3515-3531(1994). RN [47] {ECO:0007744|PDB:1WQ1} RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-166 IN COMPLEX WITH RP RASA1/RASGAP. RX PubMed=9219684; DOI=10.1126/science.277.5324.333; RA Scheffzek K., Ahmadian M.R., Kabsch W., Wiesmuller L., Lautwein A., RA Schmitz F., Wittinghofer A.; RT "The Ras-RasGAP complex: structural basis for GTPase activation and its RT loss in oncogenic Ras mutants."; RL Science 277:333-338(1997). RN [48] {ECO:0007744|PDB:1CTQ, ECO:0007744|PDB:1QRA} RP X-RAY CRYSTALLOGRAPHY (1.26 ANGSTROMS). RX PubMed=10574788; DOI=10.1016/s0969-2126(00)80021-0; RA Scheidig A.J., Burmester C., Goody R.S.; RT "The pre-hydrolysis state of p21(ras) in complex with GTP: new insights RT into the role of water molecules in the GTP hydrolysis reaction of ras-like RT proteins."; RL Structure 7:1311-1324(1999). RN [49] {ECO:0007744|PDB:1LF0, ECO:0007744|PDB:1LF5} RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-166 IN COMPLEXES WITH GTP RP ANALOGS. RX PubMed=12213964; DOI=10.1073/pnas.192453199; RA Hall B.E., Bar-Sagi D., Nassar N.; RT "The structural basis for the transition from Ras-GTP to Ras-GDP."; RL Proc. Natl. Acad. Sci. U.S.A. 99:12138-12142(2002). RN [50] RP STRUCTURE BY NMR OF 1-166, S-NITROSYLATION, FUNCTION, MUTAGENESIS OF RP CYS-118, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12740440; DOI=10.1073/pnas.1037299100; RA Williams J.G., Pappu K., Campbell S.L.; RT "Structural and biochemical studies of p21Ras S-nitrosylation and nitric RT oxide-mediated guanine nucleotide exchange."; RL Proc. Natl. Acad. Sci. U.S.A. 100:6376-6381(2003). RN [51] {ECO:0007744|PDB:2CE2, ECO:0007744|PDB:2CL0, ECO:0007744|PDB:2CL6, ECO:0007744|PDB:2CL7, ECO:0007744|PDB:2CLC, ECO:0007744|PDB:2CLD, ECO:0007744|PDB:2EVW} RP X-RAY CRYSTALLOGRAPHY (1.00 ANGSTROMS) OF 1-166 IN COMPLEX WITH GTP AND RP MAGNESIUM. RX PubMed=16698776; DOI=10.1529/biophysj.105.078931; RA Klink B.U., Goody R.S., Scheidig A.J.; RT "A newly designed microspectrofluorometer for kinetic studies on protein RT crystals in combination with x-ray diffraction."; RL Biophys. J. 91:981-992(2006). RN [52] {ECO:0007744|PDB:2RGA, ECO:0007744|PDB:2RGB, ECO:0007744|PDB:2RGC, ECO:0007744|PDB:2RGD, ECO:0007744|PDB:2RGE, ECO:0007744|PDB:2RGG} RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-166 IN COMPLEXES WITH GTP RP ANALOG, CHARACTERIZATION OF VARIANTS LEU-61 AND LYS-61, AND MUTAGENESIS OF RP GLN-61. RX PubMed=18073111; DOI=10.1016/j.str.2007.10.011; RA Buhrman G., Wink G., Mattos C.; RT "Transformation efficiency of RasQ61 mutants linked to structural features RT of the switch regions in the presence of Raf."; RL Structure 15:1618-1629(2007). RN [53] {ECO:0007744|PDB:3DDC} RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-166 IN COMPLEX WITH RASSF5. RX PubMed=18596699; DOI=10.1038/emboj.2008.125; RA Stieglitz B., Bee C., Schwarz D., Yildiz O., Moshnikova A., RA Khokhlatchev A., Herrmann C.; RT "Novel type of Ras effector interaction established between tumour RT suppressor NORE1A and Ras switch II."; RL EMBO J. 27:1995-2005(2008). RN [54] {ECO:0007744|PDB:7VV8, ECO:0007744|PDB:7VV9, ECO:0007744|PDB:7VVG} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1-166 IN COMPLEX WITH MAPKAP1, RP AND INTERACTION WITH MAPKAP1. RX PubMed=35522713; DOI=10.1073/pnas.2119990119; RA Zheng Y., Ding L., Meng X., Potter M., Kearney A.L., Zhang J., Sun J., RA James D.E., Yang G., Zhou C.; RT "Structural insights into Ras regulation by SIN1."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2119990119-e2119990119(2022). RN [55] RP VARIANT SER-12. RX PubMed=1459726; DOI=10.1002/ijc.2910520606; RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., RA Yamamoto H., Tsuchida N.; RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous- RT cell carcinoma."; RL Int. J. Cancer 52:867-872(1992). RN [56] RP INVOLVEMENT IN NMTC2, AND VARIANT NMTC2 LYS-61. RX PubMed=12727991; DOI=10.1210/jc.2002-021907; RA Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn G.W. II, RA Tallini G., Kroll T.G., Nikiforov Y.E.; RT "RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: RT evidence for distinct molecular pathways in thyroid follicular carcinoma."; RL J. Clin. Endocrinol. Metab. 88:2318-2326(2003). RN [57] RP VARIANTS CSTLO ALA-12; SER-12; VAL-12 AND ASP-13. RX PubMed=16170316; DOI=10.1038/ng1641; RA Aoki Y., Niihori T., Kawame H., Kurosawa K., Ohashi H., Tanaka Y., RA Filocamo M., Kato K., Suzuki Y., Kure S., Matsubara Y.; RT "Germline mutations in HRAS proto-oncogene cause Costello syndrome."; RL Nat. Genet. 37:1038-1040(2005). RN [58] RP VARIANTS CSTLO ALA-12; SER-12 AND CYS-13. RX PubMed=16329078; DOI=10.1002/ajmg.a.31047; RA Gripp K.W., Lin A.E., Stabley D.L., Nicholson L., Scott C.I. Jr., Doyle D., RA Aoki Y., Matsubara Y., Zackai E.H., Lapunzina P., Gonzalez-Meneses A., RA Holbrook J., Agresta C.A., Gonzalez I.L., Sol-Church K.; RT "HRAS mutation analysis in Costello syndrome: genotype and phenotype RT correlation."; RL Am. J. Med. Genet. A 140:1-7(2006). RN [59] RP VARIANTS CSTLO SER-12; CYS-12; GLU-12; ALA-12 AND ARG-117. RX PubMed=16443854; DOI=10.1136/jmg.2005.040352; RA Kerr B., Delrue M.-A., Sigaudy S., Perveen R., Marche M., Burgelin I., RA Stef M., Tang B., Eden O.B., O'Sullivan J., De Sandre-Giovannoli A., RA Reardon W., Brewer C., Bennett C., Quarell O., M'Cann E., Donnai D., RA Stewart F., Hennekam R., Cave H., Verloes A., Philip N., Lacombe D., RA Levy N., Arveiler B., Black G.; RT "Genotype-phenotype correlation in Costello syndrome: HRAS mutation RT analysis in 43 cases."; RL J. Med. Genet. 43:401-405(2006). RN [60] RP VARIANTS CSTLO SER-12 AND THR-146. RX PubMed=17054105; DOI=10.1002/humu.20431; RA Zampino G., Pantaleoni F., Carta C., Cobellis G., Vasta I., Neri C., RA Pogna E.A., De Feo E., Delogu A., Sarkozy A., Atzeri F., Selicorni A., RA Rauen K.A., Cytrynbaum C.S., Weksberg R., Dallapiccola B., Ballabio A., RA Gelb B.D., Neri G., Tartaglia M.; RT "Diversity, parental germline origin, and phenotypic spectrum of de novo RT HRAS missense changes in Costello syndrome."; RL Hum. Mutat. 28:265-272(2007). RN [61] RP VARIANTS CMEMS VAL-12; SER-12; LYS-22 AND LYS-63. RX PubMed=17412879; DOI=10.1136/jmg.2007.049270; RA van der Burgt I., Kupsky W., Stassou S., Nadroo A., Barroso C., Diem A., RA Kratz C.P., Dvorsky R., Ahmadian M.R., Zenker M.; RT "Myopathy caused by HRAS germline mutations: implications for disturbed RT myogenic differentiation in the presence of constitutive HRas activation."; RL J. Med. Genet. 44:459-462(2007). RN [62] RP VARIANTS CSTLO ILE-58 AND VAL-146. RX PubMed=18247425; DOI=10.1002/ajmg.a.32227; RA Gripp K.W., Innes A.M., Axelrad M.E., Gillan T.L., Parboosingh J.S., RA Davies C., Leonard N.J., Lapointe M., Doyle D., Catalano S., Nicholson L., RA Stabley D.L., Sol-Church K.; RT "Costello syndrome associated with novel germline HRAS mutations: an RT attenuated phenotype?"; RL Am. J. Med. Genet. A 146:683-690(2008). RN [63] RP VARIANTS CSTLO ASP-12 AND CYS-12. RX PubMed=18039947; DOI=10.1136/jmg.2007.054411; RA Lo I.F., Brewer C., Shannon N., Shorto J., Tang B., Black G., Soo M.T., RA Ng D.K., Lam S.T., Kerr B.; RT "Severe neonatal manifestations of Costello syndrome."; RL J. Med. Genet. 45:167-171(2008). RN [64] RP VARIANT CSTLO GLU-37 INS. RX PubMed=19995790; DOI=10.1093/hmg/ddp548; RA Gremer L., De Luca A., Merbitz-Zahradnik T., Dallapiccola B., Morlot S., RA Tartaglia M., Kutsche K., Ahmadian M.R., Rosenberger G.; RT "Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP RT binding and underlies Costello syndrome by promoting enhanced growth RT factor-dependent MAPK and AKT activation."; RL Hum. Mol. Genet. 19:790-802(2010). RN [65] RP VARIANT SFM ARG-13, AND CHARACTERIZATION OF VARIANT SFM ARG-13. RX PubMed=22683711; DOI=10.1038/ng.2316; RA Groesser L., Herschberger E., Ruetten A., Ruivenkamp C., Lopriore E., RA Zutt M., Langmann T., Singer S., Klingseisen L., Schneider-Brachert W., RA Toll A., Real F.X., Landthaler M., Hafner C.; RT "Postzygotic HRAS and KRAS mutations cause nevus sebaceous and RT Schimmelpenning syndrome."; RL Nat. Genet. 44:783-787(2012). CC -!- FUNCTION: Involved in the activation of Ras protein signal transduction CC (PubMed:22821884). Ras proteins bind GDP/GTP and possess intrinsic CC GTPase activity (PubMed:12740440, PubMed:14500341, PubMed:9020151). CC {ECO:0000269|PubMed:12740440, ECO:0000269|PubMed:14500341, CC ECO:0000269|PubMed:22821884, ECO:0000269|PubMed:9020151}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2; CC Evidence={ECO:0000269|PubMed:9020151}; CC -!- ACTIVITY REGULATION: Alternates between an inactive form bound to GDP CC and an active form bound to GTP. Activated by a guanine nucleotide- CC exchange factor (GEF) and inactivated by a GTPase-activating protein CC (GAP). CC -!- SUBUNIT: In its GTP-bound form interacts with PLCE1 (PubMed:11022048). CC Interacts with TBC1D10C (PubMed:17230191). Interacts with RGL3 (By CC similarity). Interacts with HSPD1 (By similarity). Found in a complex CC with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14 (By similarity). CC Interacts (active GTP-bound form) with RGS14 (via RBD 1 domain) (By CC similarity). Forms a signaling complex with RASGRP1 and DGKZ CC (PubMed:11257115). Interacts with RASSF5 (PubMed:18596699). Interacts CC with PDE6D (PubMed:11980706). Interacts with IKZF3 (PubMed:10369681). CC Interacts with RACK1 (PubMed:14500341). Interacts with PIK3CG; the CC interaction is required for membrane recruitment and beta-gamma G CC protein dimer-dependent activation of the PI3K gamma complex CC PIK3CG:PIK3R6 (By similarity). Interacts with RAPGEF2 (PubMed:10608844, CC PubMed:11598133). Interacts (active GTP-bound form) with both SHOC2 and CC PP1c (all isoforms) to form a tertiary complex; SHOC2 and PP1c CC preferably bind M-Ras/MRAS, but they also bind K-Ras/KRAS, N-Ras/NRAS CC and H-Ras/HRAS (PubMed:35768504, PubMed:35831509, PubMed:36175670). CC Interacts (GTP-bound form) with MAPKAP1/SIN1; inhibiting H-Ras/HRAS CC activity (PubMed:35522713). {ECO:0000250|UniProtKB:P20171, CC ECO:0000250|UniProtKB:Q61411, ECO:0000269|PubMed:10369681, CC ECO:0000269|PubMed:10608844, ECO:0000269|PubMed:11022048, CC ECO:0000269|PubMed:11257115, ECO:0000269|PubMed:11598133, CC ECO:0000269|PubMed:11980706, ECO:0000269|PubMed:14500341, CC ECO:0000269|PubMed:17230191, ECO:0000269|PubMed:18596699, CC ECO:0000269|PubMed:35522713, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35831509, ECO:0000269|PubMed:36175670}. CC -!- INTERACTION: CC P01112; Q99996-3: AKAP9; NbExp=3; IntAct=EBI-350145, EBI-11022349; CC P01112; P53677-2: AP3M2; NbExp=3; IntAct=EBI-350145, EBI-12177015; CC P01112; P10398: ARAF; NbExp=7; IntAct=EBI-350145, EBI-365961; CC P01112; Q9NXL2-1: ARHGEF38; NbExp=3; IntAct=EBI-350145, EBI-18172597; CC P01112; Q9UII2: ATP5IF1; NbExp=3; IntAct=EBI-350145, EBI-718459; CC P01112; Q9H7T9: AUNIP; NbExp=3; IntAct=EBI-350145, EBI-10693257; CC P01112; Q00994: BEX3; NbExp=3; IntAct=EBI-350145, EBI-741753; CC P01112; Q9H2G9: BLZF1; NbExp=4; IntAct=EBI-350145, EBI-2548012; CC P01112; P15056: BRAF; NbExp=9; IntAct=EBI-350145, EBI-365980; CC P01112; Q7Z569: BRAP; NbExp=3; IntAct=EBI-350145, EBI-349900; CC P01112; Q5PSV4: BRMS1L; NbExp=3; IntAct=EBI-350145, EBI-5666615; CC P01112; Q9ULD4-2: BRPF3; NbExp=3; IntAct=EBI-350145, EBI-23662416; CC P01112; Q96LL4: C8orf48; NbExp=3; IntAct=EBI-350145, EBI-751596; CC P01112; Q03135: CAV1; NbExp=2; IntAct=EBI-350145, EBI-603614; CC P01112; Q96HB5: CCDC120; NbExp=3; IntAct=EBI-350145, EBI-744556; CC P01112; Q49A88-3: CCDC14; NbExp=3; IntAct=EBI-350145, EBI-12105646; CC P01112; Q96GN5-2: CDCA7L; NbExp=3; IntAct=EBI-350145, EBI-9091443; CC P01112; P24941: CDK2; NbExp=3; IntAct=EBI-350145, EBI-375096; CC P01112; O95674: CDS2; NbExp=3; IntAct=EBI-350145, EBI-3913685; CC P01112; Q9H3R5: CENPH; NbExp=3; IntAct=EBI-350145, EBI-1003700; CC P01112; Q9Y4F5-3: CEP170B; NbExp=3; IntAct=EBI-350145, EBI-12950757; CC P01112; Q86XR8: CEP57; NbExp=3; IntAct=EBI-350145, EBI-308614; CC P01112; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-350145, EBI-11953200; CC P01112; Q8WUX9: CHMP7; NbExp=4; IntAct=EBI-350145, EBI-749253; CC P01112; Q14117: DPYS; NbExp=3; IntAct=EBI-350145, EBI-12275416; CC P01112; Q9Y6W6: DUSP10; NbExp=3; IntAct=EBI-350145, EBI-3443946; CC P01112; O14641: DVL2; NbExp=3; IntAct=EBI-350145, EBI-740850; CC P01112; A0AVK6: E2F8; NbExp=3; IntAct=EBI-350145, EBI-7779316; CC P01112; Q8NB25: FAM184A; NbExp=3; IntAct=EBI-350145, EBI-9917523; CC P01112; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-350145, EBI-8468186; CC P01112; Q969H0: FBXW7; NbExp=5; IntAct=EBI-350145, EBI-359574; CC P01112; O94868-3: FCHSD2; NbExp=3; IntAct=EBI-350145, EBI-11958845; CC P01112; P15407: FOSL1; NbExp=3; IntAct=EBI-350145, EBI-744510; CC P01112; P15408: FOSL2; NbExp=3; IntAct=EBI-350145, EBI-3893419; CC P01112; P52655: GTF2A1; NbExp=3; IntAct=EBI-350145, EBI-389518; CC P01112; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-350145, EBI-2514791; CC P01112; Q9BT25: HAUS8; NbExp=3; IntAct=EBI-350145, EBI-2558143; CC P01112; Q8IV36: HID1; NbExp=3; IntAct=EBI-350145, EBI-743438; CC P01112; O43248: HOXC11; NbExp=3; IntAct=EBI-350145, EBI-2652631; CC P01112; Q53GQ0: HSD17B12; NbExp=3; IntAct=EBI-350145, EBI-2963255; CC P01112; P10809: HSPD1; NbExp=3; IntAct=EBI-350145, EBI-352528; CC P01112; Q8NDH6-2: ICA1L; NbExp=3; IntAct=EBI-350145, EBI-12141931; CC P01112; Q8IY31-2: IFT20; NbExp=3; IntAct=EBI-350145, EBI-11742277; CC P01112; Q8NA54: IQUB; NbExp=3; IntAct=EBI-350145, EBI-10220600; CC P01112; Q13352: ITGB3BP; NbExp=3; IntAct=EBI-350145, EBI-712105; CC P01112; P28290-2: ITPRID2; NbExp=3; IntAct=EBI-350145, EBI-25863618; CC P01112; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-350145, EBI-14069005; CC P01112; Q2M2Z5: KIZ; NbExp=3; IntAct=EBI-350145, EBI-2554344; CC P01112; Q6P597: KLC3; NbExp=3; IntAct=EBI-350145, EBI-1643885; CC P01112; P57682: KLF3; NbExp=3; IntAct=EBI-350145, EBI-8472267; CC P01112; Q9UH77: KLHL3; NbExp=3; IntAct=EBI-350145, EBI-8524663; CC P01112; P08727: KRT19; NbExp=3; IntAct=EBI-350145, EBI-742756; CC P01112; Q14525: KRT33B; NbExp=3; IntAct=EBI-350145, EBI-1049638; CC P01112; Q14847-2: LASP1; NbExp=3; IntAct=EBI-350145, EBI-9088686; CC P01112; Q96LR2: LURAP1; NbExp=3; IntAct=EBI-350145, EBI-741355; CC P01112; P27338: MAOB; NbExp=3; IntAct=EBI-350145, EBI-3911344; CC P01112; Q99558: MAP3K14; NbExp=3; IntAct=EBI-350145, EBI-358011; CC P01112; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-350145, EBI-348259; CC P01112; Q8TAC0: MGC27345; NbExp=3; IntAct=EBI-350145, EBI-25851300; CC P01112; Q5JXC2: MIIP; NbExp=3; IntAct=EBI-350145, EBI-2801965; CC P01112; Q8NEH6: MNS1; NbExp=3; IntAct=EBI-350145, EBI-743811; CC P01112; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-350145, EBI-995714; CC P01112; Q96HT8: MRFAP1L1; NbExp=3; IntAct=EBI-350145, EBI-748896; CC P01112; Q9GZM8: NDEL1; NbExp=3; IntAct=EBI-350145, EBI-928842; CC P01112; P21359: NF1; NbExp=3; IntAct=EBI-350145, EBI-1172917; CC P01112; Q8N5V2: NGEF; NbExp=3; IntAct=EBI-350145, EBI-718372; CC P01112; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-350145, EBI-2802743; CC P01112; Q9BZ95-3: NSD3; NbExp=3; IntAct=EBI-350145, EBI-22002759; CC P01112; A5D8V7: ODAD3; NbExp=3; IntAct=EBI-350145, EBI-8466445; CC P01112; O43482: OIP5; NbExp=3; IntAct=EBI-350145, EBI-536879; CC P01112; Q9BR81: PCDHGC3; NbExp=3; IntAct=EBI-350145, EBI-22012354; CC P01112; O15534: PER1; NbExp=3; IntAct=EBI-350145, EBI-2557276; CC P01112; Q9BUL5: PHF23; NbExp=3; IntAct=EBI-350145, EBI-722852; CC P01112; O00329: PIK3CD; NbExp=2; IntAct=EBI-350145, EBI-718309; CC P01112; O00329-2: PIK3CD; NbExp=2; IntAct=EBI-350145, EBI-6470902; CC P01112; Q9UPR0: PLCL2; NbExp=3; IntAct=EBI-350145, EBI-311059; CC P01112; Q96I34: PPP1R16A; NbExp=3; IntAct=EBI-350145, EBI-710402; CC P01112; Q15435-3: PPP1R7; NbExp=3; IntAct=EBI-350145, EBI-10695066; CC P01112; P04049: RAF1; NbExp=30; IntAct=EBI-350145, EBI-365996; CC P01112; P11233: RALA; NbExp=2; IntAct=EBI-350145, EBI-1036803; CC P01112; Q15311: RALBP1; NbExp=3; IntAct=EBI-350145, EBI-749285; CC P01112; Q12967: RALGDS; NbExp=3; IntAct=EBI-350145, EBI-365861; CC P01112; P52306: RAP1GDS1; NbExp=2; IntAct=EBI-350145, EBI-746389; CC P01112; Q9NS23-2: RASSF1; NbExp=2; IntAct=EBI-350145, EBI-438698; CC P01112; Q9NS23-4: RASSF1; NbExp=4; IntAct=EBI-350145, EBI-438710; CC P01112; Q8WWW0: RASSF5; NbExp=2; IntAct=EBI-350145, EBI-367390; CC P01112; Q8TBY0: RBM46; NbExp=3; IntAct=EBI-350145, EBI-12068216; CC P01112; Q9P2K3-2: RCOR3; NbExp=3; IntAct=EBI-350145, EBI-1504830; CC P01112; Q9NZL6: RGL1; NbExp=4; IntAct=EBI-350145, EBI-365926; CC P01112; O15211: RGL2; NbExp=3; IntAct=EBI-350145, EBI-712355; CC P01112; Q8IXN7: RIMKLA; NbExp=3; IntAct=EBI-350145, EBI-21890191; CC P01112; Q13671: RIN1; NbExp=15; IntAct=EBI-350145, EBI-366017; CC P01112; Q13671-1: RIN1; NbExp=2; IntAct=EBI-350145, EBI-366030; CC P01112; Q8WVD3: RNF138; NbExp=3; IntAct=EBI-350145, EBI-749039; CC P01112; Q9BY12-3: SCAPER; NbExp=3; IntAct=EBI-350145, EBI-25837959; CC P01112; Q13435: SF3B2; NbExp=3; IntAct=EBI-350145, EBI-749111; CC P01112; Q13485: SMAD4; NbExp=5; IntAct=EBI-350145, EBI-347263; CC P01112; Q12824: SMARCB1; NbExp=3; IntAct=EBI-350145, EBI-358419; CC P01112; Q13573: SNW1; NbExp=3; IntAct=EBI-350145, EBI-632715; CC P01112; Q07889: SOS1; NbExp=11; IntAct=EBI-350145, EBI-297487; CC P01112; Q86W54-2: SPATA24; NbExp=3; IntAct=EBI-350145, EBI-12041693; CC P01112; P12931: SRC; NbExp=2; IntAct=EBI-350145, EBI-621482; CC P01112; Q92783-2: STAM; NbExp=3; IntAct=EBI-350145, EBI-12025738; CC P01112; O75886: STAM2; NbExp=3; IntAct=EBI-350145, EBI-373258; CC P01112; Q13586: STIM1; NbExp=4; IntAct=EBI-350145, EBI-448878; CC P01112; Q8N4C7: STX19; NbExp=3; IntAct=EBI-350145, EBI-8484990; CC P01112; O75528: TADA3; NbExp=3; IntAct=EBI-350145, EBI-473249; CC P01112; P54274-2: TERF1; NbExp=3; IntAct=EBI-350145, EBI-711018; CC P01112; Q9BXU0: TEX12; NbExp=3; IntAct=EBI-350145, EBI-12090309; CC P01112; Q5T0J7-2: TEX35; NbExp=3; IntAct=EBI-350145, EBI-12833746; CC P01112; Q5T1C6: THEM4; NbExp=3; IntAct=EBI-350145, EBI-7684443; CC P01112; Q8IUR5-4: TMTC1; NbExp=3; IntAct=EBI-350145, EBI-9089156; CC P01112; P36406: TRIM23; NbExp=3; IntAct=EBI-350145, EBI-740098; CC P01112; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-350145, EBI-11525489; CC P01112; Q99598: TSNAX; NbExp=3; IntAct=EBI-350145, EBI-21353855; CC P01112; Q6PF05: TTC23L; NbExp=3; IntAct=EBI-350145, EBI-8656864; CC P01112; Q9UGJ1-2: TUBGCP4; NbExp=3; IntAct=EBI-350145, EBI-10964469; CC P01112; Q9Y5Z9: UBIAD1; NbExp=9; IntAct=EBI-350145, EBI-2819725; CC P01112; P22415: USF1; NbExp=3; IntAct=EBI-350145, EBI-1054489; CC P01112; Q495M9: USH1G; NbExp=3; IntAct=EBI-350145, EBI-8601749; CC P01112; Q9H270: VPS11; NbExp=3; IntAct=EBI-350145, EBI-373380; CC P01112; Q8NEZ2: VPS37A; NbExp=3; IntAct=EBI-350145, EBI-2850578; CC P01112; P19544-6: WT1; NbExp=3; IntAct=EBI-350145, EBI-11745701; CC P01112; O43829: ZBTB14; NbExp=3; IntAct=EBI-350145, EBI-10176632; CC P01112; Q9C0F3: ZNF436; NbExp=3; IntAct=EBI-350145, EBI-8489702; CC P01112; Q7Z637; NbExp=3; IntAct=EBI-350145, EBI-25831475; CC P01112; Q86V28; NbExp=3; IntAct=EBI-350145, EBI-10259496; CC P01112; P42337: Pik3ca; Xeno; NbExp=3; IntAct=EBI-350145, EBI-641748; CC P01112; Q9Z0S9: Rabac1; Xeno; NbExp=4; IntAct=EBI-350145, EBI-476965; CC P01112; Q9EQZ6: Rapgef4; Xeno; NbExp=3; IntAct=EBI-350145, EBI-772212; CC P01112; P27671: Rasgrf1; Xeno; NbExp=2; IntAct=EBI-350145, EBI-645522; CC P01112; Q5EBH1: Rassf5; Xeno; NbExp=13; IntAct=EBI-350145, EBI-960530; CC P01112; Q5EBH1-1: Rassf5; Xeno; NbExp=3; IntAct=EBI-350145, EBI-960543; CC P01112-2; P52306-5: RAP1GDS1; NbExp=5; IntAct=EBI-13290525, EBI-12832744; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P20171}; CC Lipid-anchor; Cytoplasmic side. Golgi apparatus. Golgi apparatus CC membrane; Lipid-anchor. Note=The active GTP-bound form is localized CC most strongly to membranes than the inactive GDP-bound form (By CC similarity). Shuttles between the plasma membrane and the Golgi CC apparatus. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Cytoplasm, CC perinuclear region. Note=Colocalizes with RACK1 to the perinuclear CC region. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=H-Ras4A, p21; CC IsoId=P01112-1; Sequence=Displayed; CC Name=2; Synonyms=H-RasIDX, p19; CC IsoId=P01112-2; Sequence=VSP_041597; CC -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:14500341}. CC -!- PTM: Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of CC de- and re-palmitoylation regulates rapid exchange between plasma CC membrane and Golgi. CC -!- PTM: S-nitrosylated; critical for redox regulation. Important for CC stimulating guanine nucleotide exchange. No structural perturbation on CC nitrosylation. CC -!- PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14- CC prostaglandin-J2 is autocatalytic and reversible. It may occur as an CC alternative to other cysteine modifications, such as S-nitrosylation CC and S-palmitoylation. CC -!- PTM: Acetylation at Lys-104 prevents interaction with guanine CC nucleotide exchange factors (GEFs). {ECO:0000250}. CC -!- PTM: Fatty-acylated at Lys-170. {ECO:0000269|PubMed:29239724}. CC -!- PTM: Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at CC Lys-170 in a non-degradative manner, leading to inhibit Ras signaling CC by decreasing Ras association with membranes. CC {ECO:0000269|PubMed:30442762}. CC -!- PTM: (Microbial infection) Glucosylated at Thr-35 by P.sordellii toxin CC TcsL (PubMed:19744486, PubMed:8626575, PubMed:8626586, PubMed:9632667). CC Monoglucosylation completely prevents the recognition of the downstream CC effector, blocking the GTPases in their inactive form, leading to CC inhibit Ras signaling (PubMed:8626575, PubMed:8626586, PubMed:9632667). CC {ECO:0000269|PubMed:19744486, ECO:0000269|PubMed:8626575, CC ECO:0000269|PubMed:8626586, ECO:0000269|PubMed:9632667}. CC -!- DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition CC characterized by prenatally increased growth, postnatal growth CC deficiency, intellectual disability, distinctive facial appearance, CC cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic CC cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin CC and musculoskeletal abnormalities. {ECO:0000269|PubMed:16170316, CC ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854, CC ECO:0000269|PubMed:17054105, ECO:0000269|PubMed:18039947, CC ECO:0000269|PubMed:18247425, ECO:0000269|PubMed:19995790}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Congenital myopathy with excess of muscle spindles (CMEMS) CC [MIM:218040]: Variant of Costello syndrome. CC {ECO:0000269|PubMed:17412879}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Thyroid cancer, non-medullary, 2 (NMTC2) [MIM:188470]: A form CC of non-medullary thyroid cancer (NMTC), a cancer characterized by CC tumors originating from the thyroid follicular cells. NMTCs represent CC approximately 95% of all cases of thyroid cancer and are classified CC into papillary, follicular, Hurthle cell, and anaplastic neoplasms. CC {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Mutations which change positions 12, 13 or 61 activate CC the potential of HRAS to transform cultured cells and are implicated in CC a variety of human tumors. {ECO:0000269|PubMed:3670300}. CC -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in CC tissues of the urinary bladder. It often presents with multiple tumors CC appearing at different times and at different sites in the bladder. CC Most bladder cancers are transitional cell carcinomas that begin in CC cells that normally make up the inner lining of the bladder. Other CC types of bladder cancer include squamous cell carcinoma (cancer that CC begins in thin, flat cells) and adenocarcinoma (cancer that begins in CC cells that make and release mucus and other fluids). Bladder cancer is CC a complex disorder with both genetic and environmental influences. CC {ECO:0000269|PubMed:6298635, ECO:0000269|PubMed:6844927}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A CC disease characterized by sebaceous nevi, often on the face, associated CC with variable ipsilateral abnormalities of the central nervous system, CC ocular anomalies, and skeletal defects. Many oral manifestations have CC been reported, not only including hypoplastic and malformed teeth, and CC mucosal papillomatosis, but also ankyloglossia, hemihyperplastic CC tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone CC cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous CC nevi follow the lines of Blaschko and these can continue as linear CC intraoral lesions, as in mucosal papillomatosis. CC {ECO:0000269|PubMed:22683711}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the small GTPase superfamily. Ras family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/108/HRAS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J00277; AAB02605.1; -; Genomic_DNA. DR EMBL; AJ437024; CAD24594.1; -; mRNA. DR EMBL; AF493916; AAM12630.1; -; mRNA. DR EMBL; CR536579; CAG38816.1; -; mRNA. DR EMBL; CR542271; CAG47067.1; -; mRNA. DR EMBL; BT019421; AAV38228.1; -; mRNA. DR EMBL; EF015887; ABI97389.1; -; Genomic_DNA. DR EMBL; AB451336; BAG70150.1; -; mRNA. DR EMBL; AB451485; BAG70299.1; -; mRNA. DR EMBL; CH471158; EAX02337.1; -; Genomic_DNA. DR EMBL; CH471158; EAX02338.1; -; Genomic_DNA. DR EMBL; BC006499; AAH06499.1; -; mRNA. DR EMBL; BC095471; AAH95471.1; -; mRNA. DR EMBL; M17232; AAA35685.1; -; Genomic_DNA. DR CCDS; CCDS7698.1; -. [P01112-1] DR CCDS; CCDS7699.1; -. [P01112-2] DR PIR; A93299; TVHUH. DR RefSeq; NP_001123914.1; NM_001130442.3. [P01112-1] DR RefSeq; NP_001304983.1; NM_001318054.1. DR RefSeq; NP_005334.1; NM_005343.4. [P01112-1] DR RefSeq; NP_789765.1; NM_176795.5. [P01112-2] DR RefSeq; XP_054224585.1; XM_054368610.1. [P01112-1] DR PDB; 121P; X-ray; 1.54 A; A=1-166. DR PDB; 1AA9; NMR; -; A=1-171. DR PDB; 1AGP; X-ray; 2.30 A; A=1-166. DR PDB; 1BKD; X-ray; 2.80 A; R=1-166. DR PDB; 1CLU; X-ray; 1.70 A; A=1-166. DR PDB; 1CRP; NMR; -; A=1-166. DR PDB; 1CRQ; NMR; -; A=1-166. DR PDB; 1CRR; NMR; -; A=1-166. DR PDB; 1CTQ; X-ray; 1.26 A; A=1-166. DR PDB; 1GNP; X-ray; 2.70 A; A=1-166. DR PDB; 1GNQ; X-ray; 2.50 A; A=1-166. DR PDB; 1GNR; X-ray; 1.85 A; A=1-166. DR PDB; 1HE8; X-ray; 3.00 A; B=1-166. DR PDB; 1IAQ; X-ray; 2.90 A; A/B/C=1-166. DR PDB; 1IOZ; X-ray; 2.00 A; A=1-171. DR PDB; 1JAH; X-ray; 1.80 A; A=1-166. DR PDB; 1JAI; X-ray; 1.80 A; A=1-166. DR PDB; 1K8R; X-ray; 3.00 A; A=1-166. DR PDB; 1LF0; X-ray; 1.70 A; A=1-166. DR PDB; 1LF5; X-ray; 1.70 A; A=1-166. DR PDB; 1LFD; X-ray; 2.10 A; B/D=1-167. DR PDB; 1NVU; X-ray; 2.20 A; Q/R=1-166. DR PDB; 1NVV; X-ray; 2.18 A; Q/R=1-166. DR PDB; 1NVW; X-ray; 2.70 A; Q/R=1-166. DR PDB; 1NVX; X-ray; 3.20 A; Q/R=1-166. DR PDB; 1P2S; X-ray; 2.45 A; A=1-166. DR PDB; 1P2T; X-ray; 2.00 A; A=1-166. DR PDB; 1P2U; X-ray; 2.00 A; A=1-166. DR PDB; 1P2V; X-ray; 2.30 A; A=1-166. DR PDB; 1PLJ; X-ray; 2.80 A; A=1-166. DR PDB; 1PLK; X-ray; 2.80 A; A=1-166. DR PDB; 1PLL; X-ray; 2.80 A; A=1-166. DR PDB; 1Q21; X-ray; 2.20 A; A=1-171. DR PDB; 1QRA; X-ray; 1.60 A; A=1-166. DR PDB; 1RVD; X-ray; 1.90 A; A=1-166. DR PDB; 1WQ1; X-ray; 2.50 A; R=1-166. DR PDB; 1XCM; X-ray; 1.84 A; A=1-167. DR PDB; 1XD2; X-ray; 2.70 A; A/B=1-166. DR PDB; 1XJ0; X-ray; 1.70 A; A=1-166. DR PDB; 1ZVQ; X-ray; 2.00 A; A=1-166. DR PDB; 1ZW6; X-ray; 1.50 A; A=1-166. DR PDB; 221P; X-ray; 2.30 A; A=1-166. DR PDB; 2C5L; X-ray; 1.90 A; A/B=1-166. DR PDB; 2CE2; X-ray; 1.00 A; X=1-166. DR PDB; 2CL0; X-ray; 1.80 A; X=1-166. DR PDB; 2CL6; X-ray; 1.24 A; X=1-166. DR PDB; 2CL7; X-ray; 1.25 A; X=1-166. DR PDB; 2CLC; X-ray; 1.30 A; X=1-166. DR PDB; 2CLD; X-ray; 1.22 A; X=1-166. DR PDB; 2EVW; X-ray; 1.05 A; X=1-166. DR PDB; 2LCF; NMR; -; A=1-166. DR PDB; 2LWI; NMR; -; A=1-166. DR PDB; 2N42; NMR; -; A=1-166. DR PDB; 2N46; NMR; -; A=1-166. DR PDB; 2Q21; X-ray; 2.20 A; A=1-171. DR PDB; 2QUZ; X-ray; 1.49 A; A=1-166. DR PDB; 2RGA; X-ray; 1.90 A; A=1-166. DR PDB; 2RGB; X-ray; 1.35 A; A=1-166. DR PDB; 2RGC; X-ray; 1.60 A; A=1-166. DR PDB; 2RGD; X-ray; 2.00 A; A=1-166. DR PDB; 2RGE; X-ray; 1.40 A; A=1-166. DR PDB; 2RGG; X-ray; 1.45 A; A=1-166. DR PDB; 2UZI; X-ray; 2.00 A; R=1-166. DR PDB; 2VH5; X-ray; 2.70 A; R=1-166. DR PDB; 2X1V; X-ray; 1.70 A; A=1-166. DR PDB; 3DDC; X-ray; 1.80 A; A=1-166. DR PDB; 3I3S; X-ray; 1.36 A; R=1-166. DR PDB; 3K8Y; X-ray; 1.30 A; A=1-166. DR PDB; 3K9L; X-ray; 1.80 A; A/B/C=1-166. DR PDB; 3K9N; X-ray; 2.00 A; A=1-166. DR PDB; 3KKM; X-ray; 1.70 A; A=1-166. DR PDB; 3KKN; X-ray; 2.09 A; A=1-166. DR PDB; 3KUD; X-ray; 2.15 A; A=1-166. DR PDB; 3L8Y; X-ray; 2.02 A; A=1-166. DR PDB; 3L8Z; X-ray; 1.44 A; A=1-166. DR PDB; 3LBH; X-ray; 1.85 A; A=1-166. DR PDB; 3LBI; X-ray; 2.09 A; A=1-166. DR PDB; 3LBN; X-ray; 1.86 A; A=1-166. DR PDB; 3LO5; X-ray; 2.57 A; A/C/E=1-166. DR PDB; 3OIU; X-ray; 1.32 A; A=1-166. DR PDB; 3OIV; X-ray; 1.84 A; A=1-166. DR PDB; 3OIW; X-ray; 1.30 A; A=1-166. DR PDB; 3RRY; X-ray; 1.60 A; A=1-166. DR PDB; 3RRZ; X-ray; 1.60 A; A=1-166. DR PDB; 3RS0; X-ray; 1.40 A; A=1-166. DR PDB; 3RS2; X-ray; 1.84 A; A=1-166. DR PDB; 3RS3; X-ray; 1.52 A; A=1-166. DR PDB; 3RS4; X-ray; 1.70 A; A=1-166. DR PDB; 3RS5; X-ray; 1.68 A; A=1-166. DR PDB; 3RS7; X-ray; 1.70 A; A=1-166. DR PDB; 3RSL; X-ray; 1.70 A; A=1-166. DR PDB; 3RSO; X-ray; 1.60 A; A=1-166. DR PDB; 3TGP; X-ray; 1.31 A; A=1-166. DR PDB; 421P; X-ray; 2.20 A; A=1-166. DR PDB; 4DLR; X-ray; 1.32 A; A=1-166. DR PDB; 4DLS; X-ray; 1.82 A; A=1-166. DR PDB; 4DLT; X-ray; 1.70 A; A=1-166. DR PDB; 4DLU; X-ray; 1.60 A; A=1-166. DR PDB; 4DLV; X-ray; 1.57 A; A=1-166. DR PDB; 4DLW; X-ray; 1.72 A; A=1-166. DR PDB; 4DLX; X-ray; 1.73 A; A=1-166. DR PDB; 4DLY; X-ray; 1.57 A; A=1-166. DR PDB; 4DLZ; X-ray; 1.66 A; A=1-166. DR PDB; 4DST; X-ray; 2.30 A; A=2-167. DR PDB; 4DSU; X-ray; 1.70 A; A=2-167. DR PDB; 4EFL; X-ray; 1.90 A; A=1-166. DR PDB; 4EFM; X-ray; 1.90 A; A=1-166. DR PDB; 4EFN; X-ray; 2.30 A; A=1-166. DR PDB; 4G0N; X-ray; 2.45 A; A=1-166. DR PDB; 4G3X; X-ray; 3.25 A; A=1-166. DR PDB; 4K81; X-ray; 2.40 A; B/D/F/H=1-166. DR PDB; 4L9S; X-ray; 1.61 A; A=1-166. DR PDB; 4L9W; X-ray; 1.95 A; A=1-166. DR PDB; 4NYI; X-ray; 2.96 A; Q/R=1-166. DR PDB; 4NYJ; X-ray; 2.85 A; Q/R=1-166. DR PDB; 4NYM; X-ray; 3.55 A; Q/R=1-166. DR PDB; 4Q21; X-ray; 2.00 A; A=1-189. DR PDB; 4RSG; Neutron; 1.91 A; A=1-166. DR PDB; 4URU; X-ray; 2.83 A; R=1-166. DR PDB; 4URV; X-ray; 2.58 A; R=1-166. DR PDB; 4URW; X-ray; 2.76 A; R=1-166. DR PDB; 4URX; X-ray; 2.49 A; R=1-166. DR PDB; 4URY; X-ray; 2.47 A; R=1-166. DR PDB; 4URZ; X-ray; 2.24 A; R=1-166. DR PDB; 4US0; X-ray; 2.17 A; R=1-166. DR PDB; 4US1; X-ray; 2.65 A; R=1-166. DR PDB; 4US2; X-ray; 2.48 A; R=1-166. DR PDB; 4XVQ; X-ray; 1.89 A; A=1-166. DR PDB; 4XVR; X-ray; 2.03 A; A=1-166. DR PDB; 521P; X-ray; 2.60 A; A=1-166. DR PDB; 5B2Z; X-ray; 1.56 A; A=1-166. DR PDB; 5B30; X-ray; 1.60 A; A=1-166. DR PDB; 5E95; X-ray; 1.40 A; A=1-166. DR PDB; 5P21; X-ray; 1.35 A; A=1-166. DR PDB; 5VBE; X-ray; 1.57 A; A=1-166. DR PDB; 5VBZ; X-ray; 2.20 A; A/B/C=1-166. DR PDB; 5WDO; X-ray; 1.65 A; A=1-166. DR PDB; 5WDP; X-ray; 1.35 A; A=1-166. DR PDB; 5WDQ; X-ray; 1.25 A; A=1-166. DR PDB; 5WFO; X-ray; 1.99 A; Q/R=1-166. DR PDB; 5WFP; X-ray; 2.08 A; Q/R=1-166. DR PDB; 5WFQ; X-ray; 2.26 A; Q/R=1-166. DR PDB; 5WFR; X-ray; 2.46 A; Q/R=1-166. DR PDB; 5WPL; X-ray; 2.15 A; A/D/G/J=1-166. DR PDB; 5X9S; X-ray; 2.50 A; A=1-166. DR PDB; 5ZC6; NMR; -; A=1-166. DR PDB; 621P; X-ray; 2.40 A; A=1-166. DR PDB; 6AMB; X-ray; 2.50 A; A=1-168. DR PDB; 6AXG; X-ray; 3.30 A; B/D/F/H/J/L=1-166. DR PDB; 6BVI; X-ray; 1.75 A; A/C=1-166. DR PDB; 6BVJ; X-ray; 1.75 A; A/C=1-166. DR PDB; 6BVK; X-ray; 1.80 A; A/C=1-166. DR PDB; 6BVL; X-ray; 1.75 A; A/C=1-166. DR PDB; 6BVM; X-ray; 1.80 A; A/C=1-166. DR PDB; 6CUO; X-ray; 1.73 A; A/C=1-166. DR PDB; 6CUP; X-ray; 1.83 A; A/C=1-166. DR PDB; 6CUR; X-ray; 1.73 A; A/C=1-166. DR PDB; 6D55; X-ray; 1.68 A; A/C=1-166. DR PDB; 6D56; X-ray; 1.68 A; A/C=1-166. DR PDB; 6D59; X-ray; 1.70 A; A/C=1-166. DR PDB; 6D5E; X-ray; 1.75 A; A/C=1-166. DR PDB; 6D5G; X-ray; 1.92 A; A/C=1-166. DR PDB; 6D5H; X-ray; 1.80 A; A/C=1-166. DR PDB; 6D5J; X-ray; 1.75 A; A/C=1-166. DR PDB; 6D5L; X-ray; 1.70 A; A/C=1-166. DR PDB; 6D5M; X-ray; 2.08 A; Q/R=1-166. DR PDB; 6D5V; X-ray; 2.04 A; Q/R=1-166. DR PDB; 6D5W; X-ray; 2.48 A; Q/R=1-166. DR PDB; 6DZH; X-ray; 1.95 A; A/B/C=1-166. DR PDB; 6E6C; X-ray; 1.90 A; A=1-166. DR PDB; 6E6P; X-ray; 1.93 A; A/B/C=1-166. DR PDB; 6MQT; X-ray; 1.50 A; A/B/C/D/E/F/G/H=1-166. DR PDB; 6NTC; X-ray; 2.90 A; A=1-166. DR PDB; 6NTD; X-ray; 3.15 A; A=1-166. DR PDB; 6Q21; X-ray; 1.95 A; A/B/C/D=1-171. DR PDB; 6V94; X-ray; 1.80 A; A/C=1-166. DR PDB; 6V9F; X-ray; 1.85 A; A/C=1-166. DR PDB; 6V9J; X-ray; 1.76 A; A/C=1-166. DR PDB; 6V9L; X-ray; 1.70 A; A/C=1-166. DR PDB; 6V9M; X-ray; 1.65 A; A/C=1-166. DR PDB; 6V9N; X-ray; 1.65 A; A/C=1-166. DR PDB; 6V9O; X-ray; 1.80 A; A/C=1-166. DR PDB; 6ZJ0; X-ray; 1.76 A; A=1-166. DR PDB; 6ZL3; X-ray; 2.03 A; A=1-166. DR PDB; 721P; X-ray; 2.00 A; A=1-166. DR PDB; 7DPH; X-ray; 1.54 A; A=1-166. DR PDB; 7DPJ; X-ray; 1.98 A; A=1-166. DR PDB; 7JHP; X-ray; 2.77 A; A=1-166. DR PDB; 7JIF; X-ray; 1.76 A; A=1-166. DR PDB; 7JIG; X-ray; 2.32 A; A=1-166. DR PDB; 7JIH; X-ray; 1.99 A; A/B=1-166. DR PDB; 7JII; X-ray; 1.53 A; A/B=1-166. DR PDB; 7L0F; X-ray; 1.98 A; A/E/G/L=1-166. DR PDB; 7L0G; X-ray; 2.54 A; A/B/E/G=1-166. DR PDB; 7OG9; X-ray; 1.75 A; A=1-166. DR PDB; 7OGA; X-ray; 1.90 A; A=1-166. DR PDB; 7OGB; X-ray; 1.85 A; A=1-166. DR PDB; 7OGC; X-ray; 1.70 A; A=1-166. DR PDB; 7OGD; X-ray; 1.95 A; A=1-166. DR PDB; 7OGE; X-ray; 2.10 A; A=1-166. DR PDB; 7OGF; X-ray; 1.80 A; A=1-166. DR PDB; 7TAM; X-ray; 1.87 A; A=1-166. DR PDB; 7VV8; X-ray; 1.70 A; A=1-166. DR PDB; 7VV9; X-ray; 1.60 A; A=1-170. DR PDB; 7VVG; X-ray; 1.70 A; A=1-166. DR PDB; 821P; X-ray; 1.50 A; A=1-166. DR PDB; 8BE6; X-ray; 2.90 A; R=1-166. DR PDB; 8BE7; X-ray; 3.00 A; R=1-166. DR PDB; 8BE8; X-ray; 2.40 A; R=1-166. DR PDB; 8BE9; X-ray; 2.51 A; R=1-166. DR PDB; 8BEA; X-ray; 2.47 A; R=1-166. DR PDB; 8BOS; X-ray; 2.10 A; R=1-166. DR PDB; 8BWG; X-ray; 1.32 A; R=1-166. DR PDB; 8CNJ; X-ray; 1.35 A; A/B=1-166. DR PDB; 8CNN; X-ray; 1.48 A; A=1-166. DR PDB; 8ELK; X-ray; 1.80 A; A=1-189. DR PDB; 8ELR; X-ray; 2.05 A; A=1-189. DR PDB; 8ELS; X-ray; 2.27 A; A=1-189. DR PDB; 8ELT; X-ray; 1.66 A; A=1-189. DR PDB; 8ELU; X-ray; 1.93 A; A=1-189. DR PDB; 8ELV; X-ray; 2.15 A; A=1-189. DR PDB; 8ELW; X-ray; 1.70 A; A=1-189. DR PDB; 8ELX; X-ray; 1.98 A; A=1-189. DR PDB; 8ELY; X-ray; 1.75 A; A=1-189. DR PDB; 8ELZ; X-ray; 1.96 A; A=1-189. DR PDB; 8EM0; X-ray; 2.11 A; A=1-189. DR PDB; 8FG3; X-ray; 1.49 A; A=1-166. DR PDB; 8FG4; X-ray; 1.85 A; A=1-166. DR PDB; 8OSM; X-ray; 2.05 A; A=1-166. DR PDB; 8OSN; X-ray; 1.80 A; A=1-166. DR PDB; 8OSO; X-ray; 2.50 A; A=1-166. DR PDB; 8TBG; X-ray; 1.20 A; A/B=1-166. DR PDB; 8TLR; X-ray; 1.70 A; A=1-166. DR PDB; 8WWC; X-ray; 2.80 A; A/B=1-166. DR PDBsum; 121P; -. DR PDBsum; 1AA9; -. DR PDBsum; 1AGP; -. DR PDBsum; 1BKD; -. DR PDBsum; 1CLU; -. DR PDBsum; 1CRP; -. DR PDBsum; 1CRQ; -. DR PDBsum; 1CRR; -. DR PDBsum; 1CTQ; -. DR PDBsum; 1GNP; -. DR PDBsum; 1GNQ; -. DR PDBsum; 1GNR; -. DR PDBsum; 1HE8; -. DR PDBsum; 1IAQ; -. DR PDBsum; 1IOZ; -. DR PDBsum; 1JAH; -. DR PDBsum; 1JAI; -. DR PDBsum; 1K8R; -. DR PDBsum; 1LF0; -. DR PDBsum; 1LF5; -. DR PDBsum; 1LFD; -. DR PDBsum; 1NVU; -. DR PDBsum; 1NVV; -. DR PDBsum; 1NVW; -. DR PDBsum; 1NVX; -. DR PDBsum; 1P2S; -. DR PDBsum; 1P2T; -. DR PDBsum; 1P2U; -. DR PDBsum; 1P2V; -. DR PDBsum; 1PLJ; -. DR PDBsum; 1PLK; -. DR PDBsum; 1PLL; -. DR PDBsum; 1Q21; -. DR PDBsum; 1QRA; -. DR PDBsum; 1RVD; -. DR PDBsum; 1WQ1; -. DR PDBsum; 1XCM; -. DR PDBsum; 1XD2; -. DR PDBsum; 1XJ0; -. DR PDBsum; 1ZVQ; -. DR PDBsum; 1ZW6; -. DR PDBsum; 221P; -. DR PDBsum; 2C5L; -. DR PDBsum; 2CE2; -. DR PDBsum; 2CL0; -. DR PDBsum; 2CL6; -. DR PDBsum; 2CL7; -. DR PDBsum; 2CLC; -. DR PDBsum; 2CLD; -. DR PDBsum; 2EVW; -. DR PDBsum; 2LCF; -. DR PDBsum; 2LWI; -. DR PDBsum; 2N42; -. DR PDBsum; 2N46; -. DR PDBsum; 2Q21; -. DR PDBsum; 2QUZ; -. DR PDBsum; 2RGA; -. DR PDBsum; 2RGB; -. DR PDBsum; 2RGC; -. DR PDBsum; 2RGD; -. DR PDBsum; 2RGE; -. DR PDBsum; 2RGG; -. DR PDBsum; 2UZI; -. DR PDBsum; 2VH5; -. DR PDBsum; 2X1V; -. DR PDBsum; 3DDC; -. DR PDBsum; 3I3S; -. DR PDBsum; 3K8Y; -. DR PDBsum; 3K9L; -. DR PDBsum; 3K9N; -. DR PDBsum; 3KKM; -. DR PDBsum; 3KKN; -. DR PDBsum; 3KUD; -. DR PDBsum; 3L8Y; -. DR PDBsum; 3L8Z; -. DR PDBsum; 3LBH; -. DR PDBsum; 3LBI; -. DR PDBsum; 3LBN; -. DR PDBsum; 3LO5; -. DR PDBsum; 3OIU; -. DR PDBsum; 3OIV; -. DR PDBsum; 3OIW; -. DR PDBsum; 3RRY; -. DR PDBsum; 3RRZ; -. DR PDBsum; 3RS0; -. DR PDBsum; 3RS2; -. DR PDBsum; 3RS3; -. DR PDBsum; 3RS4; -. DR PDBsum; 3RS5; -. DR PDBsum; 3RS7; -. DR PDBsum; 3RSL; -. DR PDBsum; 3RSO; -. DR PDBsum; 3TGP; -. DR PDBsum; 421P; -. DR PDBsum; 4DLR; -. DR PDBsum; 4DLS; -. DR PDBsum; 4DLT; -. DR PDBsum; 4DLU; -. DR PDBsum; 4DLV; -. DR PDBsum; 4DLW; -. DR PDBsum; 4DLX; -. DR PDBsum; 4DLY; -. DR PDBsum; 4DLZ; -. DR PDBsum; 4DST; -. DR PDBsum; 4DSU; -. DR PDBsum; 4EFL; -. DR PDBsum; 4EFM; -. DR PDBsum; 4EFN; -. DR PDBsum; 4G0N; -. DR PDBsum; 4G3X; -. DR PDBsum; 4K81; -. DR PDBsum; 4L9S; -. DR PDBsum; 4L9W; -. DR PDBsum; 4NYI; -. DR PDBsum; 4NYJ; -. DR PDBsum; 4NYM; -. DR PDBsum; 4Q21; -. DR PDBsum; 4RSG; -. DR PDBsum; 4URU; -. DR PDBsum; 4URV; -. DR PDBsum; 4URW; -. DR PDBsum; 4URX; -. DR PDBsum; 4URY; -. DR PDBsum; 4URZ; -. DR PDBsum; 4US0; -. DR PDBsum; 4US1; -. DR PDBsum; 4US2; -. DR PDBsum; 4XVQ; -. DR PDBsum; 4XVR; -. DR PDBsum; 521P; -. DR PDBsum; 5B2Z; -. DR PDBsum; 5B30; -. DR PDBsum; 5E95; -. DR PDBsum; 5P21; -. DR PDBsum; 5VBE; -. DR PDBsum; 5VBZ; -. DR PDBsum; 5WDO; -. DR PDBsum; 5WDP; -. DR PDBsum; 5WDQ; -. DR PDBsum; 5WFO; -. DR PDBsum; 5WFP; -. DR PDBsum; 5WFQ; -. DR PDBsum; 5WFR; -. DR PDBsum; 5WPL; -. DR PDBsum; 5X9S; -. DR PDBsum; 5ZC6; -. DR PDBsum; 621P; -. DR PDBsum; 6AMB; -. DR PDBsum; 6AXG; -. DR PDBsum; 6BVI; -. DR PDBsum; 6BVJ; -. DR PDBsum; 6BVK; -. DR PDBsum; 6BVL; -. DR PDBsum; 6BVM; -. DR PDBsum; 6CUO; -. DR PDBsum; 6CUP; -. DR PDBsum; 6CUR; -. DR PDBsum; 6D55; -. DR PDBsum; 6D56; -. DR PDBsum; 6D59; -. DR PDBsum; 6D5E; -. DR PDBsum; 6D5G; -. DR PDBsum; 6D5H; -. DR PDBsum; 6D5J; -. DR PDBsum; 6D5L; -. DR PDBsum; 6D5M; -. DR PDBsum; 6D5V; -. DR PDBsum; 6D5W; -. DR PDBsum; 6DZH; -. DR PDBsum; 6E6C; -. DR PDBsum; 6E6P; -. DR PDBsum; 6MQT; -. DR PDBsum; 6NTC; -. DR PDBsum; 6NTD; -. DR PDBsum; 6Q21; -. DR PDBsum; 6V94; -. DR PDBsum; 6V9F; -. DR PDBsum; 6V9J; -. DR PDBsum; 6V9L; -. DR PDBsum; 6V9M; -. DR PDBsum; 6V9N; -. DR PDBsum; 6V9O; -. DR PDBsum; 6ZJ0; -. DR PDBsum; 6ZL3; -. DR PDBsum; 721P; -. DR PDBsum; 7DPH; -. DR PDBsum; 7DPJ; -. DR PDBsum; 7JHP; -. DR PDBsum; 7JIF; -. DR PDBsum; 7JIG; -. DR PDBsum; 7JIH; -. DR PDBsum; 7JII; -. DR PDBsum; 7L0F; -. DR PDBsum; 7L0G; -. DR PDBsum; 7OG9; -. DR PDBsum; 7OGA; -. DR PDBsum; 7OGB; -. DR PDBsum; 7OGC; -. DR PDBsum; 7OGD; -. DR PDBsum; 7OGE; -. DR PDBsum; 7OGF; -. DR PDBsum; 7TAM; -. DR PDBsum; 7VV8; -. DR PDBsum; 7VV9; -. DR PDBsum; 7VVG; -. DR PDBsum; 821P; -. DR PDBsum; 8BE6; -. DR PDBsum; 8BE7; -. DR PDBsum; 8BE8; -. DR PDBsum; 8BE9; -. DR PDBsum; 8BEA; -. DR PDBsum; 8BOS; -. DR PDBsum; 8BWG; -. DR PDBsum; 8CNJ; -. DR PDBsum; 8CNN; -. DR PDBsum; 8ELK; -. DR PDBsum; 8ELR; -. DR PDBsum; 8ELS; -. DR PDBsum; 8ELT; -. DR PDBsum; 8ELU; -. DR PDBsum; 8ELV; -. DR PDBsum; 8ELW; -. DR PDBsum; 8ELX; -. DR PDBsum; 8ELY; -. DR PDBsum; 8ELZ; -. DR PDBsum; 8EM0; -. DR PDBsum; 8FG3; -. DR PDBsum; 8FG4; -. DR PDBsum; 8OSM; -. DR PDBsum; 8OSN; -. DR PDBsum; 8OSO; -. DR PDBsum; 8TBG; -. DR PDBsum; 8TLR; -. DR PDBsum; 8WWC; -. DR AlphaFoldDB; P01112; -. DR BMRB; P01112; -. DR SMR; P01112; -. DR BioGRID; 109501; 710. DR ComplexPortal; CPX-26353; SHOC2-HRAS-PPP1CA complex. DR ComplexPortal; CPX-395; GTPase HRAS - Son of sevenless homolog 1 complex. DR CORUM; P01112; -. DR DIP; DIP-1050N; -. DR ELM; P01112; -. DR FunCoup; P01112; 3079. DR IntAct; P01112; 623. DR MINT; P01112; -. DR STRING; 9606.ENSP00000407586; -. DR BindingDB; P01112; -. DR ChEMBL; CHEMBL2167; -. DR DrugBank; DB04315; Guanosine-5'-Diphosphate. DR DrugBank; DB04137; Guanosine-5'-Triphosphate. DR DrugBank; DB02210; Hexane-1,6-Diol. DR DrugBank; DB08751; N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE. DR DrugBank; DB03226; Trifluoroethanol. DR DrugBank; DB15588; Ursolic acid. DR DrugCentral; P01112; -. DR GuidetoPHARMACOLOGY; 2822; -. DR GlyCosmos; P01112; 1 site, No reported glycans. DR GlyGen; P01112; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P01112; -. DR PhosphoSitePlus; P01112; -. DR SwissPalm; P01112; -. DR BioMuta; HRAS; -. DR DMDM; 131869; -. DR CPTAC; CPTAC-1551; -. DR CPTAC; CPTAC-1552; -. DR jPOST; P01112; -. DR MassIVE; P01112; -. DR PaxDb; 9606-ENSP00000407586; -. DR PeptideAtlas; P01112; -. DR ProteomicsDB; 51321; -. [P01112-1] DR ProteomicsDB; 51322; -. [P01112-2] DR Pumba; P01112; -. DR ABCD; P01112; 6 sequenced antibodies. DR Antibodypedia; 22506; 827 antibodies from 38 providers. DR CPTC; P01112; 4 antibodies. DR DNASU; 3265; -. DR Ensembl; ENST00000311189.8; ENSP00000309845.7; ENSG00000174775.19. [P01112-1] DR Ensembl; ENST00000397594.7; ENSP00000380722.3; ENSG00000174775.19. [P01112-2] DR Ensembl; ENST00000397596.6; ENSP00000380723.2; ENSG00000174775.19. [P01112-1] DR Ensembl; ENST00000417302.7; ENSP00000388246.1; ENSG00000174775.19. [P01112-2] DR Ensembl; ENST00000451590.5; ENSP00000407586.1; ENSG00000174775.19. [P01112-1] DR Ensembl; ENST00000493230.5; ENSP00000434023.1; ENSG00000174775.19. [P01112-2] DR Ensembl; ENST00000610977.3; ENSP00000480686.1; ENSG00000276536.4. [P01112-1] DR Ensembl; ENST00000615062.2; ENSP00000482366.1; ENSG00000276536.4. [P01112-1] DR Ensembl; ENST00000616241.4; ENSP00000480317.1; ENSG00000276536.4. [P01112-2] DR Ensembl; ENST00000631404.1; ENSP00000488757.1; ENSG00000276536.4. [P01112-1] DR Ensembl; ENST00000631967.1; ENSP00000488225.1; ENSG00000276536.4. [P01112-2] DR Ensembl; ENST00000634098.1; ENSP00000488296.1; ENSG00000276536.4. [P01112-2] DR GeneID; 3265; -. DR KEGG; hsa:3265; -. DR MANE-Select; ENST00000311189.8; ENSP00000309845.7; NM_005343.4; NP_005334.1. DR UCSC; uc010qvw.3; human. [P01112-1] DR AGR; HGNC:5173; -. DR CIViC; 3265; 22 evidence items across 22 molecular profiles. DR ClinPGx; PA29444; -. DR CTD; 3265; -. DR DisGeNET; 3265; -. DR GeneCards; HRAS; -. DR GeneReviews; HRAS; -. DR HGNC; HGNC:5173; HRAS. DR HPA; ENSG00000174775; Low tissue specificity. DR MalaCards; HRAS; -. DR MIM; 109800; phenotype. DR MIM; 163200; phenotype. DR MIM; 188470; phenotype. DR MIM; 190020; gene. DR MIM; 218040; phenotype. DR OpenTargets; ENSG00000174775; -. DR Orphanet; 3071; Costello syndrome. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2612; Linear nevus sebaceus syndrome. DR Orphanet; 2874; Phakomatosis pigmentokeratotica. DR Orphanet; 79414; Woolly hair nevus. DR VEuPathDB; HostDB:ENSG00000174775; -. DR eggNOG; KOG0395; Eukaryota. DR GeneTree; ENSGT00940000155653; -. DR HOGENOM; CLU_041217_9_8_1; -. DR InParanoid; P01112; -. DR OMA; HYREQIR; -. DR OrthoDB; 5976022at2759; -. DR PAN-GO; P01112; 6 GO annotations based on evolutionary models. DR PhylomeDB; P01112; -. DR BRENDA; 3.6.5.2; 2681. DR PathwayCommons; P01112; -. DR Reactome; R-HSA-112412; SOS-mediated signalling. DR Reactome; R-HSA-1169092; Activation of RAS in B cells. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-167044; Signalling to RAS. DR Reactome; R-HSA-171007; p38MAPK events. DR Reactome; R-HSA-179812; GRB2 events in EGFR signaling. DR Reactome; R-HSA-180336; SHC1 events in EGFR signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-375165; NCAM signaling for neurite out-growth. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1. DR Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3. DR Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling. DR Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling. DR Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5658442; Regulation of RAS by GAPs. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8851805; MET activates RAS signaling. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9027284; Erythropoietin activates RAS. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR Reactome; R-HSA-9648002; RAS processing. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9753510; Signaling by RAS GAP mutants. DR Reactome; R-HSA-9753512; Signaling by RAS GTPase mutants. DR SABIO-RK; P01112; -. DR SignaLink; P01112; -. DR SIGNOR; P01112; -. DR Agora; ENSG00000174775; -. DR BioGRID-ORCS; 3265; 28 hits in 1176 CRISPR screens. DR EvolutionaryTrace; P01112; -. DR GeneWiki; HRAS; -. DR GenomeRNAi; 3265; -. DR Pharos; P01112; Tchem. DR PRO; PR:P01112; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; P01112; protein. DR Bgee; ENSG00000174775; Expressed in skin of abdomen and 97 other cell types or tissues. DR ExpressionAtlas; P01112; baseline and differential. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:1905360; C:GTPase complex; IPI:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0003925; F:G protein activity; IEA:UniProtKB-EC. DR GO; GO:0019003; F:GDP binding; IMP:CAFA. DR GO; GO:0005525; F:GTP binding; IDA:UniProtKB. DR GO; GO:0003924; F:GTPase activity; IDA:WormBase. DR GO; GO:0160185; F:phospholipase C activator activity; IDA:UniProtKB. DR GO; GO:0043495; F:protein-membrane adaptor activity; IEA:Ensembl. DR GO; GO:0060612; P:adipose tissue development; IEA:Ensembl. DR GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc. DR GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0090398; P:cellular senescence; IDA:BHF-UCL. DR GO; GO:0006935; P:chemotaxis; TAS:ProtInc. DR GO; GO:0042832; P:defense response to protozoan; IEA:Ensembl. DR GO; GO:0006897; P:endocytosis; IEA:Ensembl. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; TAS:Reactome. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0090402; P:oncogene-induced cell senescence; IEA:Ensembl. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:BHF-UCL. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL. DR GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl. DR GO; GO:0046330; P:positive regulation of JNK cascade; IDA:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:2000630; P:positive regulation of miRNA metabolic process; IDA:BHF-UCL. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IMP:UniProtKB. DR GO; GO:1900029; P:positive regulation of ruffle assembly; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0032729; P:positive regulation of type II interferon production; IEA:Ensembl. DR GO; GO:0090303; P:positive regulation of wound healing; IDA:BHF-UCL. DR GO; GO:0007265; P:Ras protein signal transduction; IDA:BHF-UCL. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:BHF-UCL. DR GO; GO:0051726; P:regulation of cell cycle; IDA:BHF-UCL. DR GO; GO:0042127; P:regulation of cell population proliferation; IDA:ComplexPortal. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:0098696; P:regulation of neurotransmitter receptor localization to postsynaptic specialization membrane; IDA:SynGO. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ComplexPortal. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; NAS:ProtInc. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0042088; P:T-helper 1 type immune response; IEA:Ensembl. DR CDD; cd04138; H_N_K_Ras_like; 1. DR DisProt; DP00153; -. DR FunFam; 3.40.50.300:FF:000096; KRAS proto-oncogene, GTPase; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR005225; Small_GTP-bd. DR InterPro; IPR001806; Small_GTPase. DR InterPro; IPR020849; Small_GTPase_Ras-type. DR NCBIfam; TIGR00231; small_GTP; 1. DR PANTHER; PTHR24070; RAS, DI-RAS, AND RHEB FAMILY MEMBERS OF SMALL GTPASE SUPERFAMILY; 1. DR Pfam; PF00071; Ras; 1. DR PRINTS; PR00449; RASTRNSFRMNG. DR SMART; SM00175; RAB; 1. DR SMART; SM00173; RAS; 1. DR SMART; SM00174; RHO; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS51421; RAS; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell membrane; Cytoplasm; KW Direct protein sequencing; Disease variant; Glycoprotein; Golgi apparatus; KW GTP-binding; Hydrolase; Isopeptide bond; Lipoprotein; Membrane; KW Methylation; Nucleotide-binding; Nucleus; Palmitate; Prenylation; KW Proteomics identification; Proto-oncogene; Reference proteome; KW S-nitrosylation; Ubl conjugation. FT CHAIN 1..186 FT /note="GTPase HRas" FT /id="PRO_0000042996" FT INIT_MET 1 FT /note="Removed; alternate" FT /evidence="ECO:0000269|Ref.12" FT CHAIN 2..186 FT /note="GTPase HRas, N-terminally processed" FT /id="PRO_0000326476" FT PROPEP 187..189 FT /note="Removed in mature form" FT /id="PRO_0000042997" FT REGION 166..185 FT /note="Hypervariable region" FT MOTIF 32..40 FT /note="Effector region" FT BINDING 13..18 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 29..35 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 59..60 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 116..119 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT BINDING 145..147 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:16698776, FT ECO:0000305|PubMed:35522713" FT MOD_RES 1 FT /note="N-acetylmethionine; in GTPase HRas; alternate" FT /evidence="ECO:0000269|Ref.12" FT MOD_RES 2 FT /note="N-acetylthreonine; in GTPase HRas, N-terminally FT processed" FT /evidence="ECO:0000269|Ref.12" FT MOD_RES 118 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:9020151" FT MOD_RES 186 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000269|PubMed:8626715" FT LIPID 181 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:15705808, FT ECO:0000269|PubMed:16000296, ECO:0000269|PubMed:2661017, FT ECO:0000269|PubMed:8626715" FT LIPID 184 FT /note="S-(15-deoxy-Delta12,14-prostaglandin J2-9- FT yl)cysteine; alternate" FT /evidence="ECO:0000269|PubMed:12684535" FT LIPID 184 FT /note="S-palmitoyl cysteine; alternate" FT /evidence="ECO:0000269|PubMed:15705808, FT ECO:0000269|PubMed:16000296, ECO:0000269|PubMed:2661017, FT ECO:0000269|PubMed:8626715" FT LIPID 186 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000269|PubMed:8626715" FT CARBOHYD 35 FT /note="(Microbial infection) O-linked (Glc) threonine; by FT P.sordellii toxin TcsL" FT /evidence="ECO:0000269|PubMed:19744486, FT ECO:0000269|PubMed:8626575, ECO:0000269|PubMed:8626586, FT ECO:0000269|PubMed:9632667" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:30442762" FT VAR_SEQ 152..189 FT /note="VEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKCVLS -> SRSGSSSSSG FT TLWDPPGPM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14500341, FT ECO:0000303|PubMed:15489334" FT /id="VSP_041597" FT VARIANT 12 FT /note="G -> A (in CSTLO; dbSNP:rs104894230)" FT /evidence="ECO:0000269|PubMed:16170316, FT ECO:0000269|PubMed:16329078, ECO:0000269|PubMed:16443854" FT /id="VAR_026106" FT VARIANT 12 FT /note="G -> C (in CSTLO; dbSNP:rs104894229)" FT /evidence="ECO:0000269|PubMed:16443854, FT ECO:0000269|PubMed:18039947" FT /id="VAR_045975" FT VARIANT 12 FT /note="G -> D (in CSTLO; severe mutation; FT dbSNP:rs104894230)" FT /evidence="ECO:0000269|PubMed:18039947" FT /id="VAR_068816" FT VARIANT 12 FT /note="G -> E (in CSTLO)" FT /evidence="ECO:0000269|PubMed:16443854" FT /id="VAR_045976" FT VARIANT 12 FT /note="G -> S (in CSTLO and CMEMS; also found in patients FT with oral squamous cell carcinoma; dbSNP:rs104894229)" FT /evidence="ECO:0000269|PubMed:1459726, FT ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078, FT ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105, FT ECO:0000269|PubMed:17412879" FT /id="VAR_006837" FT VARIANT 12 FT /note="G -> V (in CSTLO, bladder carcinoma and CMEMS; FT constitutively activated; interacts and recruits PLCE1 to FT plasma membrane; dbSNP:rs104894230)" FT /evidence="ECO:0000269|PubMed:11022048, FT ECO:0000269|PubMed:15546861, ECO:0000269|PubMed:16170316, FT ECO:0000269|PubMed:17412879" FT /id="VAR_006836" FT VARIANT 13 FT /note="G -> C (in CSTLO; dbSNP:rs104894228)" FT /evidence="ECO:0000269|PubMed:16329078" FT /id="VAR_026107" FT VARIANT 13 FT /note="G -> D (in CSTLO; dbSNP:rs104894226)" FT /evidence="ECO:0000269|PubMed:16170316" FT /id="VAR_026108" FT VARIANT 13 FT /note="G -> R (in SFM; somatic mutation; shows constitutive FT activation of the MAPK and PI3K-AKT signaling pathways; FT dbSNP:rs104894228)" FT /evidence="ECO:0000269|PubMed:22683711" FT /id="VAR_068817" FT VARIANT 22 FT /note="Q -> K (in CMEMS; dbSNP:rs121917757)" FT /evidence="ECO:0000269|PubMed:17412879" FT /id="VAR_045977" FT VARIANT 37 FT /note="E -> EE (in CSTLO)" FT /evidence="ECO:0000269|PubMed:19995790" FT /id="VAR_068818" FT VARIANT 58 FT /note="T -> I (in CSTLO; dbSNP:rs121917758)" FT /evidence="ECO:0000269|PubMed:18247425" FT /id="VAR_045978" FT VARIANT 61 FT /note="Q -> K (in NMTC2; somatic mutation; increases FT transformation of cultured cell lines; dbSNP:rs28933406)" FT /evidence="ECO:0000269|PubMed:12727991, FT ECO:0000269|PubMed:18073111" FT /id="VAR_045979" FT VARIANT 61 FT /note="Q -> L (in melanoma; strongly reduced GTP hydrolysis FT in the presence of RAF1; increases transformation of FT cultured cell lines; dbSNP:rs121913233)" FT /evidence="ECO:0000269|PubMed:18073111" FT /id="VAR_006838" FT VARIANT 63 FT /note="E -> K (in CMEMS; dbSNP:rs121917756)" FT /evidence="ECO:0000269|PubMed:17412879" FT /id="VAR_045980" FT VARIANT 89 FT /note="S -> C (found in a patient with severe fetal hydrops FT and pleural effusion; uncertain significance; decreased FT activation of Ras protein signal transduction; FT dbSNP:rs755322824)" FT /evidence="ECO:0000269|PubMed:22821884" FT /id="VAR_078259" FT VARIANT 117 FT /note="K -> R (in CSTLO; dbSNP:rs104894227)" FT /evidence="ECO:0000269|PubMed:16443854" FT /id="VAR_045981" FT VARIANT 146 FT /note="A -> T (in CSTLO; dbSNP:rs104894231)" FT /evidence="ECO:0000269|PubMed:17054105" FT /id="VAR_045982" FT VARIANT 146 FT /note="A -> V (in CSTLO; dbSNP:rs121917759)" FT /evidence="ECO:0000269|PubMed:18247425" FT /id="VAR_045983" FT MUTAGEN 17 FT /note="S->N: Dominant negative. Prevents PLCE1 EGF-induced FT recruitment to plasma membrane. No effect on subcellular FT location of isoform 2." FT /evidence="ECO:0000269|PubMed:11022048, FT ECO:0000269|PubMed:14500341" FT MUTAGEN 26 FT /note="N->G: Loss of interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 29 FT /note="V->A: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 32 FT /note="Y->F: Loss of interaction and recruitment to plasma FT membrane of PLCE1; when associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 34 FT /note="P->G: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 35 FT /note="T->S: Loss of interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 37 FT /note="E->G: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 38 FT /note="D->N: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 39 FT /note="S->C: No effect on interaction with PLCE1; when FT associated with V-12." FT /evidence="ECO:0000269|PubMed:11022048" FT MUTAGEN 59 FT /note="A->T: Loss of GTPase activity and creation of an FT autophosphorylation site." FT MUTAGEN 61 FT /note="Q->I: Moderately increased transformation of FT cultured cell lines." FT /evidence="ECO:0000269|PubMed:18073111" FT MUTAGEN 61 FT /note="Q->R: Promotes interaction with SHOC2 and PP1C." FT /evidence="ECO:0000269|PubMed:35831509" FT MUTAGEN 61 FT /note="Q->V: Strongly increased transformation of cultured FT cell lines." FT /evidence="ECO:0000269|PubMed:18073111" FT MUTAGEN 83 FT /note="A->T: GTP-binding activity reduced by factor of 30." FT /evidence="ECO:0000269|PubMed:3088563" FT MUTAGEN 118 FT /note="C->S: Abolishes S-nitrosylation. No stimulation of FT guanine nucleotide exchange." FT /evidence="ECO:0000269|PubMed:12740440, FT ECO:0000269|PubMed:9020151" FT MUTAGEN 119 FT /note="D->N: Loss of GTP-binding activity." FT /evidence="ECO:0000269|PubMed:3088563" FT MUTAGEN 144 FT /note="T->I: GTP-binding activity reduced by factor of 25." FT /evidence="ECO:0000269|PubMed:3088563" FT MUTAGEN 164..165 FT /note="RQ->AV: Loss of GTP-binding activity." FT /evidence="ECO:0000269|PubMed:3011420" FT MUTAGEN 167..185 FT /note="KLRKLNPPDESGPGCMSCK->RLRRLNPPDESGPGCMSCR: In H-Ras- FT 3KR mutant; decreased fatty-acylation." FT /evidence="ECO:0000269|PubMed:29239724" FT MUTAGEN 170 FT /note="K->R: Increased Ras signaling due to impaired FT ubiquitination." FT /evidence="ECO:0000269|PubMed:30442762" FT MUTAGEN 181 FT /note="C->S: Exclusively localized in Golgi. Non- FT specifically localized on all endomembranes; when FT associated with S-184." FT /evidence="ECO:0000269|PubMed:15705808, FT ECO:0000269|PubMed:8626715" FT MUTAGEN 184 FT /note="C->S: Loss of S-(15-deoxy-Delta12,14-prostaglandin FT J2-9-yl)cysteine stimulation of Ras-GTPase activity. Mainly FT localized in Golgi. Non-specifically localized on all FT endomembranes; when associated with S-181." FT /evidence="ECO:0000269|PubMed:12684535, FT ECO:0000269|PubMed:15705808, ECO:0000269|PubMed:8626715" FT STRAND 3..11 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 12..15 FT /evidence="ECO:0007829|PDB:6V9M" FT HELIX 16..25 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 27..31 FT /evidence="ECO:0007829|PDB:1XCM" FT STRAND 34..37 FT /evidence="ECO:0007829|PDB:1XD2" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 49..57 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 60..63 FT /evidence="ECO:0007829|PDB:2CLD" FT HELIX 66..74 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 76..83 FT /evidence="ECO:0007829|PDB:2CE2" FT TURN 84..86 FT /evidence="ECO:0007829|PDB:1CRP" FT HELIX 87..104 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:7VV9" FT STRAND 111..116 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 120..122 FT /evidence="ECO:0007829|PDB:2CLD" FT HELIX 127..136 FT /evidence="ECO:0007829|PDB:2CE2" FT STRAND 141..144 FT /evidence="ECO:0007829|PDB:2CE2" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:2CE2" FT HELIX 152..164 FT /evidence="ECO:0007829|PDB:2CE2" SQ SEQUENCE 189 AA; 21298 MW; EE6DC2D933E2856A CRC64; MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHQYREQI KRVKDSDDVP MVLVGNKCDL AARTVESRQA QDLARSYGIP YIETSAKTRQ GVEDAFYTLV REIRQHKLRK LNPPDESGPG CMSCKCVLS // ID RASK_HUMAN Reviewed; 189 AA. AC P01116; A8K8Z5; B0LPF9; P01118; Q96D10; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 28-JAN-2026, entry version 268. DE RecName: Full=GTPase KRas; DE EC=3.6.5.2 {ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:39809765}; DE AltName: Full=K-Ras 2; DE AltName: Full=Ki-Ras; DE AltName: Full=c-K-ras; DE AltName: Full=c-Ki-ras; DE Contains: DE RecName: Full=GTPase KRas, N-terminally processed; DE Flags: Precursor; GN Name=KRAS; Synonyms=KRAS2, RASK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RX PubMed=6308466; DOI=10.1038/304501a0; RA McGrath J.P., Capon D.J., Smith D.H., Chen E.Y., Seeburg P.H., RA Goeddel D.V., Levinson A.D.; RT "Structure and organization of the human Ki-ras proto-oncogene and a RT related processed pseudogene."; RL Nature 304:501-506(1983). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RC TISSUE=Lung carcinoma; RX PubMed=6308465; DOI=10.1038/304497a0; RA Shimizu K., Birnbaum D., Ruley M.A., Fasano O., Suard Y., Edlund L., RA Taparowsky E., Goldfarb M., Wigler M.; RT "Structure of the Ki-ras gene of the human lung carcinoma cell line Calu- RT 1."; RL Nature 304:497-500(1983). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RC TISSUE=Colon carcinoma, and Lung; RX PubMed=6308467; DOI=10.1038/304507a0; RA Capon D.J., Seeburg P.H., McGrath J.P., Hayflick J.S., Edman U., RA Levinson A.D., Goeddel D.V.; RT "Activation of Ki-ras2 gene in human colon and lung carcinomas by two RT different point mutations."; RL Nature 304:507-513(1983). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B), AND VARIANT COLON RP CANCER VAL-12. RC TISSUE=Colon carcinoma; RX PubMed=6092920; DOI=10.1128/mcb.4.8.1577-1582.1984; RA McCoy M.S., Bargmann C.I., Weinberg R.A.; RT "Human colon carcinoma Ki-ras2 oncogene and its corresponding proto- RT oncogene."; RL Mol. Cell. Biol. 4:1577-1582(1984). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2B). RX PubMed=3310850; RA Kahn S., Yamamoto F., Almoguera C., Winter E., Forrester K., Jordano J., RA Perucho M.; RT "The c-K-ras gene and human cancer (review)."; RL Anticancer Res. 7:639-652(1987). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B). RC TISSUE=Brain; RA Puhl H.L. III, Ikeda S.R., Aronstam R.S.; RT "cDNA clones of human proteins involved in signal transduction sequenced by RT the Guthrie cDNA resource center (www.cdna.org)."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG RP CARCINOMA HIS-61. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG SeattleSNPs variation discovery resource; RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG RP CARCINOMA HIS-61. RC TISSUE=Lung carcinoma; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT LUNG CARCINOMA RP CYS-12. RC TISSUE=Lung carcinoma; RX PubMed=6320174; DOI=10.1073/pnas.81.1.71; RA Nakano H., Yamamoto F., Neville C., Evans D., Mizuno T., Perucho M.; RT "Isolation of transforming sequences of two human lung carcinomas: RT structural and functional analysis of the activated c-K-ras oncogenes."; RL Proc. Natl. Acad. Sci. U.S.A. 81:71-75(1984). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-96. RC TISSUE=Pancreatic carcinoma; RX PubMed=3855240; DOI=10.1016/s0006-291x(85)80140-6; RA Hirai H., Okabe T., Anraku Y., Fujisawa M., Urabe A., Takaku F.; RT "Activation of the c-K-ras oncogene in a human pancreas carcinoma."; RL Biochem. Biophys. Res. Commun. 127:168-174(1985). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT GASC VAL-12. RX PubMed=3034404; RA Deng G., Lu Y., Chen S., Miao J., Lu G., Li H., Cai H., Xu X., Zheng E., RA Liu P.; RT "Activated c-Ha-ras oncogene with a guanine to thymine transversion at the RT twelfth codon in a human stomach cancer cell line."; RL Cancer Res. 47:3195-3198(1987). RN [15] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-36, AND VARIANT BLADDER/LUNG CANCER RP ARG-12. RC TISSUE=Lung carcinoma; RX PubMed=6695174; DOI=10.1126/science.6695174; RA Santos E., Martin-Zanca D., Reddy P.E., Pierotti M.A., Porta G., RA Barbacid M.; RT "Malignant activation of a K-ras oncogene in lung carcinoma but not in RT normal tissue of the same patient."; RL Science 223:661-664(1984). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37. RX PubMed=3932274; RA Sekiya T., Tokunaga A., Fushimi M.; RT "Essential region for transforming activity of human c-Ha-ras-1."; RL Jpn. J. Cancer Res. 76:787-791(1985). RN [17] RP PROTEIN SEQUENCE OF 1-41; 43-147 AND 150-161, CLEAVAGE OF INITIATOR RP METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Cervix carcinoma; RA Bienvenut W.V., Calvo F., Kolch W.; RL Submitted (FEB-2008) to UniProtKB. RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-96. RC TISSUE=Lung carcinoma; RX PubMed=6096811; DOI=10.1093/nar/12.23.8873; RA Yamamoto F., Perucho M.; RT "Activation of a human c-K-ras oncogene."; RL Nucleic Acids Res. 12:8873-8885(1984). RN [19] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=19744486; DOI=10.1016/j.febslet.2009.09.006; RA Huelsenbeck S.C., Klose I., Reichenbach M., Huelsenbeck J., Genth H.; RT "Distinct kinetics of (H/K/N)Ras glucosylation and Rac1 glucosylation RT catalysed by Clostridium sordellii lethal toxin."; RL FEBS Lett. 583:3133-3139(2009). RN [20] RP INTERACTION WITH RAP1GDS1. RX PubMed=20709748; DOI=10.1074/jbc.m110.129916; RA Berg T.J., Gastonguay A.J., Lorimer E.L., Kuhnmuench J.R., Li R., RA Fields A.P., Williams C.L.; RT "Splice variants of SmgGDS control small GTPase prenylation and membrane RT localization."; RL J. Biol. Chem. 285:35255-35266(2010). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP ACETYLATION AT LYS-104, VARIANT VAL-12, FUNCTION, AND ACTIVITY REGULATION. RX PubMed=22711838; DOI=10.1073/pnas.1201487109; RA Yang M.H., Nickerson S., Kim E.T., Liot C., Laurent G., Spang R., RA Philips M.R., Shan Y., Shaw D.E., Bar-Sagi D., Haigis M.C., Haigis K.M.; RT "Regulation of RAS oncogenicity by acetylation."; RL Proc. Natl. Acad. Sci. U.S.A. 109:10843-10848(2012). RN [23] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PDE6D. RX PubMed=23698361; DOI=10.1038/nature12205; RA Zimmermann G., Papke B., Ismail S., Vartak N., Chandra A., Hoffmann M., RA Hahn S.A., Triola G., Wittinghofer A., Bastiaens P.I., Waldmann H.; RT "Small molecule inhibition of the KRAS-PDE? interaction impairs oncogenic RT KRAS signalling."; RL Nature 497:638-642(2013). RN [24] RP FUNCTION, AND CHARACTERIZATION OF VARIANT COLON CANCER VAL-12. RX PubMed=24623306; DOI=10.7554/elife.02313; RA Serra R.W., Fang M., Park S.M., Hutchinson L., Green M.R.; RT "A KRAS-directed transcriptional silencing pathway that mediates the CpG RT island methylator phenotype."; RL Elife 3:E02313-E02313(2014). RN [25] RP INTERACTION WITH RAP1GDS1, AND ISOPRENYLATION AT CYS-186. RX PubMed=24415755; DOI=10.1074/jbc.m113.527192; RA Schuld N.J., Vervacke J.S., Lorimer E.L., Simon N.C., Hauser A.D., RA Barbieri J.T., Distefano M.D., Williams C.L.; RT "The chaperone protein SmgGDS interacts with small GTPases entering the RT prenylation pathway by recognizing the last amino acid in the CAAX motif."; RL J. Biol. Chem. 289:6862-6876(2014). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [27] RP PALMITOYLATION AT CYS-180; LYS-182; LYS-184 AND LYS-185, DEPALMITOYLATION RP BY SIRT2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-180 AND RP 182-LYS--LYS-185. RX PubMed=29239724; DOI=10.7554/elife.32436; RA Jing H., Zhang X., Wisner S.A., Chen X., Spiegelman N.A., Linder M.E., RA Lin H.; RT "SIRT2 and lysine fatty acylation regulate the transforming activity of K- RT Ras4a."; RL Elife 6:0-0(2017). RN [28] RP INTERACTION WITH GPR31. RX PubMed=28619714; DOI=10.1083/jcb.201609096; RA Fehrenbacher N., Tojal da Silva I., Ramirez C., Zhou Y., Cho K.J., RA Kuchay S., Shi J., Thomas S., Pagano M., Hancock J.F., Bar-Sagi D., RA Philips M.R.; RT "The G protein-coupled receptor GPR31 promotes membrane association of RT KRAS."; RL J. Cell Biol. 216:2329-2338(2017). RN [29] RP UBIQUITINATION AT LYS-170. RX PubMed=30442762; DOI=10.1126/science.aap7607; RA Steklov M., Pandolfi S., Baietti M.F., Batiuk A., Carai P., Najm P., RA Zhang M., Jang H., Renzi F., Cai Y., Abbasi Asbagh L., Pastor T., RA De Troyer M., Simicek M., Radaelli E., Brems H., Legius E., Tavernier J., RA Gevaert K., Impens F., Messiaen L., Nussinov R., Heymans S., Eyckerman S., RA Sablina A.A.; RT "Mutations in LZTR1 drive human disease by dysregulating RAS RT ubiquitination."; RL Science 362:1177-1182(2018). RN [30] RP UBIQUITINATION. RX PubMed=30442766; DOI=10.1126/science.aap8210; RA Bigenzahn J.W., Collu G.M., Kartnig F., Pieraks M., Vladimer G.I., RA Heinz L.X., Sedlyarov V., Schischlik F., Fauster A., Rebsamen M., RA Parapatics K., Blomen V.A., Mueller A.C., Winter G.E., Kralovics R., RA Brummelkamp T.R., Mlodzik M., Superti-Furga G.; RT "LZTR1 is a regulator of RAS ubiquitination and signaling."; RL Science 362:1171-1177(2018). RN [31] RP INTERACTION WITH PPP1CA; PPP1CB AND SHOC2. RX PubMed=36175670; DOI=10.1038/s41594-022-00841-4; RA Bonsor D.A., Alexander P., Snead K., Hartig N., Drew M., Messing S., RA Finci L.I., Nissley D.V., McCormick F., Esposito D., Rodriguez-Viciana P., RA Stephen A.G., Simanshu D.K.; RT "Structure of the SHOC2-MRAS-PP1c complex provides insights into RAF RT activation and Noonan syndrome."; RL Nat. Struct. Mol. Biol. 29:966-977(2022). RN [32] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [33] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2, AND CHARACTERIZATION OF RP VARIANT GLN-61. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [34] RP INTERACTION WITH PPP1CA AND SHOC2, AND CHARACTERIZATION OF VARIANT GLN-61. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1-164 IN COMPLEX WITH THE GTP RP ANALOG GUANOSINE-5'-DIPHOSPHATE, AND ACTIVITY REGULATION. RX PubMed=22566140; DOI=10.1002/anie.201201358; RA Sun Q., Burke J.P., Phan J., Burns M.C., Olejniczak E.T., Waterson A.G., RA Lee T., Rossanese O.W., Fesik S.W.; RT "Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated RT activation."; RL Angew. Chem. Int. Ed. Engl. 51:6140-6143(2012). RN [36] RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 2-164 IN COMPLEX WITH GTP ANALOGS RP AND MAGNESIUM, FUNCTION, ACTIVITY REGULATION, INTERACTION WITH SOS1, AND RP SUBCELLULAR LOCATION. RX PubMed=22431598; DOI=10.1073/pnas.1116510109; RA Maurer T., Garrenton L.S., Oh A., Pitts K., Anderson D.J., Skelton N.J., RA Fauber B.P., Pan B., Malek S., Stokoe D., Ludlam M.J., Bowman K.K., Wu J., RA Giannetti A.M., Starovasnik M.A., Mellman I., Jackson P.K., Rudolph J., RA Wang W., Fang G.; RT "Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS- RT mediated nucleotide exchange activity."; RL Proc. Natl. Acad. Sci. U.S.A. 109:5299-5304(2012). RN [37] {ECO:0007744|PDB:5TAR, ECO:0007744|PDB:5TB5} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 2-164, ISOPRENYLATION AT CYS-186, RP AND METHYLATION AT CYS-186. RX PubMed=27791178; DOI=10.1073/pnas.1615316113; RA Dharmaiah S., Bindu L., Tran T.H., Gillette W.K., Frank P.H., Ghirlando R., RA Nissley D.V., Esposito D., McCormick F., Stephen A.G., Simanshu D.K.; RT "Structural basis of recognition of farnesylated and methylated KRAS4b by RT PDEdelta."; RL Proc. Natl. Acad. Sci. U.S.A. 113:E6766-E6775(2016). RN [38] {ECO:0007744|PDB:7LC1, ECO:0007744|PDB:7LC2} RP X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) IN COMPLEX WITH MAPKAP1, INTERACTION RP WITH MAPKAP1, AND MUTAGENESIS OF ASP-38 AND TYR-40. RX PubMed=34380736; DOI=10.1073/pnas.2103261118; RA Castel P., Dharmaiah S., Sale M.J., Messing S., Rizzuto G., RA Cuevas-Navarro A., Cheng A., Trnka M.J., Urisman A., Esposito D., RA Simanshu D.K., McCormick F.; RT "RAS interaction with Sin1 is dispensable for mTORC2 assembly and RT activity."; RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021). RN [39] {ECO:0007744|PDB:7VVB} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) IN COMPLEX WITH MAPKAP1, AND RP INTERACTION WITH MAPKAP1. RX PubMed=35522713; DOI=10.1073/pnas.2119990119; RA Zheng Y., Ding L., Meng X., Potter M., Kearney A.L., Zhang J., Sun J., RA James D.E., Yang G., Zhou C.; RT "Structural insights into Ras regulation by SIN1."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2119990119-e2119990119(2022). RN [40] RP VARIANT BREAST CANCER ASP-13. RX PubMed=3627975; DOI=10.1093/nar/15.15.5963; RA Kozma S.C., Bogaard M.E., Buser K., Saurer S.M., Bos J.L., Groner B., RA Hynes N.E.; RT "The human c-Kirsten ras gene is activated by a novel mutation in codon 13 RT in the breast carcinoma cell line MDA-MB231."; RL Nucleic Acids Res. 15:5963-5971(1987). RN [41] RP VARIANT BLADDER CANCER THR-59. RX PubMed=1553789; DOI=10.1007/bf00296523; RA Grimmond S.M., Raghavan D., Russell P.J.; RT "Detection of a rare point mutation in Ki-ras of a human bladder cancer RT xenograft by polymerase chain reaction and direct sequencing."; RL Urol. Res. 20:121-126(1992). RN [42] RP VARIANTS PANCREATIC CARCINOMA ASP-12 AND VAL-12. RX PubMed=8439212; DOI=10.1097/00000658-199302000-00007; RA Motojima K., Urano T., Nagata Y., Shiku H., Tsurifune T., Kanematsu T.; RT "Detection of point mutations in the Kirsten-ras oncogene provides evidence RT for the multicentricity of pancreatic carcinoma."; RL Ann. Surg. 217:138-143(1993). RN [43] RP VARIANTS GASC SER-12 AND ASP-12. RX PubMed=7773929; RX DOI=10.1002/1097-0142(19950615)75:12<2794::aid-cncr2820751203>3.0.co;2-f; RA Lee K.H., Lee J.S., Suh C., Kim S.W., Kim S.B., Lee J.H., Lee M.S., RA Park M.Y., Sun H.S., Kim S.H.; RT "Clinicopathologic significance of the K-ras gene codon 12 point mutation RT in stomach cancer. An analysis of 140 cases."; RL Cancer 75:2794-2801(1995). RN [44] RP INVOLVEMENT IN AML, VARIANT GLY-10 INS, AND CHARACTERIZATION OF VARIANT RP GLY-10 INS. RX PubMed=8955068; DOI=10.1074/jbc.271.51.32491; RA Bollag G., Adler F., elMasry N., McCabe P.C., Conner E. Jr., Thompson P., RA McCormick F., Shannon K.; RT "Biochemical characterization of a novel KRAS insertion mutation from a RT human leukemia."; RL J. Biol. Chem. 271:32491-32494(1996). RN [45] RP VARIANTS GASC ASN-5; VAL-12; ASP-13 AND THR-59. RX PubMed=14534542; DOI=10.1038/sj.onc.1206749; RA Lee S.H., Lee J.W., Soung Y.H., Kim H.S., Park W.S., Kim S.Y., Lee J.H., RA Park J.Y., Cho Y.G., Kim C.J., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J.; RT "BRAF and KRAS mutations in stomach cancer."; RL Oncogene 22:6942-6945(2003). RN [46] RP VARIANT PYLOCYTIC ASTROCYTOMA ARG-13. RX PubMed=16247081; DOI=10.1212/01.wnl.0000180409.78098.d7; RA Sharma M.K., Zehnbauer B.A., Watson M.A., Gutmann D.H.; RT "RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic RT astrocytoma."; RL Neurology 65:1335-1336(2005). RN [47] RP VARIANTS NS3 GLY-152 AND VAL-153 (ISOFORM 2). RX PubMed=16773572; DOI=10.1086/504394; RA Carta C., Pantaleoni F., Bocchinfuso G., Stella L., Vasta I., Sarkozy A., RA Digilio C., Palleschi A., Pizzuti A., Grammatico P., Zampino G., RA Dallapiccola B., Gelb B.D., Tartaglia M.; RT "Germline missense mutations affecting KRAS Isoform B are associated with a RT severe Noonan syndrome phenotype."; RL Am. J. Hum. Genet. 79:129-135(2006). RN [48] RP VARIANTS LUNG CARCINOMA CYS-12; ASP-12; SER-12; VAL-12 AND HIS-61. RX PubMed=16533793; DOI=10.1158/1078-0432.ccr-05-1981; RA Tam I.Y.S., Chung L.P., Suen W.S., Wang E., Wong M.C.M., Ho K.K., Lam W.K., RA Chiu S.W., Girard L., Minna J.D., Gazdar A.F., Wong M.P.; RT "Distinct epidermal growth factor receptor and KRAS mutation patterns in RT non-small cell lung cancer patients with different tobacco exposure and RT clinicopathologic features."; RL Clin. Cancer Res. 12:1647-1653(2006). RN [49] RP VARIANT CFC2 ARG-60. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [50] RP VARIANTS NS3 ILE-14 AND ILE-58, VARIANT CFC2 ARG-34, AND CHARACTERIZATION RP OF VARIANTS NS3 ILE-14 AND ILE-58. RX PubMed=16474405; DOI=10.1038/ng1748; RA Schubbert S., Zenker M., Rowe S.L., Boell S., Klein C., Bollag G., RA van der Burgt I., Musante L., Kalscheuer V., Wehner L.-E., Nguyen H., RA West B., Zhang K.Y.J., Sistermans E., Rauch A., Niemeyer C.M., Shannon K., RA Kratz C.P.; RT "Germline KRAS mutations cause Noonan syndrome."; RL Nat. Genet. 38:331-336(2006). RN [51] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-12; ASP-12; SER-12; VAL-12; ASP-13; RP ARG-61; ASN-117 AND THR-146. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [52] RP VARIANTS JMML ASP-12; SER-12 AND ASP-13. RX PubMed=17332249; DOI=10.1182/blood-2006-09-046649; RA Matsuda K., Shimada A., Yoshida N., Ogawa A., Watanabe A., Yajima S., RA Iizuka S., Koike K., Yanai F., Kawasaki K., Yanagimachi M., Kikuchi A., RA Ohtsuka Y., Hidaka E., Yamauchi K., Tanaka M., Yanagisawa R., Nakazawa Y., RA Shiohara M., Manabe A., Kojima S., Koike K.; RT "Spontaneous improvement of hematologic abnormalities in patients having RT juvenile myelomonocytic leukemia with specific RAS mutations."; RL Blood 109:5477-5480(2007). RN [53] RP VARIANT NS3 GLU-5. RX PubMed=17468812; DOI=10.1007/s10038-007-0146-1; RA Bertola D.R., Pereira A.C., Brasil A.S., Albano L.M., Kim C.A., RA Krieger J.E.; RT "Further evidence of genetic heterogeneity in Costello syndrome: RT involvement of the KRAS gene."; RL J. Hum. Genet. 52:521-526(2007). RN [54] RP VARIANTS NS3 ILE-14; ARG-22; LEU-34; GLN-34; MET-36; VAL-153 AND ILE-156 RP (ISOFORM 2), VARIANT CFC2 GLU-22, AND VARIANTS ASN-5 AND LEU-156 (ISOFORM RP 2). RX PubMed=17056636; DOI=10.1136/jmg.2006.046300; RA Zenker M., Lehmann K., Schulz A.L., Barth H., Hansmann D., Koenig R., RA Korinthenberg R., Kreiss-Nachtsheim M., Meinecke P., Morlot S., Mundlos S., RA Quante A.S., Raskin S., Schnabel D., Wehner L.E., Kratz C.P., Horn D., RA Kutsche K.; RT "Expansion of the genotypic and phenotypic spectrum in patients with KRAS RT germline mutations."; RL J. Med. Genet. 44:131-135(2007). RN [55] RP VARIANTS NS3 ILE-58 AND SER-60. RX PubMed=19396835; DOI=10.1002/ajmg.a.32786; RA Kratz C.P., Zampino G., Kriek M., Kant S.G., Leoni C., Pantaleoni F., RA Oudesluys-Murphy A.M., Di Rocco C., Kloska S.P., Tartaglia M., Zenker M.; RT "Craniosynostosis in patients with Noonan syndrome caused by germline KRAS RT mutations."; RL Am. J. Med. Genet. A 149:1036-1040(2009). RN [56] RP CHARACTERIZATION OF VARIANTS NS3 ILE-14; ARG-22; LEU-34; ILE-58 AND VAL-153 RP (ISOFORM 2), CHARACTERIZATION OF VARIANTS CFC2 GLU-22; ARG-34 AND ARG-60, RP CHARACTERIZATION OF VARIANTS ASN-5 AND LEU-156 (ISOFORM 2), FUNCTION, AND RP CATALYTIC ACTIVITY. RX PubMed=20949621; DOI=10.1002/humu.21377; RA Gremer L., Merbitz-Zahradnik T., Dvorsky R., Cirstea I.C., Kratz C.P., RA Zenker M., Wittinghofer A., Ahmadian M.R.; RT "Germline KRAS mutations cause aberrant biochemical and physical properties RT leading to developmental disorders."; RL Hum. Mutat. 32:33-43(2011). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, CHARACTERIZATION OF RP VARIANT VAL-12, AND MUTAGENESIS OF GLN-61. RX PubMed=39809765; DOI=10.1038/s41467-025-55967-y; RA Bernal Astrain G., Strakhova R., Jo C.H., Teszner E., Killoran R.C., RA Smith M.J.; RT "The small GTPase MRAS is a broken switch."; RL Nat. Commun. 16:647-647(2025). RN [58] RP VARIANTS CFC2 HIS-71 AND GLU-147. RX PubMed=21797849; DOI=10.1111/j.1399-0004.2011.01754.x; RA Stark Z., Gillessen-Kaesbach G., Ryan M.M., Cirstea I.C., Gremer L., RA Ahmadian M.R., Savarirayan R., Zenker M.; RT "Two novel germline KRAS mutations: expanding the molecular and clinical RT phenotype."; RL Clin. Genet. 81:590-594(2012). RN [59] RP VARIANTS OES ASP-13 AND PHE-19, AND INVOLVEMENT IN OES. RX PubMed=25808193; DOI=10.1002/ajmg.a.37048; RA Peacock J.D., Dykema K.J., Toriello H.V., Mooney M.R., Scholten D.J. II, RA Winn M.E., Borgman A., Duesbery N.S., Hiemenga J.A., Liu C., Campbell S., RA Nickoloff B.P., Williams B.O., Steensma M.; RT "Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS RT alterations."; RL Am. J. Med. Genet. A 167:1429-1435(2015). RN [60] RP VARIANTS OES THR-146 AND VAL-146, AND INVOLVEMENT IN OES. RX PubMed=26970110; DOI=10.1111/cge.12775; RA Boppudi S., Boegershausen N., Hove H.B., Percin E.F., Aslan D., Dvorsky R., RA Kayhan G., Li Y., Cursiefen C., Tantcheva-Poor I., Toft P.B., Bartsch O., RA Lissewski C., Wieland I., Jakubiczka S., Wollnik B., Ahmadian M.R., RA Heindl L.M., Zenker M.; RT "Specific mosaic KRAS mutations affecting codon 146 cause oculoectodermal RT syndrome and encephalocraniocutaneous lipomatosis."; RL Clin. Genet. 90:334-342(2016). RN [61] RP VARIANT SFM ASP-12, VARIANTS OES THR-146 AND VAL-146, INVOLVEMENT IN SFM, RP AND INVOLVEMENT IN OES. RX PubMed=30891959; DOI=10.1002/mgg3.625; RA Chacon-Camacho O.F., Lopez-Moreno D., Morales-Sanchez M.A., Hofmann E., RA Pacheco-Quito M., Wieland I., Cortes-Gonzalez V., Villanueva-Mendoza C., RA Zenker M., Zenteno J.C.; RT "Expansion of the phenotypic spectrum and description of molecular findings RT in a cohort of patients with oculocutaneous mosaic RASopathies."; RL Mol. Genet. Genomic Med. 7:E625-E625(2019). RN [62] RP VARIANTS ALA-12; ASP-12; CYS-12; VAL-12; ASN-117 AND THR-146. RX PubMed=34820593; DOI=10.1200/po.21.00223; RA van 't Erve I., Wesdorp N.J., Medina J.E., Ferreira L., Leal A., RA Huiskens J., Bolhuis K., van Waesberghe J.T.M., Swijnenburg R.J., RA van den Broek D., Velculescu V.E., Kazemier G., Punt C.J.A., Meijer G.A., RA Fijneman R.J.A.; RT "KRAS A146 mutations are associated with distinct clinical behavior in RT patients with colorectal liver metastases."; RL JCO Precis. Oncol. 5:0-0(2021). CC -!- FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase CC activity (PubMed:20949621, PubMed:39809765). Plays an important role in CC the regulation of cell proliferation (PubMed:22711838, CC PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation CC and ultimately degradation of GJA1 (By similarity). Plays a role in CC promoting oncogenic events by inducing transcriptional silencing of CC tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a CC ZNF304-dependent manner (PubMed:24623306). CC {ECO:0000250|UniProtKB:P08644, ECO:0000269|PubMed:20949621, CC ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:23698361, CC ECO:0000269|PubMed:24623306, ECO:0000269|PubMed:39809765}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2; CC Evidence={ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:39809765}; CC -!- ACTIVITY REGULATION: Alternates between an inactive form bound to GDP CC and an active form bound to GTP (PubMed:22566140, PubMed:22431598, CC PubMed:39809765). Activated by a guanine nucleotide-exchange factor CC (GEF) and inactivated by a GTPase-activating protein (GAP) CC (PubMed:22711838). Interaction with SOS1 promotes exchange of bound GDP CC to GTP (PubMed:22566140, PubMed:22431598, PubMed:39809765). CC {ECO:0000269|PubMed:22431598, ECO:0000269|PubMed:22566140, CC ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:39809765}. CC -!- SUBUNIT: Interacts with PHLPP (By similarity). Interacts (active GTP- CC bound form preferentially) with RGS14 (By similarity). Interacts (when CC farnesylated) with PDE6D; this promotes dissociation from the cell CC membrane (PubMed:23698361). Interacts with SOS1 (PubMed:22431598). CC Interacts (when farnesylated) with GPR31 (PubMed:28619714). Interacts CC with RAP1GDS1 (PubMed:20709748, PubMed:24415755). Interacts (active CC GTP-bound form) with both SHOC2 and PP1c (all isoforms) to form a CC tertiary complex; SHOC2 and PP1c preferably bind M-Ras/MRAS, but they CC also bind K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS (PubMed:35768504, CC PubMed:35830882, PubMed:35831509, PubMed:36175670). Interacts (GTP- CC bound form) with MAPKAP1/SIN1; inhibiting K-Ras/KRAS activity CC (PubMed:34380736, PubMed:35522713). {ECO:0000250|UniProtKB:P08644, CC ECO:0000269|PubMed:20709748, ECO:0000269|PubMed:22431598, CC ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:24415755, CC ECO:0000269|PubMed:28619714, ECO:0000269|PubMed:34380736, CC ECO:0000269|PubMed:35522713, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509, CC ECO:0000269|PubMed:36175670}. CC -!- SUBUNIT: [Isoform 2B]: Interacts with GPR31; in a farnelysation- CC dependent manner. {ECO:0000269|PubMed:28619714}. CC -!- INTERACTION: CC P01116; Q96II5: ARAF; NbExp=3; IntAct=EBI-367415, EBI-9383168; CC P01116; Q99755: PIP5K1A; NbExp=9; IntAct=EBI-367415, EBI-726414; CC P01116; P04049: RAF1; NbExp=6; IntAct=EBI-367415, EBI-365996; CC P01116; P50749: RASSF2; NbExp=2; IntAct=EBI-367415, EBI-960081; CC P01116-2; P05067: APP; NbExp=3; IntAct=EBI-367427, EBI-77613; CC P01116-2; P49354: FNTA; NbExp=2; IntAct=EBI-367427, EBI-602336; CC P01116-2; O00270: GPR31; NbExp=4; IntAct=EBI-367427, EBI-34583813; CC P01116-2; P01116-2: KRAS; NbExp=6; IntAct=EBI-367427, EBI-367427; CC P01116-2; P04049: RAF1; NbExp=3; IntAct=EBI-367427, EBI-365996; CC P01116-2; Q04631: Fnta; Xeno; NbExp=3; IntAct=EBI-367427, EBI-602447; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22431598, CC ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:29239724}; Lipid-anchor CC {ECO:0000269|PubMed:29239724, ECO:0000305|PubMed:23698361}; Cytoplasmic CC side {ECO:0000305|PubMed:23698361}. Endomembrane system CC {ECO:0000269|PubMed:29239724}. Cytoplasm, cytosol CC {ECO:0000269|PubMed:23698361}. CC -!- SUBCELLULAR LOCATION: [Isoform 2B]: Cell membrane CC {ECO:0000269|PubMed:28619714}; Lipid-anchor CC {ECO:0000305|PubMed:28619714}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Comment=Isoforms differ in the C-terminal region which is encoded by CC two alternative exons (IVA and IVB).; CC Name=2A; Synonyms=K-Ras4A {ECO:0000303|PubMed:29239724}; CC IsoId=P01116-1; Sequence=Displayed; CC Name=2B; Synonyms=K-Ras4B; CC IsoId=P01116-2, P01118-1; CC Sequence=VSP_011140, VSP_011141; CC -!- PTM: Acetylation at Lys-104 prevents interaction with guanine CC nucleotide exchange factors (GEFs). {ECO:0000269|PubMed:22711838, CC ECO:0000269|Ref.17}. CC -!- PTM: Palmitoylated at Lys-182, Lys-184 and Lys-185 (PubMed:29239724). CC Palmitoylation on lysine residues is promoted by palmitoylation at Cys- CC 180 (PubMed:29239724). Lysine-depalmitoylation by SIRT2 promotes its CC localization to endomembranes in endocytic pathways (PubMed:29239724). CC {ECO:0000269|PubMed:29239724}. CC -!- PTM: Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at CC Lys-170 in a non-degradative manner, leading to inhibit Ras signaling CC by decreasing Ras association with membranes. CC {ECO:0000305|PubMed:30442762, ECO:0000305|PubMed:30442766}. CC -!- PTM: (Microbial infection) Glucosylated at Thr-35 by P.sordellii toxin CC TcsL. {ECO:0000269|PubMed:19744486}. CC -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of CC acute leukemia, a cancer of the white blood cells. AML is a malignant CC disease of bone marrow characterized by maturational arrest of CC hematopoietic precursors at an early stage of development. Clonal CC expansion of myeloid blasts occurs in bone marrow, blood, and other CC tissue. Myelogenous leukemias develop from changes in cells that CC normally produce neutrophils, basophils, eosinophils and monocytes. CC {ECO:0000269|PubMed:8955068}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. {ECO:0000269|PubMed:17332249}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Noonan syndrome 3 (NS3) [MIM:609942]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:16474405, CC ECO:0000269|PubMed:16773572, ECO:0000269|PubMed:17056636, CC ECO:0000269|PubMed:17468812, ECO:0000269|PubMed:19396835, CC ECO:0000269|PubMed:20949621}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:14534542, CC ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:7773929}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Defects in KRAS are a cause of pylocytic astrocytoma CC (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord CC derived from glial cells which vary from histologically benign forms to CC highly anaplastic and malignant tumors. {ECO:0000269|PubMed:16247081}. CC -!- DISEASE: Cardiofaciocutaneous syndrome 2 (CFC2) [MIM:615278]: A form of CC cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder CC characterized by a distinctive facial appearance, heart defects and CC intellectual disability. Heart defects include pulmonic stenosis, CC atrial septal defects and hypertrophic cardiomyopathy. Some affected CC individuals present with ectodermal abnormalities such as sparse, CC friable hair, hyperkeratotic skin lesions and a generalized ichthyosis- CC like condition. Typical facial features are similar to Noonan syndrome. CC They include high forehead with bitemporal constriction, hypoplastic CC supraorbital ridges, downslanting palpebral fissures, a depressed nasal CC bridge, and posteriorly angulated ears with prominent helices. CFC2 CC patients often do not have the skin abnormalities, such as ichthyosis, CC hyperkeratosis, and hemangioma observed in CFC1. CC {ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:16474405, CC ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:20949621, CC ECO:0000269|PubMed:21797849}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=KRAS mutations are involved in cancer development. CC {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:1553789, CC ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:24623306, CC ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:3627975, CC ECO:0000269|PubMed:6092920, ECO:0000269|PubMed:6695174, CC ECO:0000269|PubMed:7773929}. CC -!- DISEASE: Oculoectodermal syndrome (OES) [MIM:600268]: A syndrome CC characterized by the association of epibulbar dermoids and aplasia CC cutis congenita. Affected individuals show multiple, asymmetric, CC atrophic, non-scarring and hairless regions that may be associated with CC hamartomas. Ectodermal changes include linear hyperpigmentation that CC may follow the lines of Blaschko and rarely epidermal nevus-like CC lesions. Epibulbar dermoids may be uni-or bilateral. Additional ocular CC anomalies such as skin tags of the upper eyelid, rarely optic nerve or CC retinal changes, and microphthalmia can be present. The phenotypic CC expression is highly variable, and various other abnormalities have CC occasionally been reported including growth failure, lymphedema, CC cardiovascular defects, as well as neurodevelopmental symptoms like CC developmental delay, epilepsy, learning difficulties, and behavioral CC abnormalities. Benign tumor-like lesions such as nonossifying fibromas CC of the long bones and giant cell granulomas of the jaws have repeatedly CC been observed and appear to be age-dependent, becoming a common CC manifestation in individuals aged 5 years or older. CC {ECO:0000269|PubMed:25808193, ECO:0000269|PubMed:26970110, CC ECO:0000269|PubMed:30891959}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A CC disease characterized by sebaceous nevi, often on the face, associated CC with variable ipsilateral abnormalities of the central nervous system, CC ocular anomalies, and skeletal defects. Many oral manifestations have CC been reported, not only including hypoplastic and malformed teeth, and CC mucosal papillomatosis, but also ankyloglossia, hemihyperplastic CC tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone CC cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous CC nevi follow the lines of Blaschko and these can continue as linear CC intraoral lesions, as in mucosal papillomatosis. CC {ECO:0000269|PubMed:30891959}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the small GTPase superfamily. Ras family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/91/KRAS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L00049; AAB59444.1; -; Genomic_DNA. DR EMBL; L00045; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00046; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00047; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00048; AAB59445.1; -; Genomic_DNA. DR EMBL; L00045; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; L00046; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; L00047; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; M54968; AAB41942.1; -; mRNA. DR EMBL; AF493917; AAM12631.1; -; mRNA. DR EMBL; BT007153; AAP35817.1; -; mRNA. DR EMBL; AK292510; BAF85199.1; -; mRNA. DR EMBL; CH471094; EAW96511.1; -; Genomic_DNA. DR EMBL; CH471094; EAW96512.1; -; Genomic_DNA. DR EMBL; EU332849; ABY87538.1; -; Genomic_DNA. DR EMBL; BC013572; AAH13572.1; -; mRNA. DR EMBL; K01519; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; K01520; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M25876; AAA35683.1; -; Genomic_DNA. DR EMBL; M34904; AAA36149.1; -; Genomic_DNA. DR EMBL; M30539; AAA36557.1; -; Genomic_DNA. DR EMBL; X01669; CAA25828.1; -; Genomic_DNA. DR EMBL; X02825; CAA26593.1; -; Genomic_DNA. DR EMBL; K03210; AAA36554.1; -; Genomic_DNA. DR EMBL; K03209; AAA36554.1; JOINED; Genomic_DNA. DR CCDS; CCDS8702.1; -. [P01116-2] DR CCDS; CCDS8703.1; -. [P01116-1] DR PIR; A93311; TVHUK. DR PIR; B93311; TVHU2K. DR RefSeq; NP_001356715.1; NM_001369786.1. [P01116-1] DR RefSeq; NP_001356716.1; NM_001369787.1. [P01116-2] DR RefSeq; NP_004976.2; NM_004985.4. [P01116-2] DR RefSeq; NP_203524.1; NM_033360.4. [P01116-1] DR PDB; 1D8D; X-ray; 2.00 A; P=178-188. DR PDB; 1D8E; X-ray; 3.00 A; P=178-188. DR PDB; 1KZO; X-ray; 2.20 A; C=169-173. DR PDB; 1KZP; X-ray; 2.10 A; C=169-173. DR PDB; 1N4P; X-ray; 2.65 A; M/N=185-189. DR PDB; 1N4Q; X-ray; 2.40 A; M/N/O/P/Q/R=185-189. DR PDB; 1N4R; X-ray; 2.80 A; M/N/O/P/Q/R=185-189. DR PDB; 1N4S; X-ray; 2.60 A; M/N/O/P/Q/R=185-189. DR PDB; 2MSC; NMR; -; B=1-186. DR PDB; 2MSD; NMR; -; B=1-186. DR PDB; 2MSE; NMR; -; B=1-186. DR PDB; 3GFT; X-ray; 2.27 A; A/B/C/D/E/F=1-164. DR PDB; 4DSN; X-ray; 2.03 A; A=2-164. DR PDB; 4DSO; X-ray; 1.85 A; A=2-164. DR PDB; 4EPR; X-ray; 2.00 A; A=1-164. DR PDB; 4EPT; X-ray; 2.00 A; A=1-164. DR PDB; 4EPV; X-ray; 1.35 A; A=1-164. DR PDB; 4EPW; X-ray; 1.70 A; A=1-164. DR PDB; 4EPX; X-ray; 1.76 A; A=1-164. DR PDB; 4EPY; X-ray; 1.80 A; A=1-164. DR PDB; 4L8G; X-ray; 1.52 A; A=1-169. DR PDB; 4LDJ; X-ray; 1.15 A; A=1-164. DR PDB; 4LPK; X-ray; 1.50 A; A/B=1-169. DR PDB; 4LRW; X-ray; 2.15 A; A/B=1-169. DR PDB; 4LUC; X-ray; 1.29 A; A/B=1-169. DR PDB; 4LV6; X-ray; 1.50 A; A/B=1-169. DR PDB; 4LYF; X-ray; 1.57 A; A/B/C=1-169. DR PDB; 4LYH; X-ray; 1.37 A; A/B/C=1-169. DR PDB; 4LYJ; X-ray; 1.93 A; A=1-169. DR PDB; 4M1O; X-ray; 1.57 A; A/B/C=1-169. DR PDB; 4M1S; X-ray; 1.55 A; A/B/C=1-169. DR PDB; 4M1T; X-ray; 1.70 A; A/B/C=1-169. DR PDB; 4M1W; X-ray; 1.58 A; A/B/C=1-169. DR PDB; 4M1Y; X-ray; 1.49 A; A/B/C=1-169. DR PDB; 4M21; X-ray; 1.94 A; A/B/C=1-169. DR PDB; 4M22; X-ray; 2.09 A; A/B/C=1-169. DR PDB; 4NMM; X-ray; 1.89 A; A=1-164. DR PDB; 4OBE; X-ray; 1.24 A; A/B=1-164. DR PDB; 4PZY; X-ray; 1.88 A; A/B=1-164. DR PDB; 4PZZ; X-ray; 1.40 A; A=1-164. DR PDB; 4Q01; X-ray; 1.29 A; A/B=1-164. DR PDB; 4Q02; X-ray; 1.70 A; A=1-164. DR PDB; 4Q03; X-ray; 1.20 A; A=1-164. DR PDB; 4QL3; X-ray; 1.04 A; A=1-11, A=13-164. DR PDB; 4TQ9; X-ray; 1.49 A; A/B=1-164. DR PDB; 4TQA; X-ray; 1.13 A; A/B=1-164. DR PDB; 4WA7; X-ray; 1.99 A; A=1-164. DR PDB; 5F2E; X-ray; 1.40 A; A=1-169. DR PDB; 5KYK; X-ray; 2.70 A; A/B/C=1-167. DR PDB; 5MLA; X-ray; 2.19 A; A=1-166. DR PDB; 5MLB; X-ray; 3.22 A; A/C/E/G=1-166. DR PDB; 5O2S; X-ray; 3.22 A; A/C/E/G=1-166. DR PDB; 5O2T; X-ray; 2.19 A; A=1-166. DR PDB; 5OCG; X-ray; 1.48 A; A=2-189. DR PDB; 5OCO; X-ray; 1.66 A; A/B/C/D/E/F=1-169. DR PDB; 5OCT; X-ray; 2.07 A; A/B/C/D/E/F=1-169. DR PDB; 5TAR; X-ray; 1.90 A; A=2-164. DR PDB; 5TB5; X-ray; 2.00 A; A/C=2-164. DR PDB; 5UFE; X-ray; 2.30 A; A=1-166. DR PDB; 5UFQ; X-ray; 2.20 A; A/B=1-166. DR PDB; 5UK9; X-ray; 1.89 A; A/B=1-166. DR PDB; 5UQW; X-ray; 1.50 A; A/B=1-164. DR PDB; 5US4; X-ray; 1.83 A; A/B=1-164. DR PDB; 5USJ; X-ray; 1.94 A; A/B/C/D/E/F=1-164. DR PDB; 5V6S; X-ray; 1.70 A; A=1-169. DR PDB; 5V6V; X-ray; 1.72 A; A/B=1-169. DR PDB; 5V71; X-ray; 2.23 A; A/B/C/D/E/F=1-167. DR PDB; 5V9L; X-ray; 1.98 A; A/B/C=1-167. DR PDB; 5V9O; X-ray; 1.56 A; A=1-167. DR PDB; 5V9U; X-ray; 1.38 A; A/B=1-169. DR PDB; 5VBM; X-ray; 1.49 A; A=1-169. DR PDB; 5VP7; X-ray; 1.70 A; A/F=1-169. DR PDB; 5VPI; X-ray; 1.62 A; A/B=1-169. DR PDB; 5VPY; X-ray; 2.00 A; A/B=1-169. DR PDB; 5VPZ; X-ray; 1.85 A; A/B=1-169. DR PDB; 5VQ0; X-ray; 2.30 A; A/B=1-169. DR PDB; 5VQ1; X-ray; 1.78 A; A/B=1-169. DR PDB; 5VQ2; X-ray; 1.96 A; A/B=1-169. DR PDB; 5VQ6; X-ray; 1.99 A; A/B=1-169. DR PDB; 5VQ8; X-ray; 2.30 A; A/B=1-169. DR PDB; 5W22; X-ray; 1.76 A; A/B=1-169. DR PDB; 5WHA; X-ray; 2.04 A; A/D/G/J=1-166. DR PDB; 5WHB; X-ray; 2.18 A; A/D/G/J=1-166. DR PDB; 5WHD; X-ray; 1.64 A; A/B/C/D=1-166. DR PDB; 5WHE; X-ray; 1.91 A; A/D/G/J=1-166. DR PDB; 5WLB; X-ray; 1.72 A; A/D=1-166. DR PDB; 5WPM; X-ray; 1.72 A; A=1-166. DR PDB; 5XCO; X-ray; 1.25 A; A=1-169. DR PDB; 5YXZ; X-ray; 1.70 A; A=1-169. DR PDB; 5YY1; X-ray; 1.69 A; A=1-169. DR PDB; 6ARK; X-ray; 1.75 A; A=1-169. DR PDB; 6ASA; X-ray; 2.54 A; A=1-167. DR PDB; 6ASE; X-ray; 1.55 A; A=1-169. DR PDB; 6B0V; X-ray; 1.29 A; A/B=1-169. DR PDB; 6B0Y; X-ray; 1.43 A; A/B=1-169. DR PDB; 6BOF; X-ray; 1.40 A; A/B=2-169. DR PDB; 6BP1; X-ray; 2.00 A; A=1-169. DR PDB; 6CC9; NMR; -; B=1-186. DR PDB; 6CCH; NMR; -; B=1-186. DR PDB; 6CCX; NMR; -; B=1-186. DR PDB; 6CU6; X-ray; 1.50 A; A/B/C=1-169. DR PDB; 6E6F; X-ray; 3.40 A; A/B=1-166. DR PDB; 6E6G; X-ray; 1.93 A; A=1-166. DR PDB; 6EPL; X-ray; 2.55 A; R=1-169. DR PDB; 6EPM; X-ray; 2.50 A; R=1-169. DR PDB; 6EPN; X-ray; 2.50 A; R=1-169. DR PDB; 6EPO; X-ray; 2.40 A; R=1-169. DR PDB; 6EPP; X-ray; 2.40 A; R=1-169. DR PDB; 6F76; X-ray; 2.20 A; A/B/C/D/E/F=1-169. DR PDB; 6FA1; X-ray; 1.97 A; A/C/D/F=1-167, B/E=1-169. DR PDB; 6FA2; X-ray; 2.60 A; A/B/C/D/E/F=1-167. DR PDB; 6FA3; X-ray; 1.82 A; A/B/C/D/E/F=1-167. DR PDB; 6FA4; X-ray; 2.02 A; A/B/C/D/E/F=1-169. DR PDB; 6GJ5; X-ray; 1.50 A; A/B=1-169. DR PDB; 6GJ6; X-ray; 1.76 A; A=1-169. DR PDB; 6GJ7; X-ray; 1.67 A; A=1-169. DR PDB; 6GJ8; X-ray; 1.65 A; A=1-167. DR PDB; 6GOD; X-ray; 1.71 A; A=2-173. DR PDB; 6GOE; X-ray; 1.60 A; A=2-169. DR PDB; 6GOF; X-ray; 1.98 A; A=2-173. DR PDB; 6GOG; X-ray; 2.05 A; A/B/C/D/E/F=1-169. DR PDB; 6GOM; X-ray; 1.63 A; A/B/C/D/E/F=1-167. DR PDB; 6GQT; X-ray; 1.69 A; A/B/C/D/E/F=1-167. DR PDB; 6GQW; X-ray; 2.80 A; A/B/C/D/E/F=1-167. DR PDB; 6GQX; X-ray; 2.20 A; A/B/C/D/E/F=1-167. DR PDB; 6GQY; X-ray; 2.75 A; A/B/C/D/E/F=1-167. DR PDB; 6H46; X-ray; 2.22 A; A=1-166. DR PDB; 6H47; X-ray; 1.70 A; A=1-166. DR PDB; 6JTN; X-ray; 1.90 A; C=10-19. DR PDB; 6JTO; X-ray; 1.70 A; C=10-19. DR PDB; 6JTP; X-ray; 1.90 A; C=10-18. DR PDB; 6M9W; X-ray; 1.50 A; A=2-169. DR PDB; 6MBQ; X-ray; 1.35 A; A=2-166. DR PDB; 6MBT; X-ray; 1.45 A; A/B=1-169. DR PDB; 6MBU; X-ray; 1.45 A; A/B=1-169. DR PDB; 6MNX; X-ray; 2.20 A; A/B/C/D/E/F=1-169. DR PDB; 6MQG; X-ray; 1.50 A; A=3-169. DR PDB; 6MQN; X-ray; 1.60 A; A/B/C=1-169. DR PDB; 6MS9; X-ray; 1.49 A; A/B/C=1-169. DR PDB; 6MTA; X-ray; 2.15 A; A/B/C=1-169. DR PDB; 6N2J; X-ray; 1.80 A; A=1-169. DR PDB; 6N2K; X-ray; 1.72 A; A=1-169. DR PDB; 6O36; X-ray; 2.00 A; A/B/C=1-167. DR PDB; 6O46; X-ray; 1.90 A; A/B/C=1-167. DR PDB; 6O4Y; X-ray; 1.58 A; C=7-14. DR PDB; 6O4Z; X-ray; 1.50 A; C=5-12. DR PDB; 6O51; X-ray; 1.55 A; C=6-14. DR PDB; 6O53; X-ray; 1.40 A; C=5-14. DR PDB; 6OB2; X-ray; 2.85 A; A/C=1-169. DR PDB; 6OB3; X-ray; 2.10 A; A/C=1-169. DR PDB; 6OIM; X-ray; 1.65 A; A=1-169. DR PDB; 6P0Z; X-ray; 1.01 A; A/B=2-169. DR PDB; 6P8W; X-ray; 2.10 A; A/B=1-169. DR PDB; 6P8X; X-ray; 2.11 A; A/B/C/D=1-169. DR PDB; 6P8Y; X-ray; 2.31 A; A/B=1-169. DR PDB; 6P8Z; X-ray; 1.65 A; A/B=1-169. DR PDB; 6PGO; X-ray; 1.60 A; A/B=1-169. DR PDB; 6PGP; X-ray; 1.50 A; A/B=1-169. DR PDB; 6PQ3; X-ray; 1.75 A; A=1-169. DR PDB; 6PTS; NMR; -; B=1-186. DR PDB; 6PTW; NMR; -; B=1-186. DR PDB; 6QUU; X-ray; 1.48 A; A/B=1-169. DR PDB; 6QUV; X-ray; 1.48 A; A/B=1-169. DR PDB; 6QUW; X-ray; 1.24 A; A/B=1-169. DR PDB; 6QUX; X-ray; 1.62 A; A/B=1-169. DR PDB; 6T5B; X-ray; 1.37 A; A=1-169. DR PDB; 6T5U; X-ray; 1.72 A; B=1-166. DR PDB; 6T5V; X-ray; 1.31 A; A=1-169. DR PDB; 6TAM; X-ray; 1.64 A; A=1-169. DR PDB; 6TAN; X-ray; 1.16 A; A=1-169. DR PDB; 6USX; X-ray; 2.27 A; A/B=1-169. DR PDB; 6USZ; X-ray; 2.03 A; A=1-169. DR PDB; 6UT0; X-ray; 1.94 A; A/B/C/D=1-169. DR PDB; 6V5L; NMR; -; A=1-169. DR PDB; 6V65; X-ray; 2.76 A; C=1-169. DR PDB; 6V6F; X-ray; 2.54 A; C=1-169. DR PDB; 6VC8; X-ray; 2.50 A; A/B/C=1-169. DR PDB; 6VJJ; X-ray; 1.40 A; A=1-169. DR PDB; 6W4E; NMR; -; B/C=2-186. DR PDB; 6W4F; NMR; -; B/C=2-186. DR PDB; 6WGN; X-ray; 1.60 A; A/B/C=1-169. DR PDB; 6WS2; X-ray; 1.59 A; A/B/C/D=1-169. DR PDB; 6WS4; X-ray; 1.84 A; A/B/C/D=1-169. DR PDB; 6XGU; X-ray; 2.70 A; A=1-169. DR PDB; 6XGV; X-ray; 2.11 A; A=1-169. DR PDB; 6XHA; X-ray; 2.87 A; A=1-169. DR PDB; 6XHB; X-ray; 2.50 A; A=1-169. DR PDB; 6YR8; X-ray; 1.90 A; A=1-166. DR PDB; 6YXW; X-ray; 2.06 A; A/C=1-167. DR PDB; 6ZL5; X-ray; 1.65 A; A=1-169. DR PDB; 6ZLI; X-ray; 1.73 A; A/B=1-169. DR PDB; 7A1W; X-ray; 1.76 A; A=1-169. DR PDB; 7A1X; X-ray; 1.32 A; A=1-164. DR PDB; 7A1Y; X-ray; 2.00 A; A=1-164. DR PDB; 7A47; X-ray; 2.16 A; A/C/E=1-169. DR PDB; 7ACA; X-ray; 1.57 A; A/B/C/D=1-169. DR PDB; 7ACF; X-ray; 1.91 A; A/B/C/D=1-169. DR PDB; 7ACH; X-ray; 1.90 A; A/B=1-169. DR PDB; 7ACQ; X-ray; 1.86 A; A/B/C=1-169. DR PDB; 7C40; X-ray; 2.52 A; A=1-167. DR PDB; 7C41; X-ray; 2.28 A; A/G/J/M=1-167. DR PDB; 7EW9; X-ray; 2.13 A; A/B/C=1-169. DR PDB; 7EWA; X-ray; 2.25 A; A/B/C=1-169. DR PDB; 7EWB; X-ray; 1.99 A; A/B/C=1-169. DR PDB; 7EYX; X-ray; 1.82 A; A=2-169. DR PDB; 7F0W; X-ray; 1.39 A; A=2-169. DR PDB; 7KFZ; EM; 3.47 A; A/C=1-169. DR PDB; 7KMR; X-ray; 1.51 A; A=1-186. DR PDB; 7KYZ; NMR; -; A=1-189. DR PDB; 7LC1; X-ray; 2.35 A; A/C=1-169. DR PDB; 7LC2; X-ray; 2.70 A; A/B=1-169. DR PDB; 7LGI; NMR; -; A=1-169. DR PDB; 7LZ5; X-ray; 1.50 A; A=1-164. DR PDB; 7MDP; X-ray; 1.96 A; A=1-169. DR PDB; 7MQU; NMR; -; A=1-169. DR PDB; 7NY8; X-ray; 1.80 A; A/B=1-167. DR PDB; 7O70; X-ray; 1.18 A; A/D=1-169. DR PDB; 7OK3; X-ray; 1.60 A; A=1-169. DR PDB; 7OK4; X-ray; 1.70 A; A=1-169. DR PDB; 7OO7; X-ray; 1.48 A; A/D=1-164. DR PDB; 7Q9U; X-ray; 2.24 A; AAA/BBB=1-176. DR PDB; 7R0M; X-ray; 1.61 A; A/B=1-169. DR PDB; 7R0N; X-ray; 1.20 A; A=1-169. DR PDB; 7R0Q; X-ray; 1.95 A; A/B=1-169. DR PDB; 7ROV; X-ray; 1.32 A; A/B=1-189. DR PDB; 7RP2; X-ray; 2.20 A; A=1-169. DR PDB; 7RP3; X-ray; 2.00 A; A=2-169. DR PDB; 7RP4; X-ray; 2.15 A; A/B=2-169. DR PDB; 7RPZ; X-ray; 1.30 A; A=1-169. DR PDB; 7RSC; NMR; -; A/B=2-186. DR PDB; 7RSE; NMR; -; A/B=2-186. DR PDB; 7RT1; X-ray; 1.27 A; A=1-169. DR PDB; 7RT2; X-ray; 1.59 A; A=1-169. DR PDB; 7RT3; X-ray; 1.56 A; A=1-169. DR PDB; 7RT4; X-ray; 2.10 A; A=1-169. DR PDB; 7RT5; X-ray; 1.29 A; A=1-169. DR PDB; 7SCW; X-ray; 1.98 A; A=1-189. DR PDB; 7SCX; X-ray; 1.96 A; A=1-189. DR PDB; 7STF; EM; 3.14 A; C=7-16. DR PDB; 7T1F; X-ray; 2.20 A; A/B/C=1-169. DR PDB; 7T47; X-ray; 1.27 A; A=1-164. DR PDB; 7TLE; X-ray; 1.99 A; A=1-164. DR PDB; 7TLG; X-ray; 1.80 A; A/B=1-164. DR PDB; 7TLK; X-ray; 1.71 A; A/B=1-164. DR PDB; 7U8H; X-ray; 1.70 A; A/B/C/D=1-169. DR PDB; 7VVB; X-ray; 1.70 A; A=1-189. DR PDB; 7W5R; X-ray; 3.87 A; A/E/I/M/Q/U=1-167. DR PDB; 7YCC; X-ray; 1.79 A; A/B/C=1-169. DR PDB; 7YCE; X-ray; 1.80 A; A=1-169. DR PDB; 7YUZ; X-ray; 1.88 A; A=2-174. DR PDB; 7YV1; X-ray; 1.45 A; A=2-174. DR PDB; 8AFB; X-ray; 1.12 A; A=1-164. DR PDB; 8AFC; X-ray; 2.41 A; A/B=1-164. DR PDB; 8AFD; X-ray; 1.63 A; A/B/C/D=1-164. DR PDB; 8AQ5; X-ray; 1.80 A; A=1-169. DR PDB; 8AQ7; X-ray; 1.65 A; A/B=1-169. DR PDB; 8AZR; X-ray; 1.60 A; A=1-164. DR PDB; 8AZV; X-ray; 1.05 A; A=1-164. DR PDB; 8AZX; X-ray; 1.04 A; A=1-164. DR PDB; 8AZY; X-ray; 1.09 A; A=1-169. DR PDB; 8AZZ; X-ray; 1.02 A; A=1-164. DR PDB; 8B00; X-ray; 1.04 A; A=1-164. DR PDB; 8B69; X-ray; 3.07 A; B/D=1-169. DR PDB; 8B6I; X-ray; 1.70 A; A/B=1-169. DR PDB; 8B78; X-ray; 1.11 A; A=1-164. DR PDB; 8BE3; X-ray; 1.85 A; A/R=1-169. DR PDB; 8BE4; X-ray; 1.90 A; R=1-169. DR PDB; 8BE5; X-ray; 3.13 A; R=1-169. DR PDB; 8BLR; X-ray; 1.40 A; A=2-169. DR PDB; 8CPR; X-ray; 2.00 A; A=2-169. DR PDB; 8CX5; X-ray; 1.72 A; A/B=1-169. DR PDB; 8DGS; EM; 4.30 A; E=1-169. DR PDB; 8DGT; EM; 3.90 A; F=1-169. DR PDB; 8DNI; X-ray; 1.50 A; A=1-169. DR PDB; 8DNJ; X-ray; 1.81 A; A/B/C=1-169. DR PDB; 8DNK; X-ray; 2.23 A; A=1-169. DR PDB; 8DVG; X-ray; 2.59 A; C=7-16. DR PDB; 8EBZ; X-ray; 1.20 A; A=1-169. DR PDB; 8ECR; X-ray; 1.42 A; A/B=1-186. DR PDB; 8EDY; X-ray; 1.18 A; A=1-186. DR PDB; 8EER; X-ray; 1.18 A; A=1-186. DR PDB; 8EIE; X-ray; 1.41 A; A=1-186. DR PDB; 8EPW; X-ray; 2.00 A; A=1-169. DR PDB; 8EZG; X-ray; 2.52 A; A=1-167. DR PDB; 8F0M; X-ray; 2.44 A; A/C=1-169. DR PDB; 8FMI; X-ray; 1.12 A; A=1-169. DR PDB; 8FMJ; X-ray; 1.33 A; A=1-169. DR PDB; 8FMK; X-ray; 1.48 A; A=1-169. DR PDB; 8G42; EM; 3.02 A; B=1-169. DR PDB; 8G47; EM; 3.19 A; B=1-169. DR PDB; 8G4F; EM; 2.91 A; B=1-166. DR PDB; 8G4H; EM; 2.87 A; B=1-169. DR PDB; 8G9P; X-ray; 1.50 A; A/B=1-169. DR PDB; 8G9Q; X-ray; 1.40 A; A=1-169. DR PDB; 8I5C; X-ray; 3.34 A; C/H/M/R/W/b/g/l/q/v=8-16. DR PDB; 8I5D; X-ray; 3.30 A; P=8-16. DR PDB; 8I5E; X-ray; 2.20 A; P=8-16. DR PDB; 8JGD; X-ray; 1.60 A; A=1-169. DR PDB; 8JHL; X-ray; 2.10 A; A=1-169. DR PDB; 8JJS; X-ray; 1.53 A; A=2-174. DR PDB; 8K4T; X-ray; 2.30 A; C/F=7-16. DR PDB; 8K4V; X-ray; 3.10 A; C/F/I/L=7-16. DR PDB; 8K50; X-ray; 2.80 A; C/F/I/L=7-16. DR PDB; 8ONV; X-ray; 1.01 A; A=1-164. DR PDB; 8PI0; NMR; -; A=1-167. DR PDB; 8PIY; NMR; -; A=1-169. DR PDB; 8QU8; EM; 3.50 A; F=1-164. DR PDB; 8QUG; X-ray; 1.56 A; A=1-164. DR PDB; 8QVU; X-ray; 2.24 A; A/E=1-189. DR PDB; 8QW6; X-ray; 2.20 A; A/E=1-169. DR PDB; 8QW7; X-ray; 2.36 A; A/E=1-169. DR PDB; 8R7W; X-ray; 1.16 A; A/B=1-169. DR PDB; 8R7X; X-ray; 1.31 A; A/B=1-169. DR PDB; 8RNI; X-ray; 2.49 A; C=7-16. DR PDB; 8RRO; X-ray; 3.50 A; E/J/O/T/Y/d/i/n=7-16. DR PDB; 8S8C; X-ray; 1.90 A; A=1-169. DR PDB; 8STM; X-ray; 2.00 A; A/B/C/D=1-169. DR PDB; 8STN; X-ray; 2.03 A; A/B=1-169. DR PDB; 8T4V; X-ray; 1.47 A; A/B=1-169. DR PDB; 8T71; X-ray; 1.80 A; A/B=1-177. DR PDB; 8T72; X-ray; 1.60 A; A/B/C=1-177. DR PDB; 8T73; X-ray; 1.50 A; A/B=1-169. DR PDB; 8T74; X-ray; 1.65 A; A=1-177. DR PDB; 8T75; X-ray; 2.65 A; A/C/E/G=1-177. DR PDB; 8TBF; X-ray; 1.50 A; A/B=1-169. DR PDB; 8TBH; X-ray; 1.50 A; A/B=1-169. DR PDB; 8TBJ; X-ray; 1.45 A; A/B=1-169. DR PDB; 8TBK; X-ray; 1.26 A; A/B=1-169. DR PDB; 8TBL; X-ray; 1.88 A; A/B=1-169. DR PDB; 8TBM; X-ray; 1.57 A; A/B=1-169. DR PDB; 8TBN; X-ray; 1.46 A; A/B=1-169. DR PDB; 8TVK; X-ray; 1.04 A; A=1-169. DR PDB; 8TXE; X-ray; 1.35 A; A/B=1-169. DR PDB; 8TXG; X-ray; 1.50 A; A=1-169. DR PDB; 8TXH; X-ray; 1.20 A; A/B=1-169. DR PDB; 8TXJ; X-ray; 1.40 A; A=1-169. DR PDB; 8TXK; X-ray; 1.38 A; A=1-169. DR PDB; 8TY2; X-ray; 1.41 A; A=1-169. DR PDB; 8TY8; X-ray; 1.40 A; A=1-169. DR PDB; 8TY9; X-ray; 1.43 A; A=1-169. DR PDB; 8UDR; EM; 3.10 A; C=7-16. DR PDB; 8UN3; X-ray; 2.07 A; A/B/C/D=2-167. DR PDB; 8UN4; X-ray; 1.57 A; A=2-169. DR PDB; 8UN5; X-ray; 1.31 A; A/B=2-167. DR PDB; 8V39; X-ray; 2.10 A; A/B/C=1-169. DR PDB; 8V3A; X-ray; 1.67 A; A/B=1-169. DR PDB; 8VGQ; EM; 2.80 A; A=1-169. DR PDB; 8VJZ; X-ray; 1.90 A; C=7-16. DR PDB; 8VR9; EM; 3.06 A; C=8-16. DR PDB; 8VRA; EM; 3.12 A; C=7-16. DR PDB; 8VRB; EM; 3.25 A; C=7-16. DR PDB; 8WTE; X-ray; 2.17 A; G/J=8-16. DR PDB; 8WUL; X-ray; 2.36 A; K/N/Q/T=8-16. DR PDB; 8X6R; X-ray; 1.85 A; A/B/C/D/E/F=1-169. DR PDB; 8YIV; X-ray; 2.10 A; C=55-64. DR PDB; 8YJ2; X-ray; 2.26 A; C=55-64. DR PDB; 9AX6; X-ray; 1.65 A; A/B=1-169. DR PDB; 9BAI; X-ray; 1.49 A; A/B/C/D=1-169. DR PDB; 9BAJ; X-ray; 1.49 A; A/B/C/D=1-169. DR PDB; 9BAK; X-ray; 1.67 A; A/B/C/D=1-169. DR PDB; 9BFV; X-ray; 1.20 A; A/B=1-169. DR PDB; 9BFW; X-ray; 1.20 A; A=1-169. DR PDB; 9BFX; X-ray; 1.40 A; A/B=1-169. DR PDB; 9BFY; X-ray; 1.26 A; A/B=1-169. DR PDB; 9BFZ; X-ray; 1.80 A; A/B=1-169. DR PDB; 9BG1; X-ray; 1.51 A; A/B=1-169. DR PDB; 9BG2; X-ray; 1.64 A; A/B=1-169. DR PDB; 9BG4; X-ray; 1.14 A; A/B=1-169. DR PDB; 9BG5; X-ray; 1.67 A; A/B=1-164. DR PDB; 9BG6; X-ray; 1.66 A; A/B=1-169. DR PDB; 9BG7; X-ray; 1.60 A; A/B=1-169. DR PDB; 9BG9; X-ray; 1.58 A; A/B=1-164. DR PDB; 9BGA; X-ray; 1.41 A; A/B=1-169. DR PDB; 9BGB; X-ray; 1.68 A; A/B=1-164. DR PDB; 9BGC; X-ray; 1.87 A; A/B=1-169. DR PDB; 9BHO; X-ray; 1.89 A; A/C=1-169. DR PDB; 9BHP; X-ray; 2.10 A; A/C=1-169. DR PDB; 9BHQ; X-ray; 1.90 A; A/C=1-169. DR PDB; 9BI1; X-ray; 1.65 A; A/C=1-169. DR PDB; 9BI2; X-ray; 2.15 A; A/C=1-169. DR PDB; 9BL0; X-ray; 1.66 A; A/B=1-169. DR PDB; 9C15; X-ray; 2.81 A; B=1-169. DR PDB; 9DMM; X-ray; 1.90 A; A=1-169. DR PDB; 9E5D; X-ray; 1.36 A; A=1-169. DR PDB; 9E5F; X-ray; 1.35 A; A=1-169. DR PDB; 9E9H; X-ray; 1.65 A; A=1-169. DR PDB; 9E9I; X-ray; 1.18 A; A=1-169. DR PDB; 9G0Y; X-ray; 1.31 A; A=1-169. DR PDB; 9G4B; X-ray; 1.14 A; A=1-169. DR PDB; 9GBJ; X-ray; 1.71 A; A=1-169. DR PDB; 9GGT; X-ray; 1.71 A; A=1-169. DR PDB; 9GGU; X-ray; 1.60 A; A=1-169. DR PDB; 9GGV; X-ray; 1.19 A; A=1-169. DR PDB; 9GGW; X-ray; 1.82 A; A/B=1-169. DR PDB; 9GGX; X-ray; 1.30 A; A=1-169. DR PDB; 9GGY; X-ray; 1.27 A; A=1-169. DR PDB; 9GGZ; X-ray; 1.37 A; A=1-169. DR PDB; 9GH0; X-ray; 1.57 A; A=1-169. DR PDB; 9GH1; X-ray; 1.33 A; A=1-169. DR PDB; 9GH2; X-ray; 1.35 A; A=1-169. DR PDB; 9KPM; X-ray; 1.41 A; A=1-169. DR PDB; 9KPN; X-ray; 1.29 A; A/B=1-169. DR PDBsum; 1D8D; -. DR PDBsum; 1D8E; -. DR PDBsum; 1KZO; -. DR PDBsum; 1KZP; -. DR PDBsum; 1N4P; -. DR PDBsum; 1N4Q; -. DR PDBsum; 1N4R; -. DR PDBsum; 1N4S; -. DR PDBsum; 2MSC; -. DR PDBsum; 2MSD; -. DR PDBsum; 2MSE; -. DR PDBsum; 3GFT; -. DR PDBsum; 4DSN; -. DR PDBsum; 4DSO; -. DR PDBsum; 4EPR; -. DR PDBsum; 4EPT; -. DR PDBsum; 4EPV; -. DR PDBsum; 4EPW; -. DR PDBsum; 4EPX; -. DR PDBsum; 4EPY; -. DR PDBsum; 4L8G; -. DR PDBsum; 4LDJ; -. DR PDBsum; 4LPK; -. DR PDBsum; 4LRW; -. DR PDBsum; 4LUC; -. DR PDBsum; 4LV6; -. DR PDBsum; 4LYF; -. DR PDBsum; 4LYH; -. DR PDBsum; 4LYJ; -. DR PDBsum; 4M1O; -. DR PDBsum; 4M1S; -. DR PDBsum; 4M1T; -. DR PDBsum; 4M1W; -. DR PDBsum; 4M1Y; -. DR PDBsum; 4M21; -. DR PDBsum; 4M22; -. DR PDBsum; 4NMM; -. DR PDBsum; 4OBE; -. DR PDBsum; 4PZY; -. DR PDBsum; 4PZZ; -. DR PDBsum; 4Q01; -. DR PDBsum; 4Q02; -. DR PDBsum; 4Q03; -. DR PDBsum; 4QL3; -. DR PDBsum; 4TQ9; -. DR PDBsum; 4TQA; -. DR PDBsum; 4WA7; -. DR PDBsum; 5F2E; -. DR PDBsum; 5KYK; -. DR PDBsum; 5MLA; -. DR PDBsum; 5MLB; -. DR PDBsum; 5O2S; -. DR PDBsum; 5O2T; -. DR PDBsum; 5OCG; -. DR PDBsum; 5OCO; -. DR PDBsum; 5OCT; -. DR PDBsum; 5TAR; -. DR PDBsum; 5TB5; -. DR PDBsum; 5UFE; -. DR PDBsum; 5UFQ; -. DR PDBsum; 5UK9; -. DR PDBsum; 5UQW; -. DR PDBsum; 5US4; -. DR PDBsum; 5USJ; -. DR PDBsum; 5V6S; -. DR PDBsum; 5V6V; -. DR PDBsum; 5V71; -. DR PDBsum; 5V9L; -. DR PDBsum; 5V9O; -. DR PDBsum; 5V9U; -. DR PDBsum; 5VBM; -. DR PDBsum; 5VP7; -. DR PDBsum; 5VPI; -. DR PDBsum; 5VPY; -. DR PDBsum; 5VPZ; -. DR PDBsum; 5VQ0; -. DR PDBsum; 5VQ1; -. DR PDBsum; 5VQ2; -. DR PDBsum; 5VQ6; -. DR PDBsum; 5VQ8; -. DR PDBsum; 5W22; -. DR PDBsum; 5WHA; -. DR PDBsum; 5WHB; -. DR PDBsum; 5WHD; -. DR PDBsum; 5WHE; -. DR PDBsum; 5WLB; -. DR PDBsum; 5WPM; -. DR PDBsum; 5XCO; -. DR PDBsum; 5YXZ; -. DR PDBsum; 5YY1; -. DR PDBsum; 6ARK; -. DR PDBsum; 6ASA; -. DR PDBsum; 6ASE; -. DR PDBsum; 6B0V; -. DR PDBsum; 6B0Y; -. DR PDBsum; 6BOF; -. DR PDBsum; 6BP1; -. DR PDBsum; 6CC9; -. DR PDBsum; 6CCH; -. DR PDBsum; 6CCX; -. DR PDBsum; 6CU6; -. DR PDBsum; 6E6F; -. DR PDBsum; 6E6G; -. DR PDBsum; 6EPL; -. DR PDBsum; 6EPM; -. DR PDBsum; 6EPN; -. DR PDBsum; 6EPO; -. DR PDBsum; 6EPP; -. DR PDBsum; 6F76; -. DR PDBsum; 6FA1; -. DR PDBsum; 6FA2; -. DR PDBsum; 6FA3; -. DR PDBsum; 6FA4; -. DR PDBsum; 6GJ5; -. DR PDBsum; 6GJ6; -. DR PDBsum; 6GJ7; -. DR PDBsum; 6GJ8; -. DR PDBsum; 6GOD; -. DR PDBsum; 6GOE; -. DR PDBsum; 6GOF; -. DR PDBsum; 6GOG; -. DR PDBsum; 6GOM; -. DR PDBsum; 6GQT; -. DR PDBsum; 6GQW; -. DR PDBsum; 6GQX; -. DR PDBsum; 6GQY; -. DR PDBsum; 6H46; -. DR PDBsum; 6H47; -. DR PDBsum; 6JTN; -. DR PDBsum; 6JTO; -. DR PDBsum; 6JTP; -. DR PDBsum; 6M9W; -. DR PDBsum; 6MBQ; -. DR PDBsum; 6MBT; -. DR PDBsum; 6MBU; -. DR PDBsum; 6MNX; -. DR PDBsum; 6MQG; -. DR PDBsum; 6MQN; -. DR PDBsum; 6MS9; -. DR PDBsum; 6MTA; -. DR PDBsum; 6N2J; -. DR PDBsum; 6N2K; -. DR PDBsum; 6O36; -. DR PDBsum; 6O46; -. DR PDBsum; 6O4Y; -. DR PDBsum; 6O4Z; -. DR PDBsum; 6O51; -. DR PDBsum; 6O53; -. DR PDBsum; 6OB2; -. DR PDBsum; 6OB3; -. DR PDBsum; 6OIM; -. DR PDBsum; 6P0Z; -. DR PDBsum; 6P8W; -. DR PDBsum; 6P8X; -. DR PDBsum; 6P8Y; -. DR PDBsum; 6P8Z; -. DR PDBsum; 6PGO; -. DR PDBsum; 6PGP; -. DR PDBsum; 6PQ3; -. DR PDBsum; 6PTS; -. DR PDBsum; 6PTW; -. DR PDBsum; 6QUU; -. DR PDBsum; 6QUV; -. DR PDBsum; 6QUW; -. DR PDBsum; 6QUX; -. DR PDBsum; 6T5B; -. DR PDBsum; 6T5U; -. DR PDBsum; 6T5V; -. DR PDBsum; 6TAM; -. DR PDBsum; 6TAN; -. DR PDBsum; 6USX; -. DR PDBsum; 6USZ; -. DR PDBsum; 6UT0; -. DR PDBsum; 6V5L; -. DR PDBsum; 6V65; -. DR PDBsum; 6V6F; -. DR PDBsum; 6VC8; -. DR PDBsum; 6VJJ; -. DR PDBsum; 6W4E; -. DR PDBsum; 6W4F; -. DR PDBsum; 6WGN; -. DR PDBsum; 6WS2; -. DR PDBsum; 6WS4; -. DR PDBsum; 6XGU; -. DR PDBsum; 6XGV; -. DR PDBsum; 6XHA; -. DR PDBsum; 6XHB; -. DR PDBsum; 6YR8; -. DR PDBsum; 6YXW; -. DR PDBsum; 6ZL5; -. DR PDBsum; 6ZLI; -. DR PDBsum; 7A1W; -. DR PDBsum; 7A1X; -. DR PDBsum; 7A1Y; -. DR PDBsum; 7A47; -. DR PDBsum; 7ACA; -. DR PDBsum; 7ACF; -. DR PDBsum; 7ACH; -. DR PDBsum; 7ACQ; -. DR PDBsum; 7C40; -. DR PDBsum; 7C41; -. DR PDBsum; 7EW9; -. DR PDBsum; 7EWA; -. DR PDBsum; 7EWB; -. DR PDBsum; 7EYX; -. DR PDBsum; 7F0W; -. DR PDBsum; 7KFZ; -. DR PDBsum; 7KMR; -. DR PDBsum; 7KYZ; -. DR PDBsum; 7LC1; -. DR PDBsum; 7LC2; -. DR PDBsum; 7LGI; -. DR PDBsum; 7LZ5; -. DR PDBsum; 7MDP; -. DR PDBsum; 7MQU; -. DR PDBsum; 7NY8; -. DR PDBsum; 7O70; -. DR PDBsum; 7OK3; -. DR PDBsum; 7OK4; -. DR PDBsum; 7OO7; -. DR PDBsum; 7Q9U; -. DR PDBsum; 7R0M; -. DR PDBsum; 7R0N; -. DR PDBsum; 7R0Q; -. DR PDBsum; 7ROV; -. DR PDBsum; 7RP2; -. DR PDBsum; 7RP3; -. DR PDBsum; 7RP4; -. DR PDBsum; 7RPZ; -. DR PDBsum; 7RSC; -. DR PDBsum; 7RSE; -. DR PDBsum; 7RT1; -. DR PDBsum; 7RT2; -. DR PDBsum; 7RT3; -. DR PDBsum; 7RT4; -. DR PDBsum; 7RT5; -. DR PDBsum; 7SCW; -. DR PDBsum; 7SCX; -. DR PDBsum; 7STF; -. DR PDBsum; 7T1F; -. DR PDBsum; 7T47; -. DR PDBsum; 7TLE; -. DR PDBsum; 7TLG; -. DR PDBsum; 7TLK; -. DR PDBsum; 7U8H; -. DR PDBsum; 7VVB; -. DR PDBsum; 7W5R; -. DR PDBsum; 7YCC; -. DR PDBsum; 7YCE; -. DR PDBsum; 7YUZ; -. DR PDBsum; 7YV1; -. DR PDBsum; 8AFB; -. DR PDBsum; 8AFC; -. DR PDBsum; 8AFD; -. DR PDBsum; 8AQ5; -. DR PDBsum; 8AQ7; -. DR PDBsum; 8AZR; -. DR PDBsum; 8AZV; -. DR PDBsum; 8AZX; -. DR PDBsum; 8AZY; -. DR PDBsum; 8AZZ; -. DR PDBsum; 8B00; -. DR PDBsum; 8B69; -. DR PDBsum; 8B6I; -. DR PDBsum; 8B78; -. DR PDBsum; 8BE3; -. DR PDBsum; 8BE4; -. DR PDBsum; 8BE5; -. DR PDBsum; 8BLR; -. DR PDBsum; 8CPR; -. DR PDBsum; 8CX5; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8DNI; -. DR PDBsum; 8DNJ; -. DR PDBsum; 8DNK; -. DR PDBsum; 8DVG; -. DR PDBsum; 8EBZ; -. DR PDBsum; 8ECR; -. DR PDBsum; 8EDY; -. DR PDBsum; 8EER; -. DR PDBsum; 8EIE; -. DR PDBsum; 8EPW; -. DR PDBsum; 8EZG; -. DR PDBsum; 8F0M; -. DR PDBsum; 8FMI; -. DR PDBsum; 8FMJ; -. DR PDBsum; 8FMK; -. DR PDBsum; 8G42; -. DR PDBsum; 8G47; -. DR PDBsum; 8G4F; -. DR PDBsum; 8G4H; -. DR PDBsum; 8G9P; -. DR PDBsum; 8G9Q; -. DR PDBsum; 8I5C; -. DR PDBsum; 8I5D; -. DR PDBsum; 8I5E; -. DR PDBsum; 8JGD; -. DR PDBsum; 8JHL; -. DR PDBsum; 8JJS; -. DR PDBsum; 8K4T; -. DR PDBsum; 8K4V; -. DR PDBsum; 8K50; -. DR PDBsum; 8ONV; -. DR PDBsum; 8PI0; -. DR PDBsum; 8PIY; -. DR PDBsum; 8QU8; -. DR PDBsum; 8QUG; -. DR PDBsum; 8QVU; -. DR PDBsum; 8QW6; -. DR PDBsum; 8QW7; -. DR PDBsum; 8R7W; -. DR PDBsum; 8R7X; -. DR PDBsum; 8RNI; -. DR PDBsum; 8RRO; -. DR PDBsum; 8S8C; -. DR PDBsum; 8STM; -. DR PDBsum; 8STN; -. DR PDBsum; 8T4V; -. DR PDBsum; 8T71; -. DR PDBsum; 8T72; -. DR PDBsum; 8T73; -. DR PDBsum; 8T74; -. DR PDBsum; 8T75; -. DR PDBsum; 8TBF; -. DR PDBsum; 8TBH; -. DR PDBsum; 8TBJ; -. DR PDBsum; 8TBK; -. DR PDBsum; 8TBL; -. DR PDBsum; 8TBM; -. DR PDBsum; 8TBN; -. DR PDBsum; 8TVK; -. DR PDBsum; 8TXE; -. DR PDBsum; 8TXG; -. DR PDBsum; 8TXH; -. DR PDBsum; 8TXJ; -. DR PDBsum; 8TXK; -. DR PDBsum; 8TY2; -. DR PDBsum; 8TY8; -. DR PDBsum; 8TY9; -. DR PDBsum; 8UDR; -. DR PDBsum; 8UN3; -. DR PDBsum; 8UN4; -. DR PDBsum; 8UN5; -. DR PDBsum; 8V39; -. DR PDBsum; 8V3A; -. DR PDBsum; 8VGQ; -. DR PDBsum; 8VJZ; -. DR PDBsum; 8VR9; -. DR PDBsum; 8VRA; -. DR PDBsum; 8VRB; -. DR PDBsum; 8WTE; -. DR PDBsum; 8WUL; -. DR PDBsum; 8X6R; -. DR PDBsum; 8YIV; -. DR PDBsum; 8YJ2; -. DR PDBsum; 9AX6; -. DR PDBsum; 9BAI; -. DR PDBsum; 9BAJ; -. DR PDBsum; 9BAK; -. DR PDBsum; 9BFV; -. DR PDBsum; 9BFW; -. DR PDBsum; 9BFX; -. DR PDBsum; 9BFY; -. DR PDBsum; 9BFZ; -. DR PDBsum; 9BG1; -. DR PDBsum; 9BG2; -. DR PDBsum; 9BG4; -. DR PDBsum; 9BG5; -. DR PDBsum; 9BG6; -. DR PDBsum; 9BG7; -. DR PDBsum; 9BG9; -. DR PDBsum; 9BGA; -. DR PDBsum; 9BGB; -. DR PDBsum; 9BGC; -. DR PDBsum; 9BHO; -. DR PDBsum; 9BHP; -. DR PDBsum; 9BHQ; -. DR PDBsum; 9BI1; -. DR PDBsum; 9BI2; -. DR PDBsum; 9BL0; -. DR PDBsum; 9C15; -. DR PDBsum; 9DMM; -. DR PDBsum; 9E5D; -. DR PDBsum; 9E5F; -. DR PDBsum; 9E9H; -. DR PDBsum; 9E9I; -. DR PDBsum; 9G0Y; -. DR PDBsum; 9G4B; -. DR PDBsum; 9GBJ; -. DR PDBsum; 9GGT; -. DR PDBsum; 9GGU; -. DR PDBsum; 9GGV; -. DR PDBsum; 9GGW; -. DR PDBsum; 9GGX; -. DR PDBsum; 9GGY; -. DR PDBsum; 9GGZ; -. DR PDBsum; 9GH0; -. DR PDBsum; 9GH1; -. DR PDBsum; 9GH2; -. DR PDBsum; 9KPM; -. DR PDBsum; 9KPN; -. DR AlphaFoldDB; P01116; -. DR BMRB; P01116; -. DR EMDB; EMD-18657; -. DR EMDB; EMD-22857; -. DR EMDB; EMD-29713; -. DR EMDB; EMD-29715; -. DR EMDB; EMD-29719; -. DR EMDB; EMD-29720; -. DR EMDB; EMD-42151; -. DR EMDB; EMD-43221; -. DR EMDB; EMD-43478; -. DR EMDB; EMD-43479; -. DR EMDB; EMD-43480; -. DR EMDB; EMD-70124; -. DR SASBDB; P01116; -. DR SMR; P01116; -. DR BioGRID; 110043; 3005. DR ComplexPortal; CPX-26355; SHOC2-KRAS-PPP1CA complex. DR CORUM; P01116; -. DR DIP; DIP-33951N; -. DR FunCoup; P01116; 3194. DR IntAct; P01116; 549. DR MINT; P01116; -. DR STRING; 9606.ENSP00000256078; -. DR BindingDB; P01116; -. DR ChEMBL; CHEMBL2189121; -. DR DrugBank; DB07771; [(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID. DR DrugBank; DB15568; Adagrasib. DR DrugBank; DB07780; Farnesyl diphosphate. DR DrugBank; DB15569; Sotorasib. DR DrugCentral; P01116; -. DR GuidetoPHARMACOLOGY; 2824; -. DR GlyCosmos; P01116; 1 site, No reported glycans. DR GlyGen; P01116; 1 site. DR iPTMnet; P01116; -. DR PhosphoSitePlus; P01116; -. DR SwissPalm; P01116; -. DR BioMuta; KRAS; -. DR DMDM; 131875; -. DR CPTAC; CPTAC-1550; -. DR jPOST; P01116; -. DR MassIVE; P01116; -. DR PaxDb; 9606-ENSP00000256078; -. DR PeptideAtlas; P01116; -. DR ProteomicsDB; 51323; -. [P01116-1] DR ProteomicsDB; 51324; -. [P01116-2] DR Pumba; P01116; -. DR TopDownProteomics; P01116-2; -. [P01116-2] DR ABCD; P01116; 18 sequenced antibodies. DR Antibodypedia; 24248; 916 antibodies from 40 providers. DR CPTC; P01116; 6 antibodies. DR DNASU; 3845; -. DR Ensembl; ENST00000256078.10; ENSP00000256078.5; ENSG00000133703.15. [P01116-1] DR Ensembl; ENST00000311936.8; ENSP00000308495.3; ENSG00000133703.15. [P01116-2] DR Ensembl; ENST00000685328.1; ENSP00000508921.1; ENSG00000133703.15. [P01116-2] DR Ensembl; ENST00000688940.1; ENSP00000509238.1; ENSG00000133703.15. [P01116-2] DR GeneID; 3845; -. DR KEGG; hsa:3845; -. DR MANE-Select; ENST00000311936.8; ENSP00000308495.3; NM_004985.5; NP_004976.2. [P01116-2] DR UCSC; uc001rgp.3; human. [P01116-1] DR AGR; HGNC:6407; -. DR CIViC; 3845; 1 clinical assertion and 480 evidence items across 102 molecular profiles. DR ClinPGx; PA30196; -. DR CTD; 3845; -. DR DisGeNET; 3845; -. DR GeneCards; KRAS; -. DR GeneReviews; KRAS; -. DR HGNC; HGNC:6407; KRAS. DR HPA; ENSG00000133703; Low tissue specificity. DR MalaCards; KRAS; -. DR MIM; 163200; phenotype. DR MIM; 190070; gene. DR MIM; 600268; phenotype. DR MIM; 601626; phenotype. DR MIM; 607785; phenotype. DR MIM; 609942; phenotype. DR MIM; 613659; phenotype. DR MIM; 615278; phenotype. DR OpenTargets; ENSG00000133703; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2396; Encephalocraniocutaneous lipomatosis. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 86834; Juvenile myelomonocytic leukemia. DR Orphanet; 2612; Linear nevus sebaceus syndrome. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 3339; Oculoectodermal syndrome. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 268114; RAS-associated autoimmune leukoproliferative disease. DR VEuPathDB; HostDB:ENSG00000133703; -. DR eggNOG; KOG0395; Eukaryota. DR GeneTree; ENSGT00940000155871; -. DR HOGENOM; CLU_041217_9_8_1; -. DR InParanoid; P01116; -. DR OMA; CCGGCVI; -. DR OrthoDB; 5976022at2759; -. DR PAN-GO; P01116; 5 GO annotations based on evolutionary models. DR PhylomeDB; P01116; -. DR BRENDA; 3.6.5.2; 2681. DR PathwayCommons; P01116; -. DR Reactome; R-HSA-112412; SOS-mediated signalling. DR Reactome; R-HSA-1169092; Activation of RAS in B cells. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-167044; Signalling to RAS. DR Reactome; R-HSA-171007; p38MAPK events. DR Reactome; R-HSA-179812; GRB2 events in EGFR signaling. DR Reactome; R-HSA-180336; SHC1 events in EGFR signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-375165; NCAM signaling for neurite out-growth. DR Reactome; R-HSA-4086398; Ca2+ pathway. [P01116-2] DR Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1. DR Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3. DR Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling. DR Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling. DR Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5658442; Regulation of RAS by GAPs. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8851805; MET activates RAS signaling. DR Reactome; R-HSA-8951936; RUNX3 regulates p14-ARF. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9027284; Erythropoietin activates RAS. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR Reactome; R-HSA-9648002; RAS processing. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9674555; Signaling by CSF3 (G-CSF). DR Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9753510; Signaling by RAS GAP mutants. DR Reactome; R-HSA-9753512; Signaling by RAS GTPase mutants. DR SignaLink; P01116; -. DR SIGNOR; P01116; -. DR Agora; ENSG00000133703; -. DR BioGRID-ORCS; 3845; 259 hits in 1133 CRISPR screens. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; KRAS; human. DR EvolutionaryTrace; P01116; -. DR GeneWiki; KRAS; -. DR GenomeRNAi; 3845; -. DR Pharos; P01116; Tclin. DR PRO; PR:P01116; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; P01116; protein. DR Bgee; ENSG00000133703; Expressed in trigeminal ganglion and 218 other cell types or tissues. DR ExpressionAtlas; P01116; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0003925; F:G protein activity; IEA:UniProtKB-EC. DR GO; GO:0019003; F:GDP binding; IBA:GO_Central. DR GO; GO:0019002; F:GMP binding; IEA:Ensembl. DR GO; GO:0005525; F:GTP binding; IBA:GO_Central. DR GO; GO:0003924; F:GTPase activity; IMP:DisProt. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030275; F:LRR domain binding; IEA:Ensembl. DR GO; GO:0044877; F:protein-containing complex binding; IDA:MGI. DR GO; GO:0043495; F:protein-membrane adaptor activity; IEA:Ensembl. DR GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl. DR GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0007565; P:female pregnancy; IEA:Ensembl. DR GO; GO:0021897; P:forebrain astrocyte development; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; TAS:Reactome. DR GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl. DR GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0060252; P:positive regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:0035022; P:positive regulation of Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0016601; P:Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0007265; P:Ras protein signal transduction; IBA:GO_Central. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl. DR GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl. DR GO; GO:0009629; P:response to gravity; IEA:Ensembl. DR GO; GO:0035900; P:response to isolation stress; IEA:Ensembl. DR GO; GO:0051385; P:response to mineralocorticoid; IEA:Ensembl. DR GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0060509; P:type I pneumocyte differentiation; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd04138; H_N_K_Ras_like; 1. DR DisProt; DP03860; -. DR FunFam; 3.40.50.300:FF:000096; KRAS proto-oncogene, GTPase; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR005225; Small_GTP-bd. DR InterPro; IPR001806; Small_GTPase. DR InterPro; IPR020849; Small_GTPase_Ras-type. DR NCBIfam; TIGR00231; small_GTP; 1. DR PANTHER; PTHR24070; RAS, DI-RAS, AND RHEB FAMILY MEMBERS OF SMALL GTPASE SUPERFAMILY; 1. DR Pfam; PF00071; Ras; 1. DR PRINTS; PR00449; RASTRNSFRMNG. DR SMART; SM00175; RAB; 1. DR SMART; SM00176; RAN; 1. DR SMART; SM00173; RAS; 1. DR SMART; SM00174; RHO; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS51421; RAS; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cardiomyopathy; KW Cell membrane; Cytoplasm; Deafness; Direct protein sequencing; KW Disease variant; Ectodermal dysplasia; Glycoprotein; GTP-binding; KW Hydrolase; Intellectual disability; Isopeptide bond; Lipoprotein; Membrane; KW Methylation; Nucleotide-binding; Palmitate; Prenylation; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Ubl conjugation. FT CHAIN 1..186 FT /note="GTPase KRas" FT /id="PRO_0000082641" FT INIT_MET 1 FT /note="Removed; alternate" FT /evidence="ECO:0000269|Ref.17" FT CHAIN 2..186 FT /note="GTPase KRas, N-terminally processed" FT /id="PRO_0000326480" FT PROPEP 187..189 FT /note="Removed in mature form" FT /evidence="ECO:0000305|PubMed:27791178" FT /id="PRO_0000281291" FT REGION 166..185 FT /note="Hypervariable region" FT MOTIF 32..40 FT /note="Effector region" FT BINDING 10..18 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 29..35 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 59..60 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 116..119 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT MOD_RES 1 FT /note="N-acetylmethionine; in GTPase KRas; alternate" FT /evidence="ECO:0000269|Ref.17" FT MOD_RES 2 FT /note="N-acetylthreonine; in GTPase KRas, N-terminally FT processed" FT /evidence="ECO:0000269|Ref.17" FT MOD_RES 104 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:22711838" FT MOD_RES 186 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000269|PubMed:27791178, FT ECO:0007744|PDB:5TAR, ECO:0007744|PDB:5TB5" FT LIPID 180 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 182 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000269|PubMed:29239724" FT LIPID 184 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 185 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 186 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000269|PubMed:27791178, FT ECO:0000305|PubMed:24415755, ECO:0007744|PDB:5TAR, FT ECO:0007744|PDB:5TB5" FT CARBOHYD 35 FT /note="(Microbial infection) O-linked (Glc) threonine; by FT P.sordellii toxin TcsL" FT /evidence="ECO:0000269|PubMed:19744486" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000305|PubMed:30442762" FT VAR_SEQ 151..153 FT /note="RVE -> GVD (in isoform 2B)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3310850, FT ECO:0000303|Ref.6, ECO:0000303|Ref.7" FT /id="VSP_011140" FT VAR_SEQ 165..189 FT /note="QYRLKKISKEEKTPGCVKIKKCIIM -> KHKEKMSKDGKKKKKKSKTKCVI FT M (in isoform 2B)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3310850, FT ECO:0000303|Ref.6, ECO:0000303|Ref.7" FT /id="VSP_011141" FT VARIANT 5 FT /note="K -> E (in NS3; dbSNP:rs193929331)" FT /evidence="ECO:0000269|PubMed:17468812" FT /id="VAR_065144" FT VARIANT 5 FT /note="K -> N (in GASC; found also in a patient with FT Costello syndrome; exhibits only minor alterations in its FT in vitro biochemical behavior compared to wild-type FT protein; dbSNP:rs104894361)" FT /evidence="ECO:0000269|PubMed:14534542" FT /id="VAR_064849" FT VARIANT 10 FT /note="G -> GG (in AML; expression in 3T3 cell causes FT cellular transformation; expression in COS cells activates FT the Ras-MAPK signaling pathway; lower GTPase activity; FT faster GDP dissociation rate)" FT /evidence="ECO:0000269|PubMed:8955068" FT /id="VAR_034601" FT VARIANT 12 FT /note="G -> A (in colorectal cancer samples; somatic FT mutation; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036305" FT VARIANT 12 FT /note="G -> C (in lung carcinoma; somatic mutation; also FT found in metastatic colorectal cancer; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:34820593, ECO:0000269|PubMed:6320174" FT /id="VAR_006839" FT VARIANT 12 FT /note="G -> D (in GASC, JMML and SFM; somatic mutation; FT also found in pancreatic carcinoma and lung carcinoma; also FT found in metastatic colorectal cancer; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:30891959, ECO:0000269|PubMed:34820593, FT ECO:0000269|PubMed:7773929, ECO:0000269|PubMed:8439212" FT /id="VAR_016026" FT VARIANT 12 FT /note="G -> R (in lung cancer and bladder cancer; somatic FT mutation; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:6695174" FT /id="VAR_016027" FT VARIANT 12 FT /note="G -> S (in GASC and JMML; also found in lung FT carcinoma; somatic mutation; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:7773929" FT /id="VAR_016028" FT VARIANT 12 FT /note="G -> V (in GASC; also found in lung carcinoma, FT pancreatic carcinoma and colon cancer; also found in FT metastatic colorectal cancer; somatic mutation; it is FT constitutively activated and stimulates transcription FT activation of tumor suppressor genes in non-transformed FT fibroblasts; promotes GTP binding; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:24623306, FT ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:34820593, FT ECO:0000269|PubMed:39809765, ECO:0000269|PubMed:6092920, FT ECO:0000269|PubMed:8439212" FT /id="VAR_006840" FT VARIANT 13 FT /note="G -> D (in GASC, JMML and OES; also found in a FT breast carcinoma cell line; somatic mutation; FT dbSNP:rs112445441)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:25808193, ECO:0000269|PubMed:3627975" FT /id="VAR_016029" FT VARIANT 13 FT /note="G -> R (in pylocytic astrocytoma; somatic mutation; FT increase activation of the Ras pathway; dbSNP:rs121913535)" FT /evidence="ECO:0000269|PubMed:16247081" FT /id="VAR_065145" FT VARIANT 14 FT /note="V -> I (in NS3; affects activity and impairs FT responsiveness to GTPase activating proteins; characterized FT by a strong increase of both intrinsic and guanine FT nucleotide exchanged factor-catalyzed nucleotide exchange FT leading to an increased level of the activated state; FT dbSNP:rs104894365)" FT /evidence="ECO:0000269|PubMed:16474405" FT /id="VAR_026109" FT VARIANT 19 FT /note="L -> F (in OES; somatic mutation; FT dbSNP:rs121913538)" FT /evidence="ECO:0000269|PubMed:25808193" FT /id="VAR_083261" FT VARIANT 22 FT /note="Q -> E (in CFC2; exhibits an increase in intrinsic FT and guanine nucleotide exchange factor catalyzed nucleotide FT exchange in combination with an impaired GTPase-activating FT protein-stimulated GTP hydrolysis but functional in FT interaction with effectors; dbSNP:rs121913236)" FT /evidence="ECO:0000269|PubMed:17056636, FT ECO:0000269|PubMed:20949621" FT /id="VAR_064850" FT VARIANT 22 FT /note="Q -> R (in NS3; impairs GTPase-activating protein FT stimulated GTP hydrolysis with unaffected intrinsic FT functions and a virtually functional effector interaction; FT dbSNP:rs727503110)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064851" FT VARIANT 34 FT /note="P -> L (in NS3; characterized by a defective GTPase- FT activating protein sensitivity and a strongly reduced FT interaction with effectors; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064852" FT VARIANT 34 FT /note="P -> Q (in NS3; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064853" FT VARIANT 34 FT /note="P -> R (in CFC2; characterized by a defective FT GTPase-activating protein sensitivity and a strongly FT reduced interaction with effectors; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:16474405, FT ECO:0000269|PubMed:20949621" FT /id="VAR_026110" FT VARIANT 36 FT /note="I -> M (in NS3; dbSNP:rs727503109)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064854" FT VARIANT 58 FT /note="T -> I (in NS3; affects activity and impairs FT responsiveness to GTPase activating proteins; exhibits only FT minor alterations in its in vitro biochemical behavior FT compared to wild-type protein; dbSNP:rs104894364)" FT /evidence="ECO:0000269|PubMed:16474405, FT ECO:0000269|PubMed:19396835" FT /id="VAR_026111" FT VARIANT 59 FT /note="A -> T (in GASC; also found in bladder cancer; FT somatic mutation; dbSNP:rs121913528)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:1553789" FT /id="VAR_016030" FT VARIANT 60 FT /note="G -> R (in CFC2; characterized by a defective FT GTPase-activating protein sensitivity and a strongly FT reduced interaction with effectors; dbSNP:rs104894359)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:20949621" FT /id="VAR_026112" FT VARIANT 60 FT /note="G -> S (in NS3; dbSNP:rs104894359)" FT /evidence="ECO:0000269|PubMed:19396835" FT /id="VAR_065146" FT VARIANT 61 FT /note="Q -> H (in lung carcinoma; dbSNP:rs17851045)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:16533793, ECO:0000269|Ref.7" FT /id="VAR_006841" FT VARIANT 61 FT /note="Q -> R (in a colorectal cancer sample; somatic FT mutation; promotes interaction with SHOC2 and PP1C; FT dbSNP:rs121913240)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509" FT /id="VAR_036306" FT VARIANT 71 FT /note="Y -> H (in CFC2; dbSNP:rs387907205)" FT /evidence="ECO:0000269|PubMed:21797849" FT /id="VAR_069784" FT VARIANT 117 FT /note="K -> N (in colorectal cancer samples; somatic FT mutation; dbSNP:rs770248150)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036307" FT VARIANT 146 FT /note="A -> T (in OES; somatic mutation; also found in FT colorectal cancer samples; dbSNP:rs121913527)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:26970110, ECO:0000269|PubMed:30891959, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036308" FT VARIANT 146 FT /note="A -> V (in OES; somatic mutation; FT dbSNP:rs1057519725)" FT /evidence="ECO:0000269|PubMed:26970110, FT ECO:0000269|PubMed:30891959" FT /id="VAR_083262" FT VARIANT 147 FT /note="K -> E (in CFC2; dbSNP:rs387907206)" FT /evidence="ECO:0000269|PubMed:21797849" FT /id="VAR_069785" FT MUTAGEN 38 FT /note="D->A: Decreased interaction with MAPKAP1/SIN1." FT /evidence="ECO:0000269|PubMed:34380736" FT MUTAGEN 40 FT /note="Y->A: Decreased interaction with MAPKAP1/SIN1." FT /evidence="ECO:0000269|PubMed:34380736" FT MUTAGEN 61 FT /note="Q->L: Promotes GTP binding." FT /evidence="ECO:0000269|PubMed:39809765" FT MUTAGEN 180 FT /note="C->S: Abolished palmitoylation on Cys; reduced FT palmitoylation on Lys residues." FT /evidence="ECO:0000269|PubMed:29239724" FT MUTAGEN 182..185 FT /note="KIKK->RIRR: In K-Ras-3KR; abolished lysine- FT palmitoylation." FT /evidence="ECO:0000269|PubMed:29239724" FT STRAND 3..9 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 12..14 FT /evidence="ECO:0007829|PDB:6EPO" FT HELIX 16..25 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 28..32 FT /evidence="ECO:0007829|PDB:7F0W" FT TURN 34..36 FT /evidence="ECO:0007829|PDB:6H46" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 49..57 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 60..62 FT /evidence="ECO:0007829|PDB:4Q01" FT HELIX 66..73 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 76..83 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 87..91 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 93..104 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:5VBM" FT STRAND 111..116 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 120..122 FT /evidence="ECO:0007829|PDB:4OBE" FT HELIX 127..137 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 141..143 FT /evidence="ECO:0007829|PDB:8ONV" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 152..164 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 169..172 FT /evidence="ECO:0007829|PDB:5OCG" FT STRAND 175..177 FT /evidence="ECO:0007829|PDB:4DSN" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:5TB5" FT VARIANT P01116-2:152 FT /note="V -> G (in NS3; dbSNP:rs104894367)" FT /evidence="ECO:0000305" FT /id="VAR_082908" FT VARIANT P01116-2:153 FT /note="D -> V (in CFC2 and NS3; exhibits only minor FT alterations in its in vitro biochemical behavior compared FT to wild-type protein; dbSNP:rs104894360)" FT /evidence="ECO:0000305" FT /id="VAR_082909" FT VARIANT P01116-2:156 FT /note="F -> I (in NS3; the patient also has features of FT cardiofaciocutaneous syndrome; dbSNP:rs397517042)" FT /evidence="ECO:0000305" FT /id="VAR_082910" FT VARIANT P01116-2:156 FT /note="F -> L (found in a patient with Costello syndrome; FT exhibits an increase in intrinsic and guanine nucleotide FT exchange factor catalyzed nucleotide exchange in FT combination with an impaired GTPase-activating protein- FT stimulated GTP hydrolysis but functional in interaction FT with effectors; dbSNP:rs104894362)" FT /evidence="ECO:0000305" FT /id="VAR_082911" FT MUTAGEN P01116-2:185 FT /note="C->S: Abolished interaction with GPR131." FT /evidence="ECO:0000269|PubMed:28619714" SQ SEQUENCE 189 AA; 21656 MW; 973547B2E11C2C81 CRC64; MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHHYREQI KRVKDSEDVP MVLVGNKCDL PSRTVDTKQA QDLARSYGIP FIETSAKTRQ RVEDAFYTLV REIRQYRLKK ISKEEKTPGC VKIKKCIIM // ID RNZ2_HUMAN Reviewed; 826 AA. AC Q9BQ52; B4DPL9; Q6IA94; Q9HAS8; Q9HAS9; Q9NVT1; DT 16-JAN-2004, integrated into UniProtKB/Swiss-Prot. DT 16-JAN-2004, sequence version 2. DT 28-JAN-2026, entry version 203. DE RecName: Full=Zinc phosphodiesterase ELAC protein 2; DE EC=3.1.26.11; DE AltName: Full=ElaC homolog protein 2; DE AltName: Full=Heredity prostate cancer protein 2; DE AltName: Full=Ribonuclease Z 2; DE Short=RNase Z 2; DE AltName: Full=tRNA 3 endonuclease 2; DE AltName: Full=tRNase Z 2; DE Flags: Precursor; GN Name=ELAC2; Synonyms=HPC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP HPC2 LEU-217; THR-541 AND HIS-781. RX PubMed=11175785; DOI=10.1038/84808; RA Tavtigian S.V., Simard J., Teng D.H.F., Abtin V., Baumgard M., Beck A., RA Camp N.J., Carillo A.R., Chen Y., Dayananth P., Desrochers M., Dumont M., RA Farnham J.M., Frank D., Frye C., Ghaffari S., Gupte J.S., Hu R., Iliev D., RA Janecki T., Kort E.N., Laity K.E., Leavitt A., Leblanc G., RA McArthur-Morrison J., Pederson A., Penn B., Peterson K.T., Reid J.E., RA Richards S., Schroeder M., Smith R., Snyder S.C., Swedlund B., Swensen J., RA Thomas A., Tranchant M., Woodland A.-M., Labrie F., Skolnick M.H., RA Neuhausen S., Rommens J., Cannon-Albright L.A.; RT "A candidate prostate cancer susceptibility gene at chromosome 17p."; RL Nat. Genet. 27:172-180(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4). RC TISSUE=Hippocampus, Liver, Teratocarcinoma, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT HPC2 RP LEU-217. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT HPC2 RP LEU-217. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP ENZYME ACTIVITY, AND CHARACTERIZATION OF VARIANTS HPC2 LEU-217; THR-541 AND RP HIS-781. RX PubMed=12711671; DOI=10.1093/nar/gkg337; RA Takaku H., Minagawa A., Takagi M., Nashimoto M.; RT "A candidate prostate cancer susceptibility gene encodes tRNA 3' processing RT endoribonuclease."; RL Nucleic Acids Res. 31:2272-2278(2003). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-199, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [9] RP INTERACTION WITH PTCD1. RX PubMed=21857155; DOI=10.4161/cc.10.17.17060; RA Sanchez M.I., Mercer T.R., Davies S.M., Shearwood A.M., Nygard K.K., RA Richman T.R., Mattick J.S., Rackham O., Filipovska A.; RT "RNA processing in human mitochondria."; RL Cell Cycle 10:2904-2916(2011). RN [10] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21593607; DOI=10.4161/rna.8.4.15393; RA Brzezniak L.K., Bijata M., Szczesny R.J., Stepien P.P.; RT "Involvement of human ELAC2 gene product in 3' end processing of RT mitochondrial tRNAs."; RL RNA Biol. 8:616-626(2011). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-199; SER-208; SER-229; RP SER-618 AND SER-736, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=24703694; DOI=10.1016/j.cmet.2014.03.013; RA Bogenhagen D.F., Martin D.W., Koller A.; RT "Initial steps in RNA processing and ribosome assembly occur at RT mitochondrial DNA nucleoids."; RL Cell Metab. 19:618-629(2014). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-208 AND SER-212, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=10986046; DOI=10.1086/303096; RA Rebbeck T.R., Walker A.H., Zeigler-Johnson C., Weisburg S., Martin A.-M., RA Nathanson K.L., Wein A.J., Malkowicz S.B.; RT "Association of HPC2/ELAC2 genotypes and prostate cancer."; RL Am. J. Hum. Genet. 67:1014-1019(2000). RN [16] RP VARIANT HPC2 VAL-622. RX PubMed=11507049; RA Roekman A., Ikonen T., Mononen N., Autio V., Matikainen M.P., RA Koivisto P.A., Tammela T.L.J., Kallioniemi O.-P., Schleutker J.; RT "ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer."; RL Cancer Res. 61:6038-6041(2001). RN [17] RP VARIANTS HPC2 GLN-211; LEU-217; ARG-487; THR-541 AND ARG-806. RX PubMed=11522646; RA Wang L., McDonnell S.K., Elkins D.A., Slager S.L., Christensen E., RA Marks A.F., Cunningham J.M., Peterson B.J., Jacobsen S.J., Cerhan J.R., RA Blute M.L., Schaid D.J., Thibodeau S.N.; RT "Role of HPC2/ELAC2 in hereditary prostate cancer."; RL Cancer Res. 61:6494-6499(2001). RN [18] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12522685; DOI=10.1007/s100380200099; RA Fujiwara H., Emi M., Nagai H., Nishimura T., Konishi N., Kubota Y., RA Ichikawa T., Takahashi S., Shuin T., Habuchi T., Ogawa O., Inoue K., RA Skolnick M.H., Swensen J., Camp N.J., Tavtigian S.V.; RT "Association of common missense changes in ELAC2 (HPC2) with prostate RT cancer in a Japanese case-control series."; RL J. Hum. Genet. 47:641-648(2002). RN [19] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12515253; DOI=10.1086/344516; RA Camp N.J., Tavtigian S.V.; RT "Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in RT ELAC2 (HPC2) and prostate cancer."; RL Am. J. Hum. Genet. 71:1475-1478(2002). RN [20] RP VARIANT LEU-627. RX PubMed=12949798; DOI=10.1002/ijc.11347; RA Takahashi H., Lu W., Watanabe M., Katoh T., Furusato M., Tsukino H., RA Nakao H., Sudo A., Suzuki H., Akakura K., Ikemoto I., Asano K., Ito T., RA Wakui S., Muto T., Hano H.; RT "Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic RT cancer risk in Japanese men."; RL Int. J. Cancer 107:224-228(2003). RN [21] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12783937; DOI=10.1093/jnci/95.11.818; RA Severi G., Giles G.G., Southey M.C., Tesoriero A., Tilley W., Neufing P., RA Morris H., English D.R., McCredie M.R., Boyle P., Hopper J.L.; RT "ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate RT cancer."; RL J. Natl. Cancer Inst. 95:818-824(2003). RN [22] RP VARIANT [LARGE SCALE ANALYSIS] HPC2 LEU-217. RX PubMed=18987736; DOI=10.1038/nature07485; RA Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., RA Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L., RA Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A., RA Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V., RA Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R., RA Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E., RA Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S., RA Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A., RA DiPersio J.F., Wilson R.K.; RT "DNA sequencing of a cytogenetically normal acute myeloid leukaemia RT genome."; RL Nature 456:66-72(2008). RN [23] RP VARIANTS COXPD17 LEU-154; PHE-423 AND ILE-520. RX PubMed=23849775; DOI=10.1016/j.ajhg.2013.06.006; RA Haack T.B., Kopajtich R., Freisinger P., Wieland T., Rorbach J., RA Nicholls T.J., Baruffini E., Walther A., Danhauser K., Zimmermann F.A., RA Husain R.A., Schum J., Mundy H., Ferrero I., Strom T.M., Meitinger T., RA Taylor R.W., Minczuk M., Mayr J.A., Prokisch H.; RT "ELAC2 mutations cause a mitochondrial RNA processing defect associated RT with hypertrophic cardiomyopathy."; RL Am. J. Hum. Genet. 93:211-223(2013). CC -!- FUNCTION: Zinc phosphodiesterase, which displays mitochondrial tRNA 3'- CC processing endonuclease activity. Involved in tRNA maturation, by CC removing a 3'-trailer from precursor tRNA (PubMed:21593607). Associates CC with mitochondrial DNA complexes at the nucleoids to initiate RNA CC processing and ribosome assembly (PubMed:24703694). CC {ECO:0000269|PubMed:21593607, ECO:0000269|PubMed:24703694}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Endonucleolytic cleavage of RNA, removing extra 3' nucleotides CC from tRNA precursor, generating 3' termini of tRNAs. A 3'-hydroxy CC group is left at the tRNA terminus and a 5'-phosphoryl group is left CC at the trailer molecule.; EC=3.1.26.11; CC Evidence={ECO:0000269|PubMed:12711671}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000305}; CC -!- SUBUNIT: Homodimer (By similarity). Interacts with PTCD1. {ECO:0000250, CC ECO:0000269|PubMed:21857155}. CC -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:21593607}. CC Mitochondrion matrix, mitochondrion nucleoid CC {ECO:0000269|PubMed:24703694}. Nucleus {ECO:0000269|PubMed:21593607}. CC Note=Mainly mitochondrial. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9BQ52-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9BQ52-2; Sequence=VSP_009169, VSP_009171, VSP_009172; CC Name=3; CC IsoId=Q9BQ52-3; Sequence=VSP_009168, VSP_009170; CC Name=4; CC IsoId=Q9BQ52-4; Sequence=VSP_043449; CC -!- TISSUE SPECIFICITY: Widely expressed. Highly expressed in heart, CC placenta, liver, skeletal muscle, kidney, pancreas, testis and ovary. CC Weakly expressed in brain, lung, spleen, thymus, prostate, small CC intestine, colon and leukocytes. {ECO:0000269|PubMed:11175785}. CC -!- DISEASE: Prostate cancer, hereditary, 2 (HPC2) [MIM:614731]: A CC condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:10986046, CC ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11507049, CC ECO:0000269|PubMed:11522646, ECO:0000269|PubMed:12515253, CC ECO:0000269|PubMed:12522685, ECO:0000269|PubMed:12711671, CC ECO:0000269|PubMed:12783937, ECO:0000269|PubMed:15489334, CC ECO:0000269|PubMed:18987736, ECO:0000269|Ref.3}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Combined oxidative phosphorylation deficiency 17 (COXPD17) CC [MIM:615440]: An autosomal recessive disorder of mitochondrial CC dysfunction characterized by onset of severe hypertrophic CC cardiomyopathy in the first year of life. Other features include CC hypotonia, poor growth, lactic acidosis, and failure to thrive. The CC disorder may be fatal in early childhood. CC {ECO:0000269|PubMed:23849775}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the RNase Z family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40437/ELAC2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF304369; AAG24440.1; -; Genomic_DNA. DR EMBL; AF304370; AAG24441.1; -; mRNA. DR EMBL; AK001392; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AK124838; BAC85964.1; -; mRNA. DR EMBL; AK125030; BAC86026.1; -; mRNA. DR EMBL; AK298397; BAG60631.1; -; mRNA. DR EMBL; CR457261; CAG33542.1; -; mRNA. DR EMBL; AC005277; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC001939; AAH01939.1; -; mRNA. DR EMBL; BC004158; AAH04158.1; -; mRNA. DR CCDS; CCDS11164.1; -. [Q9BQ52-1] DR CCDS; CCDS54093.1; -. [Q9BQ52-4] DR RefSeq; NP_001159434.1; NM_001165962.2. [Q9BQ52-4] DR RefSeq; NP_060597.4; NM_018127.6. [Q9BQ52-1] DR RefSeq; NP_776065.1; NM_173717.1. DR PDB; 8CBL; EM; 2.79 A; E=1-826. DR PDB; 8RR1; EM; 2.93 A; E=32-826. DR PDB; 8RR3; EM; 3.40 A; E=32-826. DR PDB; 8RR4; EM; 3.20 A; E=32-826. DR PDB; 8Z0P; EM; 3.10 A; A=1-826. DR PDB; 8Z1F; EM; 4.30 A; A=1-826. DR PDB; 8Z1G; EM; 3.70 A; A=1-826. DR PDB; 9EY0; EM; 2.78 A; E=31-826. DR PDB; 9EY1; EM; 2.90 A; E=31-826. DR PDB; 9EY2; EM; 2.96 A; E=31-826. DR PDBsum; 8CBL; -. DR PDBsum; 8RR1; -. DR PDBsum; 8RR3; -. DR PDBsum; 8RR4; -. DR PDBsum; 8Z0P; -. DR PDBsum; 8Z1F; -. DR PDBsum; 8Z1G; -. DR PDBsum; 9EY0; -. DR PDBsum; 9EY1; -. DR PDBsum; 9EY2; -. DR AlphaFoldDB; Q9BQ52; -. DR EMDB; EMD-16544; -. DR EMDB; EMD-19453; -. DR EMDB; EMD-19455; -. DR EMDB; EMD-19457; -. DR EMDB; EMD-39710; -. DR EMDB; EMD-39726; -. DR EMDB; EMD-39727; -. DR EMDB; EMD-50050; -. DR EMDB; EMD-50051; -. DR EMDB; EMD-50052; -. DR SMR; Q9BQ52; -. DR BioGRID; 121937; 198. DR ComplexPortal; CPX-2240; Mitochondrial RNase Z complex. DR FunCoup; Q9BQ52; 3637. DR IntAct; Q9BQ52; 55. DR MINT; Q9BQ52; -. DR STRING; 9606.ENSP00000337445; -. DR GlyGen; Q9BQ52; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9BQ52; -. DR MetOSite; Q9BQ52; -. DR PhosphoSitePlus; Q9BQ52; -. DR SwissPalm; Q9BQ52; -. DR BioMuta; ELAC2; -. DR DMDM; 41017788; -. DR jPOST; Q9BQ52; -. DR MassIVE; Q9BQ52; -. DR PaxDb; 9606-ENSP00000337445; -. DR PeptideAtlas; Q9BQ52; -. DR ProteomicsDB; 78627; -. [Q9BQ52-1] DR ProteomicsDB; 78628; -. [Q9BQ52-2] DR ProteomicsDB; 78629; -. [Q9BQ52-3] DR ProteomicsDB; 78630; -. [Q9BQ52-4] DR Pumba; Q9BQ52; -. DR Antibodypedia; 13065; 203 antibodies from 30 providers. DR DNASU; 60528; -. DR Ensembl; ENST00000338034.9; ENSP00000337445.4; ENSG00000006744.20. [Q9BQ52-1] DR Ensembl; ENST00000426905.7; ENSP00000405223.3; ENSG00000006744.20. [Q9BQ52-4] DR GeneID; 60528; -. DR KEGG; hsa:60528; -. DR MANE-Select; ENST00000338034.9; ENSP00000337445.4; NM_018127.7; NP_060597.4. DR UCSC; uc002gnz.5; human. [Q9BQ52-1] DR AGR; HGNC:14198; -. DR ClinPGx; PA27739; -. DR CTD; 60528; -. DR DisGeNET; 60528; -. DR GeneCards; ELAC2; -. DR HGNC; HGNC:14198; ELAC2. DR HPA; ENSG00000006744; Low tissue specificity. DR MalaCards; ELAC2; -. DR MIM; 176807; phenotype. DR MIM; 605367; gene. DR MIM; 614731; phenotype. DR MIM; 615440; phenotype. DR OpenTargets; ENSG00000006744; -. DR Orphanet; 369913; Combined oxidative phosphorylation defect type 17. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000006744; -. DR eggNOG; KOG2121; Eukaryota. DR GeneTree; ENSGT00730000111191; -. DR HOGENOM; CLU_006220_2_0_1; -. DR InParanoid; Q9BQ52; -. DR OMA; INYICQL; -. DR OrthoDB; 527344at2759; -. DR PAN-GO; Q9BQ52; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9BQ52; -. DR BRENDA; 3.1.26.11; 2681. DR PathwayCommons; Q9BQ52; -. DR Reactome; R-HSA-6784531; tRNA processing in the nucleus. DR Reactome; R-HSA-6785470; tRNA processing in the mitochondrion. DR Reactome; R-HSA-8868766; rRNA processing in the mitochondrion. DR Reactome; R-HSA-9708296; tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis. DR SignaLink; Q9BQ52; -. DR Agora; ENSG00000006744; -. DR BioGRID-ORCS; 60528; 738 hits in 1175 CRISPR screens. DR CD-CODE; F701F3BC; PcG body. DR ChiTaRS; ELAC2; human. DR GeneWiki; ELAC2; -. DR GenomeRNAi; 60528; -. DR Pharos; Q9BQ52; Tbio. DR PRO; PR:Q9BQ52; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q9BQ52; protein. DR Bgee; ENSG00000006744; Expressed in adrenal tissue and 202 other cell types or tissues. DR ExpressionAtlas; Q9BQ52; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005759; C:mitochondrial matrix; IDA:FlyBase. DR GO; GO:0042645; C:mitochondrial nucleoid; IDA:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0042781; F:3'-tRNA processing endoribonuclease activity; IBA:GO_Central. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0004521; F:RNA endonuclease activity; TAS:Reactome. DR GO; GO:0004549; F:tRNA-specific ribonuclease activity; EXP:Reactome. DR GO; GO:1990180; P:mitochondrial tRNA 3'-end processing; IMP:UniProtKB. DR GO; GO:0090646; P:mitochondrial tRNA processing; TAS:Reactome. DR GO; GO:0042780; P:tRNA 3'-end processing; TAS:Reactome. DR GO; GO:0016078; P:tRNA decay; TAS:Reactome. DR CDD; cd07718; RNaseZ_ELAC1_ELAC2-C-term-like_MBL-fold; 1. DR CDD; cd16296; RNaseZ_ELAC2-N-term-like_MBL-fold; 1. DR FunFam; 3.60.15.10:FF:000014; Zinc phosphodiesterase ELAC protein 2; 1. DR Gene3D; 3.60.15.10; Ribonuclease Z/Hydroxyacylglutathione hydrolase-like; 2. DR InterPro; IPR036866; RibonucZ/Hydroxyglut_hydro. DR InterPro; IPR047151; RNZ2-like. DR InterPro; IPR027794; tRNase_Z_dom. DR PANTHER; PTHR12553; ZINC PHOSPHODIESTERASE ELAC PROTEIN 2; 1. DR PANTHER; PTHR12553:SF49; ZINC PHOSPHODIESTERASE ELAC PROTEIN 2; 1. DR Pfam; PF23023; Anti-Pycsar_Apyc1; 1. DR Pfam; PF13691; Lactamase_B_4; 1. DR SUPFAM; SSF56281; Metallo-hydrolase/oxidoreductase; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Disease variant; Endonuclease; KW Hydrolase; Metal-binding; Mitochondrion; Mitochondrion nucleoid; Nuclease; KW Nucleus; Phosphoprotein; Primary mitochondrial disease; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Transit peptide; tRNA processing; Zinc. FT TRANSIT 1..16 FT /note="Mitochondrion" FT /evidence="ECO:0000255" FT CHAIN 17..826 FT /note="Zinc phosphodiesterase ELAC protein 2" FT /id="PRO_0000155828" FT REGION 16..51 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 188..231 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 798..826 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 27..38 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 208..224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 808..820 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 199 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 208 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 212 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 229 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 618 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 736 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..372 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009168" FT VAR_SEQ 1..94 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009169" FT VAR_SEQ 188..227 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043449" FT VAR_SEQ 373..406 FT /note="NCASVHNLRSHKIQTQLNLIHPDIFPLLTSFRCK -> MRTVPQFTTFAATR FT FKPSSTSSTRTSSPCSPVSA (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009170" FT VAR_SEQ 554..595 FT /note="GLPSILLQRERALASLGKPLHPLLVVAPNQLKAWLQQYHNQC -> VSVGLD FT HKAGAWRRHCHVELALWLRLFLRFQTCPELLLLISG (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009171" FT VAR_SEQ 596..826 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009172" FT VARIANT 52 FT /note="S -> F (in dbSNP:rs9895963)" FT /id="VAR_038210" FT VARIANT 154 FT /note="F -> L (in COXPD17; dbSNP:rs397515465)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070844" FT VARIANT 211 FT /note="R -> Q (in HPC2; dbSNP:rs148419785)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017425" FT VARIANT 217 FT /note="S -> L (in HPC2; risk factor for disease FT development; does not affect the enzymatic activity; FT dbSNP:rs4792311)" FT /evidence="ECO:0000269|PubMed:10986046, FT ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11522646, FT ECO:0000269|PubMed:12515253, ECO:0000269|PubMed:12522685, FT ECO:0000269|PubMed:12711671, ECO:0000269|PubMed:12783937, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:18987736, FT ECO:0000269|Ref.3" FT /id="VAR_017426" FT VARIANT 423 FT /note="L -> F (in COXPD17; dbSNP:rs397515466)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070845" FT VARIANT 436 FT /note="D -> N (in dbSNP:rs3760317)" FT /id="VAR_038211" FT VARIANT 487 FT /note="G -> R (in HPC2; dbSNP:rs752234492)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017427" FT VARIANT 520 FT /note="T -> I (in COXPD17; dbSNP:rs397515463)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070846" FT VARIANT 541 FT /note="A -> T (in HPC2; risk factor for disease FT development; does not affect the enzymatic activity; FT dbSNP:rs5030739)" FT /evidence="ECO:0000269|PubMed:10986046, FT ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11522646, FT ECO:0000269|PubMed:12515253, ECO:0000269|PubMed:12522685, FT ECO:0000269|PubMed:12711671, ECO:0000269|PubMed:12783937" FT /id="VAR_017428" FT VARIANT 622 FT /note="E -> V (in HPC2; higher frequency in prostate cancer FT cases; dbSNP:rs119484087)" FT /evidence="ECO:0000269|PubMed:11507049" FT /id="VAR_017429" FT VARIANT 627 FT /note="S -> L (in dbSNP:rs78105154)" FT /evidence="ECO:0000269|PubMed:12949798" FT /id="VAR_017430" FT VARIANT 781 FT /note="R -> H (in HPC2; does not affect the enzymatic FT activity; dbSNP:rs119484086)" FT /evidence="ECO:0000269|PubMed:11175785, FT ECO:0000269|PubMed:12711671" FT /id="VAR_017431" FT VARIANT 806 FT /note="G -> R (in HPC2; dbSNP:rs770669443)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017432" FT CONFLICT 165 FT /note="V -> M (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 406 FT /note="Missing (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 592 FT /note="H -> Y (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 754 FT /note="F -> L (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT HELIX 38..46 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 58..65 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 68..70 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 72..80 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 82..85 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 91..97 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 107..109 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 111..114 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 115..118 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 121..131 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 134..141 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 144..155 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 161..167 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 176..186 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 239..247 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 256..262 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 268..270 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 272..279 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 284..286 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 289..291 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 293..296 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 305..310 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 314..316 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 317..321 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 324..330 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 338..343 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 346..349 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 352..360 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 365..369 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 380..392 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 394..396 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 416..418 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 424..429 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 432..434 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 443..451 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 453..455 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 456..468 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 481..487 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 489..492 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:8Z0P" FT STRAND 499..507 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 510..514 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 520..528 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 529..531 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 532..537 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 539..543 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 546..548 FT /evidence="ECO:0007829|PDB:8Z0P" FT HELIX 549..552 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 555..569 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 576..580 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 584..594 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 599..601 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 602..608 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 619..632 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 634..639 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 643..647 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 651..655 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 660..663 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 671..676 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 677..679 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 681..686 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 691..693 FT /evidence="ECO:0007829|PDB:8RR1" FT HELIX 694..700 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 705..715 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 720..723 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 729..731 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 740..742 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 743..745 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 750..753 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 754..763 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 764..770 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 772..790 FT /evidence="ECO:0007829|PDB:9EY0" SQ SEQUENCE 826 AA; 92219 MW; 4AE701C755EC7339 CRC64; MWALCSLLRS AAGRTMSQGR TISQAPARRE RPRKDPLRHL RTREKRGPSG CSGGPNTVYL QVVAAGSRDS GAALYVFSEF NRYLFNCGEG VQRLMQEHKL KVARLDNIFL TRMHWSNVGG LSGMILTLKE TGLPKCVLSG PPQLEKYLEA IKIFSGPLKG IELAVRPHSA PEYEDETMTV YQIPIHSEQR RGKHQPWQSP ERPLSRLSPE RSSDSESNEN EPHLPHGVSQ RRGVRDSSLV VAFICKLHLK RGNFLVLKAK EMGLPVGTAA IAPIIAAVKD GKSITHEGRE ILAEELCTPP DPGAAFVVVE CPDESFIQPI CENATFQRYQ GKADAPVALV VHMAPASVLV DSRYQQWMER FGPDTQHLVL NENCASVHNL RSHKIQTQLN LIHPDIFPLL TSFRCKKEGP TLSVPMVQGE CLLKYQLRPR REWQRDAIIT CNPEEFIVEA LQLPNFQQSV QEYRRSAQDG PAPAEKRSQY PEIIFLGTGS AIPMKIRNVS ATLVNISPDT SLLLDCGEGT FGQLCRHYGD QVDRVLGTLA AVFVSHLHAD HHTGLPSILL QRERALASLG KPLHPLLVVA PNQLKAWLQQ YHNQCQEVLH HISMIPAKCL QEGAEISSPA VERLISSLLR TCDLEEFQTC LVRHCKHAFG CALVHTSGWK VVYSGDTMPC EALVRMGKDA TLLIHEATLE DGLEEEAVEK THSTTSQAIS VGMRMNAEFI MLNHFSQRYA KVPLFSPNFS EKVGVAFDHM KVCFGDFPTM PKLIPPLKAL FAGDIEEMEE RREKRELRQV RAALLSRELA GGLEDGEPQQ KRAHTEEPQA KKVRAQ // ID SPEG_HUMAN Reviewed; 3267 AA. AC Q15772; A8K0G6; A8MRU0; Q27J74; Q695L1; Q6FGA6; Q6ZQW1; Q6ZTL8; Q9P2P9; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 16-DEC-2008, sequence version 4. DT 28-JAN-2026, entry version 210. DE RecName: Full=Striated muscle preferentially expressed protein kinase; DE EC=2.7.11.1; DE AltName: Full=Aortic preferentially expressed protein 1; DE Short=APEG-1; GN Name=SPEG; Synonyms=APEG1, KIAA1297; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, SUBCELLULAR RP LOCATION, AND INDUCTION. RX PubMed=8663449; DOI=10.1074/jbc.271.29.17354; RA Hsieh C.-M., Yoshizumi M., Endege W.O., Kho C.-J., Jain M.K., Kashiki S., RA de Los Santos R., Lee W.-S., Perrella M.A., Lee M.-E.; RT "APEG-1, a novel gene preferentially expressed in aortic smooth muscle RT cells, is down-regulated by vascular injury."; RL J. Biol. Chem. 271:17354-17359(1996). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Cerebellum, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 12-129 (ISOFORM 1), AND ALTERNATIVE PROMOTER RP USAGE. RX PubMed=16545539; DOI=10.1016/j.ygeno.2006.01.009; RA Tam J.L.Y., Triantaphyllopoulos K., Todd H., Raguz S., de Wit T., RA Morgan J.E., Partridge T.A., Makrinou E., Grosveld F., Antoniou M.; RT "The human desmin locus: gene organization and LCR-mediated transcriptional RT control."; RL Genomics 87:733-746(2006). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 130-3267 (ISOFORM 1), TISSUE SPECIFICITY, AND RP VARIANT THR-2687. RX PubMed=15185077; DOI=10.1007/s00427-004-0413-5; RA Sutter S.B., Raeker M.O., Borisov A.B., Russell M.W.; RT "Orthologous relationship of obscurin and Unc-89: phylogeny of a novel RT family of tandem myosin light chain kinases."; RL Dev. Genes Evol. 214:352-359(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 982-3267 (ISOFORM 1), AND VARIANT RP THR-2687. RC TISSUE=Brain; RX PubMed=10718198; DOI=10.1093/dnares/7.1.65; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVI. The RT complete sequences of 150 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:65-73(2000). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-488, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP X-RAY CRYSTALLOGRAPHY (0.96 ANGSTROMS) OF 864-962, AND SUBUNIT. RX PubMed=16354304; DOI=10.1186/1472-6807-5-21; RA Manjasetty B.A., Niesen F.H., Scheich C., Roske Y., Goetz F., Behlke J., RA Sievert V., Heinemann U., Bussow K.; RT "X-ray structure of engineered human aortic preferentially expressed RT protein-1 (APEG-1)."; RL BMC Struct. Biol. 5:21-21(2005). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-206; CYS-934; GLN-966; LEU-1103; RP VAL-1135; ASP-1178; TRP-1234; GLN-1340; CYS-1621; TRP-1903; THR-2687; RP MET-2742 AND ARG-3079. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [13] RP INTERACTION WITH MTM1, INVOLVEMENT IN CNM5, AND VARIANT CNM5 VAL-2757. RX PubMed=25087613; DOI=10.1016/j.ajhg.2014.07.004; RA Agrawal P.B., Pierson C.R., Joshi M., Liu X., Ravenscroft G., RA Moghadaszadeh B., Talabere T., Viola M., Swanson L.C., Haliloglu G., RA Talim B., Yau K.S., Allcock R.J., Laing N.G., Perrella M.A., Beggs A.H.; RT "SPEG interacts with myotubularin, and its deficiency causes centronuclear RT myopathy with dilated cardiomyopathy."; RL Am. J. Hum. Genet. 95:218-226(2014). CC -!- FUNCTION: Isoform 3 may have a role in regulating the growth and CC differentiation of arterial smooth muscle cells. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with MTM1. Isoform 3 is found as a monomer or CC homodimer. {ECO:0000269|PubMed:16354304, ECO:0000269|PubMed:25087613}. CC -!- INTERACTION: CC Q15772; Q99873: PRMT1; NbExp=3; IntAct=EBI-1384196, EBI-78738; CC Q15772-4; O75031: HSF2BP; NbExp=3; IntAct=EBI-12175897, EBI-7116203; CC Q15772-4; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-12175897, EBI-16439278; CC Q15772-4; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-12175897, EBI-79165; CC Q15772-4; Q99873-3: PRMT1; NbExp=3; IntAct=EBI-12175897, EBI-17165527; CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=4; CC Name=4; CC IsoId=Q15772-5; Sequence=Displayed; CC Name=2; CC IsoId=Q15772-3; Sequence=VSP_018259, VSP_018261, VSP_018262; CC Name=3; Synonyms=APEG1; CC IsoId=Q15772-4; Sequence=VSP_018258, VSP_018261, VSP_018262; CC Name=1; Synonyms=SPEG; CC IsoId=Q15772-1; Sequence=VSP_036071; CC -!- TISSUE SPECIFICITY: Isoform 1 is preferentially expressed in striated CC muscle. Non-kinase form such as isoform 3 is predominantly expressed in CC the aorta. Isoform 3 appears to be expressed only in highly CC differentiated ASMC in normal vessel walls and down-regulated in CC dedifferentiated ASMC in vivo. In response to vascular injuries ASMC CC dedifferentiate and change from a quiescent and contractile phenotype CC to a proliferative and synthetic phenotype. This proliferation of CC vascular smooth muscle cells is one of the most prominent features of CC atherosclerosis. {ECO:0000269|PubMed:15185077, CC ECO:0000269|PubMed:8663449}. CC -!- INDUCTION: Isoform 3 is quickly down-regulated in response to vascular CC injury, when ASMC cells change from a quiescent to a proliferative CC phenotype. {ECO:0000269|PubMed:8663449}. CC -!- PTM: May be autophosphorylated. CC -!- DISEASE: Myopathy, centronuclear, 5 (CNM5) [MIM:615959]: A form of CC centronuclear myopathy, a congenital muscle disorder characterized by CC progressive muscular weakness and wasting involving mainly limb girdle, CC trunk, and neck muscles. It may also affect distal muscles. Weakness CC may be present during childhood or adolescence or may not become CC evident until the third decade of life. Ptosis is a frequent clinical CC feature. The most prominent histopathologic features include high CC frequency of centrally located nuclei in muscle fibers not secondary to CC regeneration, radial arrangement of sarcoplasmic strands around the CC central nuclei, and predominance and hypotrophy of type 1 fibers. CNM5 CC features include severe neonatal hypotonia with respiratory CC insufficiency, difficulty feeding, and delayed motor development. Some CC patients die in infancy, and some develop dilated cardiomyopathy. CC {ECO:0000269|PubMed:25087613}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: Expression is under the tight control of the locus CC control region (LCRs). CC -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative promoter usage. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative splicing. CC {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAY15052.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=ABD61734.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U57099; AAC50599.1; -; mRNA. DR EMBL; AK126500; BAC86568.1; -; mRNA. DR EMBL; AK289531; BAF82220.1; -; mRNA. DR EMBL; CR542201; CAG46998.1; -; mRNA. DR EMBL; AC053503; AAY15052.1; ALT_SEQ; Genomic_DNA. DR EMBL; CH471063; EAW70747.1; -; Genomic_DNA. DR EMBL; BC006346; AAH06346.1; -; mRNA. DR EMBL; DQ395348; ABD61734.1; ALT_FRAME; mRNA. DR EMBL; AY603755; AAT80901.1; -; mRNA. DR EMBL; AB037718; BAA92535.1; -; mRNA. DR CCDS; CCDS42824.1; -. [Q15772-5] DR CCDS; CCDS54432.1; -. [Q15772-4] DR RefSeq; NP_001166947.1; NM_001173476.2. [Q15772-4] DR RefSeq; NP_005867.3; NM_005876.4. [Q15772-5] DR RefSeq; XP_047298873.1; XM_047442917.1. [Q15772-3] DR RefSeq; XP_047298874.1; XM_047442918.1. [Q15772-3] DR RefSeq; XP_047298875.1; XM_047442919.1. [Q15772-3] DR RefSeq; XP_047298876.1; XM_047442920.1. [Q15772-3] DR RefSeq; XP_047298877.1; XM_047442921.1. [Q15772-4] DR RefSeq; XP_047298878.1; XM_047442922.1. [Q15772-4] DR RefSeq; XP_047298879.1; XM_047442923.1. [Q15772-4] DR RefSeq; XP_054196142.1; XM_054340167.1. [Q15772-3] DR RefSeq; XP_054196143.1; XM_054340168.1. [Q15772-3] DR RefSeq; XP_054196144.1; XM_054340169.1. [Q15772-3] DR RefSeq; XP_054196145.1; XM_054340170.1. [Q15772-3] DR RefSeq; XP_054196146.1; XM_054340171.1. [Q15772-4] DR RefSeq; XP_054196147.1; XM_054340172.1. [Q15772-4] DR RefSeq; XP_054196148.1; XM_054340173.1. [Q15772-4] DR PDB; 1U2H; X-ray; 0.96 A; A=864-960. DR PDBsum; 1U2H; -. DR SMR; Q15772; -. DR BioGRID; 115579; 21. DR FunCoup; Q15772; 144. DR IntAct; Q15772; 13. DR STRING; 9606.ENSP00000311684; -. DR GlyCosmos; Q15772; 1 site, 1 glycan. DR GlyGen; Q15772; 8 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q15772; -. DR PhosphoSitePlus; Q15772; -. DR BioMuta; SPEG; -. DR DMDM; 218512143; -. DR jPOST; Q15772; -. DR MassIVE; Q15772; -. DR PaxDb; 9606-ENSP00000311684; -. DR PeptideAtlas; Q15772; -. DR ProteomicsDB; 60751; -. [Q15772-5] DR ProteomicsDB; 60752; -. [Q15772-1] DR ProteomicsDB; 60753; -. [Q15772-3] DR ProteomicsDB; 60754; -. [Q15772-4] DR Pumba; Q15772; -. DR Antibodypedia; 11575; 81 antibodies from 22 providers. DR DNASU; 10290; -. DR Ensembl; ENST00000312358.12; ENSP00000311684.7; ENSG00000072195.15. [Q15772-5] DR Ensembl; ENST00000396686.5; ENSP00000379917.1; ENSG00000072195.15. [Q15772-4] DR Ensembl; ENST00000396688.5; ENSP00000379919.1; ENSG00000072195.15. [Q15772-4] DR Ensembl; ENST00000396689.2; ENSP00000379920.2; ENSG00000072195.15. [Q15772-4] DR GeneID; 10290; -. DR KEGG; hsa:10290; -. DR MANE-Select; ENST00000312358.12; ENSP00000311684.7; NM_005876.5; NP_005867.3. DR UCSC; uc002vlq.4; human. [Q15772-5] DR AGR; HGNC:16901; -. DR ClinPGx; PA142672598; -. DR CTD; 10290; -. DR DisGeNET; 10290; -. DR GeneCards; SPEG; -. DR HGNC; HGNC:16901; SPEG. DR HPA; ENSG00000072195; Tissue enhanced (intestine). DR MalaCards; SPEG; -. DR MIM; 615950; gene. DR MIM; 615959; phenotype. DR OpenTargets; ENSG00000072195; -. DR Orphanet; 169186; Autosomal recessive centronuclear myopathy. DR VEuPathDB; HostDB:ENSG00000072195; -. DR eggNOG; KOG0032; Eukaryota. DR eggNOG; KOG0613; Eukaryota. DR GeneTree; ENSGT00940000161126; -. DR HOGENOM; CLU_000381_0_0_1; -. DR InParanoid; Q15772; -. DR OrthoDB; 2570713at2759; -. DR PAN-GO; Q15772; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q15772; -. DR PathwayCommons; Q15772; -. DR SignaLink; Q15772; -. DR SIGNOR; Q15772; -. DR Agora; ENSG00000072195; -. DR BioGRID-ORCS; 10290; 9 hits in 1166 CRISPR screens. DR ChiTaRS; SPEG; human. DR EvolutionaryTrace; Q15772; -. DR GeneWiki; SPEG; -. DR GenomeRNAi; 10290; -. DR Pharos; Q15772; Tbio. DR PRO; PR:Q15772; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q15772; protein. DR Bgee; ENSG00000072195; Expressed in popliteal artery and 171 other cell types or tissues. DR ExpressionAtlas; Q15772; baseline and differential. DR GO; GO:0005634; C:nucleus; TAS:ProtInc. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0042692; P:muscle cell differentiation; IBA:GO_Central. DR GO; GO:0007517; P:muscle organ development; TAS:ProtInc. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR CDD; cd00063; FN3; 2. DR CDD; cd20975; IgI_APEG-1_like; 1. DR CDD; cd14108; STKc_SPEG_rpt1; 1. DR CDD; cd14111; STKc_SPEG_rpt2; 1. DR FunFam; 2.60.40.10:FF:000080; Myosin light chain kinase, smooth muscle; 1. DR FunFam; 2.60.40.10:FF:000145; Myosin light chain kinase, smooth muscle; 1. DR FunFam; 1.10.510.10:FF:000363; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000497; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000538; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000784; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:001056; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000428; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000513; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000539; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000541; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000601; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 3.30.200.20:FF:000302; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 3.30.200.20:FF:000312; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 1.10.510.10:FF:000344; striated muscle preferentially expressed protein kinase isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 11. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR47633; IMMUNOGLOBULIN; 1. DR PANTHER; PTHR47633:SF3; STRIATED MUSCLE PREFERENTIALLY EXPRESSED PROTEIN KINASE; 1. DR Pfam; PF07679; I-set; 9. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF16650; SPEG_u2; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00409; IG; 9. DR SMART; SM00408; IGc2; 9. DR SMART; SM00220; S_TKc; 2. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF48726; Immunoglobulin; 9. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS50835; IG_LIKE; 8. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative promoter usage; Alternative splicing; KW ATP-binding; Differentiation; Disease variant; Disulfide bond; KW Immunoglobulin domain; Kinase; Methylation; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..3267 FT /note="Striated muscle preferentially expressed protein FT kinase" FT /id="PRO_0000072666" FT DOMAIN 43..124 FT /note="Ig-like 1" FT DOMAIN 722..810 FT /note="Ig-like 2" FT DOMAIN 869..958 FT /note="Ig-like 3" FT DOMAIN 963..1057 FT /note="Ig-like 4" FT DOMAIN 1064..1152 FT /note="Ig-like 5" FT DOMAIN 1188..1278 FT /note="Ig-like 6" FT DOMAIN 1285..1382 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1384..1480 FT /note="Ig-like 7" FT DOMAIN 1485..1573 FT /note="Ig-like 8" FT DOMAIN 1601..1854 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 2583..2673 FT /note="Ig-like 9" FT DOMAIN 2680..2774 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 2966..3218 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..33 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 132..227 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 276..714 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 812..872 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1157..1180 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1906..2060 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2074..2239 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2253..2325 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2339..2399 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2411..2452 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2466..2564 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2771..2896 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2909..2966 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 156..195 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 298..314 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 400..418 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 434..443 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 505..517 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 619..633 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 658..675 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 815..825 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 850..864 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2171..2180 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2188..2201 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2214..2224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2343..2354 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2355..2366 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2384..2395 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2466..2484 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2521..2540 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2806..2815 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2910..2924 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2937..2954 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1719 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT ACT_SITE 3085 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1607..1615 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 1630 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 2972..2980 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 2995 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 139 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 364 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 371 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 375 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 378 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 381 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 419 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 449 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 453 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 488 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 506 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 526 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 549 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 1128 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 1172 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 1988 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2014 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2015 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2037 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2055 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2055 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2109 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2130 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2139 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2177 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2376 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2380 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2410 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2414 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2438 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2439 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2444 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2448 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2521 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2524 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2559 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2771 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2774 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2949 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT DISULFID 989..1041 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2605..2657 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 1..849 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:8663449, ECO:0000303|Ref.3" FT /id="VSP_018258" FT VAR_SEQ 1..792 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_018259" FT VAR_SEQ 961..962 FT /note="AH -> GE (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8663449, FT ECO:0000303|Ref.3" FT /id="VSP_018261" FT VAR_SEQ 963..3267 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8663449, FT ECO:0000303|Ref.3" FT /id="VSP_018262" FT VAR_SEQ 3209..3267 FT /note="LQDCLAHPWLQDAYLMKLRRQTLTFTTNRLKEFLGEQRRRRAEAATRHKVLL FT RSYPGGP -> SCLSVCHKEIKMASS (in isoform 1)" FT /evidence="ECO:0000303|PubMed:10718198, FT ECO:0000303|PubMed:15185077, ECO:0000303|PubMed:16545539" FT /id="VSP_036071" FT VARIANT 206 FT /note="R -> H (in dbSNP:rs55821435)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041101" FT VARIANT 934 FT /note="R -> C (in dbSNP:rs34398769)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041102" FT VARIANT 966 FT /note="R -> Q (in dbSNP:rs34861443)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041103" FT VARIANT 1103 FT /note="P -> L (in dbSNP:rs56334571)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041104" FT VARIANT 1135 FT /note="A -> V (in dbSNP:rs55670811)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041105" FT VARIANT 1178 FT /note="E -> D (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs757589345)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041106" FT VARIANT 1234 FT /note="R -> W (in dbSNP:rs55916864)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041107" FT VARIANT 1340 FT /note="R -> Q (in dbSNP:rs34994343)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041108" FT VARIANT 1621 FT /note="R -> C (in dbSNP:rs55646900)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041109" FT VARIANT 1903 FT /note="R -> W (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs762000831)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041110" FT VARIANT 2189 FT /note="P -> L (in dbSNP:rs10755037)" FT /id="VAR_059769" FT VARIANT 2687 FT /note="P -> T (in dbSNP:rs13026308)" FT /evidence="ECO:0000269|PubMed:10718198, FT ECO:0000269|PubMed:15185077, ECO:0000269|PubMed:17344846" FT /id="VAR_041111" FT VARIANT 2742 FT /note="V -> M (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs566841339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041112" FT VARIANT 2757 FT /note="G -> V (in CNM5; dbSNP:rs587777676)" FT /evidence="ECO:0000269|PubMed:25087613" FT /id="VAR_071808" FT VARIANT 3079 FT /note="H -> R (in dbSNP:rs12464085)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041113" FT CONFLICT 71 FT /note="Q -> H (in Ref. 7; ABD61734)" FT /evidence="ECO:0000305" FT CONFLICT 73 FT /note="S -> I (in Ref. 7; ABD61734)" FT /evidence="ECO:0000305" FT CONFLICT 2047 FT /note="S -> G (in Ref. 8; AAT80901 and 9; BAA92535)" FT /evidence="ECO:0000305" FT CONFLICT 3005 FT /note="R -> P (in Ref. 8; AAT80901 and 9; BAA92535)" FT /evidence="ECO:0000305" FT STRAND 867..873 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 878..881 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 886..896 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 899..904 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 915..919 FT /evidence="ECO:0007829|PDB:1U2H" FT HELIX 921..923 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 924..931 FT /evidence="ECO:0007829|PDB:1U2H" FT HELIX 934..936 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 938..946 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 949..960 FT /evidence="ECO:0007829|PDB:1U2H" SQ SEQUENCE 3267 AA; 354289 MW; E67BEB5624144233 CRC64; MQKARGTRGE DAGTRAPPSP GVPPKRAKVG AGGGAPVAVA GAPVFLRPLK NAAVCAGSDV RLRVVVSGTP QPSLRWFRDG QLLPAPAPEP SCLWLRRCGA QDAGVYSCMA QNERGRASCE AVLTVLEVGD SETAEDDISD VQGTQRLELR DDGAFSTPTG GSDTLVGTSL DTPPTSVTGT SEEQVSWWGS GQTVLEQEAG SGGGTRRLPG SPRQAQATGA GPRHLGVEPL VRASRANLVG ASWGSEDSLS VASDLYGSAF SLYRGRALSI HVSVPQSGLR REEPDLQPQL ASEAPRRPAQ PPPSKSALLP PPSPRVGKRS PPGPPAQPAA TPTSPHRRTQ EPVLPEDTTT EEKRGKKSKS SGPSLAGTAE SRPQTPLSEA SGRLSALGRS PRLVRAGSRI LDKLQFFEER RRSLERSDSP PAPLRPWVPL RKARSLEQPK SERGAPWGTP GASQEELRAP GSVAERRRLF QQKAASLDER TRQRSPASDL ELRFAQELGR IRRSTSREEL VRSHESLRAT LQRAPSPREP GEPPLFSRPS TPKTSRAVSP AAAQPPSPSS AEKPGDEPGR PRSRGPAGRT EPGEGPQQEV RRRDQFPLTR SRAIQECRSP VPPPAADPPE ARTKAPPGRK REPPAQAVRF LPWATPGLEG AAVPQTLEKN RAGPEAEKRL RRGPEEDGPW GPWDRRGARS QGKGRRARPT SPELESSDDS YVSAGEEPLE APVFEIPLQN VVVAPGADVL LKCIITANPP PQVSWHKDGS ALRSEGRLLL RAEGERHTLL LREARAADAG SYMATATNEL GQATCAASLT VRPGGSTSPF SSPITSDEEY LSPPEEFPEP GETWPRTPTM KPSPSQNRRS SDTGSKAPPT FKVSLMDQSV REGQDVIMSI RVQGEPKPVV SWLRNRQPVR PDQRRFAEEA EGGLCRLRIL AAERGDAGFY TCKAVNEYGA RQCEARLEVR AHPESRSLAV LAPLQDVDVG AGEMALFECL VAGPTDVEVD WLCRGRLLQP ALLKCKMHFD GRKCKLLLTS VHEDDSGVYT CKLSTAKDEL TCSARLTVRP SLAPLFTRLL EDVEVLEGRA ARFDCKISGT PPPVVTWTHF GCPMEESENL RLRQDGGLHS LHIAHVGSED EGLYAVSAVN THGQAHCSAQ LYVEEPRTAA SGPSSKLEKM PSIPEEPEQG ELERLSIPDF LRPLQDLEVG LAKEAMLECQ VTGLPYPTIS WFHNGHRIQS SDDRRMTQYR DVHRLVFPAV GPQHAGVYKS VIANKLGKAA CYAHLYVTDV VPGPPDGAPQ VVAVTGRMVT LTWNPPRSLD MAIDPDSLTY TVQHQVLGSD QWTALVTGLR EPGWAATGLR KGVQHIFRVL STTVKSSSKP SPPSEPVQLL EHGPTLEEAP AMLDKPDIVY VVEGQPASVT VTFNHVEAQV VWRSCRGALL EARAGVYELS QPDDDQYCLR ICRVSRRDMG ALTCTARNRH GTQTCSVTLE LAEAPRFESI MEDVEVGAGE TARFAVVVEG KPLPDIMWYK DEVLLTESSH VSFVYEENEC SLVVLSTGAQ DGGVYTCTAQ NLAGEVSCKA ELAVHSAQTA MEVEGVGEDE DHRGRRLSDF YDIHQEIGRG AFSYLRRIVE RSSGLEFAAK FIPSQAKPKA SARREARLLA RLQHDCVLYF HEAFERRRGL VIVTELCTEE LLERIARKPT VCESEIRAYM RQVLEGIHYL HQSHVLHLDV KPENLLVWDG AAGEQQVRIC DFGNAQELTP GEPQYCQYGT PEFVAPEIVN QSPVSGVTDI WPVGVVAFLC LTGISPFVGE NDRTTLMNIR NYNVAFEETT FLSLSREARG FLIKVLVQDR LRPTAEETLE HPWFKTQAKG AEVSTDHLKL FLSRRRWQRS QISYKCHLVL RPIPELLRAP PERVWVTMPR RPPPSGGLSS SSDSEEEELE ELPSVPRPLQ PEFSGSRVSL TDIPTEDEAL GTPETGAATP MDWQEQGRAP SQDQEAPSPE ALPSPGQEPA AGASPRRGEL RRGSSAESAL PRAGPRELGR GLHKAASVEL PQRRSPSPGA TRLARGGLGE GEYAQRLQAL RQRLLRGGPE DGKVSGLRGP LLESLGGRAR DPRMARAASS EAAPHHQPPL ENRGLQKSSS FSQGEAEPRG RHRRAGAPLE IPVARLGARR LQESPSLSAL SEAQPSSPAR PSAPKPSTPK SAEPSATTPS DAPQPPAPQP AQDKAPEPRP EPVRASKPAP PPQALQTLAL PLTPYAQIIQ SLQLSGHAQG PSQGPAAPPS EPKPHAAVFA RVASPPPGAP EKRVPSAGGP PVLAEKARVP TVPPRPGSSL SSSIENLESE AVFEAKFKRS RESPLSLGLR LLSRSRSEER GPFRGAEEED GIYRPSPAGT PLELVRRPER SRSVQDLRAV GEPGLVRRLS LSLSQRLRRT PPAQRHPAWE ARGGDGESSE GGSSARGSPV LAMRRRLSFT LERLSSRLQR SGSSEDSGGA SGRSTPLFGR LRRATSEGES LRRLGLPHNQ LAAQAGATTP SAESLGSEAS ATSGSSAPGE SRSRLRWGFS RPRKDKGLSP PNLSASVQEE LGHQYVRSES DFPPVFHIKL KDQVLLEGEA ATLLCLPAAC PAPHISWMKD KKSLRSEPSV IIVSCKDGRQ LLSIPRAGKR HAGLYECSAT NVLGSITSSC TVAVARVPGK LAPPEVPQTY QDTALVLWKP GDSRAPCTYT LERRVDGESV WHPVSSGIPD CYYNVTHLPV GVTVRFRVAC ANRAGQGPFS NSSEKVFVRG TQDSSAVPSA AHQEAPVTSR PARARPPDSP TSLAPPLAPA APTPPSVTVS PSSPPTPPSQ ALSSLKAVGP PPQTPPRRHR GLQAARPAEP TLPSTHVTPS EPKPFVLDTG TPIPASTPQG VKPVSSSTPV YVVTSFVSAP PAPEPPAPEP PPEPTKVTVQ SLSPAKEVVS SPGSSPRSSP RPEGTTLRQG PPQKPYTFLE EKARGRFGVV RACRENATGR TFVAKIVPYA AEGKRRVLQE YEVLRTLHHE RIMSLHEAYI TPRYLVLIAE SCGNRELLCG LSDRFRYSED DVATYMVQLL QGLDYLHGHH VLHLDIKPDN LLLAPDNALK IVDFGSAQPY NPQALRPLGH RTGTLEFMAP EMVKGEPIGS ATDIWGAGVL TYIMLSGRSP FYEPDPQETE ARIVGGRFDA FQLYPNTSQS ATLFLRKVLS VHPWSRPSLQ DCLAHPWLQD AYLMKLRRQT LTFTTNRLKE FLGEQRRRRA EAATRHKVLL RSYPGGP // ID TITIN_HUMAN Reviewed; 34350 AA. AC Q8WZ42; A0A0A0MTS7; A6NKB1; C9JQJ2; E7EQE6; E7ET18; K7ENY1; Q10465; Q10466; AC Q15598; Q2XUS3; Q32Q60; Q4U1Z6; Q4ZG20; Q6NSG0; Q6PDB1; Q6PJP0; Q7KYM2; AC Q7KYN4; Q7KYN5; Q7LDM3; Q7Z2X3; Q8TCG8; Q8WZ51; Q8WZ52; Q8WZ53; Q8WZB3; AC Q92761; Q92762; Q9UD97; Q9UP84; Q9Y6L9; DT 13-JUN-2006, integrated into UniProtKB/Swiss-Prot. DT 18-APR-2012, sequence version 4. DT 28-JAN-2026, entry version 220. DE RecName: Full=Titin; DE EC=2.7.11.1; DE AltName: Full=Connectin; DE AltName: Full=Rhabdomyosarcoma antigen MU-RMS-40.14; GN Name=TTN; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE [MRNA] OF RP 3336-12202 (ISOFORM 4), AND VARIANTS ILE-498; GLU-1201; MET-3261; ASN-3419; RP SER-3491; GLU-12679; ILE-19762; ILE-20718; ASN-23807; MET-24980 AND RP THR-27755. RC TISSUE=Skeletal muscle; RX PubMed=7569978; DOI=10.1126/science.270.5234.293; RA Labeit S., Kolmerer B.; RT "Titins, giant proteins in charge of muscle ultrastructure and RT elasticity."; RL Science 270:293-296(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS RP LEU-1295; GLN-1572; ILE-2610; ASN-2831; SER-3491; PRO-4215; PHE-4283 AND RP ARG-12383. RX PubMed=10850961; DOI=10.1161/01.res.86.11.1114; RA Freiburg A., Trombitas K., Hell W., Cazorla O., Fougerousse F., Centner T., RA Kolmerer B., Witt C., Beckmann J.S., Gregorio C.C., Granzier H., Labeit S.; RT "Series of exon-skipping events in the elastic spring region of titin as RT the structural basis for myofibrillar elastic diversity."; RL Circ. Res. 86:1114-1121(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, TISSUE RP SPECIFICITY, INTERACTION WITH OBSCN, AND VARIANTS LEU-1295; GLN-1572; RP ILE-2610; ASN-2831; SER-3491; PRO-4215 AND PHE-4283. RX PubMed=11717165; DOI=10.1161/hh2301.100981; RA Bang M.-L., Centner T., Fornoff F., Geach A.J., Gotthardt M., McNabb M., RA Witt C.C., Labeit D., Gregorio C.C., Granzier H., Labeit S.; RT "The complete gene sequence of titin, expression of an unusual ~700 kDa RT titin isoform and its interaction with obscurin identify a novel Z-line to RT I-band linking system."; RL Circ. Res. 89:1065-1072(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-626 AND 34071-34350 (ISOFORM RP 3). RC TISSUE=Muscle, and Skeletal muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 405-709 (ISOFORMS 1 AND 2). RC TISSUE=Heart muscle; RX PubMed=8937992; DOI=10.1242/jcs.109.11.2747; RA Gautel M., Goulding D., Bullard B., Weber K., Furst D.O.; RT "The central Z-disk region of titin is assembled from a novel repeat in RT variable copy numbers."; RL J. Cell Sci. 109:2747-2754(1996). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 2023-2060, AND TISSUE SPECIFICITY. RC TISSUE=Heart muscle; RX PubMed=7819249; DOI=10.1021/bi00002a021; RA Musco G., Tziatzos C., Schuck P., Pastore A.; RT "Dissecting titin into its structural motifs: identification of an alpha RT helix near the N-terminus."; RL Biochemistry 34:553-561(1995). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3455-4473, AND VARIANTS PRO-4215 AND RP PHE-4283. RX PubMed=10051295; DOI=10.1161/01.cir.99.8.1022; RA Siu B.L., Niimura H., Osborne J.A., Fatkin D., MacRae C., Solomon S., RA Benson D.W., Seidman J.G., Seidman C.E.; RT "Familial dilated cardiomyopathy locus maps to chromosome 2q31."; RL Circulation 99:1022-1026(1999). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 9806-12017 (ISOFORM 5). RC TISSUE=Heart ventricle; RX PubMed=12785098; DOI=10.1023/a:1023410523184; RA Greaser M.L., Berri M., Warren C.M., Mozdziak P.E.; RT "Species variations in cDNA sequence and exon splicing patterns in the RT extensible I-band region of cardiac titin: relation to passive tension."; RL J. Muscle Res. Cell Motil. 23:473-482(2002). RN [10] RP PROTEIN SEQUENCE OF 11773-11783; 17908-17931; 18656-18669; 26545-26553; RP 28758-28774 AND 32920-32928, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 12947-13797. RC TISSUE=Embryonic rhabdomyosarcoma; RA Behrends U., Gotz C., Mautner J.; RT "Serological identification of rhabdomyosarcoma antigens."; RL Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE OF 14257-14543. RX PubMed=8351016; DOI=10.1212/wnl.43.8.1581; RA Gautel M., Lakey A., Barlow D.P., Holmes Z., Scales S., Leonard K., RA Labeit S., Mygland A., Gilhus N.E., Aarli J.A.; RT "Titin antibodies in myasthenia gravis: identification of a major RT immunogenic region of titin."; RL Neurology 43:1581-1585(1993). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 21021-22120, AND NUCLEOTIDE SEQUENCE [GENOMIC RP DNA] OF 23754-24284. RX PubMed=1582406; DOI=10.1002/j.1460-2075.1992.tb05222.x; RA Labeit S., Gautel M., Lakey A., Trinick J.; RT "Towards a molecular understanding of titin."; RL EMBO J. 11:1711-1716(1992). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 29701-34350, AND PHOSPHORYLATION. RX PubMed=8404852; DOI=10.1002/j.1460-2075.1993.tb06061.x; RA Gautel M., Leonard K., Labeit S.; RT "Phosphorylation of KSF motifs in the C-terminal region of titin in RT differentiating myoblasts."; RL EMBO J. 12:3827-3834(1993). RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 33119-34350. RC TISSUE=Skeletal muscle; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [16] RP INTERACTION WITH TCAP. RX PubMed=9645487; DOI=10.1016/s0014-5793(98)00501-8; RA Mues A., van der Ven P.F.M., Young P., Furst D.O., Gautel M.; RT "Two immunoglobulin-like domains of the Z-disc portion of titin interact in RT a conformation-dependent way with telethonin."; RL FEBS Lett. 428:111-114(1998). RN [17] RP INTERACTION WITH NEB. RX PubMed=12482578; DOI=10.1016/s0014-5793(02)03655-4; RA Ma K., Wang K.; RT "Interaction of nebulin SH3 domain with titin PEVK and myopalladin: RT implications for the signaling and assembly role of titin and nebulin."; RL FEBS Lett. 532:273-278(2002). RN [18] RP INTERACTION WITH FHL2. RX PubMed=12432079; DOI=10.1242/jcs.00181; RA Lange S., Auerbach D., McLoughlin P., Perriard E., Schafer B.W., RA Perriard J.-C., Ehler E.; RT "Subcellular targeting of metabolic enzymes to titin in heart muscle may be RT mediated by DRAL/FHL-2."; RL J. Cell Sci. 115:4925-4936(2002). RN [19] RP INTERACTION WITH ANK1. RX PubMed=12444090; DOI=10.1074/jbc.m209012200; RA Kontrogianni-Konstantopoulos A., Bloch R.J.; RT "The hydrophilic domain of small ankyrin-1 interacts with the two N- RT terminal immunoglobulin domains of titin."; RL J. Biol. Chem. 278:3985-3991(2003). RN [20] RP INTERACTION WITH ANKRD1; ANKRD2; ANKRD23 AND CAPN3. RX PubMed=14583192; DOI=10.1016/j.jmb.2003.09.012; RA Miller M.K., Bang M.-L., Witt C.C., Labeit D., Trombitas C., Watanabe K., RA Granzier H., McElhinny A.S., Gregorio C.C., Labeit S.; RT "The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a family RT of titin filament-based stress response molecules."; RL J. Mol. Biol. 333:951-964(2003). RN [21] RP INTERACTION WITH CRYAB. RX PubMed=14676215; DOI=10.1074/jbc.m307473200; RA Bullard B., Ferguson C., Minajeva A., Leake M.C., Gautel M., Labeit D., RA Ding L., Labeit S., Horwitz J., Leonard K.R., Linke W.A.; RT "Association of the chaperone alphaB-crystallin with titin in heart RT muscle."; RL J. Biol. Chem. 279:7917-7924(2004). RN [22] RP INTERACTION WITH TRIM63 AND TRIM55. RX PubMed=15967462; DOI=10.1016/j.jmb.2005.05.021; RA Witt S.H., Granzier H., Witt C.C., Labeit S.; RT "MURF-1 and MURF-2 target a specific subset of myofibrillar proteins RT redundantly: towards understanding MURF-dependent muscle ubiquitination."; RL J. Mol. Biol. 350:713-722(2005). RN [23] RP INTERACTION WITH LAMIN, AND SUBCELLULAR LOCATION. RX PubMed=16410549; DOI=10.1242/jcs.02728; RA Zastrow M.S., Flaherty D.B., Benian G.M., Wilson K.L.; RT "Nuclear titin interacts with A- and B-type lamins in vitro and in vivo."; RL J. Cell Sci. 119:239-249(2006). RN [24] RP REVIEW. RX PubMed=16537787; DOI=10.1152/ajpheart.00816.2005; RA Hoshijima M.; RT "Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, RT titin, and associated structures."; RL Am. J. Physiol. 290:H1313-H1325(2006). RN [25] RP INTERACTION WITH CMYA5. RX PubMed=20634290; DOI=10.1074/jbc.m110.108720; RA Sarparanta J., Blandin G., Charton K., Vihola A., Marchand S., Milic A., RA Hackman P., Ehler E., Richard I., Udd B.; RT "Interactions with M-band titin and calpain 3 link myospryn (CMYA5) to RT tibial and limb-girdle muscular dystrophies."; RL J. Biol. Chem. 285:30304-30315(2010). RN [26] RP STRUCTURE BY NMR OF 33483-33579. RX PubMed=7613868; DOI=10.1016/s0969-2126(01)00170-8; RA Pfuhl M., Pastore A.; RT "Tertiary structure of an immunoglobulin-like domain from the giant muscle RT protein titin: a new member of the I set."; RL Structure 3:391-401(1995). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 32172-32489, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH CALM, PHOSPHORYLATION AT TYR-32341, AND RP MUTAGENESIS OF LYS-32207 AND TYR-32341. RX PubMed=9804419; DOI=10.1038/27603; RA Mayans O., van der Ven P.F.M., Wilm M., Mues A., Young P., Furst D.O., RA Wilmanns M., Gautel M.; RT "Structural basis for activation of the titin kinase domain during RT myofibrillogenesis."; RL Nature 395:863-869(1998). RN [28] RP STRUCTURE BY NMR OF 22283-22385. RX PubMed=9782056; DOI=10.1016/s0969-2126(98)00129-4; RA Goll C.M., Pastore A., Nilges M.; RT "The three-dimensional structure of a type I module from titin: a prototype RT of intracellular fibronectin type III domains."; RL Structure 6:1291-1302(1998). RN [29] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 2073-2171, AND DISULFIDE BOND. RX PubMed=11525170; DOI=10.1016/s0969-2126(01)00591-3; RA Mayans O., Wuerges J., Canela S., Gautel M., Wilmanns M.; RT "Structural evidence for a possible role of reversible disulphide bridge RT formation in the elasticity of the muscle protein titin."; RL Structure 9:331-340(2001). RN [30] RP X-RAY CRYSTALLOGRAPHY (2.44 ANGSTROMS) OF 1-196 IN COMPLEX WITH TCAP. RX PubMed=16407954; DOI=10.1038/nature04343; RA Zou P., Pinotsis N., Lange S., Song Y.-H., Popov A., Mavridis I., RA Mayans O.M., Gautel M., Wilmanns M.; RT "Palindromic assembly of the giant muscle protein titin in the sarcomeric RT Z-disk."; RL Nature 439:229-233(2006). RN [31] RP VARIANT CMH9 LEU-740. RX PubMed=10462489; DOI=10.1006/bbrc.1999.1221; RA Satoh M., Takahashi M., Sakamoto T., Hiroe M., Marumo F., Kimura A.; RT "Structural analysis of the titin gene in hypertrophic cardiomyopathy: RT identification of a novel disease gene."; RL Biochem. Biophys. Res. Commun. 262:411-417(1999). RN [32] RP INVOLVEMENT IN LGMDR10, AND VARIANT TMD PRO-34315. RX PubMed=12145747; DOI=10.1086/342380; RA Hackman P., Vihola A., Haravuori H., Marchand S., Sarparanta J., RA De Seze J., Labeit S., Witt C., Peltonen L., Richard I., Udd B.; RT "Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the RT gene encoding the giant skeletal-muscle protein titin."; RL Am. J. Hum. Genet. 71:492-500(2002). RN [33] RP VARIANTS CMD1G MET-54; VAL-743; TYR-3799 AND ASN-4465, VARIANTS CYS-328; RP GLN-4084 AND PRO-4215, CHARACTERIZATION OF VARIANTS CMD1G MET-54 AND RP VAL-743, AND FUNCTION. RX PubMed=11846417; DOI=10.1006/bbrc.2002.6448; RA Itoh-Satoh M., Hayashi T., Nishi H., Koga Y., Arimura T., Koyanagi T., RA Takahashi M., Hohda S., Ueda K., Nouchi T., Hiroe M., Marumo F., RA Imaizumi T., Yasunami M., Kimura A.; RT "Titin mutations as the molecular basis for dilated cardiomyopathy."; RL Biochem. Biophys. Res. Commun. 291:385-393(2002). RN [34] RP VARIANT CMD1G ARG-976. RX PubMed=11788824; DOI=10.1038/ng815; RA Gerull B., Gramlich M., Atherton J., McNabb M., Trombitas K., RA Sasse-Klaassen S., Seidman J.G., Seidman C., Granzier H., Labeit S., RA Frenneaux M., Thierfelder L.; RT "Mutations of TTN, encoding the giant muscle filament titin, cause familial RT dilated cardiomyopathy."; RL Nat. Genet. 30:201-204(2002). RN [35] RP VARIANT TMD ASN-34306. RX PubMed=12891679; DOI=10.1002/ana.10647; RA Van den Bergh P.Y.K., Bouquiaux O., Verellen C., Marchand S., Richard I., RA Hackman P., Udd B.; RT "Tibial muscular dystrophy in a Belgian family."; RL Ann. Neurol. 54:248-251(2003). RN [36] RP VARIANT CMD1G GLN-32996. RX PubMed=16465475; DOI=10.1007/s10974-005-9018-5; RA Matsumoto Y., Hayashi T., Inagaki N., Takahashi M., Hiroi S., Nakamura T., RA Arimura T., Nakamura K., Ashizawa N., Yasunami M., Ohe T., Yano K., RA Kimura A.; RT "Functional analysis of titin/connectin N2-B mutations found in RT cardiomyopathy."; RL J. Muscle Res. Cell Motil. 26:367-374(2005). RN [37] RP VARIANT MFM9 TRP-279, CHARACTERIZATION OF VARIANT MFM9 TRP-279, AND RP INTERACTION WITH NBR1. RX PubMed=15802564; DOI=10.1126/science.1110463; RA Lange S., Xiang F., Yakovenko A., Vihola A., Hackman P., Rostkova E., RA Kristensen J., Brandmeier B., Franzen G., Hedberg B., Gunnarsson L.G., RA Hughes S.M., Marchand S., Sejersen T., Richard I., Edstroem L., Ehler E., RA Udd B., Gautel M.; RT "The kinase domain of titin controls muscle gene expression and protein RT turnover."; RL Science 308:1599-1603(2005). RN [38] RP INVOLVEMENT IN CMYO5. RX PubMed=17444505; DOI=10.1002/ana.21089; RA Carmignac V., Salih M.A.M., Quijano-Roy S., Marchand S., Al Rayess M.M., RA Mukhtar M.M., Urtizberea J.A., Labeit S., Guicheney P., Leturcq F., RA Gautel M., Fardeau M., Campbell K.P., Richard I., Estournet B., RA Ferreiro A.; RT "C-terminal titin deletions cause a novel early-onset myopathy with fatal RT cardiomyopathy."; RL Ann. Neurol. 61:340-351(2007). RN [39] RP VARIANTS [LARGE SCALE ANALYSIS] TYR-60; MET-115; CYS-328; THR-360; ILE-498; RP MET-799; ILE-811; HIS-922; ASP-937; THR-1081; ARG-1137; GLU-1201; ALA-1202; RP LEU-1295; ASP-1345; THR-1347; HIS-1350; LEU-1353; VAL-1393; CYS-1416; RP PRO-1441; VAL-1544; GLN-1572; GLY-1658; GLN-1664; ASP-1692; LEU-1744; RP GLY-1772; ILE-1907; HIS-1998; LEU-2107; THR-2118; THR-2164; TYR-2240; RP SER-2392; PHE-2432; ILE-2610; MET-2771; PHE-2823; ASN-2831; ILE-2930; RP ARG-3154; GLU-3191; LEU-3238; GLY-3250; MET-3261; GLN-3367; LYS-3482; RP LYS-3570; VAL-3590; VAL-3762; PHE-3877; LEU-3965; PRO-4215; TRP-4238; RP PHE-4283; THR-4291; ASP-4303; GLU-4427; GLU-12310; ALA-12469; CYS-12642; RP LYS-12657; GLU-12679; PHE-12720; CYS-12798; GLY-13049; LYS-13083; RP LEU-13096; ARG-13099; ALA-13297; MET-13399; THR-13418; VAL-13428; RP THR-13430; LYS-13434; ASN-13469; ASN-13495; SER-13785; HIS-13870; RP ILE-14109; GLN-14131; THR-14208; VAL-14728; THR-14999; THR-15021; RP VAL-15520; ILE-15555; GLN-15620; ILE-15629; CYS-15635; GLN-15700; RP PRO-15705; MET-15837; HIS-16058; ILE-16067; THR-16090; HIS-16195; RP CYS-16409; PRO-16424; MET-16629; ARG-16877; ASP-17060; VAL-17637; RP HIS-17838; ASN-17866; GLU-17906; ALA-18094; SER-18109; THR-18164; RP LEU-18221; THR-18222; GLN-18726; ALA-18835; LYS-18881; SER-18939; RP GLN-19000; GLN-19060; LYS-19091; SER-19224; ILE-19367; LYS-19392; RP SER-19480; GLY-19495; HIS-19665; ILE-19762; ARG-19947; MET-19956; RP GLN-19992; CYS-20057; LEU-20075; LYS-20179; THR-20198; VAL-20198; RP HIS-20331; THR-20408; LYS-20564; ILE-20718; PRO-20726; ASN-20892; RP ARG-20894; GLU-21125; SER-21403; CYS-21730; GLN-21747; ARG-21851; RP ARG-21851; ARG-21925; HIS-21995; VAL-22045; HIS-22149; ILE-22160; RP THR-22261; ASN-22306; HIS-22357; PRO-22408; HIS-22537; LEU-22584; RP PRO-22646; ALA-22670; ASP-22770; THR-22801; TRP-22823; GLN-22968; RP LEU-23074; PHE-23079; ASN-23282; TYR-23303; CYS-23306; SER-23515; RP GLN-23551; ASN-23807; ASN-23872; ALA-23891; HIS-23933; MET-23939; RP LEU-23952; GLY-24098; SER-24119; ILE-24133; ALA-24159; ALA-24239; RP LYS-24265; THR-24584; THR-24781; HIS-24799; HIS-24954; MET-24980; RP HIS-25659; THR-25679; ALA-25720; LYS-25821; LYS-25859; LYS-25879; RP VAL-25923; ILE-26045; GLU-26059; VAL-26134; CYS-26477; TYR-26843; RP ARG-27346; CYS-27652; VAL-27728; LEU-27754; THR-27755; VAL-27929; RP LEU-28132; GLN-28168; HIS-28538; THR-28572; THR-28948; VAL-28986; RP GLU-28993; VAL-28998; MET-29070; VAL-29090; CYS-29419; PRO-29479; RP LEU-29880; GLU-29976; GLY-30042; CYS-30107; PHE-30125; PRO-30211; RP THR-30412; SER-30617; ILE-30674; ILE-30809; ILE-30818; LYS-30825; RP THR-30856; ASP-30887; SER-30887; HIS-30897; HIS-30907; HIS-30946; RP PHE-31081; CYS-31107; GLY-31124; SER-31156; THR-31246; HIS-31330; RP ARG-31690; GLN-31724; ILE-31725; SER-31732; ILE-31886; CYS-32097; RP ASN-32171; ILE-32248; HIS-32281; HIS-32323; TRP-32411; VAL-32558; RP VAL-32610; VAL-32637; ALA-32922; ARG-32943; HIS-32953; LEU-33213; RP CYS-33242; MET-33387; ASP-33419; MET-33536; GLN-33568; LYS-33616; RP LEU-33620; VAL-33886; THR-33899; PRO-33904; ILE-33955 AND ALA-34115. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [40] RP VARIANTS VAL-16046 AND GLN-32742. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [41] RP VARIANTS PRO-2963 AND GLN-14750. RX PubMed=25173926; DOI=10.1161/circgenetics.113.000486; RA Girolami F., Iascone M., Tomberli B., Bardi S., Benelli M., Marseglia G., RA Pescucci C., Pezzoli L., Sana M.E., Basso C., Marziliano N., Merlini P.A., RA Fornaro A., Cecchi F., Torricelli F., Olivotto I.; RT "Novel alpha-actinin 2 variant associated with familial hypertrophic RT cardiomyopathy and juvenile atrial arrhythmias: a massively parallel RT sequencing study."; RL Circ. Cardiovasc. Genet. 7:741-750(2014). CC -!- FUNCTION: Key component in the assembly and functioning of vertebrate CC striated muscles. By providing connections at the level of individual CC microfilaments, it contributes to the fine balance of forces between CC the two halves of the sarcomere. The size and extensibility of the CC cross-links are the main determinants of sarcomere extensibility CC properties of muscle. In non-muscle cells, seems to play a role in CC chromosome condensation and chromosome segregation during mitosis. CC Might link the lamina network to chromatin or nuclear actin, or both CC during interphase. {ECO:0000269|PubMed:11846417, CC ECO:0000269|PubMed:9804419}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Full activation of the protein kinase domain CC requires both phosphorylation of Tyr-32341, preventing it from blocking CC the catalytic aspartate residue, and binding of Ca/CALM to the C- CC terminal regulatory tail of the molecule which results in ATP binding CC to the kinase. {ECO:0000269|PubMed:9804419}. CC -!- SUBUNIT: Interacts with MYOM1, MYOM2, tropomyosin and myosin. Interacts CC with actin, primarily via the PEVK domains and with MYPN (By CC similarity). Interacts with FHL2, NEB, CRYAB, LMNA/lamin-A and CC LMNB/lamin-B. Interacts with TCAP/telethonin and/or ANK1 isoform CC Mu17/ank1.5, via the first two N-terminal immunoglobulin domains. CC Interacts with TRIM63 and TRIM55, through several domains including CC immunoglobulin domains 141 and 142. Interacts with ANKRD1, ANKRD2 and CC ANKRD23, via the region between immunoglobulin domains 77 and 78 and CC interacts with CAPN3, via immunoglobulin domain 79. Interacts with NBR1 CC through the protein kinase domain. Interacts with CALM/calmodulin. CC Isoform 6 interacts with OBSCN isoform 3. Interacts with CMYA5. CC {ECO:0000250, ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:12432079, CC ECO:0000269|PubMed:12444090, ECO:0000269|PubMed:12482578, CC ECO:0000269|PubMed:14583192, ECO:0000269|PubMed:14676215, CC ECO:0000269|PubMed:15802564, ECO:0000269|PubMed:15967462, CC ECO:0000269|PubMed:16407954, ECO:0000269|PubMed:16410549, CC ECO:0000269|PubMed:20634290, ECO:0000269|PubMed:9645487, CC ECO:0000269|PubMed:9804419}. CC -!- INTERACTION: CC Q8WZ42; P12814: ACTN1; NbExp=2; IntAct=EBI-681210, EBI-351710; CC Q8WZ42; P35609: ACTN2; NbExp=16; IntAct=EBI-681210, EBI-77797; CC Q8WZ42; P62158: CALM3; NbExp=2; IntAct=EBI-681210, EBI-397435; CC Q8WZ42; P20807: CAPN3; NbExp=4; IntAct=EBI-681210, EBI-5655000; CC Q8WZ42; O75953: DNAJB5; NbExp=4; IntAct=EBI-681210, EBI-5655937; CC Q8WZ42; O75923: DYSF; NbExp=17; IntAct=EBI-681210, EBI-2799016; CC Q8WZ42; P06733: ENO1; NbExp=3; IntAct=EBI-681210, EBI-353877; CC Q8WZ42; Q9GZQ8: MAP1LC3B; NbExp=2; IntAct=EBI-681210, EBI-373144; CC Q8WZ42; Q14324: MYBPC2; NbExp=14; IntAct=EBI-681210, EBI-5653200; CC Q8WZ42; Q13203: MYBPH; NbExp=3; IntAct=EBI-681210, EBI-5655165; CC Q8WZ42; P20929: NEB; NbExp=6; IntAct=EBI-681210, EBI-1049657; CC Q8WZ42; Q5VST9: OBSCN; NbExp=15; IntAct=EBI-681210, EBI-941850; CC Q8WZ42; O75147: OBSL1; NbExp=13; IntAct=EBI-681210, EBI-1223896; CC Q8WZ42; O15061: SYNM; NbExp=3; IntAct=EBI-681210, EBI-7843148; CC Q8WZ42; O15273: TCAP; NbExp=9; IntAct=EBI-681210, EBI-954089; CC Q8WZ42; Q969Q1: TRIM63; NbExp=3; IntAct=EBI-681210, EBI-5661333; CC Q8WZ42; Q8WZ42: TTN; NbExp=16; IntAct=EBI-681210, EBI-681210; CC Q8WZ42-3; O15273: TCAP; NbExp=2; IntAct=EBI-15564183, EBI-954089; CC Q8WZ42-3; Q8WZ42-3: TTN; NbExp=9; IntAct=EBI-15564183, EBI-15564183; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305|PubMed:16410549}. Nucleus CC {ECO:0000269|PubMed:16410549}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=13; CC Comment=A number of isoforms may be produced, ranging from 27000 to CC 33000 residues in different striated muscle tissues, the size of the CC full-length protein may be up to 38138 residues.; CC Name=1; CC IsoId=Q8WZ42-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WZ42-2; Sequence=VSP_019138; CC Name=3; Synonyms=Small cardiac N2-B; CC IsoId=Q8WZ42-3; Sequence=VSP_019139, VSP_019145; CC Name=4; Synonyms=Soleus; CC IsoId=Q8WZ42-4; Sequence=VSP_019142, VSP_019151; CC Name=5; CC IsoId=Q8WZ42-5; Sequence=VSP_019147, VSP_019148, VSP_019149, CC VSP_019150, VSP_019152; CC Name=6; Synonyms=Small cardiac novex-3; CC IsoId=Q8WZ42-6; Sequence=VSP_019143, VSP_019146; CC Name=7; Synonyms=Cardiac novex-2; CC IsoId=Q8WZ42-7; Sequence=VSP_019141, VSP_019144; CC Name=8; Synonyms=Cardiac novex-1; CC IsoId=Q8WZ42-8; Sequence=VSP_019140; CC Name=9; CC IsoId=Q8WZ42-9; Sequence=VSP_019139, VSP_042903, VSP_019145; CC Name=10; CC IsoId=Q8WZ42-10; Sequence=VSP_019139, VSP_019140, VSP_019145; CC Name=11; CC IsoId=Q8WZ42-11; Sequence=VSP_019142; CC Name=12; CC IsoId=Q8WZ42-12; Sequence=VSP_045935, VSP_045929, VSP_045930, CC VSP_045931, VSP_045932, VSP_045933, CC VSP_045934; CC Name=13; CC IsoId=Q8WZ42-13; Sequence=VSP_047142; CC -!- TISSUE SPECIFICITY: Isoforms 3, 7 and 8 are expressed in cardiac CC muscle. Isoform 4 is expressed in vertebrate skeletal muscle. Isoform 6 CC is expressed in skeletal muscle (at protein level). CC {ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7819249}. CC -!- DOMAIN: ZIS1 and ZIS5 regions contain multiple SPXR consensus sites for CC ERK- and CDK-like protein kinases as well as multiple SP motifs. ZIS1 CC could adopt a closed conformation which would block the TCAP-binding CC site. CC -!- DOMAIN: The PEVK region may serve as an entropic spring of a chain of CC structural folds and may also be an interaction site to other CC myofilament proteins to form interfilament connectivity in the CC sarcomere. CC -!- PTM: Autophosphorylated. {ECO:0000250}. CC -!- DISEASE: Myopathy, myofibrillar, 9, with early respiratory failure CC (MFM9) [MIM:603689]: An autosomal dominant myopathy characterized by CC adulthood onset of weakness in proximal, distal, axial and respiratory CC muscles. Pelvic girdle weakness, foot drop and neck weakness are the CC main symptoms at onset, but ultimately the weakness usually involves CC the proximal compartment of both upper and lower limbs. Additional CC features include variable degrees of Achilles tendon contractures, CC spinal rigidity and muscle hypertrophy. Respiratory involvement often CC leads to requirement for non-invasive ventilation support. CC {ECO:0000269|PubMed:15802564}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, familial hypertrophic, 9 (CMH9) [MIM:613765]: CC A hereditary heart disorder characterized by ventricular hypertrophy, CC which is usually asymmetric and often involves the interventricular CC septum. The symptoms include dyspnea, syncope, collapse, palpitations, CC and chest pain. They can be readily provoked by exercise. The disorder CC has inter- and intrafamilial variability ranging from benign to CC malignant forms with high risk of cardiac failure and sudden cardiac CC death. {ECO:0000269|PubMed:10462489}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1G (CMD1G) [MIM:604145]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:11788824, CC ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:16465475}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Tardive tibial muscular dystrophy (TMD) [MIM:600334]: CC Autosomal dominant, late-onset distal myopathy. Muscle weakness and CC atrophy are usually confined to the anterior compartment of the lower CC leg, in particular the tibialis anterior muscle. Clinical symptoms CC usually occur at age 35-45 years or much later. CC {ECO:0000269|PubMed:12145747, ECO:0000269|PubMed:12891679}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muscular dystrophy, limb-girdle, autosomal recessive 10 CC (LGMDR10) [MIM:608807]: An autosomal recessive degenerative myopathy CC characterized by progressive weakness of the pelvic and shoulder girdle CC muscles. Severe disability is observed within 20 years of onset. CC {ECO:0000269|PubMed:12145747}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital myopathy 5 with cardiomyopathy (CMYO5) CC [MIM:611705]: An autosomal recessive, early-onset muscular disorder CC characterized by dilated cardiomyopathy, delayed motor development with CC generalized muscle weakness predominantly affecting proximal and distal CC lower limbs. Skeletal muscle biopsies show minicore-like lesions with CC mitochondrial depletion and sarcomere disorganization, centralized CC nuclei, and type 1 fiber predominance. Dystrophic changes become CC apparent in the second decade. Cardiac muscle biopsies show disruption CC of myocardial architecture, nuclear hypertrophy, and endomysial CC fibrosis. Sudden death may occurr due to cardiomyopathy. CC {ECO:0000269|PubMed:17444505}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In some isoforms, after the PEVK repeat region there is CC a long PEVK duplicated region. On account of this region, it has been CC very difficult to sequence the whole protein. The length of this region CC (ranging from 183 to 2174 residues), may be a key elastic element of CC titin. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH58824.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 553.; Evidence={ECO:0000305}; CC Sequence=AAH70170.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 627.; Evidence={ECO:0000305}; CC Sequence=CAA62188.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=CAD12455.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Titin entry; CC URL="https://en.wikipedia.org/wiki/Titin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X90568; CAA62188.1; ALT_FRAME; mRNA. DR EMBL; X90569; CAA62189.1; -; mRNA. DR EMBL; AJ277892; CAD12455.1; ALT_FRAME; Genomic_DNA. DR EMBL; AJ277892; CAD12456.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12457.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12458.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12459.1; -; Genomic_DNA. DR EMBL; AC009948; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010680; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC023270; AAX88844.1; -; Genomic_DNA. DR EMBL; FJ695199; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF459616; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013396; AAH13396.1; -; mRNA. DR EMBL; BC058824; AAH58824.1; ALT_SEQ; mRNA. DR EMBL; BC070170; AAH70170.1; ALT_SEQ; mRNA. DR EMBL; BC107797; AAI07798.1; -; mRNA. DR EMBL; X98114; CAA66795.1; -; mRNA. DR EMBL; X98115; CAA66796.1; -; mRNA. DR EMBL; X83270; CAA58243.1; -; mRNA. DR EMBL; AF058332; AAD22603.1; -; Genomic_DNA. DR EMBL; AF058332; AAD22604.1; -; Genomic_DNA. DR EMBL; AF525413; AAP80791.1; -; mRNA. DR EMBL; DQ248309; ABB55264.1; -; mRNA. DR EMBL; X64698; CAA45939.1; -; mRNA. DR EMBL; X64699; CAA45940.1; -; Genomic_DNA. DR EMBL; X64697; CAA45938.1; -; mRNA. DR EMBL; X69490; CAA49245.1; -; mRNA. DR EMBL; AL713647; CAD28458.1; -; mRNA. DR CCDS; CCDS33337.1; -. [Q8WZ42-6] DR CCDS; CCDS54421.1; -. [Q8WZ42-3] DR CCDS; CCDS54422.1; -. [Q8WZ42-9] DR CCDS; CCDS54423.1; -. [Q8WZ42-10] DR CCDS; CCDS54424.1; -. [Q8WZ42-11] DR CCDS; CCDS59435.1; -. [Q8WZ42-12] DR PIR; I38344; I38344. DR PIR; I38346; I38346. DR RefSeq; NP_001243779.1; NM_001256850.1. [Q8WZ42-1] DR RefSeq; NP_001254479.2; NM_001267550.2. [Q8WZ42-12] DR RefSeq; NP_003310.4; NM_003319.4. [Q8WZ42-3] DR RefSeq; NP_596869.4; NM_133378.4. [Q8WZ42-11] DR RefSeq; NP_596870.2; NM_133379.5. [Q8WZ42-6] DR RefSeq; NP_597676.3; NM_133432.3. [Q8WZ42-10] DR PDB; 1BPV; NMR; -; A=22283-22385. DR PDB; 1G1C; X-ray; 2.10 A; A/B=2073-2171. DR PDB; 1NCT; NMR; -; A=33483-33579. DR PDB; 1NCU; NMR; -; A=33483-33579. DR PDB; 1TIT; NMR; -; A=12680-12765. DR PDB; 1TIU; NMR; -; A=12680-12765. DR PDB; 1TKI; X-ray; 2.00 A; A/B=32172-32492. DR PDB; 1TNM; NMR; -; A=33489-33579. DR PDB; 1TNN; NMR; -; A=33489-33579. DR PDB; 1WAA; X-ray; 1.80 A; A/B/C/D/E/F=12677-12765. DR PDB; 1YA5; X-ray; 2.44 A; A/B=1-196. DR PDB; 2A38; X-ray; 2.00 A; A/B/C=1-194. DR PDB; 2BK8; X-ray; 1.69 A; A=32497-32590. DR PDB; 2F8V; X-ray; 2.75 A; A/B/C/D=1-196. DR PDB; 2ILL; X-ray; 2.20 A; A=31854-32047. DR PDB; 2J8H; X-ray; 1.99 A; A=31854-32047. DR PDB; 2J8O; X-ray; 2.49 A; A/B=31854-32047. DR PDB; 2NZI; X-ray; 2.90 A; A/B=31854-32155. DR PDB; 2RQ8; NMR; -; A=12677-12765. DR PDB; 2WP3; X-ray; 1.48 A; T=34252-34350. DR PDB; 2WWK; X-ray; 1.70 A; T=34252-34350. DR PDB; 2WWM; X-ray; 2.30 A; D/T=34252-34350. DR PDB; 2Y9R; X-ray; 1.90 A; T=34252-34350. DR PDB; 3B43; X-ray; 3.30 A; A=7945-8511. DR PDB; 3KNB; X-ray; 1.40 A; A=34253-34350. DR PDB; 3LCY; X-ray; 2.50 A; A/B/C/D=31456-31649. DR PDB; 3LPW; X-ray; 1.65 A; A/B=22877-23070. DR PDB; 3PUC; X-ray; 0.96 A; A=33774-33871. DR PDB; 3Q5O; X-ray; 2.05 A; A/B=34253-34350. DR PDB; 3QP3; X-ray; 2.00 A; A/B/C=33294-33395. DR PDB; 4C4K; X-ray; 1.95 A; T=34252-34350. DR PDB; 4JNW; X-ray; 2.06 A; A/B=32172-32492. DR PDB; 4O00; X-ray; 1.85 A; A/B=14217-14319. DR PDB; 4QEG; X-ray; 2.00 A; A=2880-2967. DR PDB; 4UOW; X-ray; 3.30 A; 1/3/5/7/9/B/D/F/H/J/L/N/P/R/T/V/X/Z=7-99. DR PDB; 5BS0; X-ray; 2.40 A; C=24337-24345. DR PDB; 5JDD; X-ray; 1.53 A; A=2795-3053. DR PDB; 5JDE; X-ray; 1.90 A; A/B=2795-3053. DR PDB; 5JDJ; X-ray; 1.74 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=2880-2967. DR PDB; 5JOE; X-ray; 2.00 A; A=9582-9671. DR PDB; 6DL4; NMR; -; A=1821-1931. DR PDB; 6FWX; X-ray; 3.00 A; A/B=1-243. DR PDB; 6H4L; X-ray; 1.60 A; A=33294-33395. DR PDB; 6HCI; X-ray; 2.12 A; A/B/C/D=32712-32816. DR PDB; 6I0Y; EM; 3.20 A; z=12677-12765. DR PDB; 6SDB; X-ray; 2.80 A; A/B/C/D/E=3-196. DR PDB; 6YGN; X-ray; 2.40 A; A/B=32046-32594. DR PDB; 7AHS; X-ray; 2.05 A; A/B/C/D=9582-9851. DR PDB; 7NIP; NMR; -; A=9504-9544. DR PDB; 8BNQ; X-ray; 2.30 A; A/B=23562-23862. DR PDB; 8BVO; X-ray; 2.55 A; A=14415-14609. DR PDB; 8BW6; X-ray; 1.95 A; A=14415-14509. DR PDB; 8BXR; X-ray; 2.70 A; A=14319-14615. DR PDB; 8G4L; EM; 6.40 A; am/an/bm/bn/m/n=22784-23867. DR PDB; 8OIY; X-ray; 2.10 A; A/B/C/D/E/F=14217-14319. DR PDB; 8OMW; X-ray; 1.05 A; A=16525-16630. DR PDB; 8OQ9; X-ray; 1.65 A; A/B/C=21497-21598. DR PDB; 8ORL; X-ray; 1.43 A; A/B/C=21497-21598. DR PDB; 8OS3; X-ray; 1.68 A; A=15210-15313. DR PDB; 8OSD; X-ray; 1.70 A; A/B=20511-20616. DR PDB; 8OT5; X-ray; 1.56 A; A/B/C/D/E/F=25430-25531. DR PDB; 8OTY; X-ray; 1.90 A; A/B/C/D=26124-26224. DR PDB; 8OVU; X-ray; 1.95 A; A/B=3500-3598. DR PDB; 8P35; X-ray; 2.20 A; A/B/C/D/E/F=3500-3598. DR PDBsum; 1BPV; -. DR PDBsum; 1G1C; -. DR PDBsum; 1NCT; -. DR PDBsum; 1NCU; -. DR PDBsum; 1TIT; -. DR PDBsum; 1TIU; -. DR PDBsum; 1TKI; -. DR PDBsum; 1TNM; -. DR PDBsum; 1TNN; -. DR PDBsum; 1WAA; -. DR PDBsum; 1YA5; -. DR PDBsum; 2A38; -. DR PDBsum; 2BK8; -. DR PDBsum; 2F8V; -. DR PDBsum; 2ILL; -. DR PDBsum; 2J8H; -. DR PDBsum; 2J8O; -. DR PDBsum; 2NZI; -. DR PDBsum; 2RQ8; -. DR PDBsum; 2WP3; -. DR PDBsum; 2WWK; -. DR PDBsum; 2WWM; -. DR PDBsum; 2Y9R; -. DR PDBsum; 3B43; -. DR PDBsum; 3KNB; -. DR PDBsum; 3LCY; -. DR PDBsum; 3LPW; -. DR PDBsum; 3PUC; -. DR PDBsum; 3Q5O; -. DR PDBsum; 3QP3; -. DR PDBsum; 4C4K; -. DR PDBsum; 4JNW; -. DR PDBsum; 4O00; -. DR PDBsum; 4QEG; -. DR PDBsum; 4UOW; -. DR PDBsum; 5BS0; -. DR PDBsum; 5JDD; -. DR PDBsum; 5JDE; -. DR PDBsum; 5JDJ; -. DR PDBsum; 5JOE; -. DR PDBsum; 6DL4; -. DR PDBsum; 6FWX; -. DR PDBsum; 6H4L; -. DR PDBsum; 6HCI; -. DR PDBsum; 6I0Y; -. DR PDBsum; 6SDB; -. DR PDBsum; 6YGN; -. DR PDBsum; 7AHS; -. DR PDBsum; 7NIP; -. DR PDBsum; 8BNQ; -. DR PDBsum; 8BVO; -. DR PDBsum; 8BW6; -. DR PDBsum; 8BXR; -. DR PDBsum; 8G4L; -. DR PDBsum; 8OIY; -. DR PDBsum; 8OMW; -. DR PDBsum; 8OQ9; -. DR PDBsum; 8ORL; -. DR PDBsum; 8OS3; -. DR PDBsum; 8OSD; -. DR PDBsum; 8OT5; -. DR PDBsum; 8OTY; -. DR PDBsum; 8OVU; -. DR PDBsum; 8P35; -. DR EMDB; EMD-0322; -. DR EMDB; EMD-29722; -. DR SASBDB; Q8WZ42; -. DR SMR; Q8WZ42; -. DR BioGRID; 113124; 328. DR ComplexPortal; CPX-101; Titin-Telethonin complex. DR CORUM; Q8WZ42; -. DR DIP; DIP-33449N; -. DR FunCoup; Q8WZ42; 665. DR IntAct; Q8WZ42; 167. DR MINT; Q8WZ42; -. DR STRING; 9606.ENSP00000467141; -. DR MoonDB; Q8WZ42; Predicted. DR CarbonylDB; Q8WZ42; -. DR GlyCosmos; Q8WZ42; 11 sites, 2 glycans. DR GlyGen; Q8WZ42; 39 sites, 3 O-linked glycans (22 sites). DR iPTMnet; Q8WZ42; -. DR MetOSite; Q8WZ42; -. DR PhosphoSitePlus; Q8WZ42; -. DR SwissPalm; Q8WZ42; -. DR BioMuta; TTN; -. DR jPOST; Q8WZ42; -. DR MassIVE; Q8WZ42; -. DR PaxDb; 9606-ENSP00000467141; -. DR PeptideAtlas; Q8WZ42; -. DR ProteomicsDB; 75209; -. [Q8WZ42-1] DR ProteomicsDB; 75210; -. [Q8WZ42-10] DR ProteomicsDB; 75211; -. [Q8WZ42-11] DR ProteomicsDB; 75212; -. [Q8WZ42-2] DR ProteomicsDB; 75213; -. [Q8WZ42-3] DR ProteomicsDB; 75214; -. [Q8WZ42-4] DR ProteomicsDB; 75215; -. [Q8WZ42-5] DR ProteomicsDB; 75216; -. [Q8WZ42-6] DR ProteomicsDB; 75217; -. [Q8WZ42-7] DR ProteomicsDB; 75218; -. [Q8WZ42-8] DR ProteomicsDB; 75219; -. [Q8WZ42-9] DR Pumba; Q8WZ42; -. DR ABCD; Q8WZ42; 2 sequenced antibodies. DR Antibodypedia; 2056; 211 antibodies from 28 providers. DR DNASU; 7273; -. DR Ensembl; ENST00000342992.11; ENSP00000343764.6; ENSG00000155657.29. [Q8WZ42-11] DR Ensembl; ENST00000359218.11; ENSP00000352154.5; ENSG00000155657.29. [Q8WZ42-10] DR Ensembl; ENST00000360870.10; ENSP00000354117.4; ENSG00000155657.29. [Q8WZ42-6] DR Ensembl; ENST00000412264.2; ENSP00000394672.2; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000460472.6; ENSP00000434586.1; ENSG00000155657.29. [Q8WZ42-3] DR Ensembl; ENST00000589042.5; ENSP00000467141.1; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000591111.5; ENSP00000465570.1; ENSG00000155657.29. [Q8WZ42-1] DR GeneID; 7273; -. DR KEGG; hsa:7273; -. DR MANE-Select; ENST00000589042.5; ENSP00000467141.1; NM_001267550.2; NP_001254479.2. [Q8WZ42-12] DR UCSC; uc002unb.4; human. [Q8WZ42-1] DR UCSC; uc031rqc.3; human. DR AGR; HGNC:12403; -. DR ClinPGx; PA37067; -. DR CTD; 7273; -. DR DisGeNET; 7273; -. DR GeneCards; TTN; -. DR GeneReviews; TTN; -. DR HGNC; HGNC:12403; TTN. DR HPA; ENSG00000155657; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MalaCards; TTN; -. DR MIM; 188840; gene. DR MIM; 600334; phenotype. DR MIM; 603689; phenotype. DR MIM; 604145; phenotype. DR MIM; 608807; phenotype. DR MIM; 611705; phenotype. DR MIM; 613765; phenotype. DR OpenTargets; ENSG00000155657; -. DR Orphanet; 169186; Autosomal recessive centronuclear myopathy. DR Orphanet; 466921; Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome. DR Orphanet; 324604; Classic multiminicore myopathy. DR Orphanet; 707983; Early-onset autosomal recessive TTN-related distal myopathy. DR Orphanet; 289377; Early-onset myopathy with fatal cardiomyopathy. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 334; Hereditary atrial fibrillation. DR Orphanet; 178464; Hereditary myopathy with early respiratory failure. DR Orphanet; 293888; Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant. DR Orphanet; 293910; Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant. DR Orphanet; 293899; Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant. DR Orphanet; 609; Tibial muscular dystrophy. DR Orphanet; 140922; Titin-related limb-girdle muscular dystrophy R10. DR VEuPathDB; HostDB:ENSG00000155657; -. DR eggNOG; KOG0613; Eukaryota. DR eggNOG; KOG4475; Eukaryota. DR GeneTree; ENSGT01150000286978; -. DR HOGENOM; CLU_000001_1_0_1; -. DR InParanoid; Q8WZ42; -. DR OMA; TSSWPEY; -. DR OrthoDB; 5969272at2759; -. DR PAN-GO; Q8WZ42; 0 GO annotations based on evolutionary models. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q8WZ42; -. DR Reactome; R-HSA-114608; Platelet degranulation. DR Reactome; R-HSA-390522; Striated Muscle Contraction. DR SignaLink; Q8WZ42; -. DR SIGNOR; Q8WZ42; -. DR Agora; ENSG00000155657; -. DR BioGRID-ORCS; 7273; 10 hits in 1181 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR ChiTaRS; TTN; human. DR EvolutionaryTrace; Q8WZ42; -. DR GeneWiki; Titin; -. DR GenomeRNAi; 7273; -. DR Pharos; Q8WZ42; Tbio. DR PRO; PR:Q8WZ42; -. DR Proteomes; UP000005640; Chromosome 2. DR Bgee; ENSG00000155657; Expressed in gluteal muscle and 163 other cell types or tissues. DR ExpressionAtlas; Q8WZ42; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IEA:UniProtKB-ARBA. DR GO; GO:0000794; C:condensed nuclear chromosome; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0031674; C:I band; IDA:BHF-UCL. DR GO; GO:0031430; C:M band; IDA:BHF-UCL. DR GO; GO:0005865; C:striated muscle thin filament; IDA:BHF-UCL. DR GO; GO:1990733; C:titin-telethonin complex; IPI:ComplexPortal. DR GO; GO:0030018; C:Z disc; IDA:BHF-UCL. DR GO; GO:0051015; F:actin filament binding; IDA:BHF-UCL. DR GO; GO:0042805; F:actinin binding; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0005516; F:calmodulin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0051371; F:muscle alpha-actinin binding; IPI:BHF-UCL. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL. DR GO; GO:0019887; F:protein kinase regulator activity; IMP:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:MGI. DR GO; GO:0008307; F:structural constituent of muscle; IMP:BHF-UCL. DR GO; GO:0097493; F:structural molecule activity conferring elasticity; IDA:BHF-UCL. DR GO; GO:0031433; F:telethonin binding; IPI:BHF-UCL. DR GO; GO:0055013; P:cardiac muscle cell development; IMP:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL. DR GO; GO:0003300; P:cardiac muscle hypertrophy; IMP:BHF-UCL. DR GO; GO:0055008; P:cardiac muscle tissue morphogenesis; IMP:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; IMP:BHF-UCL. DR GO; GO:0035995; P:detection of muscle stretch; IDA:MGI. DR GO; GO:0007076; P:mitotic chromosome condensation; IEP:BHF-UCL. DR GO; GO:0006936; P:muscle contraction; TAS:UniProtKB. DR GO; GO:0030049; P:muscle filament sliding; NAS:ComplexPortal. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:CAFA. DR GO; GO:0050714; P:positive regulation of protein secretion; IMP:CAFA. DR GO; GO:0010737; P:protein kinase A signaling; IMP:CAFA. DR GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL. DR GO; GO:0045214; P:sarcomere organization; IMP:BHF-UCL. DR GO; GO:0048769; P:sarcomerogenesis; IMP:BHF-UCL. DR GO; GO:0003009; P:skeletal muscle contraction; NAS:ComplexPortal. DR GO; GO:0030241; P:skeletal muscle myosin thick filament assembly; IMP:BHF-UCL. DR GO; GO:0030240; P:skeletal muscle thin filament assembly; IMP:BHF-UCL. DR GO; GO:0006941; P:striated muscle contraction; TAS:UniProtKB. DR CDD; cd00063; FN3; 132. DR CDD; cd00096; Ig; 31. DR CDD; cd05748; Ig_Titin_like; 28. DR CDD; cd20974; IgI_1_Titin_Z1z2-like; 2. DR CDD; cd20972; IgI_2_Titin_Z1z2-like; 1. DR CDD; cd20951; IgI_titin_I1-like; 1. DR CDD; cd05747; IgI_Titin_like; 1. DR CDD; cd20927; IgI_Titin_M1-like; 1. DR CDD; cd14104; STKc_Titin; 1. DR DisProt; DP00072; -. DR FunFam; 2.60.40.10:FF:000022; Cardiac titin; 44. DR FunFam; 2.60.40.10:FF:000800; Cardiac titin; 1. DR FunFam; 2.60.40.10:FF:000345; Muscle M-line assembly protein unc-89; 1. DR FunFam; 2.60.40.10:FF:001284; Myomesin 2; 1. DR FunFam; 2.60.40.10:FF:000147; Myosin light chain kinase; 2. DR FunFam; 2.60.40.10:FF:000107; Myosin, light chain kinase a; 2. DR FunFam; 2.60.40.10:FF:000031; Myosin-binding protein C, slow type; 7. DR FunFam; 2.60.40.10:FF:001867; Titin; 1. DR FunFam; 2.60.40.10:FF:001911; Titin; 1. DR FunFam; 1.10.510.10:FF:000329; Titin a; 1. DR FunFam; 2.60.40.10:FF:000002; Titin a; 32. DR FunFam; 2.60.40.10:FF:000112; Titin a; 8. DR FunFam; 2.60.40.10:FF:000135; Titin a; 7. DR FunFam; 2.60.40.10:FF:000160; Titin a; 1. DR FunFam; 2.60.40.10:FF:000547; Titin a; 2. DR FunFam; 2.60.40.10:FF:000672; Titin a; 1. DR FunFam; 2.60.40.10:FF:000673; Titin a; 1. DR FunFam; 2.60.40.10:FF:000811; Titin a; 1. DR FunFam; 2.60.40.10:FF:000867; Titin a; 1. DR FunFam; 2.60.40.10:FF:000891; Titin a; 1. DR FunFam; 2.60.40.10:FF:000900; Titin a; 1. DR FunFam; 2.60.40.10:FF:000981; Titin a; 1. DR FunFam; 2.60.40.10:FF:001200; Titin a; 1. DR FunFam; 2.60.40.10:FF:001399; Titin a; 1. DR FunFam; 2.60.40.10:FF:001400; Titin a; 1. DR FunFam; 2.60.40.10:FF:001459; Titin a; 1. DR FunFam; 2.60.40.10:FF:001500; Titin a; 1. DR FunFam; 2.60.40.10:FF:001579; Titin a; 1. DR FunFam; 2.60.40.10:FF:001697; Titin a; 1. DR FunFam; 3.30.200.20:FF:000286; Titin a; 1. DR FunFam; 2.60.40.10:FF:000011; Titin b; 11. DR FunFam; 2.60.40.10:FF:000629; Titin b; 1. DR FunFam; 2.60.40.10:FF:000635; Titin b; 1. DR FunFam; 2.60.40.10:FF:000779; Titin b; 1. DR FunFam; 2.60.40.10:FF:000833; Titin b; 1. DR FunFam; 2.60.40.10:FF:000859; Titin b; 1. DR FunFam; 2.60.40.10:FF:000864; Titin b; 1. DR FunFam; 2.60.40.10:FF:000901; Titin b; 1. DR FunFam; 2.60.40.10:FF:000980; Titin b; 1. DR FunFam; 2.60.40.10:FF:000986; Titin b; 1. DR FunFam; 2.60.40.10:FF:001115; Titin b; 1. DR FunFam; 2.60.40.10:FF:001190; Titin b; 1. DR FunFam; 2.60.40.10:FF:001477; Titin b; 1. DR FunFam; 2.60.40.10:FF:000034; Titin isoform A; 26. DR FunFam; 2.60.40.10:FF:000050; Titin isoform B; 8. DR FunFam; 2.60.40.10:FF:000003; Titin isoform E; 22. DR FunFam; 2.60.40.10:FF:000012; titin isoform X1; 26. DR FunFam; 2.60.40.10:FF:000073; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000127; titin isoform X1; 4. DR FunFam; 2.60.40.10:FF:000148; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000214; titin isoform X1; 7. DR FunFam; 2.60.40.10:FF:000218; titin isoform X1; 6. DR FunFam; 2.60.40.10:FF:000659; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000697; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000770; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000792; titin isoform X1; 2. DR FunFam; 2.60.40.10:FF:000983; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001003; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001213; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001229; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001272; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001327; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001328; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001342; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001343; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001344; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001345; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001350; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001365; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001367; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001382; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001385; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001408; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001430; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001434; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001454; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001476; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001544; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001581; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001610; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001612; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001663; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000714; Titin novex-3; 3. DR FunFam; 2.60.40.10:FF:001082; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001089; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001098; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001116; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001804; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:001844; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002231; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002123; Titin, tandem duplicate 1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 299. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013106; Ig_V-set. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR040849; MyBP-C_THB. DR InterPro; IPR004168; PPAK_motif. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR015129; Titin_Z_rpt. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR14340; MICROFIBRIL-ASSOCIATED GLYCOPROTEIN 3; 1. DR PANTHER; PTHR14340:SF13; TITIN; 1. DR Pfam; PF00041; fn3; 132. DR Pfam; PF07679; I-set; 162. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF02818; PPAK; 9. DR Pfam; PF18362; THB; 1. DR Pfam; PF09042; Titin_Z; 2. DR SMART; SM00060; FN3; 132. DR SMART; SM00409; IG; 167. DR SMART; SM00408; IGc2; 148. DR SMART; SM00406; IGv; 23. DR SUPFAM; SSF49265; Fibronectin type III; 74. DR SUPFAM; SSF48726; Immunoglobulin; 167. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 132. DR PROSITE; PS50835; IG_LIKE; 143. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Calcium; KW Calmodulin-binding; Cardiomyopathy; Coiled coil; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Immunoglobulin domain; Kinase; Limb-girdle muscular dystrophy; Magnesium; KW Metal-binding; Myofibrillar myopathy; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..34350 FT /note="Titin" FT /id="PRO_0000239311" FT DOMAIN 6..96 FT /note="Ig-like 1" FT DOMAIN 104..192 FT /note="Ig-like 2" FT REPEAT 417..462 FT /note="Z-repeat 1" FT REPEAT 466..511 FT /note="Z-repeat 2" FT REPEAT 512..554 FT /note="Z-repeat 3" FT REPEAT 555..600 FT /note="Z-repeat 4" FT REPEAT 601..646 FT /note="Z-repeat 5" FT REPEAT 647..691 FT /note="Z-repeat 6" FT REPEAT 692..740 FT /note="Z-repeat 7" FT DOMAIN 943..1031 FT /note="Ig-like 3" FT DOMAIN 1082..1172 FT /note="Ig-like 4" FT DOMAIN 1291..1382 FT /note="Ig-like 5" FT DOMAIN 1457..1546 FT /note="Ig-like 6" FT DOMAIN 1556..1646 FT /note="Ig-like 7" FT DOMAIN 1703..1793 FT /note="Ig-like 8" FT DOMAIN 1841..1928 FT /note="Ig-like 9" FT DOMAIN 2078..2167 FT /note="Ig-like 10" FT DOMAIN 2171..2262 FT /note="Ig-like 11" FT DOMAIN 2264..2354 FT /note="Ig-like 12" FT DOMAIN 2353..2443 FT /note="Ig-like 13" FT DOMAIN 2430..2529 FT /note="Ig-like 14" FT DOMAIN 2620..2703 FT /note="Ig-like 15" FT DOMAIN 2880..2965 FT /note="Ig-like 16" FT DOMAIN 2968..3050 FT /note="Ig-like 17" FT DOMAIN 3058..3141 FT /note="Ig-like 18" FT DOMAIN 3239..3327 FT /note="Ig-like 19" FT DOMAIN 3344..3432 FT /note="Ig-like 20" FT DOMAIN 3503..3586 FT /note="Ig-like 21" FT DOMAIN 3621..3712 FT /note="Ig-like 22" FT DOMAIN 4289..4376 FT /note="Ig-like 23" FT DOMAIN 4383..4471 FT /note="Ig-like 24" FT DOMAIN 4478..4566 FT /note="Ig-like 25" FT DOMAIN 4571..4659 FT /note="Ig-like 26" FT DOMAIN 4664..4753 FT /note="Ig-like 27" FT DOMAIN 4758..4846 FT /note="Ig-like 28" FT DOMAIN 4851..4936 FT /note="Ig-like 29" FT DOMAIN 4943..5032 FT /note="Ig-like 30" FT DOMAIN 5040..5128 FT /note="Ig-like 31" FT DOMAIN 5133..5221 FT /note="Ig-like 32" FT DOMAIN 5225..5314 FT /note="Ig-like 33" FT DOMAIN 5320..5408 FT /note="Ig-like 34" FT DOMAIN 5413..5501 FT /note="Ig-like 35" FT DOMAIN 5505..5594 FT /note="Ig-like 36" FT DOMAIN 5602..5690 FT /note="Ig-like 37" FT DOMAIN 5695..5783 FT /note="Ig-like 38" FT DOMAIN 5788..5877 FT /note="Ig-like 39" FT DOMAIN 5882..5970 FT /note="Ig-like 40" FT DOMAIN 5975..6063 FT /note="Ig-like 41" FT DOMAIN 6067..6156 FT /note="Ig-like 42" FT DOMAIN 6164..6252 FT /note="Ig-like 43" FT DOMAIN 6257..6347 FT /note="Ig-like 44" FT DOMAIN 6350..6440 FT /note="Ig-like 45" FT DOMAIN 6444..6534 FT /note="Ig-like 46" FT DOMAIN 6537..6626 FT /note="Ig-like 47" FT DOMAIN 6630..6721 FT /note="Ig-like 48" FT DOMAIN 6727..6815 FT /note="Ig-like 49" FT DOMAIN 6820..6908 FT /note="Ig-like 50" FT DOMAIN 6912..7001 FT /note="Ig-like 51" FT DOMAIN 7005..7093 FT /note="Ig-like 52" FT DOMAIN 7102..7190 FT /note="Ig-like 53" FT DOMAIN 7198..7286 FT /note="Ig-like 54" FT DOMAIN 7291..7380 FT /note="Ig-like 55" FT DOMAIN 7385..7473 FT /note="Ig-like 56" FT DOMAIN 7478..7567 FT /note="Ig-like 57" FT DOMAIN 7571..7662 FT /note="Ig-like 58" FT DOMAIN 7668..7756 FT /note="Ig-like 59" FT DOMAIN 7761..7849 FT /note="Ig-like 60" FT DOMAIN 7853..7942 FT /note="Ig-like 61" FT DOMAIN 7946..8035 FT /note="Ig-like 62" FT DOMAIN 8042..8133 FT /note="Ig-like 63" FT DOMAIN 8138..8229 FT /note="Ig-like 64" FT DOMAIN 8232..8321 FT /note="Ig-like 65" FT DOMAIN 8326..8414 FT /note="Ig-like 66" FT DOMAIN 8419..8508 FT /note="Ig-like 67" FT DOMAIN 8512..8603 FT /note="Ig-like 68" FT DOMAIN 8609..8697 FT /note="Ig-like 69" FT DOMAIN 8702..8790 FT /note="Ig-like 70" FT DOMAIN 8794..8883 FT /note="Ig-like 71" FT DOMAIN 8888..8976 FT /note="Ig-like 72" FT DOMAIN 8984..9074 FT /note="Ig-like 73" FT DOMAIN 9079..9168 FT /note="Ig-like 74" FT DOMAIN 9176..9265 FT /note="Ig-like 75" FT DOMAIN 9272..9361 FT /note="Ig-like 76" FT DOMAIN 9366..9470 FT /note="Ig-like 77" FT DOMAIN 9660..9755 FT /note="Ig-like 78" FT DOMAIN 9760..9851 FT /note="Ig-like 79" FT REPEAT 10216..10242 FT /note="PEVK 1" FT REPEAT 10244..10270 FT /note="PEVK 2" FT REPEAT 10272..10298 FT /note="PEVK 3" FT REPEAT 10300..10326 FT /note="PEVK 4" FT REPEAT 10327..10353 FT /note="PEVK 5" FT REPEAT 10355..10381 FT /note="PEVK 6" FT REPEAT 10508..10534 FT /note="PEVK 7" FT REPEAT 10536..10562 FT /note="PEVK 8" FT REPEAT 10592..10618 FT /note="PEVK 9" FT REPEAT 10878..10904 FT /note="PEVK 10" FT REPEAT 10906..10930 FT /note="PEVK 11" FT REPEAT 10932..10958 FT /note="PEVK 12" FT REPEAT 10960..10986 FT /note="PEVK 13" FT REPEAT 10987..11014 FT /note="PEVK 14" FT REPEAT 11363..11396 FT /note="PEVK 15" FT REPEAT 11397..11421 FT /note="PEVK 16" FT REPEAT 11453..11479 FT /note="PEVK 17" FT REPEAT 11481..11507 FT /note="PEVK 18" FT REPEAT 11509..11535 FT /note="PEVK 19" FT REPEAT 11537..11563 FT /note="PEVK 20" FT REPEAT 11565..11591 FT /note="PEVK 21" FT REPEAT 11657..11683 FT /note="PEVK 22" FT REPEAT 11703..11729 FT /note="PEVK 23" FT REPEAT 11745..11771 FT /note="PEVK 24" FT REPEAT 11775..11801 FT /note="PEVK 25" FT REPEAT 11836..11862 FT /note="PEVK 26" FT REPEAT 11864..11890 FT /note="PEVK 27" FT REPEAT 11893..11919 FT /note="PEVK 28" FT REPEAT 11929..11955 FT /note="PEVK 29" FT REPEAT 11966..11992 FT /note="PEVK 30" FT REPEAT 11996..12022 FT /note="PEVK 31" FT DOMAIN 12041..12133 FT /note="Ig-like 80" FT DOMAIN 12138..12222 FT /note="Ig-like 81" FT DOMAIN 12233..12318 FT /note="Ig-like 82" FT DOMAIN 12499..12584 FT /note="Ig-like 83" FT DOMAIN 12590..12672 FT /note="Ig-like 84" FT DOMAIN 12766..12850 FT /note="Ig-like 85" FT DOMAIN 12945..13032 FT /note="Ig-like 86" FT DOMAIN 13120..13206 FT /note="Ig-like 87" FT DOMAIN 13210..13295 FT /note="Ig-like 88" FT DOMAIN 13299..13384 FT /note="Ig-like 89" FT DOMAIN 13388..13478 FT /note="Ig-like 90" FT DOMAIN 13479..13562 FT /note="Ig-like 91" FT DOMAIN 13565..13655 FT /note="Ig-like 92" FT DOMAIN 13659..13748 FT /note="Ig-like 93" FT DOMAIN 13749..13833 FT /note="Ig-like 94" FT DOMAIN 13927..14012 FT /note="Ig-like 95" FT DOMAIN 14019..14114 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14120..14215 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14221..14316 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14417..14513 FT /note="Fibronectin type-III 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14517..14614 FT /note="Fibronectin type-III 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14615..14708 FT /note="Ig-like 96" FT DOMAIN 14713..14806 FT /note="Fibronectin type-III 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14812..14907 FT /note="Fibronectin type-III 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14913..15007 FT /note="Fibronectin type-III 8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15010..15107 FT /note="Fibronectin type-III 9" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15113..15207 FT /note="Fibronectin type-III 10" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15214..15310 FT /note="Fibronectin type-III 11" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15314..15402 FT /note="Ig-like 97" FT DOMAIN 15409..15503 FT /note="Fibronectin type-III 12" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15509..15604 FT /note="Fibronectin type-III 13" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15608..15724 FT /note="Ig-like 98" FT DOMAIN 15731..15826 FT /note="Fibronectin type-III 14" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15832..15926 FT /note="Fibronectin type-III 15" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15929..16025 FT /note="Fibronectin type-III 16" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16029..16119 FT /note="Ig-like 99" FT DOMAIN 16126..16218 FT /note="Fibronectin type-III 17" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16224..16318 FT /note="Fibronectin type-III 18" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16322..16420 FT /note="Ig-like 100" FT DOMAIN 16427..16522 FT /note="Fibronectin type-III 19" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16528..16628 FT /note="Fibronectin type-III 20" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16634..16734 FT /note="Fibronectin type-III 21" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16727..16834 FT /note="Ig-like 101" FT DOMAIN 16841..16934 FT /note="Fibronectin type-III 22" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16941..17041 FT /note="Fibronectin type-III 23" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17044..17139 FT /note="Ig-like 102" FT DOMAIN 17147..17240 FT /note="Fibronectin type-III 24" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17246..17345 FT /note="Fibronectin type-III 25" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17348..17445 FT /note="Fibronectin type-III 26" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17449..17536 FT /note="Ig-like 103" FT DOMAIN 17545..17640 FT /note="Fibronectin type-III 27" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17646..17741 FT /note="Fibronectin type-III 28" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17745..17834 FT /note="Ig-like 104" FT DOMAIN 17842..17935 FT /note="Fibronectin type-III 29" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17941..18036 FT /note="Fibronectin type-III 30" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18042..18139 FT /note="Fibronectin type-III 31" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18143..18228 FT /note="Ig-like 105" FT DOMAIN 18239..18333 FT /note="Fibronectin type-III 32" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18339..18431 FT /note="Fibronectin type-III 33" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18435..18526 FT /note="Ig-like 106" FT DOMAIN 18533..18632 FT /note="Fibronectin type-III 34" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18633..18727 FT /note="Fibronectin type-III 35" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18733..18829 FT /note="Fibronectin type-III 36" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18833..18924 FT /note="Ig-like 107" FT DOMAIN 18931..19025 FT /note="Fibronectin type-III 37" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19030..19124 FT /note="Fibronectin type-III 38" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19128..19219 FT /note="Ig-like 108" FT DOMAIN 19226..19321 FT /note="Fibronectin type-III 39" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19325..19420 FT /note="Fibronectin type-III 40" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19426..19527 FT /note="Fibronectin type-III 41" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19531..19617 FT /note="Ig-like 109" FT DOMAIN 19628..19722 FT /note="Fibronectin type-III 42" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19728..19823 FT /note="Fibronectin type-III 43" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19826..19914 FT /note="Ig-like 110" FT DOMAIN 19921..20017 FT /note="Fibronectin type-III 44" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20018..20116 FT /note="Fibronectin type-III 45" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20119..20217 FT /note="Fibronectin type-III 46" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20220..20311 FT /note="Ig-like 111" FT DOMAIN 20318..20411 FT /note="Fibronectin type-III 47" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20417..20512 FT /note="Fibronectin type-III 48" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20518..20613 FT /note="Fibronectin type-III 49" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20716..20813 FT /note="Fibronectin type-III 50" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20814..20908 FT /note="Fibronectin type-III 51" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20893..20996 FT /note="Ig-like 112" FT DOMAIN 21006..21101 FT /note="Fibronectin type-III 52" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21105..21200 FT /note="Fibronectin type-III 53" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21203..21299 FT /note="Fibronectin type-III 54" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21303..21395 FT /note="Ig-like 113" FT DOMAIN 21402..21495 FT /note="Fibronectin type-III 55" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21501..21596 FT /note="Fibronectin type-III 56" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21602..21697 FT /note="Fibronectin type-III 57" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21701..21793 FT /note="Ig-like 114" FT DOMAIN 21797..21891 FT /note="Fibronectin type-III 58" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21894..21986 FT /note="Fibronectin type-III 59" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21990..22083 FT /note="Ig-like 115" FT DOMAIN 22088..22182 FT /note="Fibronectin type-III 60" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22188..22283 FT /note="Fibronectin type-III 61" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22286..22382 FT /note="Fibronectin type-III 62" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22386..22477 FT /note="Ig-like 116" FT DOMAIN 22484..22578 FT /note="Fibronectin type-III 63" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22584..22679 FT /note="Fibronectin type-III 64" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22685..22781 FT /note="Fibronectin type-III 65" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22785..22874 FT /note="Ig-like 117" FT DOMAIN 22881..22976 FT /note="Fibronectin type-III 66" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22978..23071 FT /note="Fibronectin type-III 67" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23075..23163 FT /note="Ig-like 118" FT DOMAIN 23170..23264 FT /note="Fibronectin type-III 68" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23270..23364 FT /note="Fibronectin type-III 69" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23368..23463 FT /note="Fibronectin type-III 70" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23468..23555 FT /note="Ig-like 119" FT DOMAIN 23566..23660 FT /note="Fibronectin type-III 71" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23666..23761 FT /note="Fibronectin type-III 72" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23767..23863 FT /note="Fibronectin type-III 73" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23867..23954 FT /note="Ig-like 120" FT DOMAIN 23963..24057 FT /note="Fibronectin type-III 74" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24060..24153 FT /note="Fibronectin type-III 75" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24157..24241 FT /note="Ig-like 121" FT DOMAIN 24252..24346 FT /note="Fibronectin type-III 76" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24352..24446 FT /note="Fibronectin type-III 77" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24450..24546 FT /note="Fibronectin type-III 78" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24550..24641 FT /note="Ig-like 122" FT DOMAIN 24648..24742 FT /note="Fibronectin type-III 79" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24748..24843 FT /note="Fibronectin type-III 80" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24849..24945 FT /note="Fibronectin type-III 81" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24949..25038 FT /note="Ig-like 123" FT DOMAIN 25045..25139 FT /note="Fibronectin type-III 82" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25142..25235 FT /note="Fibronectin type-III 83" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25239..25325 FT /note="Ig-like 124" FT DOMAIN 25335..25428 FT /note="Fibronectin type-III 84" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25434..25529 FT /note="Fibronectin type-III 85" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25532..25627 FT /note="Fibronectin type-III 86" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25632..25722 FT /note="Ig-like 125" FT DOMAIN 25731..25825 FT /note="Fibronectin type-III 87" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25831..25926 FT /note="Fibronectin type-III 88" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25932..26028 FT /note="Fibronectin type-III 89" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26032..26121 FT /note="Ig-like 126" FT DOMAIN 26128..26222 FT /note="Fibronectin type-III 90" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26225..26318 FT /note="Fibronectin type-III 91" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26322..26410 FT /note="Ig-like 127" FT DOMAIN 26417..26510 FT /note="Fibronectin type-III 92" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26516..26611 FT /note="Fibronectin type-III 93" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26614..26710 FT /note="Fibronectin type-III 94" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26714..26801 FT /note="Ig-like 128" FT DOMAIN 26812..26906 FT /note="Fibronectin type-III 95" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26912..27007 FT /note="Fibronectin type-III 96" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27013..27107 FT /note="Fibronectin type-III 97" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27101..27196 FT /note="Ig-like 129" FT DOMAIN 27205..27296 FT /note="Fibronectin type-III 98" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27302..27392 FT /note="Fibronectin type-III 99" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27499..27593 FT /note="Fibronectin type-III 100" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27599..27694 FT /note="Fibronectin type-III 101" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27697..27793 FT /note="Fibronectin type-III 102" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27797..27888 FT /note="Ig-like 130" FT DOMAIN 27895..27989 FT /note="Fibronectin type-III 103" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27995..28090 FT /note="Fibronectin type-III 104" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28096..28192 FT /note="Fibronectin type-III 105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28196..28286 FT /note="Ig-like 131" FT DOMAIN 28295..28389 FT /note="Fibronectin type-III 106" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28392..28484 FT /note="Fibronectin type-III 107" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28488..28577 FT /note="Ig-like 132" FT DOMAIN 28583..28680 FT /note="Fibronectin type-III 108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28686..28781 FT /note="Fibronectin type-III 109" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28784..28879 FT /note="Fibronectin type-III 110" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28882..28974 FT /note="Ig-like 133" FT DOMAIN 28979..29071 FT /note="Fibronectin type-III 111" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29081..29177 FT /note="Fibronectin type-III 112" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29180..29278 FT /note="Fibronectin type-III 113" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29282..29367 FT /note="Ig-like 134" FT DOMAIN 29378..29473 FT /note="Fibronectin type-III 114" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29475..29568 FT /note="Fibronectin type-III 115" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29568..29663 FT /note="Ig-like 135" FT DOMAIN 29670..29764 FT /note="Fibronectin type-III 116" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29770..29865 FT /note="Fibronectin type-III 117" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29868..29967 FT /note="Fibronectin type-III 118" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29971..30059 FT /note="Ig-like 136" FT DOMAIN 30070..30163 FT /note="Fibronectin type-III 119" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30169..30265 FT /note="Fibronectin type-III 120" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30271..30367 FT /note="Fibronectin type-III 121" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30371..30460 FT /note="Ig-like 137" FT DOMAIN 30467..30561 FT /note="Fibronectin type-III 122" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30564..30658 FT /note="Fibronectin type-III 123" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30663..30754 FT /note="Ig-like 138" FT DOMAIN 30761..30855 FT /note="Fibronectin type-III 124" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30861..30956 FT /note="Fibronectin type-III 125" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30962..31058 FT /note="Fibronectin type-III 126" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31061..31150 FT /note="Ig-like 139" FT DOMAIN 31158..31254 FT /note="Fibronectin type-III 127" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31258..31354 FT /note="Fibronectin type-III 128" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31360..31455 FT /note="Fibronectin type-III 129" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31460..31548 FT /note="Ig-like 140" FT DOMAIN 31653..31748 FT /note="Fibronectin type-III 130" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31754..31849 FT /note="Fibronectin type-III 131" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31855..31945 FT /note="Ig-like 141" FT DOMAIN 31955..32046 FT /note="Ig-like 142" FT DOMAIN 32051..32144 FT /note="Fibronectin type-III 132" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 32178..32432 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 32496..32584 FT /note="Ig-like 143" FT DOMAIN 32617..32710 FT /note="Ig-like 144" FT DOMAIN 32722..32811 FT /note="Ig-like 145" FT DOMAIN 33301..33391 FT /note="Ig-like 146" FT DOMAIN 33488..33576 FT /note="Ig-like 147" FT DOMAIN 33645..33732 FT /note="Ig-like 148" FT DOMAIN 33779..33867 FT /note="Ig-like 149" FT DOMAIN 33963..34052 FT /note="Ig-like 150" FT DOMAIN 34061..34149 FT /note="Ig-like 151" FT DOMAIN 34256..34344 FT /note="Ig-like 152" FT REGION 244..313 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 253..341 FT /note="ZIS1" FT REGION 333..356 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 859..886 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1408..1443 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1410..1440 FT /note="ZIS5" FT REGION 4241..4272 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 9920..9945 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10039..10070 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10087..10109 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10207..10280 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10314..10361 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10412..10457 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10499..10566 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10583..10617 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10661..10743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10882..11102 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11158..11193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11362..11636 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11666..12032 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14216..14236 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14891..14921 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 15911..15939 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 16614..16654 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18614..18637 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18716..18743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 19304..19331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 27090..27110 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 31238..31267 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33213..33256 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33432..33463 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33584..33638 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33749..33777 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 529..561 FT /evidence="ECO:0000255" FT COILED 2025..2052 FT /evidence="ECO:0000255" FT COILED 3462..3487 FT /evidence="ECO:0000255" FT COILED 9534..9577 FT /evidence="ECO:0000255" FT COMPBIAS 1408..1419 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 4245..4257 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 9920..9938 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10041..10052 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10058..10070 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10087..10101 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10207..10224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10245..10265 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10329..10347 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10349..10360 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10418..10430 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10440..10457 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10684..10701 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10702..10720 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10721..10737 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10882..10944 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10961..10972 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10989..11009 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11030..11101 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11164..11190 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11388..11416 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11438..11453 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11454..11465 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11466..11479 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11496..11509 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11510..11521 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11538..11549 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11550..11563 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11580..11591 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11592..11613 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11614..11626 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11678..11696 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11704..11715 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11730..11745 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11768..11803 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11816..11825 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11834..11846 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11854..11875 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11882..11900 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11927..11936 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11948..11958 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11960..11971 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11972..11981 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11982..11995 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11996..12008 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 14223..14236 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19318..19331 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 31252..31262 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33231..33242 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33439..33450 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33594..33604 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33625..33634 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33749..33771 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 32298 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32184..32192 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32207 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 263 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 265 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 267 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 6920 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 9122 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 11503 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12007 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 12009 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12022 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 30443 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 32341 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:9804419" FT MOD_RES 33245 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33247 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33602 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33614 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT DISULFID 964..1015 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 1724..1777 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2109..2134 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:11525170" FT DISULFID 2196..2246 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 3259..3311 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4404..4455 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4499..4550 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4592..4643 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4686..4737 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4779..4830 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5061..5112 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5248..5299 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5623..5674 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5810..5861 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5903..5954 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6185..6236 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6372..6423 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6465..6516 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6748..6799 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7027..7078 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7123..7174 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7219..7270 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7313..7364 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7406..7457 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7689..7740 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7968..8019 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8064..8115 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8160..8211 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8254..8305 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8347..8398 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8630..8681 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8909..8960 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9005..9056 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9101..9152 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9294..9345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9693..9743 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12067..12117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12611..12660 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12966..13016 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13233..13283 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13322..13372 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13411..13461 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13771..13821 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 31481..31532 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 32516..32568 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 33664..33718 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 555..646 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:8937992" FT /id="VSP_019138" FT VAR_SEQ 556..601 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019139" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPKVQALDRQSSGKDVRESTKSQAVADSSFTKEESKISQKEI FT KSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTG FT EAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQF FT LTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045935" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPK (in isoform 8 and isoform 10)" FT /evidence="ECO:0000305" FT /id="VSP_019140" FT VAR_SEQ 3434 FT /note="E -> EVQALDRQSSGKDVRESAKSQAVADSSFTKEESKISQKEIKSFQGSS FT YEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTGEAPKIFL FT HLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQFLTICNVQ FT LVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 9)" FT /evidence="ECO:0000305" FT /id="VSP_042903" FT VAR_SEQ 3435..3645 FT /note="APESILHERIEQEIEMEMKEFSSSFLSAEEEGLHSAELQLSKINETLELLSE FT SPVYPTKFDSEKEGTGPIFIKEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTP FT SADYKFVFDGDDHSLIILFTKLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTET FT ESAVAKSLEKLGGPCPPHFLKELKPIRCAQGLPAIFEYTVV -> VQALDRQSSGKDVR FT ESTKSQAVADSSFTKEESKISQKEIKSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQL FT CHTASLSQIAESTELSKECAKESTGEAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDV FT TWTHEGAKIEESERLKQSQNGNIQFLTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVE FT GAPESILHERIEQEIEMEMK (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019141" FT VAR_SEQ 3454..4380 FT /note="Missing (in isoform 4 and isoform 11)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019142" FT VAR_SEQ 3455..5604 FT /note="FSSSFLSAEEEGLHSAELQLSKINETLELLSESPVYPTKFDSEKEGTGPIFI FT KEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTPSADYKFVFDGDDHSLIILFT FT KLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTETESAVAKSLEKLGGPCPPHFL FT KELKPIRCAQGLPAIFEYTVVGEPAPTVTWFKENKQLCTSVYYTIIHNPNGSGTFIVND FT PQREDSGLYICKAENMLGESTCAAELLVLLEDTDMTDTPCKAKSTPEAPEDFPQTPLKG FT PAVEALDSEQEIATFVKDTILKAALITEENQQLSYEHIAKANELSSQLPLGAQELQSIL FT EQDKLTPESTREFLCINGSIHFQPLKEPSPNLQLQIVQSQKTFSKEGILMPEEPETQAV FT LSDTEKIFPSAMSIEQINSLTVEPLKTLLAEPEGNYPQSSIEPPMHSYLTSVAEEVLSP FT KEKTVSDTNREQRVTLQKQEAQSALILSQSLAEGHVESLQSPDVMISQVNYEPLVPSEH FT SCTEGGKILIESANPLENAGQDSAVRIEEGKSLRFPLALEEKQVLLKEEHSDNVVMPPD FT QIIESKREPVAIKKVQEVQGRDLLSKESLLSGIPEEQRLNLKIQICRALQAAVASEQPG FT LFSEWLRNIEKVEVEAVNITQEPRHIMCMYLVTSAKSVTEEVTIIIEDVDPQMANLKME FT LRDALCAIIYEEIDILTAEGPRIQQGAKTSLQEEMDSFSGSQKVEPITEPEVESKYLIS FT TEEVSYFNVQSRVKYLDATPVTKGVASAVVSDEKQDESLKPSEEKEESSSESGTEEVAT FT VKIQEAEGGLIKEDGPMIHTPLVDTVSEEGDIVHLTTSITNAKEVNWYFENKLVPSDEK FT FKCLQDQNTYTLVIDKVNTEDHQGEYVCEALNDSGKTATSAKLTVVKRAAPVIKRKIEP FT LEVALGHLAKFTCEIQSAPNVRFQWFKAGREIYESDKCSIRSSKYISSLEILRTQVVDC FT GEYTCKASNEYGSVSCTATLTVTEAYPPTFLSRPKSLTTFVGKAAKFICTVTGTPVIET FT IWQKDGAALSPSPNWRISDAENKHILELSNLTIQDRGVYSCKASNKFGADICQAELIII FT DKPHFIKELEPVQSAINKKVHLECQVDEDRKVTVTWSKDGQKLPPGKDYKICFEDKIAT FT LEIPLAKLKDSGTYVCTASNEAGSSSCSATVTVREPPSFVKKVDPSYLMLPGESARLHC FT KLKGSPVIQVTWFKNNKELSESNTVRMYFVNSEAILDITDVKVEDSGSYSCEAVNDVGS FT DSCSTEIVIKEPPSFIKTLEPADIVRGTNALLQCEVSGTGPFEISWFKDKKQIRSSKKY FT RLFSQKSLVCLEIFSFNSADVGEYECVVANEVGKCGCMATHLLKEPPTFVKKVDDLIAL FT GGQTVTLQAAVRGSEPISVTWMKGQEVIREDGKIKMSFSNGVAVLIIPDVQISFGGKYT FT CLAENEAGSQTSVGELIVKEPAKIIERAELIQVTAGDPATLEYTVAGTPELKPKWYKDG FT RPLVASKKYRISFKNNVAQLKFYSAELHDSGQYTFEISNEVGSSSCETTFTVLDRDIAP FT FFTKPLRNVDSVVNGTCRLDCKIAGSLPMRVSWFKDGKEIAASDRYRIAFVEGTASLEI FT IRVDMNDAGNFTCRATNSVGSKDSSGALIVQEPPSFVTKPGSKDVLPGSAVCLKSTFQG FT STPLTIRWFKGNKELVSGGSCYITKEALESSLELYLVKTSDSGTYTCKVSNVAGGVECS FT ANLFVKEPATFVEKLEPSQLLKKGDATQLACKVTGTPPIKITWFANDREIKESSKHRMS FT FVESTAVLRLTDVGIEDSGEYMCEAQNEAGSDHCSSIVIVKESPYFTKEFKPIEVLKEY FT DVMLLAEVAGTPPFEITWFKDNTILRSGRKYKTFIQDHLVSLQILKFVAADAGEYQCRV FT TNEVGSSICSARVTLREPPSFIKKIESTSSLRGGTAAFQATLKGSLPITVTWLKDSDEI FT TEDDNIRMTFENNVASLYLSGIEVKHDGKYVCQAKNDAGIQRCSALLSVKEPATITEEA FT VSIDVTQGDPATLQVKFSGTKEITAKWFKDGQELTLGSKYKISVTDTVSILKIISTEKK FT DSGEYTFEVQNDVGRSSCKARINVLDLIIPPSF -> LFSEGESEHSERDTRDAFSDSE FT DIDHKSMAAKRYASRISSTSSWPEYFKPSFTQKLTFKYVLEGEPVVFTCRLIACPTPEM FT TWFHNNRPIPTGLRRIIKAESDLHHHSSSLEIKRVQDRDSGSYRLLAINSEGSAESTAS FT LLVIQKGQDEKYLEFLKRAERTHENVEALVERGEDRIKVDLRFTGSPFNKKQDVEQKGM FT MRTIHFKTMSSAKKTDYMYDEEYLESKSDIRGWLNVGESFLDKETKVKLQRLREARKTL FT MEKKKLSLLDTSSEISSRTLRSEASDKDILFSREDMKIRSMSDLAESYKVDHSAESIVQ FT NPHALSNQMDQNIESEELPTSFQTIVDEEIFQTEIRMSQEALVKESLPKDHLYGEILVN FT ENTQARGQLEEIMANTTIGESSTYITNVCEKEEVYETPENVSQAITPHASESFGTLVNV FT EESEEIASERIKKDDLRELQLSASTRIDEFKTEQKEENMRFFENSFRKRPQRCPPSFLQ FT EIESQEVYEGDSCNFVCHFQGYPQPIVTWYNNDMPIPRNQNFIIHSLENYSILTLSSVH FT HQNEGSITCVLFNQYGTVKTTSMLKVKAKQKHDVKAHKVPVFHDYLDEEEELALVFDQA FT KGAHPSMSQEGQTNLHLLKTNPPVPPSGDTELLSFPVEIQVTAATPIPEQDKESKEVFQ FT TEELEPKAMPQDQVTQSPKHRFVFLSDITNEPPKMLQEMPKHARCREGDSIILECLISG FT EPQPVVTWFQNGVLLKQNQKFQFEEVNCSHQLYIKDVNSQDSGKYKCVAENNSGAVESV FT SDLTVEPVTYRENSQFENIGEIYGKYSRDQQLQDQGESVRAHFYDYPAGPFTPWTNVKE FT YSVRDYFQSLETIEQIDQKEQVRCIPSREKIPRFVHGASRTIKISKPIRAEFIQCQAEG FT KERHVSEKSKLHQAEGTVYPFVDDFSDVTIKKEIRNNFGKLGRSEKENVQECAQSDYLP FT NIHSERISDSYNTKDSSAIVYEESLGEEIHYPGKKVKHRIIEFEKLHVEKGVLEKRPTR FT TSIVNPPQKKIDDKAFSLKQRESRSSNLNANMYQAEKMSPNTESDSSNIAINLKLLSSQ FT THKEFDAQEREQQEKISLIDKPAISKRAEHESPITFDLKQFHTQIKHTDVKFQELDSGQ FT PEEAYFKIQHPADTENIVFDLKQMYSHIGDPALEFQGQETREQQEIHYKEKIPSPETLQ FT PDTHNISKSVQNNVFASQEISSSQELSNRTMVEKSSIDENSISLEKEVRHVQEQNLDIL FT KTDLSLKSFSEEIYSESCALLPTSSADIEETDLSEKSCPLENGGRSSISHLKKAASEEK FT PLGVGEMEEECTLEPELAAFPKQDGGTQEYTDATLEDHRGDVQEADTLHRQLSLSQCFP FT LLMTEEQQNPGEQISTNIHASGEEKCYEEVQVQNEASFSTLEGEMIETSFSQNIPKLDE FT AHTTEAAESETSLTQYLLAAGKREVPETKDTRDQAKLVQSESITSMEVEEVTFNTVYEY FT YNQKQESLGRPLSPESDISIGVGSTTSEEISELDQFYTPPSSVEYFESPKSPDLYFNPS FT DITKQSSIHSGGETVERYSTPLGEVAERYSTPSEGEVGERYSTPPGETLERYSTPPGET FT LERYSTPPGETLERYSTPPGETLERYSTPPGETLERYSTPPGEALERYSIPTGGPNPTG FT TFKTYPSKIEREDGTPNEHFYTPTEERGSAYEIWRSDSFGTPNEAIEPKDNEMPPSFIE FT PLTKRKVYENTTLGFIVEVEGLPVPGVKWYRNKSLLEPDERIKMERVGNVCSLEISNIQ FT KGEGGEYMCHAVNIIGEAKSFANVDIMPQEERVVALPPPVTHQHVMEFDLEHTTSSRTP FT SPQEIVLEVELSEKDVKEFEKQVKIVTVPEFTPDHKSMIVSLDVLPFNFVDPNMDSREG FT EDKELKIDLEVFEMPPRFIMPICDFKIPENSDAVFKCSVIGIPTPEVKWYKEYMCIEPD FT NIKYVISEEKGSHTLKIRNVCLSDSATYRCRAVNCVGEAICRGFLTMGDSEIFAVIAKK FT SKVTLSSLMEELVLKSNYTDSFFEFQVVEGPPRFIKGISDCYAPIGTAAYFQCLVRGSP FT RPTVYWYKDGKLVQGRRFTVEESGTGFHNLFITSLVKSDEGEYRCVATNKSGMAESFAA FT LTLT (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019143" FT VAR_SEQ 3646..4380 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019144" FT VAR_SEQ 4474..11851 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019145" FT VAR_SEQ 5605..34350 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019146" FT VAR_SEQ 10382..10645 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019147" FT VAR_SEQ 10742..10931 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019148" FT VAR_SEQ 11015..11163 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019149" FT VAR_SEQ 11117 FT /note="I -> VPKKPVPEKKVPVPAPKKVEPPPPPKVPEI (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045929" FT VAR_SEQ 11133 FT /note="E -> EAPPAKVSVVPKKPEPEKKVPPPGLKKAV (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045930" FT VAR_SEQ 11223..11852 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019150" FT VAR_SEQ 11421 FT /note="K -> KAPEVPKKIVPEEKVREAVLKKPEVPPAKVPGMPKKSVQEEKSPIVI FT SEDTEMYIYEASEEAVLEEKVLVTQPQKTKPKLAKVPEPPKKVVPEDKIYVTIPKKRET FT PATKEPDTTRGIFPEVEPPEAIPEIPEHPPTEEFEVFKEVIPEGETPIVKRRKTPSPTV FT PESPREIVPVKETPMAAPLEIEIPPTKAPEAMKEVVPEMKIFEDVPEEPETPRMKTPEA FT PQEIIPAKTVPSKKREPPSVKVPEALQEIVPEKKTLVVPLRKPEVLPDEVPEALREVVP FT EKKVHPPQRAEVVPVKVHEAPKEIIPEKKVSVVPPKKPEVPPVKVPEASKEVIREEKVP FT LAPPKEPEVPPVKVPEPPKEVVPEKKAPVAPPKEPEVPPVKVPEAPKEVVPEKKVPVPP FT PKKPEVPPTKVPEVPKAAVPEKKLPEAIPPKPESPPPE (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045931" FT VAR_SEQ 11450 FT /note="P -> PKVPEAPKEVVLEKKASVAVPKKPEAPRAKVPEAAQEVVPEKKIPKA FT PIKKPEAPAVTVPEVPQEATEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKP FT EAPPATVPEVPQEIVPEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPSAPPKKPEVPP FT V (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045932" FT VAR_SEQ 11507 FT /note="E -> EVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKVPEAPKEVVLEKKASV FT AVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEVPQEAAEKEIPVAPPK FT KPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIVPEKKTLVLPKKPEVP FT PVTVPEAPKEVVLEKKVPSTPPKKPEVPPVKVPEAPKEVVPEKKVPVPPPKKPEVPPTK FT VPEVPKAAVPEKKVPEAIPPKPESPPPEVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKV FT PEAPKEVVLEKKVSVAVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEV FT PQEAAEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIV FT PEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPLAPPKKPEVPPVKVPEAPKEVVPEKK FT VPVTPPKKPEVPPVKVPEAPIEVVPEKKMPLAPPKKPEVPPVKVPEAPKEVVPEKKVPS FT APPKKPEVPPVK (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045933" FT VAR_SEQ 11507 FT /note="E -> EVFEEPEESPSAPPKKPEVPPVR (in isoform 4)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019151" FT VAR_SEQ 11790 FT /note="P -> PKEPEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVT FT KKPEVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKE FT TPPVEEREIEKYIKPEEPEPEPQPEEIPV (in isoform 13)" FT /evidence="ECO:0000305" FT /id="VSP_047142" FT VAR_SEQ 11793 FT /note="P -> PEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVTKKP FT EVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKETPP FT VEEREIEKYIKPEEPEPEPQPEEIPVKEP (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045934" FT VAR_SEQ 11985..12201 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019152" FT VARIANT 54 FT /note="V -> M (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs139517732)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026685" FT VARIANT 60 FT /note="D -> Y (in dbSNP:rs35683768)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040078" FT VARIANT 115 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs564777385)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040079" FT VARIANT 279 FT /note="R -> W (in MFM9; disrupts NBR1-binding; FT dbSNP:rs138060032)" FT /evidence="ECO:0000269|PubMed:15802564" FT /id="VAR_026634" FT VARIANT 328 FT /note="R -> C (in dbSNP:rs16866538)" FT /evidence="ECO:0000269|PubMed:11846417, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026686" FT VARIANT 360 FT /note="R -> T (in dbSNP:rs56128843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040080" FT VARIANT 498 FT /note="V -> I (in dbSNP:rs72647851)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040081" FT VARIANT 740 FT /note="R -> L (in CMH9; dbSNP:rs28933405)" FT /evidence="ECO:0000269|PubMed:10462489" FT /id="VAR_026687" FT VARIANT 743 FT /note="A -> V (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs267607157)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026688" FT VARIANT 799 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs149061352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040082" FT VARIANT 811 FT /note="T -> I (in dbSNP:rs35813871)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040083" FT VARIANT 922 FT /note="R -> H (in dbSNP:rs56046320)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040084" FT VARIANT 937 FT /note="E -> D (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040085" FT VARIANT 976 FT /note="W -> R (in CMD1G; dbSNP:rs267607155)" FT /evidence="ECO:0000269|PubMed:11788824" FT /id="VAR_026689" FT VARIANT 1081 FT /note="A -> T (in dbSNP:rs55914517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040086" FT VARIANT 1137 FT /note="G -> R (in dbSNP:rs72647870)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040087" FT VARIANT 1201 FT /note="K -> E (in dbSNP:rs10497520)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040088" FT VARIANT 1202 FT /note="V -> A (in dbSNP:rs150667217)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040089" FT VARIANT 1249 FT /note="S -> L (in dbSNP:rs1552280)" FT /id="VAR_056081" FT VARIANT 1295 FT /note="S -> L (in dbSNP:rs1552280)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040090" FT VARIANT 1345 FT /note="G -> D (in dbSNP:rs36021856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040091" FT VARIANT 1347 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267599092)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040092" FT VARIANT 1350 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs539470256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040093" FT VARIANT 1353 FT /note="V -> L (in dbSNP:rs36062108)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040094" FT VARIANT 1393 FT /note="I -> V (in dbSNP:rs16866531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040095" FT VARIANT 1416 FT /note="R -> C (in dbSNP:rs72647875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040096" FT VARIANT 1441 FT /note="R -> P (in dbSNP:rs72647876)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040097" FT VARIANT 1544 FT /note="I -> V (in dbSNP:rs72647877)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040098" FT VARIANT 1572 FT /note="R -> Q (in dbSNP:rs12476289)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040099" FT VARIANT 1658 FT /note="R -> G (in dbSNP:rs56270960)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040100" FT VARIANT 1664 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs375029799)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040101" FT VARIANT 1692 FT /note="G -> D (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs370004591)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040102" FT VARIANT 1744 FT /note="P -> L (in dbSNP:rs75686037)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040103" FT VARIANT 1772 FT /note="S -> G (in dbSNP:rs150725992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040104" FT VARIANT 1907 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040105" FT VARIANT 1998 FT /note="R -> H (in dbSNP:rs144135510)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040106" FT VARIANT 2107 FT /note="P -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040107" FT VARIANT 2118 FT /note="I -> T (in dbSNP:rs56404770)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040108" FT VARIANT 2164 FT /note="A -> T (in dbSNP:rs56285559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040109" FT VARIANT 2240 FT /note="D -> Y" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040110" FT VARIANT 2392 FT /note="G -> S (in dbSNP:rs4894048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040111" FT VARIANT 2432 FT /note="L -> F (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs571572592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040112" FT VARIANT 2610 FT /note="M -> I (in dbSNP:rs56142888)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040113" FT VARIANT 2771 FT /note="I -> M (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs576644663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040114" FT VARIANT 2823 FT /note="V -> F (in dbSNP:rs33917087)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040115" FT VARIANT 2831 FT /note="S -> N (in dbSNP:rs2306636)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040116" FT VARIANT 2930 FT /note="V -> I (in dbSNP:rs56373393)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040117" FT VARIANT 2963 FT /note="T -> P (in dbSNP:rs200875815)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074293" FT VARIANT 3026 FT /note="N -> I (in dbSNP:rs11900987)" FT /id="VAR_056082" FT VARIANT 3154 FT /note="K -> R (in dbSNP:rs4893853)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040118" FT VARIANT 3191 FT /note="Q -> E (in dbSNP:rs33997263)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040119" FT VARIANT 3238 FT /note="P -> L (in a bladder carcinoma sample; somatic FT mutation; dbSNP:rs397517792)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040120" FT VARIANT 3250 FT /note="V -> G (in dbSNP:rs55634230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040121" FT VARIANT 3261 FT /note="V -> M (in dbSNP:rs2291311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040122" FT VARIANT 3367 FT /note="R -> Q (in dbSNP:rs34819099)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040123" FT VARIANT 3419 FT /note="S -> N (in dbSNP:rs2291310)" FT /evidence="ECO:0000269|PubMed:7569978" FT /id="VAR_056083" FT VARIANT 3482 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040124" FT VARIANT 3491 FT /note="P -> S (in dbSNP:rs2627037)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7569978" FT /id="VAR_040125" FT VARIANT 3570 FT /note="E -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040126" FT VARIANT 3590 FT /note="L -> V (in dbSNP:rs55853696)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040127" FT VARIANT 3637 FT /note="P -> S (in dbSNP:rs757223770)" FT /id="VAR_056084" FT VARIANT 3762 FT /note="I -> V (in dbSNP:rs34070843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040128" FT VARIANT 3799 FT /note="S -> Y (in CMD1G)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026690" FT VARIANT 3877 FT /note="I -> F (in dbSNP:rs34618570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040129" FT VARIANT 3965 FT /note="I -> L (in dbSNP:rs56244420)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040130" FT VARIANT 4084 FT /note="R -> Q (in dbSNP:rs200431386)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026691" FT VARIANT 4215 FT /note="T -> P (in dbSNP:rs2562829)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:17344846" FT /id="VAR_026635" FT VARIANT 4238 FT /note="G -> W (in dbSNP:rs56030296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040131" FT VARIANT 4283 FT /note="L -> F (in dbSNP:rs1883085)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026636" FT VARIANT 4291 FT /note="I -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040132" FT VARIANT 4303 FT /note="G -> D (in dbSNP:rs55857742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040133" FT VARIANT 4427 FT /note="D -> E (in dbSNP:rs55906845)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040134" FT VARIANT 4465 FT /note="S -> N (in CMD1G; dbSNP:rs281864908)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026692" FT VARIANT 8288 FT /note="A -> V (in dbSNP:rs16866412)" FT /id="VAR_056085" FT VARIANT 8474 FT /note="I -> T (in dbSNP:rs4893852)" FT /id="VAR_056086" FT VARIANT 12310 FT /note="G -> E (in dbSNP:rs55723264)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040135" FT VARIANT 12383 FT /note="H -> R (in dbSNP:rs2288563)" FT /evidence="ECO:0000269|PubMed:10850961" FT /id="VAR_040136" FT VARIANT 12469 FT /note="V -> A (in dbSNP:rs34706299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040137" FT VARIANT 12642 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs199684560)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040138" FT VARIANT 12657 FT /note="E -> K (in a Wilms tumor; somatic mutation; FT dbSNP:rs778634417)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040139" FT VARIANT 12679 FT /note="K -> E (in dbSNP:rs6723526)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040140" FT VARIANT 12720 FT /note="S -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040141" FT VARIANT 12798 FT /note="R -> C (in dbSNP:rs200914097)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040142" FT VARIANT 13049 FT /note="E -> G" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040143" FT VARIANT 13083 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1458591077)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040144" FT VARIANT 13096 FT /note="R -> L (in dbSNP:rs373298007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040145" FT VARIANT 13099 FT /note="Q -> R (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040146" FT VARIANT 13297 FT /note="V -> A (in dbSNP:rs571522834)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040147" FT VARIANT 13399 FT /note="I -> M (in dbSNP:rs74580375)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040148" FT VARIANT 13418 FT /note="A -> T (in dbSNP:rs144668626)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040149" FT VARIANT 13428 FT /note="E -> V (in dbSNP:rs114331773)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040150" FT VARIANT 13430 FT /note="I -> T (in dbSNP:rs184078045)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040151" FT VARIANT 13434 FT /note="R -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040152" FT VARIANT 13469 FT /note="D -> N (in dbSNP:rs17354992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040153" FT VARIANT 13495 FT /note="K -> N (in dbSNP:rs72677225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040154" FT VARIANT 13785 FT /note="N -> S (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040155" FT VARIANT 13870 FT /note="Q -> H (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040156" FT VARIANT 14109 FT /note="V -> I (in dbSNP:rs72677232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040157" FT VARIANT 14131 FT /note="R -> Q (in dbSNP:rs72677233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040158" FT VARIANT 14208 FT /note="P -> T (in dbSNP:rs146181477)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040159" FT VARIANT 14728 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040160" FT VARIANT 14750 FT /note="R -> Q (in dbSNP:rs200944827)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074294" FT VARIANT 14999 FT /note="S -> T (in dbSNP:rs55663050)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040161" FT VARIANT 15021 FT /note="N -> T (in dbSNP:rs36043230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040162" FT VARIANT 15520 FT /note="A -> V (in dbSNP:rs16866412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040163" FT VARIANT 15555 FT /note="R -> I (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs751398376)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040164" FT VARIANT 15620 FT /note="R -> Q (in dbSNP:rs201825412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040165" FT VARIANT 15629 FT /note="S -> I (in dbSNP:rs200650668)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040166" FT VARIANT 15635 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040167" FT VARIANT 15700 FT /note="R -> Q (in dbSNP:rs370390570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040168" FT VARIANT 15705 FT /note="L -> P (in dbSNP:rs755155531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040169" FT VARIANT 15837 FT /note="I -> M (in dbSNP:rs554368924)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040170" FT VARIANT 16046 FT /note="G -> V (in dbSNP:rs780672348)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069432" FT VARIANT 16058 FT /note="R -> H (in dbSNP:rs72646808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040171" FT VARIANT 16067 FT /note="K -> I (in dbSNP:rs2303832)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040172" FT VARIANT 16090 FT /note="I -> T (in dbSNP:rs72646809)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040173" FT VARIANT 16195 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs373526624)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040174" FT VARIANT 16409 FT /note="R -> C (in dbSNP:rs55734111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040175" FT VARIANT 16424 FT /note="R -> P (in dbSNP:rs375895183)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040176" FT VARIANT 16575 FT /note="V -> M (in dbSNP:rs3813243)" FT /id="VAR_056087" FT VARIANT 16629 FT /note="I -> M (in dbSNP:rs55809450)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040177" FT VARIANT 16877 FT /note="K -> R (in dbSNP:rs72646823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040178" FT VARIANT 17060 FT /note="N -> D (in dbSNP:rs1001238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040179" FT VARIANT 17637 FT /note="I -> V (in dbSNP:rs56025724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040180" FT VARIANT 17838 FT /note="R -> H (in dbSNP:rs2288569)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040181" FT VARIANT 17866 FT /note="D -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040182" FT VARIANT 17906 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs374713701)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040183" FT VARIANT 18094 FT /note="E -> A (in dbSNP:rs769852851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040184" FT VARIANT 18109 FT /note="G -> S (in dbSNP:rs200732032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040185" FT VARIANT 18164 FT /note="R -> T (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040186" FT VARIANT 18221 FT /note="P -> L (in dbSNP:rs16866406)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040187" FT VARIANT 18222 FT /note="A -> T" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040188" FT VARIANT 18726 FT /note="R -> Q (in dbSNP:rs141973925)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040189" FT VARIANT 18835 FT /note="V -> A (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1336054298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040190" FT VARIANT 18881 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1204056923)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040191" FT VARIANT 18939 FT /note="N -> S (in dbSNP:rs1470758075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040192" FT VARIANT 19000 FT /note="R -> Q (in dbSNP:rs199895260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040193" FT VARIANT 19060 FT /note="L -> Q (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs1383995916)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040194" FT VARIANT 19091 FT /note="R -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040195" FT VARIANT 19224 FT /note="P -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040196" FT VARIANT 19367 FT /note="T -> I (in dbSNP:rs72646850)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040197" FT VARIANT 19392 FT /note="E -> K (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040198" FT VARIANT 19480 FT /note="A -> S (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040199" FT VARIANT 19495 FT /note="D -> G (in dbSNP:rs773075736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040200" FT VARIANT 19665 FT /note="R -> H (in dbSNP:rs202240487)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040201" FT VARIANT 19762 FT /note="T -> I (in dbSNP:rs2042996)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040202" FT VARIANT 19947 FT /note="G -> R (in dbSNP:rs181717727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040203" FT VARIANT 19956 FT /note="V -> M (in dbSNP:rs150661999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040204" FT VARIANT 19992 FT /note="R -> Q (in dbSNP:rs141965360)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040205" FT VARIANT 20057 FT /note="R -> C (in dbSNP:rs72646861)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040206" FT VARIANT 20075 FT /note="S -> L (in dbSNP:rs13021201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040207" FT VARIANT 20179 FT /note="T -> K" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040208" FT VARIANT 20198 FT /note="A -> T (in dbSNP:rs56378177)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040209" FT VARIANT 20198 FT /note="A -> V (in dbSNP:rs55948748)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040210" FT VARIANT 20331 FT /note="R -> H (in dbSNP:rs200217934)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040211" FT VARIANT 20359 FT /note="R -> K (in dbSNP:rs9808036)" FT /id="VAR_056088" FT VARIANT 20408 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040212" FT VARIANT 20564 FT /note="R -> K (in dbSNP:rs72646869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040213" FT VARIANT 20718 FT /note="V -> I (in dbSNP:rs2303838)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040214" FT VARIANT 20726 FT /note="S -> P (in dbSNP:rs72646873)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040215" FT VARIANT 20892 FT /note="T -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040216" FT VARIANT 20894 FT /note="S -> R (in dbSNP:rs750847940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040217" FT VARIANT 21125 FT /note="D -> E (in dbSNP:rs534340303)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040218" FT VARIANT 21403 FT /note="P -> S (in dbSNP:rs55980498)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040219" FT VARIANT 21730 FT /note="R -> C (in dbSNP:rs56141309)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040220" FT VARIANT 21747 FT /note="R -> Q (in dbSNP:rs55853138)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040221" FT VARIANT 21851 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs55713867)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040222" FT VARIANT 21925 FT /note="G -> R (in dbSNP:rs55801134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040223" FT VARIANT 21995 FT /note="R -> H (in dbSNP:rs56071233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040224" FT VARIANT 22045 FT /note="A -> V (in dbSNP:rs55903402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040225" FT VARIANT 22149 FT /note="R -> H (in dbSNP:rs55677134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040226" FT VARIANT 22160 FT /note="V -> I (in dbSNP:rs55885640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040227" FT VARIANT 22261 FT /note="I -> T (in dbSNP:rs55837610)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040228" FT VARIANT 22306 FT /note="K -> N (in dbSNP:rs56019808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040229" FT VARIANT 22357 FT /note="R -> H (in dbSNP:rs10164753)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040230" FT VARIANT 22408 FT /note="L -> P (in dbSNP:rs56399205)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040231" FT VARIANT 22537 FT /note="Q -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040232" FT VARIANT 22584 FT /note="P -> L (in dbSNP:rs55992239)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040233" FT VARIANT 22646 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040234" FT VARIANT 22670 FT /note="T -> A (in dbSNP:rs56201325)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040235" FT VARIANT 22770 FT /note="A -> D (in dbSNP:rs55991022)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040236" FT VARIANT 22801 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs764005465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040237" FT VARIANT 22823 FT /note="R -> W (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs369098292)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040238" FT VARIANT 22968 FT /note="E -> Q (in dbSNP:rs55762754)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040239" FT VARIANT 23074 FT /note="P -> L (in dbSNP:rs55713856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040240" FT VARIANT 23079 FT /note="L -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040241" FT VARIANT 23282 FT /note="D -> N (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040242" FT VARIANT 23303 FT /note="H -> Y (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040243" FT VARIANT 23306 FT /note="R -> C (in dbSNP:rs744426)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040244" FT VARIANT 23515 FT /note="A -> S (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040245" FT VARIANT 23551 FT /note="E -> Q (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040246" FT VARIANT 23807 FT /note="S -> N (in dbSNP:rs3813243)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040247" FT VARIANT 23872 FT /note="D -> N (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040248" FT VARIANT 23891 FT /note="V -> A (in dbSNP:rs55984930)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040249" FT VARIANT 23933 FT /note="Y -> H (in dbSNP:rs3813245)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040250" FT VARIANT 23939 FT /note="T -> M (in dbSNP:rs56372592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040251" FT VARIANT 23952 FT /note="F -> L (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040252" FT VARIANT 24098 FT /note="A -> G (in dbSNP:rs56391938)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040253" FT VARIANT 24098 FT /note="A -> T (in dbSNP:rs4894028)" FT /id="VAR_056089" FT VARIANT 24119 FT /note="N -> S (in dbSNP:rs3813246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040254" FT VARIANT 24133 FT /note="V -> I (in dbSNP:rs56340968)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040255" FT VARIANT 24159 FT /note="V -> A (in a head and neck squamous cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040256" FT VARIANT 24239 FT /note="T -> A (in dbSNP:rs56018860)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040257" FT VARIANT 24265 FT /note="E -> K (in dbSNP:rs56341835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040258" FT VARIANT 24584 FT /note="I -> T (in dbSNP:rs12463674)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040259" FT VARIANT 24781 FT /note="I -> T (in dbSNP:rs3731745)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040260" FT VARIANT 24799 FT /note="R -> H (in dbSNP:rs56044609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040261" FT VARIANT 24954 FT /note="D -> H (in dbSNP:rs56307213)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040262" FT VARIANT 24980 FT /note="T -> M (in dbSNP:rs3731746)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040263" FT VARIANT 25659 FT /note="R -> H (in dbSNP:rs55850344)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040264" FT VARIANT 25679 FT /note="A -> T (in dbSNP:rs56365600)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040265" FT VARIANT 25720 FT /note="P -> A (in dbSNP:rs56137800)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040266" FT VARIANT 25821 FT /note="T -> K (in dbSNP:rs55933739)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040267" FT VARIANT 25859 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs375422359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040268" FT VARIANT 25879 FT /note="N -> K (in dbSNP:rs56264840)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040269" FT VARIANT 25923 FT /note="A -> V (in dbSNP:rs55634791)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040270" FT VARIANT 26045 FT /note="V -> I (in dbSNP:rs56309296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040271" FT VARIANT 26059 FT /note="K -> E (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040272" FT VARIANT 26134 FT /note="I -> V (in dbSNP:rs3829746)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040273" FT VARIANT 26477 FT /note="R -> C (in dbSNP:rs56057221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040274" FT VARIANT 26843 FT /note="D -> Y (in dbSNP:rs56330345)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040275" FT VARIANT 27346 FT /note="K -> R (in dbSNP:rs1186947794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040276" FT VARIANT 27652 FT /note="R -> C (in dbSNP:rs191482653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040277" FT VARIANT 27728 FT /note="G -> V (in dbSNP:rs55898359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040278" FT VARIANT 27754 FT /note="F -> L (in dbSNP:rs55940667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040279" FT VARIANT 27755 FT /note="I -> T (in dbSNP:rs9808377)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040280" FT VARIANT 27929 FT /note="I -> V (in dbSNP:rs139506970)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040281" FT VARIANT 28132 FT /note="I -> L (in dbSNP:rs77853750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040282" FT VARIANT 28168 FT /note="R -> Q (in dbSNP:rs72648238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040283" FT VARIANT 28538 FT /note="R -> H (in dbSNP:rs149567378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040284" FT VARIANT 28572 FT /note="I -> T (in dbSNP:rs114026724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040285" FT VARIANT 28948 FT /note="A -> T (in dbSNP:rs148617456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040286" FT VARIANT 28986 FT /note="I -> V (in dbSNP:rs535151633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040287" FT VARIANT 28993 FT /note="G -> E (in dbSNP:rs376628842)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040288" FT VARIANT 28998 FT /note="L -> V (in dbSNP:rs373049260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040289" FT VARIANT 29070 FT /note="V -> M (in dbSNP:rs747122)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040290" FT VARIANT 29090 FT /note="I -> V (in dbSNP:rs16866391)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040291" FT VARIANT 29419 FT /note="R -> C (in dbSNP:rs750303653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040292" FT VARIANT 29479 FT /note="L -> P (in dbSNP:rs1310673663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040293" FT VARIANT 29880 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040294" FT VARIANT 29976 FT /note="D -> E (in dbSNP:rs72648256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040295" FT VARIANT 30042 FT /note="S -> G (in dbSNP:rs72648257)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040296" FT VARIANT 30107 FT /note="R -> C (in dbSNP:rs142525903)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040297" FT VARIANT 30125 FT /note="S -> F (in dbSNP:rs191484894)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040298" FT VARIANT 30211 FT /note="L -> P (in dbSNP:rs62621206)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040299" FT VARIANT 30412 FT /note="I -> T (in dbSNP:rs62621236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040300" FT VARIANT 30617 FT /note="T -> S (in a renal chromophobe cancer sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040301" FT VARIANT 30674 FT /note="T -> I (in dbSNP:rs56027402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040302" FT VARIANT 30809 FT /note="V -> I (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs397517769)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040303" FT VARIANT 30818 FT /note="F -> I (in dbSNP:rs56009327)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040304" FT VARIANT 30825 FT /note="E -> K (in dbSNP:rs55915651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040305" FT VARIANT 30856 FT /note="I -> T (in dbSNP:rs55660660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040306" FT VARIANT 30887 FT /note="G -> D (in dbSNP:rs56066673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040307" FT VARIANT 30887 FT /note="G -> S (in dbSNP:rs56233675)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040308" FT VARIANT 30897 FT /note="R -> H (in dbSNP:rs3731749)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040309" FT VARIANT 30907 FT /note="R -> H (in dbSNP:rs55676195)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040310" FT VARIANT 30946 FT /note="R -> H (in dbSNP:rs55704830)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040311" FT VARIANT 31081 FT /note="I -> F (in dbSNP:rs72648270)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040312" FT VARIANT 31107 FT /note="R -> C (in dbSNP:rs72648272)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040313" FT VARIANT 31124 FT /note="A -> G (in dbSNP:rs72648273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040314" FT VARIANT 31156 FT /note="N -> S (in dbSNP:rs149001703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040315" FT VARIANT 31246 FT /note="P -> T (in dbSNP:rs55653324)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040316" FT VARIANT 31330 FT /note="R -> H (in dbSNP:rs4894028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040317" FT VARIANT 31690 FT /note="C -> R (in dbSNP:rs56061641)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040318" FT VARIANT 31724 FT /note="R -> Q (in dbSNP:rs55742743)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040319" FT VARIANT 31725 FT /note="V -> I (in dbSNP:rs55675869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040320" FT VARIANT 31732 FT /note="G -> S (in dbSNP:rs55880786)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040321" FT VARIANT 31886 FT /note="V -> I (in dbSNP:rs2278196)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040322" FT VARIANT 32097 FT /note="R -> C (in dbSNP:rs56273463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040323" FT VARIANT 32171 FT /note="T -> N (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040324" FT VARIANT 32248 FT /note="V -> I (in dbSNP:rs34924609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040325" FT VARIANT 32281 FT /note="Q -> H (in dbSNP:rs55886356)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040326" FT VARIANT 32323 FT /note="R -> H (in dbSNP:rs55669553)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040327" FT VARIANT 32411 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs756924372)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040328" FT VARIANT 32558 FT /note="I -> V (in dbSNP:rs56347248)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040329" FT VARIANT 32610 FT /note="M -> V (in dbSNP:rs56173891)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040330" FT VARIANT 32637 FT /note="G -> V (in dbSNP:rs3731752)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040331" FT VARIANT 32742 FT /note="E -> Q (in dbSNP:rs148525155)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069433" FT VARIANT 32922 FT /note="V -> A (in dbSNP:rs55945684)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040332" FT VARIANT 32943 FT /note="L -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040333" FT VARIANT 32953 FT /note="R -> H (in dbSNP:rs3829747)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040334" FT VARIANT 32996 FT /note="R -> Q (in CMD1G; dbSNP:rs199642423)" FT /evidence="ECO:0000269|PubMed:16465475" FT /id="VAR_026693" FT VARIANT 33213 FT /note="V -> L (in dbSNP:rs55866005)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040335" FT VARIANT 33242 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1003158162)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040336" FT VARIANT 33387 FT /note="T -> M (in dbSNP:rs56001826)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040337" FT VARIANT 33419 FT /note="E -> D (in dbSNP:rs56308529)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040338" FT VARIANT 33536 FT /note="V -> M (in dbSNP:rs55865284)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040339" FT VARIANT 33568 FT /note="K -> Q (in dbSNP:rs56365812)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040340" FT VARIANT 33616 FT /note="E -> K (in dbSNP:rs56324595)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040341" FT VARIANT 33620 FT /note="P -> L (in dbSNP:rs16866380)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040342" FT VARIANT 33886 FT /note="E -> V (in dbSNP:rs55725279)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040343" FT VARIANT 33899 FT /note="I -> T (in dbSNP:rs55880440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040344" FT VARIANT 33904 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040345" FT VARIANT 33955 FT /note="T -> I (in dbSNP:rs55842557)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040346" FT VARIANT 34115 FT /note="V -> A (in dbSNP:rs16866378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040347" FT VARIANT 34306 FT /note="I -> N (in TMD; dbSNP:rs281864928)" FT /evidence="ECO:0000269|PubMed:12891679" FT /id="VAR_026694" FT VARIANT 34315 FT /note="L -> P (in TMD; dbSNP:rs267607156)" FT /evidence="ECO:0000269|PubMed:12145747" FT /id="VAR_026695" FT MUTAGEN 32207 FT /note="K->A: Disrupts catalytic activity." FT /evidence="ECO:0000269|PubMed:9804419" FT MUTAGEN 32341 FT /note="Y->E: No phosphorylation on tyrosine." FT /evidence="ECO:0000269|PubMed:9804419" FT CONFLICT 132 FT /note="T -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 255 FT /note="P -> H (in Ref. 3; CAD12455/CAD12456/CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT 1472..1474 FT /note="QTA -> ANC (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 1730 FT /note="G -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 3919 FT /note="P -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 4525 FT /note="R -> K (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 6619 FT /note="R -> E (in Ref. 1; CAA62189 and 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 7145 FT /note="D -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 7441 FT /note="S -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 8038 FT /note="A -> E (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8225 FT /note="Q -> H (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8850 FT /note="A -> P (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9693 FT /note="C -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9892 FT /note="I -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10205 FT /note="I -> V (in Ref. 3; CAD12456 and 9; AAP80791)" FT /evidence="ECO:0000305" FT CONFLICT 10305 FT /note="G -> R (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 10566 FT /note="R -> K (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10779 FT /note="R -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11424 FT /note="E -> D (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 11511 FT /note="A -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11626 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11838 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 12994 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 13795..13797 FT /note="YKF -> IQI (in Ref. 11)" FT /evidence="ECO:0000305" FT CONFLICT 14590 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 14792 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 15974 FT /note="E -> K (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 16234..16235 FT /note="TK -> QR (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17238 FT /note="R -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17423 FT /note="R -> S (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 19734 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20517 FT /note="G -> A (in Ref. 1; CAA62188 and 3; CAD12455)" FT /evidence="ECO:0000305" FT CONFLICT 20622 FT /note="L -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20775 FT /note="A -> P (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 21625 FT /note="Y -> I (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 21795..21800 FT /note="PGPVLN -> ARPSPQ (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 22176 FT /note="C -> W (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22816 FT /note="A -> D (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22837 FT /note="T -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 24176 FT /note="I -> M (in Ref. 1; CAA62188 and 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 24181 FT /note="S -> F (in Ref. 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 25731 FT /note="P -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26573 FT /note="M -> V (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26846..26848 FT /note="IVE -> HRK (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 27879 FT /note="G -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 28936 FT /note="D -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29222 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29518 FT /note="F -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29701 FT /note="T -> P (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29873 FT /note="E -> G (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29878 FT /note="T -> Q (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30209 FT /note="K -> E (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30256 FT /note="A -> R (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30496 FT /note="V -> I (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30534 FT /note="Y -> H (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30748 FT /note="S -> L (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 31303 FT /note="W -> V (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 32060 FT /note="V -> A (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33084 FT /note="D -> N (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33120 FT /note="R -> W (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33382 FT /note="A -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33424 FT /note="S -> P (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33526 FT /note="Q -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33633 FT /note="T -> I (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33716 FT /note="Y -> V (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33995 FT /note="V -> A (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 34071 FT /note="N -> G (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT CONFLICT 34082 FT /note="C -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 34253 FT /note="G -> R (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT STRAND 4..10 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 15..18 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 23..33 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 36..45 FT /evidence="ECO:0007829|PDB:2A38" FT TURN 48..50 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 55..59 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 62..69 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 76..84 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 87..98 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 102..108 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 113..116 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 119..131 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:1YA5" FT STRAND 147..155 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 158..166 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 168..170 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 172..180 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 183..194 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 199..205 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 225..233 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 236..241 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 1850..1852 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1858..1863 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1866..1869 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1871..1876 FT /evidence="ECO:0007829|PDB:6DL4" FT TURN 1891..1893 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1894..1899 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1908..1916 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1919..1929 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 2076..2082 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2087..2090 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2095..2105 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2108..2113 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2122..2130 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2133..2138 FT /evidence="ECO:0007829|PDB:1G1C" FT HELIX 2143..2145 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2147..2155 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2158..2169 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2797..2799 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2804..2807 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2812..2820 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2826..2829 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2838..2845 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2848..2853 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2858..2860 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2862..2868 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2871..2880 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2884..2886 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2891..2894 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2899..2907 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2914..2916 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2924..2932 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2935..2940 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2945..2947 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2949..2955 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2958..2967 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2971..2973 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2978..2981 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2986..2994 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3000..3003 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3012..3019 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3022..3027 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 3032..3034 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3036..3042 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3045..3053 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3504..3507 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3512..3515 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3520..3527 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3533..3538 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3547..3554 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3557..3562 FT /evidence="ECO:0007829|PDB:8OVU" FT HELIX 3567..3569 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3571..3579 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3582..3593 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 7948..7951 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7956..7958 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7964..7975 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7977..7981 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7983..7986 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7991..7996 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8001..8008 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8011..8013 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8015..8023 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8026..8036 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8044..8047 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8052..8055 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8060..8071 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8073..8078 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8087..8094 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8097..8104 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8107..8109 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8111..8119 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8122..8133 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8140..8143 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8151..8154 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8156..8166 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8169..8174 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8183..8190 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8193..8201 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8203..8205 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8207..8215 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8218..8226 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8233..8236 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8244..8247 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8249..8261 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8263..8268 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8276..8284 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8287..8294 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8297..8299 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8301..8309 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8315..8320 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8335..8337 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8343..8354 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8358..8361 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8368..8377 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8380..8385 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8390..8392 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8394..8401 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8406..8415 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8420..8423 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8436..8444 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8451..8454 FT /evidence="ECO:0007829|PDB:3B43" FT TURN 8463..8465 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8466..8468 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8472..8481 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8488..8495 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8500..8507 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 9506..9510 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9518..9525 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9530..9543 FT /evidence="ECO:0007829|PDB:7NIP" FT STRAND 9582..9587 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9592..9595 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9600..9608 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9616..9619 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9628..9635 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9638..9643 FT /evidence="ECO:0007829|PDB:5JOE" FT HELIX 9648..9650 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9652..9658 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9661..9670 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9674..9676 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9681..9684 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9689..9697 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9703..9706 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9717..9722 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9725..9732 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9735..9737 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9739..9745 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9748..9757 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9763..9765 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9770..9772 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9778..9786 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9790..9795 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9803..9811 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9814..9819 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9824..9826 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9828..9835 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9841..9850 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 12680..12682 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12687..12690 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12691..12693 FT /evidence="ECO:0007829|PDB:6I0Y" FT STRAND 12695..12705 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12709..12712 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12719..12722 FT /evidence="ECO:0007829|PDB:1TIU" FT STRAND 12723..12728 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12731..12736 FT /evidence="ECO:0007829|PDB:1WAA" FT HELIX 12741..12743 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12745..12751 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12754..12763 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 14223..14228 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14232..14240 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14252..14259 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14275..14281 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14288..14296 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14308..14314 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14319..14322 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14325..14327 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14331..14334 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14339..14349 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14352..14357 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14368..14372 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14374..14381 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14386..14388 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14390..14397 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14402..14412 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14419..14424 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14431..14436 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14446..14455 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14462..14468 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14470..14475 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14484..14492 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14506..14509 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14522..14524 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14528..14534 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14549..14555 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14568..14576 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14584..14592 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 15216..15224 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15227..15233 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15245..15252 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15268..15273 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15282..15290 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15305..15307 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 16533..16538 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16541..16546 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16559..16566 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16585..16592 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16600..16609 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16623..16626 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 20520..20528 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20531..20537 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20549..20556 FT /evidence="ECO:0007829|PDB:8OSD" FT HELIX 20568..20570 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20573..20580 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20587..20594 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 21506..21509 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21515..21518 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21532..21539 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21546..21551 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21553..21560 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21568..21577 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 22291..22296 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22299..22303 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22319..22324 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22340..22345 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22354..22361 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22367..22377 FT /evidence="ECO:0007829|PDB:1BPV" FT HELIX 22381..22384 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22883..22890 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22895..22900 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22912..22919 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22926..22932 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22934..22939 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22947..22956 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22970..22972 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22982..22987 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22992..22996 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23009..23016 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23023..23035 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23043..23052 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23568..23575 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23581..23586 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23596..23605 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23612..23618 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23620..23625 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23633..23642 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23671..23676 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23679..23683 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23697..23704 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23711..23716 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23720..23725 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23733..23742 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23769..23776 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23781..23786 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23798..23805 FT /evidence="ECO:0007829|PDB:8BNQ" FT TURN 23806..23808 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23811..23815 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23820..23827 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23835..23843 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 25439..25443 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25448..25451 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25465..25472 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25479..25481 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25486..25493 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25501..25509 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25514..25517 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 26130..26137 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26142..26147 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26157..26166 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26173..26179 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26181..26186 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26194..26203 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26206..26212 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 31458..31464 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31469..31472 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31475..31487 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31490..31495 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31498..31500 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31504..31520 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31524..31526 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31528..31535 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31540..31555 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31563..31568 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31573..31583 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31586..31591 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31600..31606 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31608..31617 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31620..31623 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31625..31632 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31637..31647 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31856..31859 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31864..31867 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31872..31879 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31885..31890 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31893..31895 FT /evidence="ECO:0007829|PDB:2J8O" FT STRAND 31899..31907 FT /evidence="ECO:0007829|PDB:2J8H" FT TURN 31908..31910 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31911..31916 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31921..31923 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31925..31933 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31936..31952 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31956..31959 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 31961..31967 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31973..31982 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31985..31992 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31997..32000 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32002..32005 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32007..32013 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 32020..32022 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32024..32032 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32035..32046 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32053..32061 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32063..32070 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32076..32078 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 32082..32089 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32095..32111 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32117..32125 FT /evidence="ECO:0007829|PDB:6YGN" FT HELIX 32142..32154 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32167..32170 FT /evidence="ECO:0007829|PDB:6YGN" FT TURN 32175..32177 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32178..32186 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32188..32197 FT /evidence="ECO:0007829|PDB:1TKI" FT TURN 32198..32201 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32202..32209 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32214..32228 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32237..32243 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32246..32251 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32259..32263 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32265..32267 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32272..32291 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32301..32303 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32304..32310 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32314..32316 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32330..32336 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32338..32340 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32343..32346 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32353..32369 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32379..32388 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32395..32398 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32403..32410 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32417..32419 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32423..32428 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32430..32433 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32436..32438 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32447..32457 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32466..32472 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32474..32476 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32483..32489 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32504..32506 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32512..32520 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32526..32531 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32538..32547 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32550..32555 FT /evidence="ECO:0007829|PDB:2BK8" FT HELIX 32560..32562 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32564..32571 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32576..32585 FT /evidence="ECO:0007829|PDB:2BK8" FT TURN 32586..32588 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32720..32726 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32731..32734 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32739..32749 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32752..32757 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32765..32767 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32768..32773 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32774..32776 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32777..32784 FT /evidence="ECO:0007829|PDB:6HCI" FT HELIX 32787..32789 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32791..32799 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32802..32813 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 33294..33297 FT /evidence="ECO:0007829|PDB:3QP3" FT STRAND 33299..33305 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33310..33313 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33318..33328 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33331..33336 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33345..33352 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33355..33360 FT /evidence="ECO:0007829|PDB:6H4L" FT HELIX 33365..33367 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33369..33377 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33380..33391 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33489..33492 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33497..33503 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33509..33512 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33514..33516 FT /evidence="ECO:0007829|PDB:1TNM" FT STRAND 33523..33526 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33532..33538 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33540..33547 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33556..33560 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33571..33577 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33777..33783 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33788..33794 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33796..33806 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33809..33814 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33821..33830 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33833..33838 FT /evidence="ECO:0007829|PDB:3PUC" FT HELIX 33843..33845 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33847..33855 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33858..33869 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 34060..34071 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34078..34088 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34091..34096 FT /evidence="ECO:0007829|PDB:4UOW" FT TURN 34104..34106 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34107..34112 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34115..34122 FT /evidence="ECO:0007829|PDB:4UOW" FT HELIX 34125..34127 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34129..34136 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34138..34148 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34254..34258 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34263..34268 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34271..34283 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34286..34291 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34300..34302 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34304..34308 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34310..34319 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34322..34324 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34326..34334 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34337..34348 FT /evidence="ECO:0007829|PDB:3KNB" FT CONFLICT Q8WZ42-6:3732 FT /note="L -> F (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT Q8WZ42-6:5139 FT /note="R -> M (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" SQ SEQUENCE 34350 AA; 3816030 MW; DEB216410AD560D9 CRC64; MTTQAPTFTQ PLQSVVVLEG STATFEAHIS GFPVPEVSWF RDGQVISTST LPGVQISFSD GRAKLTIPAV TKANSGRYSL KATNGSGQAT STAELLVKAE TAPPNFVQRL QSMTVRQGSQ VRLQVRVTGI PTPVVKFYRD GAEIQSSLDF QISQEGDLYS LLIAEAYPED SGTYSVNATN SVGRATSTAE LLVQGEEEVP AKKTKTIVST AQISESRQTR IEKKIEAHFD ARSIATVEMV IDGAAGQQLP HKTPPRIPPK PKSRSPTPPS IAAKAQLARQ QSPSPIRHSP SPVRHVRAPT PSPVRSVSPA ARISTSPIRS VRSPLLMRKT QASTVATGPE VPPPWKQEGY VASSSEAEMR ETTLTTSTQI RTEERWEGRY GVQEQVTISG AAGAAASVSA SASYAAEAVA TGAKEVKQDA DKSAAVATVV AAVDMARVRE PVISAVEQTA QRTTTTAVHI QPAQEQVRKE AEKTAVTKVV VAADKAKEQE LKSRTKEVIT TKQEQMHVTH EQIRKETEKT FVPKVVISAA KAKEQETRIS EEITKKQKQV TQEAIRQETE ITAASMVVVA TAKSTKLETV PGAQEETTTQ QDQMHLSYEK IMKETRKTVV PKVIVATPKV KEQDLVSRGR EGITTKREQV QITQEKMRKE AEKTALSTIA VATAKAKEQE TILRTRETMA TRQEQIQVTH GKVDVGKKAE AVATVVAAVD QARVREPREP GHLEESYAQQ TTLEYGYKER ISAAKVAEPP QRPASEPHVV PKAVKPRVIQ APSETHIKTT DQKGMHISSQ IKKTTDLTTE RLVHVDKRPR TASPHFTVSK ISVPKTEHGY EASIAGSAIA TLQKELSATS SAQKITKSVK APTVKPSETR VRAEPTPLPQ FPFADTPDTY KSEAGVEVKK EVGVSITGTT VREERFEVLH GREAKVTETA RVPAPVEIPV TPPTLVSGLK NVTVIEGESV TLECHISGYP SPTVTWYRED YQIESSIDFQ ITFQSGIARL MIREAFAEDS GRFTCSAVNE AGTVSTSCYL AVQVSEEFEK ETTAVTEKFT TEEKRFVESR DVVMTDTSLT EEQAGPGEPA APYFITKPVV QKLVEGGSVV FGCQVGGNPK PHVYWKKSGV PLTTGYRYKV SYNKQTGECK LVISMTFADD AGEYTIVVRN KHGETSASAS LLEEADYELL MKSQQEMLYQ TQVTAFVQEP KVGETAPGFV YSEYEKEYEK EQALIRKKMA KDTVVVRTYV EDQEFHISSF EERLIKEIEY RIIKTTLEEL LEEDGEEKMA VDISESEAVE SGFDSRIKNY RILEGMGVTF HCKMSGYPLP KIAWYKDGKR IKHGERYQMD FLQDGRASLR IPVVLPEDEG IYTAFASNIK GNAICSGKLY VEPAAPLGAP TYIPTLEPVS RIRSLSPRSV SRSPIRMSPA RMSPARMSPA RMSPARMSPG RRLEETDESQ LERLYKPVFV LKPVSFKCLE GQTARFDLKV VGRPMPETFW FHDGQQIVND YTHKVVIKED GTQSLIIVPA TPSDSGEWTV VAQNRAGRSS ISVILTVEAV EHQVKPMFVE KLKNVNIKEG SRLEMKVRAT GNPNPDIVWL KNSDIIVPHK YPKIRIEGTK GEAALKIDST VSQDSAWYTA TAINKAGRDT TRCKVNVEVE FAEPEPERKL IIPRGTYRAK EIAAPELEPL HLRYGQEQWE EGDLYDKEKQ QKPFFKKKLT SLRLKRFGPA HFECRLTPIG DPTMVVEWLH DGKPLEAANR LRMINEFGYC SLDYGVAYSR DSGIITCRAT NKYGTDHTSA TLIVKDEKSL VEESQLPEGR KGLQRIEELE RMAHEGALTG VTTDQKEKQK PDIVLYPEPV RVLEGETARF RCRVTGYPQP KVNWYLNGQL IRKSKRFRVR YDGIHYLDIV DCKSYDTGEV KVTAENPEGV IEHKVKLEIQ QREDFRSVLR RAPEPRPEFH VHEPGKLQFE VQKVDRPVDT TETKEVVKLK RAERITHEKV PEESEELRSK FKRRTEEGYY EAITAVELKS RKKDESYEEL LRKTKDELLH WTKELTEEEK KALAEEGKIT IPTFKPDKIE LSPSMEAPKI FERIQSQTVG QGSDAHFRVR VVGKPDPECE WYKNGVKIER SDRIYWYWPE DNVCELVIRD VTAEDSASIM VKAINIAGET SSHAFLLVQA KQLITFTQEL QDVVAKEKDT MATFECETSE PFVKVKWYKD GMEVHEGDKY RMHSDRKVHF LSILTIDTSD AEDYSCVLVE DENVKTTAKL IVEGAVVEFV KELQDIEVPE SYSGELECIV SPENIEGKWY HNDVELKSNG KYTITSRRGR QNLTVKDVTK EDQGEYSFVI DGKKTTCKLK MKPRPIAILQ GLSDQKVCEG DIVQLEVKVS LESVEGVWMK DGQEVQPSDR VHIVIDKQSH MLLIEDMTKE DAGNYSFTIP ALGLSTSGRV SVYSVDVITP LKDVNVIEGT KAVLECKVSV PDVTSVKWYL NDEQIKPDDR VQAIVKGTKQ RLVINRTHAS DEGPYKLIVG RVETNCNLSV EKIKIIRGLR DLTCTETQNV VFEVELSHSG IDVLWNFKDK EIKPSSKYKI EAHGKIYKLT VLNMMKDDEG KYTFYAGENM TSGKLTVAGG AISKPLTDQT VAESQEAVFE CEVANPDSKG EWLRDGKHLP LTNNIRSESD GHKRRLIIAA TKLDDIGEYT YKVATSKTSA KLKVEAVKIK KTLKNLTVTE TQDAVFTVEL THPNVKGVQW IKNGVVLESN EKYAISVKGT IYSLRIKNCA IVDESVYGFR LGRLGASARL HVETVKIIKK PKDVTALENA TVAFEVSVSH DTVPVKWFHK SVEIKPSDKH RLVSERKVHK LMLQNISPSD AGEYTAVVGQ LECKAKLFVE TLHITKTMKN IEVPETKTAS FECEVSHFNV PSMWLKNGVE IEMSEKFKIV VQGKLHQLII MNTSTEDSAE YTFVCGNDQV SATLTVTPIM ITSMLKDINA EEKDTITFEV TVNYEGISYK WLKNGVEIKS TDKCQMRTKK LTHSLNIRNV HFGDAADYTF VAGKATSTAT LYVEARHIEF RKHIKDIKVL EKKRAMFECE VSEPDITVQW MKDDQELQIT DRIKIQKEKY VHRLLIPSTR MSDAGKYTVV AGGNVSTAKL FVEGRDVRIR SIKKEVQVIE KQRAVVEFEV NEDDVDAHWY KDGIEINFQV QERHKYVVER RIHRMFISET RQSDAGEYTF VAGRNRSSVT LYVNAPEPPQ VLQELQPVTV QSGKPARFCA VISGRPQPKI SWYKEEQLLS TGFKCKFLHD GQEYTLLLIE AFPEDAAVYT CEAKNDYGVA TTSASLSVEV PEVVSPDQEM PVYPPAIITP LQDTVTSEGQ PARFQCRVSG TDLKVSWYSK DKKIKPSRFF RMTQFEDTYQ LEIAEAYPED EGTYTFVASN AVGQVSSTAN LSLEAPESIL HERIEQEIEM EMKEFSSSFL SAEEEGLHSA ELQLSKINET LELLSESPVY PTKFDSEKEG TGPIFIKEVS NADISMGDVA TLSVTVIGIP KPKIQWFFNG VLLTPSADYK FVFDGDDHSL IILFTKLEDE GEYTCMASND YGKTICSAYL KINSKGEGHK DTETESAVAK SLEKLGGPCP PHFLKELKPI RCAQGLPAIF EYTVVGEPAP TVTWFKENKQ LCTSVYYTII HNPNGSGTFI VNDPQREDSG LYICKAENML GESTCAAELL VLLEDTDMTD TPCKAKSTPE APEDFPQTPL KGPAVEALDS EQEIATFVKD TILKAALITE ENQQLSYEHI AKANELSSQL PLGAQELQSI LEQDKLTPES TREFLCINGS IHFQPLKEPS PNLQLQIVQS QKTFSKEGIL MPEEPETQAV LSDTEKIFPS AMSIEQINSL TVEPLKTLLA EPEGNYPQSS IEPPMHSYLT SVAEEVLSPK EKTVSDTNRE QRVTLQKQEA QSALILSQSL AEGHVESLQS PDVMISQVNY EPLVPSEHSC TEGGKILIES ANPLENAGQD SAVRIEEGKS LRFPLALEEK QVLLKEEHSD NVVMPPDQII ESKREPVAIK KVQEVQGRDL LSKESLLSGI PEEQRLNLKI QICRALQAAV ASEQPGLFSE WLRNIEKVEV EAVNITQEPR HIMCMYLVTS AKSVTEEVTI IIEDVDPQMA NLKMELRDAL CAIIYEEIDI LTAEGPRIQQ GAKTSLQEEM DSFSGSQKVE PITEPEVESK YLISTEEVSY FNVQSRVKYL DATPVTKGVA SAVVSDEKQD ESLKPSEEKE ESSSESGTEE VATVKIQEAE GGLIKEDGPM IHTPLVDTVS EEGDIVHLTT SITNAKEVNW YFENKLVPSD EKFKCLQDQN TYTLVIDKVN TEDHQGEYVC EALNDSGKTA TSAKLTVVKR AAPVIKRKIE PLEVALGHLA KFTCEIQSAP NVRFQWFKAG REIYESDKCS IRSSKYISSL EILRTQVVDC GEYTCKASNE YGSVSCTATL TVTEAYPPTF LSRPKSLTTF VGKAAKFICT VTGTPVIETI WQKDGAALSP SPNWRISDAE NKHILELSNL TIQDRGVYSC KASNKFGADI CQAELIIIDK PHFIKELEPV QSAINKKVHL ECQVDEDRKV TVTWSKDGQK LPPGKDYKIC FEDKIATLEI PLAKLKDSGT YVCTASNEAG SSSCSATVTV REPPSFVKKV DPSYLMLPGE SARLHCKLKG SPVIQVTWFK NNKELSESNT VRMYFVNSEA ILDITDVKVE DSGSYSCEAV NDVGSDSCST EIVIKEPPSF IKTLEPADIV RGTNALLQCE VSGTGPFEIS WFKDKKQIRS SKKYRLFSQK SLVCLEIFSF NSADVGEYEC VVANEVGKCG CMATHLLKEP PTFVKKVDDL IALGGQTVTL QAAVRGSEPI SVTWMKGQEV IREDGKIKMS FSNGVAVLII PDVQISFGGK YTCLAENEAG SQTSVGELIV KEPAKIIERA ELIQVTAGDP ATLEYTVAGT PELKPKWYKD GRPLVASKKY RISFKNNVAQ LKFYSAELHD SGQYTFEISN EVGSSSCETT FTVLDRDIAP FFTKPLRNVD SVVNGTCRLD CKIAGSLPMR VSWFKDGKEI AASDRYRIAF VEGTASLEII RVDMNDAGNF TCRATNSVGS KDSSGALIVQ EPPSFVTKPG SKDVLPGSAV CLKSTFQGST PLTIRWFKGN KELVSGGSCY ITKEALESSL ELYLVKTSDS GTYTCKVSNV AGGVECSANL FVKEPATFVE KLEPSQLLKK GDATQLACKV TGTPPIKITW FANDREIKES SKHRMSFVES TAVLRLTDVG IEDSGEYMCE AQNEAGSDHC SSIVIVKESP YFTKEFKPIE VLKEYDVMLL AEVAGTPPFE ITWFKDNTIL RSGRKYKTFI QDHLVSLQIL KFVAADAGEY QCRVTNEVGS SICSARVTLR EPPSFIKKIE STSSLRGGTA AFQATLKGSL PITVTWLKDS DEITEDDNIR MTFENNVASL YLSGIEVKHD GKYVCQAKND AGIQRCSALL SVKEPATITE EAVSIDVTQG DPATLQVKFS GTKEITAKWF KDGQELTLGS KYKISVTDTV SILKIISTEK KDSGEYTFEV QNDVGRSSCK ARINVLDLII PPSFTKKLKK MDSIKGSFID LECIVAGSHP ISIQWFKDDQ EISASEKYKF SFHDNTAFLE ISQLEGTDSG TYTCSATNKA GHNQCSGHLT VKEPPYFVEK PQSQDVNPNT RVQLKALVGG TAPMTIKWFK DNKELHSGAA RSVWKDDTST SLELFAAKAT DSGTYICQLS NDVGTATSKA TLFVKEPPQF IKKPSPVLVL RNGQSTTFEC QITGTPKIRV SWYLDGNEIT AIQKHGISFI DGLATFQISG ARVENSGTYV CEARNDAGTA SCSIELKVKE PPTFIRELKP VEVVKYSDVE LECEVTGTPP FEVTWLKNNR EIRSSKKYTL TDRVSVFNLH ITKCDPSDTG EYQCIVSNEG GSCSCSTRVA LKEPPSFIKK IENTTTVLKS SATFQSTVAG SPPISITWLK DDQILDEDDN VYISFVDSVA TLQIRSVDNG HSGRYTCQAK NESGVERCYA FLLVQEPAQI VEKAKSVDVT EKDPMTLECV VAGTPELKVK WLKDGKQIVP SRYFSMSFEN NVASFRIQSV MKQDSGQYTF KVENDFGSSS CDAYLRVLDQ NIPPSFTKKL TKMDKVLGSS IHMECKVSGS LPISAQWFKD GKEISTSAKY RLVCHERSVS LEVNNLELED TANYTCKVSN VAGDDACSGI LTVKEPPSFL VKPGRQQAIP DSTVEFKAIL KGTPPFKIKW FKDDVELVSG PKCFIGLEGS TSFLNLYSVD ASKTGQYTCH VTNDVGSDSC TTMLLVTEPP KFVKKLEASK IVKAGDSSRL ECKIAGSPEI RVVWFRNEHE LPASDKYRMT FIDSVAVIQM NNLSTEDSGD FICEAQNPAG STSCSTKVIV KEPPVFSSFP PIVETLKNAE VSLECELSGT PPFEVVWYKD KRQLRSSKKY KIASKNFHTS IHILNVDTSD IGEYHCKAQN EVGSDTCVCT VKLKEPPRFV SKLNSLTVVA GEPAELQASI EGAQPIFVQW LKEKEEVIRE SENIRITFVE NVATLQFAKA EPANAGKYIC QIKNDGGMRE NMATLMVLEP AVIVEKAGPM TVTVGETCTL ECKVAGTPEL SVEWYKDGKL LTSSQKHKFS FYNKISSLRI LSVERQDAGT YTFQVQNNVG KSSCTAVVDV SDRAVPPSFT RRLKNTGGVL GASCILECKV AGSSPISVAW FHEKTKIVSG AKYQTTFSDN VCTLQLNSLD SSDMGNYTCV AANVAGSDEC RAVLTVQEPP SFVKEPEPLE VLPGKNVTFT SVIRGTPPFK VNWFRGAREL VKGDRCNIYF EDTVAELELF NIDISQSGEY TCVVSNNAGQ ASCTTRLFVK EPAAFLKRLS DHSVEPGKSI ILESTYTGTL PISVTWKKDG FNITTSEKCN IVTTEKTCIL EILNSTKRDA GQYSCEIENE AGRDVCGALV STLEPPYFVT ELEPLEAAVG DSVSLQCQVA GTPEITVSWY KGDTKLRPTP EYRTYFTNNV ATLVFNKVNI NDSGEYTCKA ENSIGTASSK TVFRIQERQL PPSFARQLKD IEQTVGLPVT LTCRLNGSAP IQVCWYRDGV LLRDDENLQT SFVDNVATLK ILQTDLSHSG QYSCSASNPL GTASSSARLT AREPKKSPFF DIKPVSIDVI AGESADFECH VTGAQPMRIT WSKDNKEIRP GGNYTITCVG NTPHLRILKV GKGDSGQYTC QATNDVGKDM CSAQLSVKEP PKFVKKLEAS KVAKQGESIQ LECKISGSPE IKVSWFRNDS ELHESWKYNM SFINSVALLT INEASAEDSG DYICEAHNGV GDASCSTALT VKAPPVFTQK PSPVGALKGS DVILQCEISG TPPFEVVWVK DRKQVRNSKK FKITSKHFDT SLHILNLEAS DVGEYHCKAT NEVGSDTCSC SVKFKEPPRF VKKLSDTSTL IGDAVELRAI VEGFQPISVV WLKDRGEVIR ESENTRISFI DNIATLQLGS PEASNSGKYI CQIKNDAGMR ECSAVLTVLE PARIIEKPEP MTVTTGNPFA LECVVTGTPE LSAKWFKDGR ELSADSKHHI TFINKVASLK IPCAEMSDKG LYSFEVKNSV GKSNCTVSVH VSDRIVPPSF IRKLKDVNAI LGASVVLECR VSGSAPISVG WFQDGNEIVS GPKCQSSFSE NVCTLNLSLL EPSDTGIYTC VAANVAGSDE CSAVLTVQEP PSFEQTPDSV EVLPGMSLTF TSVIRGTPPF KVKWFKGSRE LVPGESCNIS LEDFVTELEL FEVQPLESGD YSCLVTNDAG SASCTTHLFV KEPATFVKRL ADFSVETGSP IVLEATYTGT PPISVSWIKD EYLISQSERC SITMTEKSTI LEILESTIED YAQYSCLIEN EAGQDICEAL VSVLEPPYFI EPLEHVEAVI GEPATLQCKV DGTPEIRISW YKEHTKLRSA PAYKMQFKNN VASLVINKVD HSDVGEYSCK ADNSVGAVAS SAVLVIKARK LPPFFARKLK DVHETLGFPV AFECRINGSE PLQVSWYKDG VLLKDDANLQ TSFVHNVATL QILQTDQSHI GQYNCSASNP LGTASSSAKL ILSEHEVPPF FDLKPVSVDL ALGESGTFKC HVTGTAPIKI TWAKDNREIR PGGNYKMTLV ENTATLTVLK VGKGDAGQYT CYASNIAGKD SCSAQLGVQE PPRFIKKLEP SRIVKQDEFT RYECKIGGSP EIKVLWYKDE TEIQESSKFR MSFVDSVAVL EMHNLSVEDS GDYTCEAHNA AGSASSSTSL KVKEPPIFRK KPHPIETLKG ADVHLECELQ GTPPFHVSWY KDKRELRSGK KYKIMSENFL TSIHILNVDA ADIGEYQCKA TNDVGSDTCV GSIALKAPPR FVKKLSDIST VVGKEVQLQT TIEGAEPISV VWFKDKGEIV RESDNIWISY SENIATLQFS RVEPANAGKY TCQIKNDAGM QECFATLSVL EPATIVEKPE SIKVTTGDTC TLECTVAGTP ELSTKWFKDG KELTSDNKYK ISFFNKVSGL KIINVAPSDS GVYSFEVQNP VGKDSCTASL QVSDRTVPPS FTRKLKETNG LSGSSVVMEC KVYGSPPISV SWFHEGNEIS SGRKYQTTLT DNTCALTVNM LEESDSGDYT CIATNMAGSD ECSAPLTVRE PPSFVQKPDP MDVLTGTNVT FTSIVKGTPP FSVSWFKGSS ELVPGDRCNV SLEDSVAELE LFDVDTSQSG EYTCIVSNEA GKASCTTHLY IKAPAKFVKR LNDYSIEKGK PLILEGTFTG TPPISVTWKK NGINVTPSQR CNITTTEKSA ILEIPSSTVE DAGQYNCYIE NASGKDSCSA QILILEPPYF VKQLEPVKVS VGDSASLQCQ LAGTPEIGVS WYKGDTKLRP TTTYKMHFRN NVATLVFNQV DINDSGEYIC KAENSVGEVS ASTFLTVQEQ KLPPSFSRQL RDVQETVGLP VVFDCAISGS EPISVSWYKD GKPLKDSPNV QTSFLDNTAT LNIFKTDRSL AGQYSCTATN PIGSASSSAR LILTEGKNPP FFDIRLAPVD AVVGESADFE CHVTGTQPIK VSWAKDSREI RSGGKYQISY LENSAHLTVL KVDKGDSGQY TCYAVNEVGK DSCTAQLNIK ERLIPPSFTK RLSETVEETE GNSFKLEGRV AGSQPITVAW YKNNIEIQPT SNCEITFKNN TLVLQVRKAG MNDAGLYTCK VSNDAGSALC TSSIVIKEPK KPPVFDQHLT PVTVSEGEYV QLSCHVQGSE PIRIQWLKAG REIKPSDRCS FSFASGTAVL ELRDVAKADS GDYVCKASNV AGSDTTKSKV TIKDKPAVAP ATKKAAVDGR LFFVSEPQSI RVVEKTTATF IAKVGGDPIP NVKWTKGKWR QLNQGGRVFI HQKGDEAKLE IRDTTKTDSG LYRCVAFNEH GEIESNVNLQ VDERKKQEKI EGDLRAMLKK TPILKKGAGE EEEIDIMELL KNVDPKEYEK YARMYGITDF RGLLQAFELL KQSQEEETHR LEIEEIERSE RDEKEFEELV SFIQQRLSQT EPVTLIKDIE NQTVLKDNDA VFEIDIKINY PEIKLSWYKG TEKLEPSDKF EISIDGDRHT LRVKNCQLKD QGNYRLVCGP HIASAKLTVI EPAWERHLQD VTLKEGQTCT MTCQFSVPNV KSEWFRNGRI LKPQGRHKTE VEHKVHKLTI ADVRAEDQGQ YTCKYEDLET SAELRIEAEP IQFTKRIQNI VVSEHQSATF ECEVSFDDAI VTWYKGPTEL TESQKYNFRN DGRCHYMTIH NVTPDDEGVY SVIARLEPRG EARSTAELYL TTKEIKLELK PPDIPDSRVP IPTMPIRAVP PEEIPPVVAP PIPLLLPTPE EKKPPPKRIE VTKKAVKKDA KKVVAKPKEM TPREEIVKKP PPPTTLIPAK APEIIDVSSK AEEVKIMTIT RKKEVQKEKE AVYEKKQAVH KEKRVFIESF EEPYDELEVE PYTEPFEQPY YEEPDEDYEE IKVEAKKEVH EEWEEDFEEG QEYYEREEGY DEGEEEWEEA YQEREVIQVQ KEVYEESHER KVPAKVPEKK APPPPKVIKK PVIEKIEKTS RRMEEEKVQV TKVPEVSKKI VPQKPSRTPV QEEVIEVKVP AVHTKKMVIS EEKMFFASHT EEEVSVTVPE VQKEIVTEEK IHVAISKRVE PPPKVPELPE KPAPEEVAPV PIPKKVEPPA PKVPEVPKKP VPEEKKPVPV PKKEPAAPPK VPEVPKKPVP EEKIPVPVAK KKEAPPAKVP EVQKGVVTEE KITIVTQREE SPPPAVPEIP KKKVPEERKP VPRKEEEVPP PPKVPALPKK PVPEEKVAVP VPVAKKAPPP RAEVSKKTVV EEKRFVAEEK LSFAVPQRVE VTRHEVSAEE EWSYSEEEEG VSISVYREEE REEEEEAEVT EYEVMEEPEE YVVEEKLHII SKRVEAEPAE VTERQEKKIV LKPKIPAKIE EPPPAKVPEA PKKIVPEKKV PAPVPKKEKV PPPKVPEEPK KPVPEKKVPP KVIKMEEPLP AKVTERHMQI TQEEKVLVAV TKKEAPPKAR VPEEPKRAVP EEKVLKLKPK REEEPPAKVT EFRKRVVKEE KVSIEAPKRE PQPIKEVTIM EEKERAYTLE EEAVSVQREE EYEEYEEYDY KEFEEYEPTE EYDQYEEYEE REYERYEEHE EYITEPEKPI PVKPVPEEPV PTKPKAPPAK VLKKAVPEEK VPVPIPKKLK PPPPKVPEEP KKVFEEKIRI SITKREKEQV TEPAAKVPMK PKRVVAEEKV PVPRKEVAPP VRVPEVPKEL EPEEVAFEEE VVTHVEEYLV EEEEEYIHEE EEFITEEEVV PVIPVKVPEV PRKPVPEEKK PVPVPKKKEA PPAKVPEVPK KPEEKVPVLI PKKEKPPPAK VPEVPKKPVP EEKVPVPVPK KVEAPPAKVP EVPKKPVPEK KVPVPAPKKV EAPPAKVPEV PKKLIPEEKK PTPVPKKVEA PPPKVPKKRE PVPVPVALPQ EEEVLFEEEI VPEEEVLPEE EEVLPEEEEV LPEEEEVLPE EEEIPPEEEE VPPEEEYVPE EEEFVPEEEV LPEVKPKVPV PAPVPEIKKK VTEKKVVIPK KEEAPPAKVP EVPKKVEEKR IILPKEEEVL PVEVTEEPEE EPISEEEIPE EPPSIEEVEE VAPPRVPEVI KKAVPEAPTP VPKKVEAPPA KVSKKIPEEK VPVPVQKKEA PPAKVPEVPK KVPEKKVLVP KKEAVPPAKG RTVLEEKVSV AFRQEVVVKE RLELEVVEAE VEEIPEEEEF HEVEEYFEEG EFHEVEEFIK LEQHRVEEEH RVEKVHRVIE VFEAEEVEVF EKPKAPPKGP EISEKIIPPK KPPTKVVPRK EPPAKVPEVP KKIVVEEKVR VPEEPRVPPT KVPEVLPPKE VVPEKKVPVP PAKKPEAPPP KVPEAPKEVV PEKKVPVPPP KKPEVPPTKV PEVPKAAVPE KKVPEAIPPK PESPPPEVPE APKEVVPEKK VPAAPPKKPE VTPVKVPEAP KEVVPEKKVP VPPPKKPEVP PTKVPEVPKV AVPEKKVPEA IPPKPESPPP EVFEEPEEVA LEEPPAEVVE EPEPAAPPQV TVPPKKPVPE KKAPAVVAKK PELPPVKVPE VPKEVVPEKK VPLVVPKKPE APPAKVPEVP KEVVPEKKVA VPKKPEVPPA KVPEVPKKPV LEEKPAVPVP ERAESPPPEV YEEPEEIAPE EEIAPEEEKP VPVAEEEEPE VPPPAVPEEP KKIIPEKKVP VIKKPEAPPP KEPEPEKVIE KPKLKPRPPP PPPAPPKEDV KEKIFQLKAI PKKKVPEKPQ VPEKVELTPL KVPGGEKKVR KLLPERKPEP KEEVVLKSVL RKRPEEEEPK VEPKKLEKVK KPAVPEPPPP KPVEEVEVPT VTKRERKIPE PTKVPEIKPA IPLPAPEPKP KPEAEVKTIK PPPVEPEPTP IAAPVTVPVV GKKAEAKAPK EEAAKPKGPI KGVPKKTPSP IEAERRKLRP GSGGEKPPDE APFTYQLKAV PLKFVKEIKD IILTESEFVG SSAIFECLVS PSTAITTWMK DGSNIRESPK HRFIADGKDR KLHIIDVQLS DAGEYTCVLR LGNKEKTSTA KLVVEELPVR FVKTLEEEVT VVKGQPLYLS CELNKERDVV WRKDGKIVVE KPGRIVPGVI GLMRALTIND ADDTDAGTYT VTVENANNLE CSSCVKVVEV IRDWLVKPIR DQHVKPKGTA IFACDIAKDT PNIKWFKGYD EIPAEPNDKT EILRDGNHLY LKIKNAMPED IAEYAVEIEG KRYPAKLTLG EREVELLKPI EDVTIYEKES ASFDAEISEA DIPGQWKLKG ELLRPSPTCE IKAEGGKRFL TLHKVKLDQA GEVLYQALNA ITTAILTVKE IELDFAVPLK DVTVPERRQA RFECVLTREA NVIWSKGPDI IKSSDKFDII ADGKKHILVI NDSQFDDEGV YTAEVEGKKT SARLFVTGIR LKFMSPLEDQ TVKEGETATF VCELSHEKMH VVWFKNDAKL HTSRTVLISS EGKTHKLEMK EVTLDDISQI KAQVKELSST AQLKVLEADP YFTVKLHDKT AVEKDEITLK CEVSKDVPVK WFKDGEEIVP SPKYSIKADG LRRILKIKKA DLKDKGEYVC DCGTDKTKAN VTVEARLIKV EKPLYGVEVF VGETAHFEIE LSEPDVHGQW KLKGQPLTAS PDCEIIEDGK KHILILHNCQ LGMTGEVSFQ AANAKSAANL KVKELPLIFI TPLSDVKVFE KDEAKFECEV SREPKTFRWL KGTQEITGDD RFELIKDGTK HSMVIKSAAF EDEAKYMFEA EDKHTSGKLI IEGIRLKFLT PLKDVTAKEK ESAVFTVELS HDNIRVKWFK NDQRLHTTRS VSMQDEGKTH SITFKDLSID DTSQIRVEAM GMSSEAKLTV LEGDPYFTGK LQDYTGVEKD EVILQCEISK ADAPVKWFKD GKEIKPSKNA VIKADGKKRM LILKKALKSD IGQYTCDCGT DKTSGKLDIE DREIKLVRPL HSVEVMETET ARFETEISED DIHANWKLKG EALLQTPDCE IKEEGKIHSL VLHNCRLDQT GGVDFQAANV KSSAHLRVKP RVIGLLRPLK DVTVTAGETA TFDCELSYED IPVEWYLKGK KLEPSDKVVP RSEGKVHTLT LRDVKLEDAG EVQLTAKDFK THANLFVKEP PVEFTKPLED QTVEEGATAV LECEVSRENA KVKWFKNGTE ILKSKKYEIV ADGRVRKLVI HDCTPEDIKT YTCDAKDFKT SCNLNVVPPH VEFLRPLTDL QVREKEMARF ECELSRENAK VKWFKDGAEI KKGKKYDIIS KGAVRILVIN KCLLDDEAEY SCEVRTARTS GMLTVLEEEA VFTKNLANIE VSETDTIKLV CEVSKPGAEV IWYKGDEEII ETGRYEILTE GRKRILVIQN AHLEDAGNYN CRLPSSRTDG KVKVHELAAE FISKPQNLEI LEGEKAEFVC SISKESFPVQ WKRDDKTLES GDKYDVIADG KKRVLVVKDA TLQDMGTYVV MVGAARAAAH LTVIEKLRIV VPLKDTRVKE QQEVVFNCEV NTEGAKAKWF RNEEAIFDSS KYIILQKDLV YTLRIRDAHL DDQANYNVSL TNHRGENVKS AANLIVEEED LRIVEPLKDI ETMEKKSVTF WCKVNRLNVT LKWTKNGEEV PFDNRVSYRV DKYKHMLTIK DCGFPDEGEY IVTAGQDKSV AELLIIEAPT EFVEHLEDQT VTEFDDAVFS CQLSREKANV KWYRNGREIK EGKKYKFEKD GSIHRLIIKD CRLDDECEYA CGVEDRKSRA RLFVEEIPVE IIRPPQDILE APGADVVFLA ELNKDKVEVQ WLRNNMVVVQ GDKHQMMSEG KIHRLQICDI KPRDQGEYRF IAKDKEARAK LELAAAPKIK TADQDLVVDV GKPLTMVVPY DAYPKAEAEW FKENEPLSTK TIDTTAEQTS FRILEAKKGD KGRYKIVLQN KHGKAEGFIN LKVIDVPGPV RNLEVTETFD GEVSLAWEEP LTDGGSKIIG YVVERRDIKR KTWVLATDRA ESCEFTVTGL QKGGVEYLFR VSARNRVGTG EPVETDNPVE ARSKYDVPGP PLNVTITDVN RFGVSLTWEP PEYDGGAEIT NYVIELRDKT SIRWDTAMTV RAEDLSATVT DVVEGQEYSF RVRAQNRIGV GKPSAATPFV KVADPIERPS PPVNLTSSDQ TQSSVQLKWE PPLKDGGSPI LGYIIERCEE GKDNWIRCNM KLVPELTYKV TGLEKGNKYL YRVSAENKAG VSDPSEILGP LTADDAFVEP TMDLSAFKDG LEVIVPNPIT ILVPSTGYPR PTATWCFGDK VLETGDRVKM KTLSAYAELV ISPSERSDKG IYTLKLENRV KTISGEIDVN VIARPSAPKE LKFGDITKDS VHLTWEPPDD DGGSPLTGYV VEKREVSRKT WTKVMDFVTD LEFTVPDLVQ GKEYLFKVCA RNKCGPGEPA YVDEPVNMST PATVPDPPEN VKWRDRTANS IFLTWDPPKN DGGSRIKGYI VERCPRGSDK WVACGEPVAE TKMEVTGLEE GKWYAYRVKA LNRQGASKPS RPTEEIQAVD TQEAPEIFLD VKLLAGLTVK AGTKIELPAT VTGKPEPKIT WTKADMILKQ DKRITIENVP KKSTVTIVDS KRSDTGTYII EAVNVCGRAT AVVEVNVLDK PGPPAAFDIT DVTNESCLLT WNPPRDDGGS KITNYVVERR ATDSEVWHKL SSTVKDTNFK ATKLIPNKEY IFRVAAENMY GVGEPVQASP ITAKYQFDPP GPPTRLEPSD ITKDAVTLTW CEPDDDGGSP ITGYWVERLD PDTDKWVRCN KMPVKDTTYR VKGLTNKKKY RFRVLAENLA GPGKPSKSTE PILIKDPIDP PWPPGKPTVK DVGKTSVRLN WTKPEHDGGA KIESYVIEML KTGTDEWVRV AEGVPTTQHL LPGLMEGQEY SFRVRAVNKA GESEPSEPSD PVLCREKLYP PSPPRWLEVI NITKNTADLK WTVPEKDGGS PITNYIVEKR DVRRKGWQTV DTTVKDTKCT VTPLTEGSLY VFRVAAENAI GQSDYTEIED SVLAKDTFTT PGPPYALAVV DVTKRHVDLK WEPPKNDGGR PIQRYVIEKK ERLGTRWVKA GKTAGPDCNF RVTDVIEGTE VQFQVRAENE AGVGHPSEPT EILSIEDPTS PPSPPLDLHV TDAGRKHIAI AWKPPEKNGG SPIIGYHVEM CPVGTEKWMR VNSRPIKDLK FKVEEGVVPD KEYVLRVRAV NAIGVSEPSE ISENVVAKDP DCKPTIDLET HDIIVIEGEK LSIPVPFRAV PVPTVSWHKD GKEVKASDRL TMKNDHISAH LEVPKSVRAD AGIYTITLEN KLGSATASIN VKVIGLPGPC KDIKASDITK SSCKLTWEPP EFDGGTPILH YVLERREAGR RTYIPVMSGE NKLSWTVKDL IPNGEYFFRV KAVNKVGGGE YIELKNPVIA QDPKQPPDPP VDVEVHNPTA EAMTITWKPP LYDGGSKIMG YIIEKIAKGE ERWKRCNEHL VPILTYTAKG LEEGKEYQFR VRAENAAGIS EPSRATPPTK AVDPIDAPKV ILRTSLEVKR GDEIALDASI SGSPYPTITW IKDENVIVPE EIKKRAAPLV RRRKGEVQEE EPFVLPLTQR LSIDNSKKGE SQLRVRDSLR PDHGLYMIKV ENDHGIAKAP CTVSVLDTPG PPINFVFEDI RKTSVLCKWE PPLDDGGSEI INYTLEKKDK TKPDSEWIVV TSTLRHCKYS VTKLIEGKEY LFRVRAENRF GPGPPCVSKP LVAKDPFGPP DAPDKPIVED VTSNSMLVKW NEPKDNGSPI LGYWLEKREV NSTHWSRVNK SLLNALKANV DGLLEGLTYV FRVCAENAAG PGKFSPPSDP KTAHDPISPP GPPIPRVTDT SSTTIELEWE PPAFNGGGEI VGYFVDKQLV GTNEWSRCTE KMIKVRQYTV KEIREGADYK LRVSAVNAAG EGPPGETQPV TVAEPQEPPA VELDVSVKGG IQIMAGKTLR IPAVVTGRPV PTKVWTKEEG ELDKDRVVID NVGTKSELII KDALRKDHGR YVITATNSCG SKFAAARVEV FDVPGPVLDL KPVVTNRKMC LLNWSDPEDD GGSEITGFII ERKDAKMHTW RQPIETERSK CDITGLLEGQ EYKFRVIAKN KFGCGPPVEI GPILAVDPLG PPTSPERLTY TERTKSTITL DWKEPRSNGG SPIQGYIIEK RRHDKPDFER VNKRLCPTTS FLVENLDEHQ MYEFRVKAVN EIGESEPSLP LNVVIQDDEV PPTIKLRLSV RGDTIKVKAG EPVHIPADVT GLPMPKIEWS KNETVIEKPT DALQITKEEV SRSEAKTELS IPKAVREDKG TYTVTASNRL GSVFRNVHVE VYDRPSPPRN LAVTDIKAES CYLTWDAPLD NGGSEITHYV IDKRDASRKK AEWEEVTNTA VEKRYGIWKL IPNGQYEFRV RAVNKYGISD ECKSDKVVIQ DPYRLPGPPG KPKVLARTKG SMLVSWTPPL DNGGSPITGY WLEKREEGSP YWSRVSRAPI TKVGLKGVEF NVPRLLEGVK YQFRAMAINA AGIGPPSEPS DPEVAGDPIF PPGPPSCPEV KDKTKSSISL GWKPPAKDGG SPIKGYIVEM QEEGTTDWKR VNEPDKLITT CECVVPNLKE LRKYRFRVKA VNEAGESEPS DTTGEIPATD IQEEPEVFID IGAQDCLVCK AGSQIRIPAV IKGRPTPKSS WEFDGKAKKA MKDGVHDIPE DAQLETAENS SVIIIPECKR SHTGKYSITA KNKAGQKTAN CRVKVMDVPG PPKDLKVSDI TRGSCRLSWK MPDDDGGDRI KGYVIEKRTI DGKAWTKVNP DCGSTTFVVP DLLSEQQYFF RVRAENRFGI GPPVETIQRT TARDPIYPPD PPIKLKIGLI TKNTVHLSWK PPKNDGGSPV THYIVECLAW DPTGTKKEAW RQCNKRDVEE LQFTVEDLVE GGEYEFRVKA VNAAGVSKPS ATVGPVTVKD QTCPPSIDLK EFMEVEEGTN VNIVAKIKGV PFPTLTWFKA PPKKPDNKEP VLYDTHVNKL VVDDTCTLVI PQSRRSDTGL YTITAVNNLG TASKEMRLNV LGRPGPPVGP IKFESVSADQ MTLSWFPPKD DGGSKITNYV IEKREANRKT WVHVSSEPKE CTYTIPKLLE GHEYVFRIMA QNKYGIGEPL DSEPETARNL FSVPGAPDKP TVSSVTRNSM TVNWEEPEYD GGSPVTGYWL EMKDTTSKRW KRVNRDPIKA MTLGVSYKVT GLIEGSDYQF RVYAINAAGV GPASLPSDPA TARDPIAPPG PPFPKVTDWT KSSADLEWSP PLKDGGSKVT GYIVEYKEEG KEEWEKGKDK EVRGTKLVVT GLKEGAFYKF RVRAVNIAGI GEPGEVTDVI EMKDRLVSPD LQLDASVRDR IVVHAGGVIR IIAYVSGKPP PTVTWNMNER TLPQEATIET TAISSSMVIK NCQRSHQGVY SLLAKNEAGE RKKTIIVDVL DVPGPVGTPF LAHNLTNESC KLTWFSPEDD GGSPITNYVI EKRESDRRAW TPVTYTVTRQ NATVQGLIQG KAYFFRIAAE NSIGMGPFVE TSEALVIREP ITVPERPEDL EVKEVTKNTV TLTWNPPKYD GGSEIINYVL ESRLIGTEKF HKVTNDNLLS RKYTVKGLKE GDTYEYRVSA VNIVGQGKPS FCTKPITCKD ELAPPTLHLD FRDKLTIRVG EAFALTGRYS GKPKPKVSWF KDEADVLEDD RTHIKTTPAT LALEKIKAKR SDSGKYCVVV ENSTGSRKGF CQVNVVDRPG PPVGPVSFDE VTKDYMVISW KPPLDDGGSK ITNYIIEKKE VGKDVWMPVT SASAKTTCKV SKLLEGKDYI FRIHAENLYG ISDPLVSDSM KAKDRFRVPD APDQPIVTEV TKDSALVTWN KPHDGGKPIT NYILEKRETM SKRWARVTKD PIHPYTKFRV PDLLEGCQYE FRVSAENEIG IGDPSPPSKP VFAKDPIAKP SPPVNPEAID TTCNSVDLTW QPPRHDGGSK ILGYIVEYQK VGDEEWRRAN HTPESCPETK YKVTGLRDGQ TYKFRVLAVN AAGESDPAHV PEPVLVKDRL EPPELILDAN MAREQHIKVG DTLRLSAIIK GVPFPKVTWK KEDRDAPTKA RIDVTPVGSK LEIRNAAHED GGIYSLTVEN PAGSKTVSVK VLVLDKPGPP RDLEVSEIRK DSCYLTWKEP LDDGGSVITN YVVERRDVAS AQWSPLSATS KKKSHFAKHL NEGNQYLFRV AAENQYGRGP FVETPKPIKA LDPLHPPGPP KDLHHVDVDK TEVSLVWNKP DRDGGSPITG YLVEYQEEGT QDWIKFKTVT NLECVVTGLQ QGKTYRFRVK AENIVGLGLP DTTIPIECQE KLVPPSVELD VKLIEGLVVK AGTTVRFPAI IRGVPVPTAK WTTDGSEIKT DEHYTVETDN FSSVLTIKNC LRRDTGEYQI TVSNAAGSKT VAVHLTVLDV PGPPTGPINI LDVTPEHMTI SWQPPKDDGG SPVINYIVEK QDTRKDTWGV VSSGSSKTKL KIPHLQKGCE YVFRVRAENK IGVGPPLDST PTVAKHKFSP PSPPGKPVVT DITENAATVS WTLPKSDGGS PITGYYMERR EVTGKWVRVN KTPIADLKFR VTGLYEGNTY EFRVFAENLA GLSKPSPSSD PIKACRPIKP PGPPINPKLK DKSRETADLV WTKPLSDGGS PILGYVVECQ KPGTAQWNRI NKDELIRQCA FRVPGLIEGN EYRFRIKAAN IVGEGEPREL AESVIAKDIL HPPEVELDVT CRDVITVRVG QTIRILARVK GRPEPDITWT KEGKVLVREK RVDLIQDLPR VELQIKEAVR ADHGKYIISA KNSSGHAQGS AIVNVLDRPG PCQNLKVTNV TKENCTISWE NPLDNGGSEI TNFIVEYRKP NQKGWSIVAS DVTKRLIKAN LLANNEYYFR VCAENKVGVG PTIETKTPIL AINPIDRPGE PENLHIADKG KTFVYLKWRR PDYDGGSPNL SYHVERRLKG SDDWERVHKG SIKETHYMVD RCVENQIYEF RVQTKNEGGE SDWVKTEEVV VKEDLQKPVL DLKLSGVLTV KAGDTIRLEA GVRGKPFPEV AWTKDKDATD LTRSPRVKID TRADSSKFSL TKAKRSDGGK YVVTATNTAG SFVAYATVNV LDKPGPVRNL KIVDVSSDRC TVCWDPPEDD GGCEIQNYIL EKCETKRMVW STYSATVLTP GTTVTRLIEG NEYIFRVRAE NKIGTGPPTE SKPVIAKTKY DKPGRPDPPE VTKVSKEEMT VVWNPPEYDG GKSITGYFLE KKEKHSTRWV PVNKSAIPER RMKVQNLLPD HEYQFRVKAE NEIGIGEPSL PSRPVVAKDP IEPPGPPTNF RVVDTTKHSI TLGWGKPVYD GGAPIIGYVV EMRPKIADAS PDEGWKRCNA AAQLVRKEFT VTSLDENQEY EFRVCAQNQV GIGRPAELKE AIKPKEILEP PEIDLDASMR KLVIVRAGCP IRLFAIVRGR PAPKVTWRKV GIDNVVRKGQ VDLVDTMAFL VIPNSTRDDS GKYSLTLVNP AGEKAVFVNV RVLDTPGPVS DLKVSDVTKT SCHVSWAPPE NDGGSQVTHY IVEKREADRK TWSTVTPEVK KTSFHVTNLV PGNEYYFRVT AVNEYGPGVP TDVPKPVLAS DPLSEPDPPR KLEVTEMTKN SATLAWLPPL RDGGAKIDGY ITSYREEEQP ADRWTEYSVV KDLSLVVTGL KEGKKYKFRV AARNAVGVSL PREAEGVYEA KEQLLPPKIL MPEQITIKAG KKLRIEAHVY GKPHPTCKWK KGEDEVVTSS HLAVHKADSS SILIIKDVTR KDSGYYSLTA ENSSGTDTQK IKVVVMDAPG PPQPPFDISD IDADACSLSW HIPLEDGGSN ITNYIVEKCD VSRGDWVTAL ASVTKTSCRV GKLIPGQEYI FRVRAENRFG ISEPLTSPKM VAQFPFGVPS EPKNARVTKV NKDCIFVAWD RPDSDGGSPI IGYLIERKER NSLLWVKAND TLVRSTEYPC AGLVEGLEYS FRIYALNKAG SSPPSKPTEY VTARMPVDPP GKPEVIDVTK STVSLIWARP KHDGGSKIIG YFVEACKLPG DKWVRCNTAP HQIPQEEYTA TGLEEKAQYQ FRAIARTAVN ISPPSEPSDP VTILAENVPP RIDLSVAMKS LLTVKAGTNV CLDATVFGKP MPTVSWKKDG TLLKPAEGIK MAMQRNLCTL ELFSVNRKDS GDYTITAENS SGSKSATIKL KVLDKPGPPA SVKINKMYSD RAMLSWEPPL EDGGSEITNY IVDKRETSRP NWAQVSATVP ITSCSVEKLI EGHEYQFRIC AENKYGVGDP VFTEPAIAKN PYDPPGRCDP PVISNITKDH MTVSWKPPAD DGGSPITGYL LEKRETQAVN WTKVNRKPII ERTLKATGLQ EGTEYEFRVT AINKAGPGKP SDASKAAYAR DPQYPPGPPA FPKVYDTTRS SVSLSWGKPA YDGGSPIIGY LVEVKRADSD NWVRCNLPQN LQKTRFEVTG LMEDTQYQFR VYAVNKIGYS DPSDVPDKHY PKDILIPPEG ELDADLRKTL ILRAGVTMRL YVPVKGRPPP KITWSKPNVN LRDRIGLDIK STDFDTFLRC ENVNKYDAGK YILTLENSCG KKEYTIVVKV LDTPGPPVNV TVKEISKDSA YVTWEPPIID GGSPIINYVV QKRDAERKSW STVTTECSKT SFRVANLEEG KSYFFRVFAE NEYGIGDPGE TRDAVKASQT PGPVVDLKVR SVSKSSCSIG WKKPHSDGGS RIIGYVVDFL TEENKWQRVM KSLSLQYSAK DLTEGKEYTF RVSAENENGE GTPSEITVVA RDDVVAPDLD LKGLPDLCYL AKENSNFRLK IPIKGKPAPS VSWKKGEDPL ATDTRVSVES SAVNTTLIVY DCQKSDAGKY TITLKNVAGT KEGTISIKVV GKPGIPTGPI KFDEVTAEAM TLKWAPPKDD GGSEITNYIL EKRDSVNNKW VTCASAVQKT TFRVTRLHEG MEYTFRVSAE NKYGVGEGLK SEPIVARHPF DVPDAPPPPN IVDVRHDSVS LTWTDPKKTG GSPITGYHLE FKERNSLLWK RANKTPIRMR DFKVTGLTEG LEYEFRVMAI NLAGVGKPSL PSEPVVALDP IDPPGKPEVI NITRNSVTLI WTEPKYDGGH KLTGYIVEKR DLPSKSWMKA NHVNVPECAF TVTDLVEGGK YEFRIRAKNT AGAISAPSES TETIICKDEY EAPTIVLDPT IKDGLTIKAG DTIVLNAISI LGKPLPKSSW SKAGKDIRPS DITQITSTPT SSMLTIKYAT RKDAGEYTIT ATNPFGTKVE HVKVTVLDVP GPPGPVEISN VSAEKATLTW TPPLEDGGSP IKSYILEKRE TSRLLWTVVS EDIQSCRHVA TKLIQGNEYI FRVSAVNHYG KGEPVQSEPV KMVDRFGPPG PPEKPEVSNV TKNTATVSWK RPVDDGGSEI TGYHVERREK KSLRWVRAIK TPVSDLRCKV TGLQEGSTYE FRVSAENRAG IGPPSEASDS VLMKDAAYPP GPPSNPHVTD TTKKSASLAW GKPHYDGGLE ITGYVVEHQK VGDEAWIKDT TGTALRITQF VVPDLQTKEK YNFRISAIND AGVGEPAVIP DVEIVEREMA PDFELDAELR RTLVVRAGLS IRIFVPIKGR PAPEVTWTKD NINLKNRANI ENTESFTLLI IPECNRYDTG KFVMTIENPA GKKSGFVNVR VLDTPGPVLN LRPTDITKDS VTLHWDLPLI DGGSRITNYI VEKREATRKS YSTATTKCHK CTYKVTGLSE GCEYFFRVMA ENEYGIGEPT ETTEPVKASE APSPPDSLNI MDITKSTVSL AWPKPKHDGG SKITGYVIEA QRKGSDQWTH ITTVKGLECV VRNLTEGEEY TFQVMAVNSA GRSAPRESRP VIVKEQTMLP ELDLRGIYQK LVIAKAGDNI KVEIPVLGRP KPTVTWKKGD QILKQTQRVN FETTATSTIL NINECVRSDS GPYPLTARNI VGEVGDVITI QVHDIPGPPT GPIKFDEVSS DFVTFSWDPP ENDGGVPISN YVVEMRQTDS TTWVELATTV IRTTYKATRL TTGLEYQFRV KAQNRYGVGP GITSACIVAN YPFKVPGPPG TPQVTAVTKD SMTISWHEPL SDGGSPILGY HVERKERNGI LWQTVSKALV PGNIFKSSGL TDGIAYEFRV IAENMAGKSK PSKPSEPMLA LDPIDPPGKP VPLNITRHTV TLKWAKPEYT GGFKITSYIV EKRDLPNGRW LKANFSNILE NEFTVSGLTE DAAYEFRVIA KNAAGAISPP SEPSDAITCR DDVEAPKIKV DVKFKDTVIL KAGEAFRLEA DVSGRPPPTM EWSKDGKELE GTAKLEIKIA DFSTNLVNKD STRRDSGAYT LTATNPGGFA KHIFNVKVLD RPGPPEGPLA VTEVTSEKCV LSWFPPLDDG GAKIDHYIVQ KRETSRLAWT NVASEVQVTK LKVTKLLKGN EYIFRVMAVN KYGVGEPLES EPVLAVNPYG PPDPPKNPEV TTITKDSMVV CWGHPDSDGG SEIINYIVER RDKAGQRWIK CNKKTLTDLR YKVSGLTEGH EYEFRIMAEN AAGISAPSPT SPFYKACDTV FKPGPPGNPR VLDTSRSSIS IAWNKPIYDG GSEITGYMVE IALPEEDEWQ IVTPPAGLKA TSYTITGLTE NQEYKIRIYA MNSEGLGEPA LVPGTPKAED RMLPPEIELD ADLRKVVTIR ACCTLRLFVP IKGRPAPEVK WARDHGESLD KASIESTSSY TLLIVGNVNR FDSGKYILTV ENSSGSKSAF VNVRVLDTPG PPQDLKVKEV TKTSVTLTWD PPLLDGGSKI KNYIVEKRES TRKAYSTVAT NCHKTSWKVD QLQEGCSYYF RVLAENEYGI GLPAETAESV KASERPLPPG KITLMDVTRN SVSLSWEKPE HDGGSRILGY IVEMQTKGSD KWATCATVKV TEATITGLIQ GEEYSFRVSA QNEKGISDPR QLSVPVIAKD LVIPPAFKLL FNTFTVLAGE DLKVDVPFIG RPTPAVTWHK DNVPLKQTTR VNAESTENNS LLTIKDACRE DVGHYVVKLT NSAGEAIETL NVIVLDKPGP PTGPVKMDEV TADSITLSWG PPKYDGGSSI NNYIVEKRDT STTTWQIVSA TVARTTIKAC RLKTGCEYQF RIAAENRYGK STYLNSEPTV AQYPFKVPGP PGTPVVTLSS RDSMEVQWNE PISDGGSRVI GYHLERKERN SILWVKLNKT PIPQTKFKTT GLEEGVEYEF RVSAENIVGI GKPSKVSECY VARDPCDPPG RPEAIIVTRN SVTLQWKKPT YDGGSKITGY IVEKKELPEG RWMKASFTNI IDTHFEVTGL VEDHRYEFRV IARNAAGVFS EPSESTGAIT ARDEVDPPRI SMDPKYKDTI VVHAGESFKV DADIYGKPIP TIQWIKGDQE LSNTARLEIK STDFATSLSV KDAVRVDSGN YILKAKNVAG ERSVTVNVKV LDRPGPPEGP VVISGVTAEK CTLAWKPPLQ DGGSDIINYI VERRETSRLV WTVVDANVQT LSCKVTKLLE GNEYTFRIMA VNKYGVGEPL ESEPVVAKNP FVVPDAPKAP EVTTVTKDSM IVVWERPASD GGSEILGYVL EKRDKEGIRW TRCHKRLIGE LRLRVTGLIE NHDYEFRVSA ENAAGLSEPS PPSAYQKACD PIYKPGPPNN PKVIDITRSS VFLSWSKPIY DGGCEIQGYI VEKCDVSVGE WTMCTPPTGI NKTNIEVEKL LEKHEYNFRI CAINKAGVGE HADVPGPIIV EEKLEAPDID LDLELRKIIN IRAGGSLRLF VPIKGRPTPE VKWGKVDGEI RDAAIIDVTS SFTSLVLDNV NRYDSGKYTL TLENSSGTKS AFVTVRVLDT PSPPVNLKVT EITKDSVSIT WEPPLLDGGS KIKNYIVEKR EATRKSYAAV VTNCHKNSWK IDQLQEGCSY YFRVTAENEY GIGLPAQTAD PIKVAEVPQP PGKITVDDVT RNSVSLSWTK PEHDGGSKII QYIVEMQAKH SEKWSECARV KSLQAVITNL TQGEEYLFRV VAVNEKGRSD PRSLAVPIVA KDLVIEPDVK PAFSSYSVQV GQDLKIEVPI SGRPKPTITW TKDGLPLKQT TRINVTDSLD LTTLSIKETH KDDGGQYGIT VANVVGQKTA SIEIVTLDKP DPPKGPVKFD DVSAESITLS WNPPLYTGGC QITNYIVQKR DTTTTVWDVV SATVARTTLK VTKLKTGTEY QFRIFAENRY GQSFALESDP IVAQYPYKEP GPPGTPFATA ISKDSMVIQW HEPVNNGGSP VIGYHLERKE RNSILWTKVN KTIIHDTQFK AQNLEEGIEY EFRVYAENIV GVGKASKNSE CYVARDPCDP PGTPEPIMVK RNEITLQWTK PVYDGGSMIT GYIVEKRDLP DGRWMKASFT NVIETQFTVS GLTEDQRYEF RVIAKNAAGA ISKPSDSTGP ITAKDEVELP RISMDPKFRD TIVVNAGETF RLEADVHGKP LPTIEWLRGD KEIEESARCE IKNTDFKALL IVKDAIRIDG GQYILRASNV AGSKSFPVNV KVLDRPGPPE GPVQVTGVTS EKCSLTWSPP LQDGGSDISH YVVEKRETSR LAWTVVASEV VTNSLKVTKL LEGNEYVFRI MAVNKYGVGE PLESAPVLMK NPFVLPGPPK SLEVTNIAKD SMTVCWNRPD SDGGSEIIGY IVEKRDRSGI RWIKCNKRRI TDLRLRVTGL TEDHEYEFRV SAENAAGVGE PSPATVYYKA CDPVFKPGPP TNAHIVDTTK NSITLAWGKP IYDGGSEILG YVVEICKADE EEWQIVTPQT GLRVTRFEIS KLTEHQEYKI RVCALNKVGL GEATSVPGTV KPEDKLEAPE LDLDSELRKG IVVRAGGSAR IHIPFKGRPT PEITWSREEG EFTDKVQIEK GVNYTQLSID NCDRNDAGKY ILKLENSSGS KSAFVTVKVL DTPGPPQNLA VKEVRKDSAF LVWEPPIIDG GAKVKNYVID KRESTRKAYA NVSSKCSKTS FKVENLTEGA IYYFRVMAEN EFGVGVPVET VDAVKAAEPP SPPGKVTLTD VSQTSASLMW EKPEHDGGSR VLGYVVEMQP KGTEKWSIVA ESKVCNAVVT GLSSGQEYQF RVKAYNEKGK SDPRVLGVPV IAKDLTIQPS LKLPFNTYSI QAGEDLKIEI PVIGRPRPNI SWVKDGEPLK QTTRVNVEET ATSTVLHIKE GNKDDFGKYT VTATNSAGTA TENLSVIVLE KPGPPVGPVR FDEVSADFVV ISWEPPAYTG GCQISNYIVE KRDTTTTTWH MVSATVARTT IKITKLKTGT EYQFRIFAEN RYGKSAPLDS KAVIVQYPFK EPGPPGTPFV TSISKDQMLV QWHEPVNDGG TKIIGYHLEQ KEKNSILWVK LNKTPIQDTK FKTTGLDEGL EYEFKVSAEN IVGIGKPSKV SECFVARDPC DPPGRPEAIV ITRNNVTLKW KKPAYDGGSK ITGYIVEKKD LPDGRWMKAS FTNVLETEFT VSGLVEDQRY EFRVIARNAA GNFSEPSDSS GAITARDEID APNASLDPKY KDVIVVHAGE TFVLEADIRG KPIPDVVWSK DGKELEETAA RMEIKSTIQK TTLVVKDCIR TDGGQYILKL SNVGGTKSIP ITVKVLDRPG PPEGPLKVTG VTAEKCYLAW NPPLQDGGAN ISHYIIEKRE TSRLSWTQVS TEVQALNYKV TKLLPGNEYI FRVMAVNKYG IGEPLESGPV TACNPYKPPG PPSTPEVSAI TKDSMVVTWA RPVDDGGTEI EGYILEKRDK EGVRWTKCNK KTLTDLRLRV TGLTEGHSYE FRVAAENAAG VGEPSEPSVF YRACDALYPP GPPSNPKVTD TSRSSVSLAW SKPIYDGGAP VKGYVVEVKE AAADEWTTCT PPTGLQGKQF TVTKLKENTE YNFRICAINS EGVGEPATLP GSVVAQERIE PPEIELDADL RKVVVLRASA TLRLFVTIKG RPEPEVKWEK AEGILTDRAQ IEVTSSFTML VIDNVTRFDS GRYNLTLENN SGSKTAFVNV RVLDSPSAPV NLTIREVKKD SVTLSWEPPL IDGGAKITNY IVEKRETTRK AYATITNNCT KTTFRIENLQ EGCSYYFRVL ASNEYGIGLP AETTEPVKVS EPPLPPGRVT LVDVTRNTAT IKWEKPESDG GSKITGYVVE MQTKGSEKWS TCTQVKTLEA TISGLTAGEE YVFRVAAVNE KGRSDPRQLG VPVIARDIEI KPSVELPFHT FNVKAREQLK IDVPFKGRPQ ATVNWRKDGQ TLKETTRVNV SSSKTVTSLS IKEASKEDVG TYELCVSNSA GSITVPITII VLDRPGPPGP IRIDEVSCDS ITISWNPPEY DGGCQISNYI VEKKETTSTT WHIVSQAVAR TSIKIVRLTT GSEYQFRVCA ENRYGKSSYS ESSAVVAEYP FSPPGPPGTP KVVHATKSTM LVTWQVPVND GGSRVIGYHL EYKERSSILW SKANKILIAD TQMKVSGLDE GLMYEYRVYA ENIAGIGKCS KSCEPVPARD PCDPPGQPEV TNITRKSVSL KWSKPHYDGG AKITGYIVER RELPDGRWLK CNYTNIQETY FEVTELTEDQ RYEFRVFARN AADSVSEPSE STGPIIVKDD VEPPRVMMDV KFRDVIVVKA GEVLKINADI AGRPLPVISW AKDGIEIEER ARTEIISTDN HTLLTVKDCI RRDTGQYVLT LKNVAGTRSV AVNCKVLDKP GPPAGPLEIN GLTAEKCSLS WGRPQEDGGA DIDYYIVEKR ETSHLAWTIC EGELQMTSCK VTKLLKGNEY IFRVTGVNKY GVGEPLESVA IKALDPFTVP SPPTSLEITS VTKESMTLCW SRPESDGGSE ISGYIIERRE KNSLRWVRVN KKPVYDLRVK STGLREGCEY EYRVYAENAA GLSLPSETSP LIRAEDPVFL PSPPSKPKIV DSGKTTITIA WVKPLFDGGA PITGYTVEYK KSDDTDWKTS IQSLRGTEYT ISGLTTGAEY VFRVKSVNKV GASDPSDSSD PQIAKEREEE PLFDIDSEMR KTLIVKAGAS FTMTVPFRGR PVPNVLWSKP DTDLRTRAYV DTTDSRTSLT IENANRNDSG KYTLTIQNVL SAASLTLVVK VLDTPGPPTN ITVQDVTKES AVLSWDVPEN DGGAPVKNYH IEKREASKKA WVSVTNNCNR LSYKVTNLQE GAIYYFRVSG ENEFGVGIPA ETKEGVKITE KPSPPEKLGV TSISKDSVSL TWLKPEHDGG SRIVHYVVEA LEKGQKNWVK CAVAKSTHHV VSGLRENSEY FFRVFAENQA GLSDPRELLL PVLIKEQLEP PEIDMKNFPS HTVYVRAGSN LKVDIPISGK PLPKVTLSRD GVPLKATMRF NTEITAENLT INLKESVTAD AGRYEITAAN SSGTTKAFIN IVVLDRPGPP TGPVVISDIT EESVTLKWEP PKYDGGSQVT NYILLKRETS TAVWTEVSAT VARTMMKVMK LTTGEEYQFR IKAENRFGIS DHIDSACVTV KLPYTTPGPP STPWVTNVTR ESITVGWHEP VSNGGSAVVG YHLEMKDRNS ILWQKANKLV IRTTHFKVTT ISAGLIYEFR VYAENAAGVG KPSHPSEPVL AIDACEPPRN VRITDISKNS VSLSWQQPAF DGGSKITGYI VERRDLPDGR WTKASFTNVT ETQFIISGLT QNSQYEFRVF ARNAVGSISN PSEVVGPITC IDSYGGPVID LPLEYTEVVK YRAGTSVKLR AGISGKPAPT IEWYKDDKEL QTNALVCVEN TTDLASILIK DADRLNSGCY ELKLRNAMGS ASATIRVQIL DKPGPPGGPI EFKTVTAEKI TLLWRPPADD GGAKITHYIV EKRETSRVVW SMVSEHLEEC IITTTKIIKG NEYIFRVRAV NKYGIGEPLE SDSVVAKNAF VTPGPPGIPE VTKITKNSMT VVWSRPIADG GSDISGYFLE KRDKKSLGWF KVLKETIRDT RQKVTGLTEN SDYQYRVCAV NAAGQGPFSE PSEFYKAADP IDPPGPPAKI RIADSTKSSI TLGWSKPVYD GGSAVTGYVV EIRQGEEEEW TTVSTKGEVR TTEYVVSNLK PGVNYYFRVS AVNCAGQGEP IEMNEPVQAK DILEAPEIDL DVALRTSVIA KAGEDVQVLI PFKGRPPPTV TWRKDEKNLG SDARYSIENT DSSSLLTIPQ VTRNDTGKYI LTIENGVGEP KSSTVSVKVL DTPAACQKLQ VKHVSRGTVT LLWDPPLIDG GSPIINYVIE KRDATKRTWS VVSHKCSSTS FKLIDLSEKT PFFFRVLAEN EIGIGEPCET TEPVKAAEVP APIRDLSMKD STKTSVILSW TKPDFDGGSV ITEYVVERKG KGEQTWSHAG ISKTCEIEVS QLKEQSVLEF RVFAKNEKGL SDPVTIGPIT VKELIITPEV DLSDIPGAQV TVRIGHNVHL ELPYKGKPKP SISWLKDGLP LKESEFVRFS KTENKITLSI KNAKKEHGGK YTVILDNAVC RIAVPITVIT LGPPSKPKGP IRFDEIKADS VILSWDVPED NGGGEITCYS IEKRETSQTN WKMVCSSVAR TTFKVPNLVK DAEYQFRVRA ENRYGVSQPL VSSIIVAKHQ FRIPGPPGKP VIYNVTSDGM SLTWDAPVYD GGSEVTGFHV EKKERNSILW QKVNTSPISG REYRATGLVE GLDYQFRVYA ENSAGLSSPS DPSKFTLAVS PVDPPGTPDY IDVTRETITL KWNPPLRDGG SKIVGYSIEK RQGNERWVRC NFTDVSECQY TVTGLSPGDR YEFRIIARNA VGTISPPSQS SGIIMTRDEN VPPIVEFGPE YFDGLIIKSG ESLRIKALVQ GRPVPRVTWF KDGVEIEKRM NMEITDVLGS TSLFVRDATR DHRGVYTVEA KNASGSAKAE IKVKVQDTPG KVVGPIRFTN ITGEKMTLWW DAPLNDGCAP ITHYIIEKRE TSRLAWALIE DKCEAQSYTA IKLINGNEYQ FRVSAVNKFG VGRPLDSDPV VAQIQYTVPD APGIPEPSNI TGNSITLTWA RPESDGGSEI QQYILERREK KSTRWVKVIS KRPISETRFK VTGLTEGNEY EFHVMAENAA GVGPASGISR LIKCREPVNP PGPPTVVKVT DTSKTTVSLE WSKPVFDGGM EIIGYIIEMC KADLGDWHKV NAEACVKTRY TVTDLQAGEE YKFRVSAING AGKGDSCEVT GTIKAVDRLT APELDIDANF KQTHVVRAGA SIRLFIAYQG RPTPTAVWSK PDSNLSLRAD IHTTDSFSTL TVENCNRNDA GKYTLTVENN SGSKSITFTV KVLDTPGPPG PITFKDVTRG SATLMWDAPL LDGGARIHHY VVEKREASRR SWQVISEKCT RQIFKVNDLA EGVPYYFRVS AVNEYGVGEP YEMPEPIVAT EQPAPPRRLD VVDTSKSSAV LAWLKPDHDG GSRITGYLLE MRQKGSDFWV EAGHTKQLTF TVERLVEKTE YEFRVKAKND AGYSEPREAF SSVIIKEPQI EPTADLTGIT NQLITCKAGS PFTIDVPISG RPAPKVTWKL EEMRLKETDR VSITTTKDRT TLTVKDSMRG DSGRYFLTLE NTAGVKTFSV TVVVIGRPGP VTGPIEVSSV SAESCVLSWG EPKDGGGTEI TNYIVEKRES GTTAWQLVNS SVKRTQIKVT HLTKYMEYSF RVSSENRFGV SKPLESAPII AEHPFVPPSA PTRPEVYHVS ANAMSIRWEE PYHDGGSKII GYWVEKKERN TILWVKENKV PCLECNYKVT GLVEGLEYQF RTYALNAAGV SKASEASRPI MAQNPVDAPG RPEVTDVTRS TVSLIWSAPA YDGGSKVVGY IIERKPVSEV GDGRWLKCNY TIVSDNFFTV TALSEGDTYE FRVLAKNAAG VISKGSESTG PVTCRDEYAP PKAELDARLH GDLVTIRAGS DLVLDAAVGG KPEPKIIWTK GDKELDLCEK VSLQYTGKRA TAVIKFCDRS DSGKYTLTVK NASGTKAVSV MVKVLDSPGP CGKLTVSRVT QEKCTLAWSL PQEDGGAEIT HYIVERRETS RLNWVIVEGE CPTLSYVVTR LIKNNEYIFR VRAVNKYGPG VPVESEPIVA RNSFTIPSPP GIPEEVGTGK EHIIIQWTKP ESDGGNEISN YLVDKREKKS LRWTRVNKDY VVYDTRLKVT SLMEGCDYQF RVTAVNAAGN SEPSEASNFI SCREPSYTPG PPSAPRVVDT TKHSISLAWT KPMYDGGTDI VGYVLEMQEK DTDQWYRVHT NATIRNTEFT VPDLKMGQKY SFRVAAVNVK GMSEYSESIA EIEPVERIEI PDLELADDLK KTVTIRAGAS LRLMVSVSGR PPPVITWSKQ GIDLASRAII DTTESYSLLI VDKVNRYDAG KYTIEAENQS GKKSATVLVK VYDTPGPCPS VKVKEVSRDS VTITWEIPTI DGGAPVNNYI VEKREAAMRA FKTVTTKCSK TLYRISGLVE GTMYYFRVLP ENIYGIGEPC ETSDAVLVSE VPLVPAKLEV VDVTKSTVTL AWEKPLYDGG SRLTGYVLEA CKAGTERWMK VVTLKPTVLE HTVTSLNEGE QYLFRIRAQN EKGVSEPRET VTAVTVQDLR VLPTIDLSTM PQKTIHVPAG RPVELVIPIA GRPPPAASWF FAGSKLRESE RVTVETHTKV AKLTIRETTI RDTGEYTLEL KNVTGTTSET IKVIILDKPG PPTGPIKIDE IDATSITISW EPPELDGGAP LSGYVVEQRD AHRPGWLPVS ESVTRSTFKF TRLTEGNEYV FRVAATNRFG IGSYLQSEVI ECRSSIRIPG PPETLQIFDV SRDGMTLTWY PPEDDGGSQV TGYIVERKEV RADRWVRVNK VPVTMTRYRS TGLTEGLEYE HRVTAINARG SGKPSRPSKP IVAMDPIAPP GKPQNPRVTD TTRTSVSLAW SVPEDEGGSK VTGYLIEMQK VDQHEWTKCN TTPTKIREYT LTHLPQGAEY RFRVLACNAG GPGEPAEVPG TVKVTEMLEY PDYELDERYQ EGIFVRQGGV IRLTIPIKGK PFPICKWTKE GQDISKRAMI ATSETHTELV IKEADRGDSG TYDLVLENKC GKKAVYIKVR VIGSPNSPEG PLEYDDIQVR SVRVSWRPPA DDGGADILGY ILERREVPKA AWYTIDSRVR GTSLVVKGLK ENVEYHFRVS AENQFGISKP LKSEEPVTPK TPLNPPEPPS NPPEVLDVTK SSVSLSWSRP KDDGGSRVTG YYIERKETST DKWVRHNKTQ ITTTMYTVTG LVPDAEYQFR IIAQNDVGLS ETSPASEPVV CKDPFDKPSQ PGELEILSIS KDSVTLQWEK PECDGGKEIL GYWVEYRQSG DSAWKKSNKE RIKDKQFTIG GLLEATEYEF RVFAENETGL SRPRRTAMSI KTKLTSGEAP GIRKEMKDVT TKLGEAAQLS CQIVGRPLPD IKWYRFGKEL IQSRKYKMSS DGRTHTLTVM TEEQEDEGVY TCIATNEVGE VETSSKLLLQ ATPQFHPGYP LKEKYYGAVG STLRLHVMYI GRPVPAMTWF HGQKLLQNSE NITIENTEHY THLVMKNVQR KTHAGKYKVQ LSNVFGTVDA ILDVEIQDKP DKPTGPIVIE ALLKNSAVIS WKPPADDGGS WITNYVVEKC EAKEGAEWQL VSSAISVTTC RIVNLTENAG YYFRVSAQNT FGISDPLEVS SVVIIKSPFE KPGAPGKPTI TAVTKDSCVV AWKPPASDGG AKIRNYYLEK REKKQNKWIS VTTEEIRETV FSVKNLIEGL EYEFRVKCEN LGGESEWSEI SEPITPKSDV PIQAPHFKEE LRNLNVRYQS NATLVCKVTG HPKPIVKWYR QGKEIIADGL KYRIQEFKGG YHQLIIASVT DDDATVYQVR ATNQGGSVSG TASLEVEVPA KIHLPKTLEG MGAVHALRGE VVSIKIPFSG KPDPVITWQK GQDLIDNNGH YQVIVTRSFT SLVFPNGVER KDAGFYVVCA KNRFGIDQKT VELDVADVPD PPRGVKVSDV SRDSVNLTWT EPASDGGSKI TNYIVEKCAT TAERWLRVGQ ARETRYTVIN LFGKTSYQFR VIAENKFGLS KPSEPSEPTI TKEDKTRAMN YDEEVDETRE VSMTKASHSS TKELYEKYMI AEDLGRGEFG IVHRCVETSS KKTYMAKFVK VKGTDQVLVK KEISILNIAR HRNILHLHES FESMEELVMI FEFISGLDIF ERINTSAFEL NEREIVSYVH QVCEALQFLH SHNIGHFDIR PENIIYQTRR SSTIKIIEFG QARQLKPGDN FRLLFTAPEY YAPEVHQHDV VSTATDMWSL GTLVYVLLSG INPFLAETNQ QIIENIMNAE YTFDEEAFKE ISIEAMDFVD RLLVKERKSR MTASEALQHP WLKQKIERVS TKVIRTLKHR RYYHTLIKKD LNMVVSAARI SCGGAIRSQK GVSVAKVKVA SIEIGPVSGQ IMHAVGEEGG HVKYVCKIEN YDQSTQVTWY FGVRQLENSE KYEITYEDGV AILYVKDITK LDDGTYRCKV VNDYGEDSSY AELFVKGVRE VYDYYCRRTM KKIKRRTDTM RLLERPPEFT LPLYNKTAYV GENVRFGVTI TVHPEPHVTW YKSGQKIKPG DNDKKYTFES DKGLYQLTIN SVTTDDDAEY TVVARNKYGE DSCKAKLTVT LHPPPTDSTL RPMFKRLLAN AECQEGQSVC FEIRVSGIPP PTLKWEKDGQ PLSLGPNIEI IHEGLDYYAL HIRDTLPEDT GYYRVTATNT AGSTSCQAHL QVERLRYKKQ EFKSKEEHER HVQKQIDKTL RMAEILSGTE SVPLTQVAKE ALREAAVLYK PAVSTKTVKG EFRLEIEEKK EERKLRMPYD VPEPRKYKQT TIEEDQRIKQ FVPMSDMKWY KKIRDQYEMP GKLDRVVQKR PKRIRLSRWE QFYVMPLPRI TDQYRPKWRI PKLSQDDLEI VRPARRRTPS PDYDFYYRPR RRSLGDISDE ELLLPIDDYL AMKRTEEERL RLEEELELGF SASPPSRSPP HFELSSLRYS SPQAHVKVEE TRKDFRYSTY HIPTKAEAST SYAELRERHA QAAYRQPKQR QRIMAEREDE ELLRPVTTTQ HLSEYKSELD FMSKEEKSRK KSRRQREVTE ITEIEEEYEI SKHAQRESSS SASRLLRRRR SLSPTYIELM RPVSELIRSR PQPAEEYEDD TERRSPTPER TRPRSPSPVS SERSLSRFER SARFDIFSRY ESMKAALKTQ KTSERKYEVL SQQPFTLDHA PRITLRMRSH RVPCGQNTRF ILNVQSKPTA EVKWYHNGVE LQESSKIHYT NTSGVLTLEI LDCHTDDSGT YRAVCTNYKG EASDYATLDV TGGDYTTYAS QRRDEEVPRS VFPELTRTEA YAVSSFKKTS EMEASSSVRE VKSQMTETRE SLSSYEHSAS AEMKSAALEE KSLEEKSTTR KIKTTLAARI LTKPRSMTVY EGESARFSCD TDGEPVPTVT WLRKGQVLST SARHQVTTTK YKSTFEISSV QASDEGNYSV VVENSEGKQE AEFTLTIQKA RVTEKAVTSP PRVKSPEPRV KSPEAVKSPK RVKSPEPSHP KAVSPTETKP TPTEKVQHLP VSAPPKITQF LKAEASKEIA KLTCVVESSV LRAKEVTWYK DGKKLKENGH FQFHYSADGT YELKINNLTE SDQGEYVCEI SGEGGTSKTN LQFMGQAFKS IHEKVSKISE TKKSDQKTTE STVTRKTEPK APEPISSKPV IVTGLQDTTV SSDSVAKFAV KATGEPRPTA IWTKDGKAIT QGGKYKLSED KGGFFLEIHK TDTSDSGLYT CTVKNSAGSV SSSCKLTIKA IKDTEAQKVS TQKTSEITPQ KKAVVQEEIS QKALRSEEIK MSEAKSQEKL ALKEEASKVL ISEEVKKSAA TSLEKSIVHE EITKTSQASE EVRTHAEIKA FSTQMSINEG QRLVLKANIA GATDVKWVLN GVELTNSEEY RYGVSGSDQT LTIKQASHRD EGILTCISKT KEGIVKCQYD LTLSKELSDA PAFISQPRSQ NINEGQNVLF TCEISGEPSP EIEWFKNNLP ISISSNVSIS RSRNVYSLEI RNASVSDSGK YTIKAKNFRG QCSATASLMV LPLVEEPSRE VVLRTSGDTS LQGSFSSQSV QMSASKQEAS FSSFSSSSAS SMTEMKFASM SAQSMSSMQE SFVEMSSSSF MGISNMTQLE SSTSKMLKAG IRGIPPKIEA LPSDISIDEG KVLTVACAFT GEPTPEVTWS CGGRKIHSQE QGRFHIENTD DLTTLIIMDV QKQDGGLYTL SLGNEFGSDS ATVNIHIRSI // ID TNI3K_HUMAN Reviewed; 835 AA. AC Q59H18; Q17RN0; Q49AR1; Q6MZS9; Q9Y2V6; DT 22-NOV-2005, integrated into UniProtKB/Swiss-Prot. DT 13-JUL-2010, sequence version 3. DT 28-JAN-2026, entry version 192. DE RecName: Full=Serine/threonine-protein kinase TNNI3K; DE EC=2.7.11.1; DE AltName: Full=Cardiac ankyrin repeat kinase; DE AltName: Full=Cardiac troponin I-interacting kinase; DE AltName: Full=TNNI3-interacting kinase; GN Name=TNNI3K {ECO:0000312|EMBL:AAH32865.1}; Synonyms=CARK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAD29632.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TISSUE SPECIFICITY, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, INTERACTION WITH TNNI3; ACTC1; RP ACTA1; MYBPC3; AIP; FABP3 AND HADHB, AND MUTAGENESIS OF LYS-490. RC TISSUE=Heart {ECO:0000312|EMBL:AAD29632.1}; RX PubMed=12721663; DOI=10.1007/s00109-003-0427-x; RA Zhao Y., Meng X.-M., Wei Y.-J., Zhao X.-W., Liu D.-Q., Cao H.-Q., RA Liew C.-C., Ding J.-F.; RT "Cloning and characterization of a novel cardiac-specific kinase that RT interacts specifically with cardiac troponin I."; RL J. Mol. Med. 81:297-304(2003). RN [2] {ECO:0000305, ECO:0000312|EMBL:AAP72030.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Jeyaseelan R.; RT "Cardiac ankyrin repeat kinase (CARK)."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [3] {ECO:0000305, ECO:0000312|EMBL:AAP72030.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain {ECO:0000312|EMBL:BAD92178.1}; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Fetal kidney; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] {ECO:0000305, ECO:0000312|EMBL:AAP72030.1} RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-785 AND TYR-833. RG SeattleSNPs variation discovery resource; RL Submitted (AUG-2006) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [7] {ECO:0000305, ECO:0000312|EMBL:AAP72030.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] {ECO:0000305, ECO:0000312|EMBL:AAH32865.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 4). RC TISSUE=Brain {ECO:0000312|EMBL:AAH32865.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP VARIANT [LARGE SCALE ANALYSIS] GLY-629. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [10] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-151; LEU-263; LEU-309; LEU-430; RP LEU-510; MET-637; THR-686 AND ILE-798. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [11] RP INVOLVEMENT IN CCDD, VARIANT CCDD ASP-526, AND CHARACTERIZATION OF VARIANT RP CCDD ASP-526. RX PubMed=24925317; DOI=10.1093/hmg/ddu297; RA Theis J.L., Zimmermann M.T., Larsen B.T., Rybakova I.N., Long P.A., RA Evans J.M., Middha S., de Andrade M., Moss R.L., Wieben E.D., Michels V.V., RA Olson T.M.; RT "TNNI3K mutation in familial syndrome of conduction system disease, atrial RT tachyarrhythmia and dilated cardiomyopathy."; RL Hum. Mol. Genet. 23:5793-5804(2014). RN [12] RP VARIANT CCDD ALA-539. RX PubMed=25791106; DOI=10.1016/j.ijcard.2015.03.130; RG Care4Rare Canada Consortium; RA Xi Y., Honeywell C., Zhang D., Schwartzentruber J., Beaulieu C.L., RA Tetreault M., Hartley T., Marton J., Vidal S.M., Majewski J., Aravind L., RA Gollob M., Boycott K.M., Gow R.M.; RT "Whole exome sequencing identifies the TNNI3K gene as a cause of familial RT conduction system disease and congenital junctional ectopic tachycardia."; RL Int. J. Cardiol. 185:114-116(2015). RN [13] RP VARIANT CCDD LYS-768, AND CHARACTERIZATION OF VARIANTS ASP-526 AND LYS-768. RX PubMed=30010057; DOI=10.1016/j.hrthm.2018.07.015; RA Podliesna S., Delanne J., Miller L., Tester D.J., Uzunyan M., Yano S., RA Klerk M., Cannon B.C., Khongphatthanayothin A., Laurent G., Bertaux G., RA Falcon-Eicher S., Wu S., Yen H.Y., Gao H., Wilde A.A.M., Faivre L., RA Ackerman M.J., Lodder E.M., Bezzina C.R.; RT "Supraventricular tachycardias, conduction disease, and cardiomyopathy in 3 RT families with the same rare variant in TNNI3K (p.Glu768Lys)."; RL Heart Rhythm 16:98-105(2019). RN [14] RP VARIANT PRO-511. RX PubMed=34440456; DOI=10.3390/genes12081282; RA Ramzan S., Tennstedt S., Tariq M., Khan S., Noor Ul Ayan H., Ali A., RA Munz M., Thiele H., Korejo A.A., Mughal A.R., Jamal S.Z., Nuernberg P., RA Baig S.M., Erdmann J., Ahmad I.; RT "A novel missense mutation in TNNI3K causes recessively inherited cardiac RT conduction disease in a consanguineous Pakistani family."; RL Genes (Basel) 12:0-0(2021). RN [15] RP VARIANTS CCDD THR-512; TYR-592 AND VAL-671, CHARACTERIZATION OF VARIANTS RP CCDD THR-512; TYR-592; VAL-671 AND LEU-742, CHARACTERIZATION OF VARIANTS RP LEU-510; PRO-511 AND THR-591, AND MUTAGENESIS OF LYS-490; ILE-512 AND RP 556-ARG--ASN-590. RX PubMed=37199186; DOI=10.1161/circgen.122.003975; RA Pham C., Andrzejczyk K., Jurgens S.J., Lekanne Deprez R., Palm K.C.A., RA Vermeer A.M.C., Nijman J., Christiaans I., Barge-Schaapveld D.Q.C.M., RA van Dessel P.F.H.M., Beekman L., Choi S.H., Lubitz S.A., RA Skoric-Milosavljevic D., van den Bersselaar L., Jansen P.R., Copier J.S., RA Ellinor P.T., Wilde A.A.M., Bezzina C.R., Lodder E.M.; RT "Genetic burden of TNNI3K in diagnostic testing of patients with dilated RT cardiomyopathy and supraventricular arrhythmias."; RL Circ. Genom. Precis. Med. 16:328-336(2023). RN [16] RP VARIANTS CCDD PHE-577 AND LEU-742, CHARACTERIZATION OF VARIANT CCDD RP PHE-577, AND AUTOPHOSPHORYLATION. RX PubMed=38424693; DOI=10.1111/cge.14504; RA Pham C., Koopmann T.T., Vinocur J.M., Blom N.A., Nogueira Silbiger V., RA Mittal K., Bootsma M., Palm K.C.A., Clur S.B., Barge-Schaapveld D.Q.C.M., RA Hamilton R.M., Lodder E.M.; RT "Reduced kinase function in two ultra-rare TNNI3K variants in families with RT congenital junctional ectopic tachycardia."; RL Clin. Genet. 106:37-46(2024). CC -!- FUNCTION: May play a role in cardiac physiology. CC {ECO:0000303|PubMed:12721663}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12721663}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12721663}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:12721663}; CC -!- SUBUNIT: Interacts with TNNI3, ACTC1, ACTA1, MYBPC3, AIP, FABP3 and CC HADHB. {ECO:0000269|PubMed:12721663}. CC -!- INTERACTION: CC Q59H18; Q9UKT5: FBXO4; NbExp=3; IntAct=EBI-704142, EBI-960409; CC Q59H18; P19429: TNNI3; NbExp=2; IntAct=EBI-704142, EBI-704146; CC Q59H18-2; P19429: TNNI3; NbExp=2; IntAct=EBI-10762055, EBI-704146; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12721663}. Cytoplasm CC {ECO:0000269|PubMed:12721663}. Note=Expressed at lower levels in the CC cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=2 {ECO:0000269|PubMed:12721663}; CC IsoId=Q59H18-2; Sequence=Displayed; CC Name=1 {ECO:0000305}; CC IsoId=Q59H18-1; Sequence=VSP_039403; CC Name=3 {ECO:0000305}; CC IsoId=Q59H18-3; Sequence=VSP_039403, VSP_051882, VSP_051883; CC Name=4 {ECO:0000305}; CC IsoId=Q59H18-4; Sequence=VSP_039403, VSP_051884, VSP_051885; CC -!- TISSUE SPECIFICITY: Highly expressed in both adult and fetal heart. CC {ECO:0000269|PubMed:12721663}. CC -!- PTM: Autophosphorylated. {ECO:0000269|PubMed:12721663, CC ECO:0000269|PubMed:38424693}. CC -!- DISEASE: Cardiac conduction disease with or without dilated CC cardiomyopathy (CCDD) [MIM:616117]: A cardiac disorder characterized by CC atrial tachyarrhythmia and conduction system disease. Some patients CC have dilated cardiomyopathy. CCDD inheritance is autosomal dominant. CC {ECO:0000269|PubMed:24925317, ECO:0000269|PubMed:25791106, CC ECO:0000269|PubMed:30010057, ECO:0000269|PubMed:37199186, CC ECO:0000269|PubMed:38424693}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 1]: Based on a naturally occurring readthrough CC transcript which produces a FPGT-TNNI3K fusion protein. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Based on a naturally occurring readthrough CC transcript which produces a FPGT-TNNI3K fusion protein. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 4]: Based on a naturally occurring readthrough CC transcript which produces a FPGT-TNNI3K fusion protein. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. MAP kinase kinase kinase subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAD92178.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAE45949.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF116826; AAD29632.1; -; mRNA. DR EMBL; AY303691; AAP72030.1; -; mRNA. DR EMBL; AB208941; BAD92178.1; ALT_INIT; Transcribed_RNA. DR EMBL; BX640903; CAE45949.1; ALT_INIT; mRNA. DR EMBL; DQ822519; ABG46944.1; -; Genomic_DNA. DR EMBL; AC093158; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC098692; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC105271; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC119672; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BX470253; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471059; EAX06415.1; -; Genomic_DNA. DR EMBL; BC032865; AAH32865.1; -; mRNA. DR EMBL; BC113539; AAI13540.1; -; mRNA. DR EMBL; BC117262; AAI17263.1; -; mRNA. DR CCDS; CCDS664.1; -. [Q59H18-2] DR RefSeq; NP_057062.1; NM_015978.3. [Q59H18-2] DR PDB; 4YFF; X-ray; 3.07 A; A/B/C/D=420-730. DR PDB; 4YFI; X-ray; 2.70 A; A/B/C/D=402-730. DR PDB; 6B5J; X-ray; 2.97 A; A/B/C/D=420-730. DR PDB; 7MGJ; X-ray; 2.95 A; A/B/C/D=402-730. DR PDB; 7MGK; X-ray; 3.10 A; A/B/C/D=420-730. DR PDBsum; 4YFF; -. DR PDBsum; 4YFI; -. DR PDBsum; 6B5J; -. DR PDBsum; 7MGJ; -. DR PDBsum; 7MGK; -. DR AlphaFoldDB; Q59H18; -. DR SMR; Q59H18; -. DR BioGRID; 119276; 19. DR BioGRID; 1529324; 1. DR FunCoup; Q59H18; 1793. DR IntAct; Q59H18; 18. DR STRING; 9606.ENSP00000322251; -. DR BindingDB; Q59H18; -. DR ChEMBL; CHEMBL5260; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q59H18; -. DR GuidetoPHARMACOLOGY; 2247; -. DR iPTMnet; Q59H18; -. DR PhosphoSitePlus; Q59H18; -. DR BioMuta; TNNI3K; -. DR DMDM; 300669705; -. DR jPOST; Q59H18; -. DR MassIVE; Q59H18; -. DR PaxDb; 9606-ENSP00000322251; -. DR PeptideAtlas; Q59H18; -. DR ProteomicsDB; 62665; -. [Q59H18-2] DR ProteomicsDB; 62666; -. [Q59H18-1] DR ProteomicsDB; 62667; -. [Q59H18-3] DR ProteomicsDB; 62668; -. [Q59H18-4] DR Antibodypedia; 2103; 149 antibodies from 22 providers. DR DNASU; 51086; -. DR Ensembl; ENST00000326637.8; ENSP00000322251.3; ENSG00000116783.16. [Q59H18-2] DR GeneID; 100526835; -. DR GeneID; 51086; -. DR KEGG; hsa:100526835; -. DR KEGG; hsa:51086; -. DR MANE-Select; ENST00000326637.8; ENSP00000322251.3; NM_015978.3; NP_057062.1. DR UCSC; uc001dgf.3; human. [Q59H18-2] DR AGR; HGNC:19661; -. DR AGR; HGNC:42952; -. DR ClinPGx; PA134976654; -. DR CTD; 100526835; -. DR CTD; 51086; -. DR DisGeNET; 100526835; -. DR DisGeNET; 51086; -. DR GeneCards; TNNI3K; -. DR HGNC; HGNC:19661; TNNI3K. DR HPA; ENSG00000116783; Tissue enriched (heart). DR MalaCards; TNNI3K; -. DR MIM; 613932; gene. DR MIM; 616117; phenotype. DR OpenTargets; ENSG00000116783; -. DR OpenTargets; ENSG00000259030; -. DR Orphanet; 436242; Hereditary atrial tachyarrhythmia-infra-Hisian cardiac conduction disease. DR VEuPathDB; HostDB:ENSG00000116783; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00940000159131; -. DR HOGENOM; CLU_017658_0_0_1; -. DR InParanoid; Q59H18; -. DR OMA; NHPCIIH; -. DR OrthoDB; 339325at2759; -. DR PAN-GO; Q59H18; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q59H18; -. DR PathwayCommons; Q59H18; -. DR SignaLink; Q59H18; -. DR Agora; ENSG00000116783; -. DR BioGRID-ORCS; 100526835; 43 hits in 928 CRISPR screens. DR BioGRID-ORCS; 51086; 14 hits in 781 CRISPR screens. DR EvolutionaryTrace; Q59H18; -. DR Pharos; Q59H18; Tchem. DR PRO; PR:Q59H18; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q59H18; protein. DR Bgee; ENSG00000116783; Expressed in apex of heart and 97 other cell types or tissues. DR ExpressionAtlas; Q59H18; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0086069; P:bundle of His cell to Purkinje myocyte communication; IMP:BHF-UCL. DR GO; GO:0036289; P:peptidyl-serine autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1903779; P:regulation of cardiac conduction; IGI:BHF-UCL. DR GO; GO:0055117; P:regulation of cardiac muscle contraction; IMP:BHF-UCL. DR GO; GO:0002027; P:regulation of heart rate; IMP:BHF-UCL. DR CDD; cd14064; PKc_TNNI3K; 1. DR FunFam; 1.10.510.10:FF:000259; Serine/threonine-protein kinase TNNI3K; 1. DR FunFam; 1.25.40.20:FF:000077; Serine/threonine-protein kinase TNNI3K; 1. DR FunFam; 1.25.40.20:FF:000155; Serine/threonine-protein kinase TNNI3K; 1. DR FunFam; 1.25.40.20:FF:000089; serine/threonine-protein kinase TNNI3K; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 3. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR PANTHER; PTHR24198; ANKYRIN REPEAT AND PROTEIN KINASE DOMAIN-CONTAINING PROTEIN; 1. DR PANTHER; PTHR24198:SF183; SUPPRESSOR_ENHANCER OF LIN-12; 1. DR Pfam; PF12796; Ank_2; 3. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR01415; ANKYRIN. DR SMART; SM00248; ANK; 10. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. DR PROSITE; PS50088; ANK_REPEAT; 6. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ANK repeat; ATP-binding; KW Cardiomyopathy; Coiled coil; Cytoplasm; Disease variant; Kinase; Magnesium; KW Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..835 FT /note="Serine/threonine-protein kinase TNNI3K" FT /id="PRO_0000086757" FT REPEAT 66..96 FT /note="ANK 1" FT REPEAT 100..129 FT /note="ANK 2" FT REPEAT 133..162 FT /note="ANK 3" FT REPEAT 166..195 FT /note="ANK 4" FT REPEAT 199..228 FT /note="ANK 5" FT REPEAT 234..263 FT /note="ANK 6" FT REPEAT 269..298 FT /note="ANK 7" FT REPEAT 304..335 FT /note="ANK 8" FT REPEAT 339..368 FT /note="ANK 9" FT REPEAT 381..410 FT /note="ANK 10" FT DOMAIN 463..723 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 732..751 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 21..51 FT /evidence="ECO:0000255" FT COMPBIAS 732..746 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 588 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 469..477 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 490 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT VAR_SEQ 1..13 FT /note="MGNYKSRPTQTCT -> MAAARDPPEVSLREATQRKLRRFSELRGKLVARGE FT FWDIVAITAADEKQELAYNQQLSEKLKRKELPLGVQYHVFVDPAGAKIGNGGSTLCALQ FT CLEKLYGDKWNSFTILLIHS (in isoform 1, isoform 3 and isoform FT 4)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005, ECO:0000303|Ref.3" FT /id="VSP_039403" FT VAR_SEQ 591..596 FT /note="SHNILL -> RYFFPK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_051882" FT VAR_SEQ 597..835 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_051883" FT VAR_SEQ 708..742 FT /note="GRPEFSEVVMKLEECLCNIELMSPASSNSSGSLSP -> AKSRPSHYPVSSV FT YTETLKKKNEDRFGMWIEYLRR (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051884" FT VAR_SEQ 743..835 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051885" FT VARIANT 151 FT /note="D -> H (in dbSNP:rs34874695)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041223" FT VARIANT 263 FT /note="P -> L (in dbSNP:rs34521608)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041224" FT VARIANT 309 FT /note="F -> L" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041225" FT VARIANT 430 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041226" FT VARIANT 510 FT /note="V -> L (decreased autophosphorylation; FT dbSNP:rs34335537)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:37199186" FT /id="VAR_041227" FT VARIANT 511 FT /note="S -> P (found in a consaguineous family with FT autosomal recessive cardiac conduction disease; uncertain FT significance; no effect on phosphorylation)" FT /evidence="ECO:0000269|PubMed:34440456, FT ECO:0000269|PubMed:37199186" FT /id="VAR_089865" FT VARIANT 512 FT /note="I -> T (in CCDD; uncertain significance; increased FT autophosphorylation; dbSNP:rs2100520576)" FT /evidence="ECO:0000269|PubMed:37199186" FT /id="VAR_089866" FT VARIANT 526 FT /note="G -> D (in CCDD; pathogenic; the mutation results in FT decreased protein solubility; causes abnormal aggregation; FT markedly reduced protein expression is observed in the FT sarcoplasm and nuclei of patient cardiomyocytes; severely FT reduced autophosphorylation; dbSNP:rs606231469)" FT /evidence="ECO:0000269|PubMed:24925317, FT ECO:0000269|PubMed:30010057" FT /id="VAR_072650" FT VARIANT 539 FT /note="T -> A (in CCDD; uncertain significance; FT dbSNP:rs1662479663)" FT /evidence="ECO:0000269|PubMed:25791106, FT ECO:0000269|PubMed:30010057" FT /id="VAR_089867" FT VARIANT 577 FT /note="L -> F (in CCDD; likely pathogenic; severely FT decreased autophosphorylation; dbSNP:rs201010209)" FT /evidence="ECO:0000269|PubMed:38424693" FT /id="VAR_089868" FT VARIANT 591 FT /note="S -> T (no effect on autophosphorylation; FT dbSNP:rs145260115)" FT /evidence="ECO:0000269|PubMed:37199186" FT /id="VAR_089869" FT VARIANT 592 FT /note="H -> Y (in CCDD; uncertain significance; increased FT autophosphorylation; dbSNP:rs567089878)" FT /evidence="ECO:0000269|PubMed:37199186" FT /id="VAR_089870" FT VARIANT 629 FT /note="R -> G (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035639" FT VARIANT 637 FT /note="T -> M (in dbSNP:rs2274260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041228" FT VARIANT 671 FT /note="A -> V (in CCDD; uncertain significance; increased FT autophosphorylation; dbSNP:rs201064243)" FT /evidence="ECO:0000269|PubMed:37199186" FT /id="VAR_089871" FT VARIANT 686 FT /note="I -> T (in dbSNP:rs3737564)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041229" FT VARIANT 742 FT /note="P -> L (in CCDD; uncertain significance; decreased FT autophosphorylation; dbSNP:rs1210821808)" FT /evidence="ECO:0000269|PubMed:37199186, FT ECO:0000269|PubMed:38424693" FT /id="VAR_089872" FT VARIANT 768 FT /note="E -> K (in CCDD; likely pathogenic; increased FT autophosphorylation; dbSNP:rs202238194)" FT /evidence="ECO:0000269|PubMed:30010057" FT /id="VAR_089873" FT VARIANT 785 FT /note="A -> G (in dbSNP:rs45578635)" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_038821" FT VARIANT 798 FT /note="M -> I (in a head & Neck squamous cell carcinoma FT sample; somatic mutation; dbSNP:rs201613442)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041230" FT VARIANT 833 FT /note="D -> Y (in dbSNP:rs45614933)" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_038822" FT MUTAGEN 490 FT /note="K->R: Loss of autophosphorylation activity." FT /evidence="ECO:0000269|PubMed:12721663, FT ECO:0000269|PubMed:37199186" FT MUTAGEN 512 FT /note="I->F: Increased autophosphorylation." FT /evidence="ECO:0000269|PubMed:37199186" FT MUTAGEN 556..590 FT /note="Missing: Loss of autophosphorylation." FT /evidence="ECO:0000269|PubMed:37199186" FT CONFLICT 127 FT /note="I -> V (in Ref. 8; AAH32865)" FT /evidence="ECO:0000305" FT CONFLICT 250 FT /note="I -> M (in Ref. 4; CAE45949)" FT /evidence="ECO:0000305" FT CONFLICT 367 FT /note="N -> S (in Ref. 4; CAE45949)" FT /evidence="ECO:0000305" FT CONFLICT 629 FT /note="R -> L (in Ref. 8; AAH32865)" FT /evidence="ECO:0000305" FT HELIX 442..451 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 454..456 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 460..462 FT /evidence="ECO:0007829|PDB:4YFI" FT STRAND 463..470 FT /evidence="ECO:0007829|PDB:4YFI" FT STRAND 473..482 FT /evidence="ECO:0007829|PDB:4YFI" FT STRAND 485..492 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 502..515 FT /evidence="ECO:0007829|PDB:4YFI" FT STRAND 524..528 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 532..534 FT /evidence="ECO:0007829|PDB:4YFI" FT STRAND 536..540 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 547..552 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 560..578 FT /evidence="ECO:0007829|PDB:4YFI" FT STRAND 580..582 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 591..593 FT /evidence="ECO:0007829|PDB:4YFI" FT STRAND 594..596 FT /evidence="ECO:0007829|PDB:4YFI" FT STRAND 602..604 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 628..630 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 633..636 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 637..639 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 645..660 FT /evidence="ECO:0007829|PDB:4YFI" FT TURN 664..667 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 670..678 FT /evidence="ECO:0007829|PDB:4YFI" FT STRAND 688..690 FT /evidence="ECO:0007829|PDB:7MGK" FT HELIX 692..701 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 706..708 FT /evidence="ECO:0007829|PDB:4YFI" FT HELIX 712..725 FT /evidence="ECO:0007829|PDB:4YFI" SQ SEQUENCE 835 AA; 92851 MW; 3B21484B434F46E8 CRC64; MGNYKSRPTQ TCTDEWKKKV SESYVITIER LEDDLQIKEK ELTELRNIFG SDEAFSKVNL NYRTENGLSL LHLCCICGGK KSHIRTLMLK GLRPSRLTRN GFTALHLAVY KDNAELITSL LHSGADIQQV GYGGLTALHI ATIAGHLEAA DVLLQHGANV NIQDAVFFTP LHIAAYYGHE QVTRLLLKFG ADVNVSGEVG DRPLHLASAK GFLNIAKLLM EEGSKADVNA QDNEDHVPLH FCSRFGHHDI VKYLLQSDLE VQPHVVNIYG DTPLHLACYN GKFEVAKEII QISGTESLTK ENIFSETAFH SACTYGKSID LVKFLLDQNV ININHQGRDG HTGLHSACYH GHIRLVQFLL DNGADMNLVA CDPSRSSGEK DEQTCLMWAY EKGHDAIVTL LKHYKRPQDE LPCNEYSQPG GDGSYVSVPS PLGKIKSMTK EKADILLLRA GLPSHFHLQL SEIEFHEIIG SGSFGKVYKG RCRNKIVAIK RYRANTYCSK SDVDMFCREV SILCQLNHPC VIQFVGACLN DPSQFAIVTQ YISGGSLFSL LHEQKRILDL QSKLIIAVDV AKGMEYLHNL TQPIIHRDLN SHNILLYEDG HAVVADFGES RFLQSLDEDN MTKQPGNLRW MAPEVFTQCT RYTIKADVFS YALCLWEILT GEIPFAHLKP AAAAADMAYH HIRPPIGYSI PKPISSLLIR GWNACPEGRP EFSEVVMKLE ECLCNIELMS PASSNSSGSL SPSSSSDCLV NRGGPGRSHV AALRSRFELE YALNARSYAA LSQSAGQYSS QGLSLEEMKR SLQYTPIDKY GYVSDPMSSM HFHSCRNSSS FEDSS //